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Background: People with severe mental illness experience poorer health outcomes than the general
population. Diabetes contributes significantly to this health gap.
Objectives: The objectives were to identify the determinants of diabetes and to explore variation in
diabetes outcomes for people with severe mental illness.
Design: Under a social inequalities framework, a concurrent mixed-methods design combined analysis
of linked primary care records with qualitative interviews.
Setting: The quantitative study was carried out in general practices in England (2000–16). The qualitative
study was a community study (undertaken in the North West and in Yorkshire and the Humber).
Participants: The quantitative study used the longitudinal health records of 32,781 people with severe
mental illness (a subset of 3448 people had diabetes) and 9551 ‘controls’ (with diabetes but no severe
mental illness), matched on age, sex and practice, from the Clinical Practice Research Datalink (GOLD
version). The qualitative study participants comprised 39 adults with diabetes and severe mental
illness, nine family members and 30 health-care staff.
Data sources: The Clinical Practice Research Datalink (GOLD) individual patient data were linked
to Hospital Episode Statistics, Office for National Statistics mortality data and the Index of
Multiple Deprivation.
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Results: People with severe mental illness were more likely to have diabetes if they were taking
atypical antipsychotics, were living in areas of social deprivation, or were of Asian or black ethnicity.
A substantial minority developed diabetes prior to severe mental illness. Compared with people with
diabetes alone, people with both severe mental illness and diabetes received more frequent physical
checks, maintained tighter glycaemic and blood pressure control, and had fewer recorded physical
comorbidities and elective admissions, on average. However, they had more emergency admissions
(incidence rate ratio 1.14, 95% confidence interval 0.96 to 1.36) and a significantly higher risk of
all-cause mortality than people with diabetes but no severe mental illness (hazard ratio 1.89, 95%
confidence interval 1.59 to 2.26). These paradoxical results may be explained by other findings. For
example, people with severe mental illness and diabetes were more likely to live in socially deprived
areas, which is associated with reduced frequency of health checks, poorer health outcomes and higher
mortality risk. In interviews, participants frequently described prioritising their mental illness over their
diabetes (e.g. tolerating antipsychotic side effects, despite awareness of harmful impacts on diabetes
control) and feeling overwhelmed by competing treatment demands from multiple morbidities. Both
service users and practitioners acknowledged misattributing physical symptoms to poor mental health
(‘diagnostic overshadowing’).
Limitations: Data may not be nationally representative for all relevant covariates, and the
completeness of recording varied across practices.
Conclusions: People with severe mental illness and diabetes experience poorer health outcomes than,
and deficiencies in some aspects of health care compared with, people with diabetes alone.
Future work: These findings can inform the development of targeted interventions aimed at
addressing inequalities in this population.
Study registration: National Institute for Health Research (NIHR) Central Portfolio Management
System (37024); and ClinicalTrials.gov NCT03534921.
Funding: This project was funded by the NIHR Health Services and Delivery Research programme and
will be published in full in Health Services and Delivery Research; Vol. 9, No. 10. See the NIHR Journals
Library website for further project information.
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A&E accident and emergency
BIC Bayesian information criterion
BMI body mass index
CHD coronary heart disease
CI confidence interval
COPD chronic obstructive pulmonary
disease
CPN community psychiatric nurse
CPRD Clinical Practice Research
Datalink
DESMOND Diabetes Education and Self
Management for Ongoing and
Newly Diagnosed
DIAMONDS DIAbetes and Mental illness:
improving Outcomes aND
Services




HES Hospital Episode Statistics
HR hazard ratio
HRG Healthcare Resource Group
ICD-10 International Statistical
Classification of Diseases and
Related Health Problems, Tenth
Revision
IMD Index of Multiple Deprivation
IRR incidence rate ratio
LSOA lower-layer super output area
NDA National Diabetes Audit
NICE National Institute for Health
and Care Excellence
NIHR National Institute for Health
Research
ONS Office for National Statistics
OR odds ratio
PIP Personal Independence Payment
PPI patient and public involvement
QOF Quality and Outcomes
Framework
SMI severe mental illness
SSC Study Steering Committee
T2DM type 2 diabetes mellitus
UTS up to standard
WHO World Health Organization
YLD years lived with disability
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Severe mental illness refers to a group of illnesses, such as schizophrenia, that greatly interferewith life activities. People with severe mental illness die earlier and have worse physical health
than the general population. They are more than twice as likely to develop diabetes and to get more
complications from having diabetes. It is currently unclear how severe mental illness interacts with
diabetes or how having both conditions influences health-care use.
We looked at general practice records from large numbers of patients across England. We also interviewed
39 people with severe mental illness and diabetes, nine family members and 30 health-care professionals
across the North West, and Yorkshire and the Humber.
Key findings
In people with severe mental illness, older age, being from an ethnic minority, living in a deprived area,
having multiple health conditions and using certain medications predicted the development of diabetes.
For people with both severe mental illness and diabetes, being older, living in deprived areas and
having lots of different health conditions led to poorer physical and mental health outcomes.
Participants with severe mental illness said that they put dealing with their mental illness above caring
for their physical health. They also struggled to manage lots of health problems.
Physical health problems were often overlooked by health-care services because physical and mental
health problems are often treated in separate services. A keyworker responsible for co-ordinating care
could help to bridge this gap.
Good social support, diabetes knowledge and better mental health (like better mood) were things that
helped people with severe mental illness to better manage their diabetes. Health-care staff wanted
more training about physical or mental health problems.
Participants’ low levels of physical activity and poor mental and physical health were barriers
to effective diabetes management. These barriers need to be thought about when designing
better treatments.
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In this study, we used mixed methods to identify and explore determinants of diabetes risk andoutcomes for people with severe mental illness. We integrated findings from an analysis of English
anonymised longitudinal medical records from primary care; qualitative interviews with people with
severe mental illness, their family members and health-care professionals living in the north of
England; and service user workshops. We found that people with severe mental illness and diabetes
experience poorer health outcomes than, and deficiencies in some aspects of health care compared
with, people with diabetes alone.
Background
The average life expectancy for people with severe mental illnesses, such as schizophrenia or bipolar
disorder, is 15–20 years lower than for the general population. Diabetes contributes significantly to
this inequality, being two to three times more prevalent in this population. Various risk factors have
been implicated, including side effects of antipsychotics and unhealthy lifestyles, which often occur in
the context of socioeconomic disadvantage and health-care inequality.
Objectives
l In people with severe mental illness: to identify which sociodemographic, illness, family history and
lifestyle factors are associated with the development of diabetes.
l In people with severe mental illness and diabetes: to identify which sociodemographic, illness, family
history and lifestyle factors are associated with variations in diabetes and mental health outcomes.
l In people with severe mental illness: to compare the health-care interventions and physical and
mental health outcomes of people with diabetes with those of people without diabetes.
l In people with diabetes: to compare the health-care interventions and physical and mental health
outcomes of people with severe mental illness with those of people without severe mental illness.
l To understand the factors that are associated with access to, and receipt of, diabetes care and to
explore the experience of diabetes health care by people with severe mental illness.
l To compare diabetes care provision for people with and people without severe mental illness,
and to estimate costs for these.
l To identify which health-care interventions (e.g. medication, referrals and care pathways) may be
associated with better diabetes outcomes for people with severe mental illness and diabetes.
Methods
Design
Under a social inequalities framework, a concurrent triangulation mixed-methods design was used,
comprising (1) a quantitative longitudinal observational study of anonymised individual patient records
of adults diagnosed with severe mental illness and (2) a qualitative interview study of people with
coexisting severe mental illness and diabetes, family members who support them and health-care
staff involved in the care of this patient population. The mixed-methods design was underpinned by a
pragmatic paradigm, which acknowledged that each data type provided a different, but complementary,
view of the relationship between severe mental illness and diabetes, and that combining the two
facilitated a more complete understanding.
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Quantitative longitudinal observational study
Study population
Adult patients (aged ≥ 18 years) living in England registered with a general practice contributing
research-standard data to the Clinical Practice Research Datalink (GOLD version) for the study period,
1 April 2000 to 31 March 2016.
Data sets
The Clinical Practice Research Datalink is the world’s largest computerised database of anonymised
longitudinal medical records from primary care. Electronically linked data for individuals in the study
population were obtained from the following sources: Hospital Episode Statistics data for hospital
admissions, the Office for National Statistics for date of death and the Index of Multiple Deprivation
for area deprivation at practice and patient level.
Variables
Lists of potential determinants of diabetes in severe mental illness, poor diabetes-related outcomes,
care pathways and interventions were collated and used, together with expert consultation, to inform
the selection of a priori variables for exploration.
Statistical analysis
A range of regression models was used for statistical analyses, taking account of the hierarchical
structure of the data. Linear, logistic and survival regression models were developed, as appropriate,
depending on the outcome variable of interest. Multilevel mixed effects were estimated to account
for the correlation in the longitudinal health records of the same patient, as well as the unobserved
correlation at practice level. Analyses were conducted in line with the inequalities framework, which
sought to quantify the absolute and relative effect of social inequalities on quality of care and
outcomes. Specifically, when sample size permitted, we stratified analyses, for example by ethnicity,
and/or used deprivation and disadvantage markers, such as the Index of Multiple Deprivation, as
independent variables to estimate gap or gradient effects.
Qualitative interview study
Interviews were conducted in person or over the telephone (according to participant preference), using
topic guides.
Study population
Study participants were (1) adult patients (aged ≥ 18 years) of the English NHS (from the North West,
and Yorkshire and the Humber) with a recorded diagnosis of severe mental illness (not currently
experiencing an acute relapse) and diabetes (type 1 or type 2, excluding gestational diabetes), living in
the community; (2) relatives involved in the care of a person with severe mental illness and diabetes;
and (3) health-care staff (commissioners, clinicians, nurses and other staff) who worked with people
with severe mental illness and diabetes. All participants were required to have the capacity to consent
to participation.
Sampling
Maximum variation purposive sampling was used, informed by demographic and illness characteristics
identified during the scoping of the literature and expert consultation. People with severe mental
illness and diabetes were sampled from rural and urban areas, areas of wealth and deprivation, and
areas with diverse communities. Family members were recruited in the same manner. Health-care staff
were also sampled purposively (general practitioners, practice nurses, diabetes nurses, mental health
nurses, case managers, psychiatrists and diabetologists). Recruitment continued until data saturation
was reached.
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Recruitment
People with severe mental illness were identified by NHS general practice and mental health service
staff using practice database and caseload searches. Participating individuals with severe mental
illness and diabetes were asked to identify a person who supports them, who was then approached
by the research team. Relatives who were known to clinicians were also approached. Potential
participants were also recruited via existing research cohorts (if they had agreed to be contacted for
future research) and clinic or website advertisements. For health-care staff recruitment, lead clinicians
in participating general practices and mental health services were asked to identify health-care staff
with experience of providing services to this population.
Data collection
Separate semistructured interview guides for individuals with severe mental illness and diabetes,
family members and health-care staff were developed in partnership with study co-investigators,
patient and public involvement and the findings from the scoping of the literature. The topic guides
were amended iteratively as the project progressed. Data collection took place between April and
December 2018. Written or audio-recorded verbal informed consent was obtained from all participants.
With participants’ permission, interviews were audio-recorded, or, if participants preferred, handwritten
notes were made during and following the interview.
Data analysis
Data were analysed using NVivo 11 and 12 (QSR International, Warrington, UK). The framework
method was employed, which combines deductive analysis of a priori themes identified through
expert consultation and scoping of the literature, with inductive analysis of themes that emerged from
the data. Analysis comprised a five-stage process of scaffolding (identifying and extracting themes),
indexing (labelling and sorting data to test the framework), coding (coding the data to the framework),
descriptive analysis (categorising and classifying data into higher-order themes) and explanatory
analysis (detecting thematic patterns and relationships). As well as examining thematic patterns across
the data, deviant cases were compared to understand the variation in managing diabetes within the
sample. The key steps of the analysis were conducted by at least two researchers, and emerging
findings were reviewed regularly by the project team and the patient and public involvement panel.
Mixed-methods analysis
The primary method for integration was ‘convergence’, which involved bringing together the quantitative
and qualitative results to generate a more comprehensive understanding of the comorbid relationship
between severe mental illness and diabetes. Co-design workshops also formed part of this process to
ensure that study findings, and the integration of these, were interpreted by service users and health-
care providers in addition to the research team. The principle of transformation was used to create
merged descriptive summaries, underpinned by the study’s social inequalities theoretical framework.
Results
Quantitative results
The key predictors for people with severe mental illness developing diabetes were older age (odds ratio
1.17, 95% confidence interval 1.14 to 1.21), until around 60 years of age; being of South Asian (odds
ratio 2.47, 95% confidence interval 1.78 to 3.42) or black ethnicity (odds ratio 1.85, 95% confidence
interval 1.25 to 2.75) (compared with white ethnicity); socioeconomic deprivation (most deprived
compared with least deprived fifth, odds ratio 1.86, 95% confidence interval 1.39 to 2.48), physical
comorbidity versus none; and the use of atypical antipsychotics versus no antipsychotic use (odds ratio
1.39, 95% confidence interval 1.16 to 1.67).
Common predictors for worse physical health outcomes for people with severe mental illness and
diabetes were older age, socioeconomic deprivation and multimorbidity.
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People with severe mental illness and diabetes had better glycaemic and blood pressure control and
were more likely to receive physical health checks than people with diabetes and no severe mental
illness (blood pressure: incidence rate ratio 1.03, 95% confidence interval 1.01 to 1.06; cholesterol:
incidence rate ratio 1.05, 95% confidence interval 1.03 to 1.08; body mass index: incidence rate ratio
1.09, 95% confidence interval 1.06 to 1.11). Having a severe mental illness increased the likelihood of
all-cause mortality (hazard ratio 1.89, 95% confidence interval 1.59 to 2.26) and depression (odds ratio
1.86, 95% confidence interval 1.63 to 2.12) in people with diabetes. The number of elective admissions
for macrovascular complications was significantly lower for people with severe mental illness (incidence
rate ratio 0.64, 95% confidence interval 0.47 to 0.88), whereas the rate of emergency admissions was
elevated (incidence rate ratio 1.14, 95% confidence interval 0.96 to 1.36).
People with severe mental illness and diabetes incur higher health-care costs (mean difference of
£2363.90 per person per year) than people with diabetes alone; these are driven mainly by increased
costs of secondary care.
Qualitative results
Interviews were conducted with 39 people with comorbid severe mental illness and diabetes, nine
family members and 30 health-care staff. One interview was conducted with assistance from a
translator. Eight key themes were identified:
1. mental illness affects everything
2. multimorbidity and diabetes management
3. interacting conditions and overlapping symptoms
4. mood and diabetes management
5. informal support networks
6. diabetes health care
7. diabetes knowledge and education
8. person-centred care.
The data suggested that social support, diabetes knowledge and mental health state are related
to diabetes management. Staff emphasised the need for additional information and training on
multimorbidity. There was evidence that physical health was diagnostically overshadowed at patient,
professional and systems levels. Many participants highlighted the links between antipsychotics and
increased appetite, lethargy and weight gain. Sedentary lifestyles and poor mental and physical health
represented barriers to effective diabetes management. Difficulties navigating health-care systems
were also reported.
Mixed-methods evidence synthesis
The key topics identified were as follows:
l Diagnostic overshadowing may explain why observed high levels of general practice contacts and
diabetes checks failed to improve diabetes outcomes. This paradox may reflect structural and
attitudinal separation of health services for mental or physical conditions, influencing patient and
professional behaviours towards prioritising concerns over psychosis rather than diabetes.
l Depression and low mood, like diabetes, were often overlooked because of patients’ and health-care
professionals’ readiness to attribute psychological distress to psychosis. The consequence of
untreated depression could be an important predictor of physical health problems in people with
severe mental illness, as well as an outcome of comorbid diabetes.
l Better diabetes control, or hidden fluctuation? Fluctuations in the diabetes control of people with
severe mental illness may require more frequent monitoring than the currently recommended
annual diabetes check.
l The complex impacts of multimorbidity threatened to overwhelm many participants, who responded
by prioritising management of their mental illness, potentially to the detriment of their diabetes.
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l Participants were aware that antipsychotic medication can cause side effects that could be
detrimental to their diabetes, but they resigned themselves to tolerating these to better manage
their mental disorder.
l Social relationships with others, including friends and family and health-care providers, were
identified as an important resource for supporting health management, and also reported as being
deficient by many participants.
Limitations
Geographically, practices with large list sizes in urban areas in the south and north-west of England are
over-represented in the Clinical Practice Research Datalink data set, whereas practices in the north-east
are under-represented. The quantitative analyses are based on observational data; we were unable to
control for unobserved confounders. The true variation in the level of diabetes control achieved may not
have been observed because of the large gaps between diabetes checks. There was inconsistent quality
observed in the recording of measures by general practices. Qualitative interviews were conducted only
when a participant’s mental illness was stable, limiting the findings to those likely to be better managing
their conditions. All study findings were limited to patients who were in contact with their general practice.
Conclusions
Improving diabetes outcomes for people with severe mental illness is a high-priority area, nationally
and globally. Understanding how risk factors combine to generate a high prevalence of diabetes and
poor diabetes outcomes is a necessary first step in developing tailored health-care interventions to
improve outcomes for people with comorbid diabetes and severe mental illness. Better prevention and
management of diabetes have the potential to significantly reduce the risk of diabetes complications,
deliver large cost savings for the NHS and help improve both life expectancy and healthy years lived
in people with severe mental illness.
Implications for practice
This study has clarified how existing severe mental illness and diabetes care pathways and
interventions need to be better integrated to deal with the challenges of multimorbidity and to
improve health outcomes for this population in England. The results suggest that people with severe
mental illness need regular diabetes screening, and increased, specific, targeted support to best
manage their diabetes alongside their mental health. A key worker using a case management approach
could support navigation of services and provide continuity of care, while increasing social capital.
Recommendations for research
Future research should focus on exploring the relationship between health checks and outcomes,
between severe mental illness and other long-term physical health conditions and whether or not
diabetes is a risk factor for older-age onset of psychosis. Further exploration of the effectiveness of
bespoke diabetes interventions for people with severe mental illness is required.
Study registration
This study is registered as National Institute for Health Research (NIHR) Central Portfolio Management
System (37024); and ClinicalTrials.gov NCT03534921.
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Definition of severe mental illness
Severe mental illness (SMI) describes a group of mental disorders that are persistent, cause serious
functional impairment and substantially interfere with, or limit, major life activities. A key feature of
SMI is the presence of psychosis, which is a loss of contact with external reality. Both the American
Psychiatric Association1 and the World Health Organization2 (WHO) definitions of psychosis require
the presence of hallucinations (i.e. perceptions occurring in the absence of corresponding external or
somatic stimuli) and/or delusions (i.e. fixed false beliefs). These symptoms may be accompanied by
cognitive impairment, disordered thinking and problems with motivation, energy and mood.
Although there is some debate about which conditions come under the SMI umbrella, there is consensus
that the term includes schizophrenia, bipolar disorder and depression with psychotic symptoms.3–5
Schizophrenia is characterised by diverse psychopathology including delusions, hallucinations and
‘negative symptoms’, such as impaired motivation, reduction in interest, limited spontaneous speech,
social withdrawal and cognitive impairment. Psychotic symptoms tend to relapse and remit, although
around 20% of people with schizophrenia may experience chronic unremitting residual symptoms.6
Negative symptoms tend to be persistent and are associated with long-term effects on social functioning.
By contrast, bipolar disorder typically has an ‘episodic’ course, with recovery between relapses. It causes
extreme mood swings ranging from mania or intense happiness, grandiosity, euphoria or irritability
or decreased need for sleep, to low mood and depressive symptoms. Typically, a person with bipolar
disorder cycles from one extreme to the other, while experiencing periods with few or no symptoms
in between. Major depression is similarly a relapsing–remitting disorder, but it can have a chronic
presentation. It is characterised by a persistent feeling of sadness or lack of interest in outside stimuli.
When accompanied by psychotic symptoms, it is categorised as SMI.
Severe mental illness includes several other conditions, such as schizoaffective disorder and persistent
delusional disorder, with symptoms that overlap with schizophrenia, bipolar disorder or severe
depression. Apart from the presence of psychosis, these illnesses typically have a severe and enduring
impact over the life course, affecting education, employment, relationships and wealth.7–9
Global burden of disease due to severe mental illness
Although lifetime prevalence of SMI is < 5% (consistent across the world), these conditions contribute
a large and increasing global burden of illness. The global age-standardised point prevalence of
schizophrenia is estimated to be 0.28% [95% confidence interval (CI) 0.24% to 0.31%], but it contributes
13.4 (95% CI 9.9 to 16.7) million years lived with disability (YLD), equivalent to 1.7% of total YLD.10
Similarly, the age-standardised prevalence rate of bipolar disorder is estimated to be 0.7% (95% CI
0.6% to 0.8%), contributing 1.3% of total YLD.11
Treatment of severe mental illness
Treatment of SMI includes a combination of psychotropic medication, psychological therapies and
psychosocial support.
In recognition of the high risk of comorbid physical conditions and the socioeconomic impacts of SMI,
treatment guidelines also include provision of annual general practitioner (GP) health checks to monitor
physical health; smoking cessation support; and supported employment, exercise and diet programmes.12,13
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The majority of people with SMI are likely to be prescribed antipsychotics, either typical (sometimes
called ‘first generation’, developed in the 1950s) or atypical (sometimes called ‘second generation’,
developed in the 1990s).14 Although all antipsychotics have been associated with side effects such as
drowsiness, tremors, muscle spasms and weight gain, atypical antipsychotics are thought to have fewer
extrapyramidal (motor control) side effects, but some may be associated with greater metabolic side
effects and weight gain.14
Comorbid physical conditions and excess mortality and morbidity in severe mental illness
Burden-of-disease estimates do not account for the premature mortality and morbidity due to physical
illnesses in SMI. People with SMI die, on average, 15–20 years earlier,15 with a death rate 3.7 times
higher16 than the general population. Recent evidence indicates that this ‘mortality gap’ is widening
for people with schizophrenia and bipolar disorder.17,18 Suicide accounts for around 15% of the increased
mortality, but the majority of premature deaths are due to physical disorders, including non-communicable
diseases, such as diabetes. Rates of such disorders are increased in people with SMI, typically being two to
three times higher.4,19,20 It is estimated that as many as two out of three premature deaths among people
with SMI are due to preventable physical illnesses.15
Most of the risk factors for developing conditions such as diabetes are likely to be the same in people
with SMI and the general population, but there are multiple additional reasons that could explain the
high prevalence seen in SMI populations and the excess mortality from physical disorders. Mental and
physical disorders have a complex bidirectional relationship, sharing individual and socioenvironmental
risk factors (e.g. childhood adversity and social and economic disadvantage).21,22 Medications for mental
illness are often associated with adverse metabolic side effects, increasing the risk of cardiometabolic
disorders. Sedentary behaviour is common because of the motivational deficits associated with these
disorders, or the side effects of treatment such as tiredness and sedation. Additional health risk behaviours
such as smoking, alcohol use and unhealthy diets are also elevated. Problems with cognition, energy and
motivation also pose challenges for accessing and adhering to medical treatment for physical conditions.
Moreover, people with SMI may be less likely to receive adequate treatment because of ‘diagnostic
overshadowing’, whereby health-care services attribute reported physical symptoms to mental illness,
and, consequently, fail to fully investigate and treat these symptoms.23
Comorbid physical disorders such as diabetes can therefore both drive, and be a consequence of, the
significant health and socioeconomic inequalities faced by people with SMI. A better understanding of
the determinants, and improved prevention and treatment of physical illness, could help to tackle the
inequalities for this group.
Diabetes mellitus
Diabetes mellitus is a complex metabolic disorder characterised by chronic hyperglycaemia as a result of
relative insulin deficiency, resistance or both. In 2019, the International Diabetes Federation estimated
that 463 million people (1 in 11 of the global population) had diabetes and estimated an increase to
700 million by 2045. Approximately 4 million people in the UK are currently living with diabetes.24
Diabetes is associated with several short- and long-term complications that cause considerable morbidity,
reduced quality of life and shortened life expectancy. These include acute metabolic perturbations
(hypoglycaemia, diabetic ketoacidosis and hyperosmolar hyperglycaemic state), macrovascular disease
(coronary artery disease, peripheral vascular disease and stroke) and microvascular disease (retinopathy,
nephropathy and neuropathy). Diabetes was responsible for approximately 4.2 million deaths worldwide,
or 11.3% of all deaths, in 2017, outnumbering the combined number of global deaths from human
immunodeficiency virus/acquired immunodeficiency syndrome, tuberculosis and malaria.24
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Type 2 diabetes mellitus (T2DM), which results from a combination of insulin resistance and less severe
insulin deficiency, is the commonest form of diabetes, accounting for 90–95% of all cases. The rapid
rise in T2DM largely explains the global epidemic, which is driven by an ageing population, longer
survival with T2DM, earlier age at onset and better diagnosis. The prevalence of T2DM has increased
as rates of obesity have risen.
Several risk factors have been identified for T2DM. The major modifiable risk factors are poor-quality
diet and reduced physical activity. Smoking, mental illness (and psychotropic medication) and decreased
sleep have also been implicated. Environmental risk factors include urbanisation, poverty and toxins.
Non-modifiable risks include family history, ethnicity, birthweight and fetal under- and over nutrition,
and history of gestational diabetes.25
It is estimated that, worldwide, approximately half of people with diabetes are unaware of their
condition; however, this is lower in high-income countries, in part because of the introduction of
screening programmes to systematically identify those with undiagnosed diabetes.
Once diabetes is considered, it is relatively easy to diagnose by the laboratory measurement of fasting
plasma glucose (≥ 7.0 mmol/l), random glucose (> 11.0 mmol/l) or a 2-hour plasma glucose after a 75-g
oral glucose tolerance test (> 11.0 mmol/l). The use of glycated haemoglobin (HbA1c) (≥ 48 mmol/mol)
was introduced by the WHO as an alternative method in 2011.
Prevention of diabetes
Clinical trials have shown that it is possible to prevent or delay the development of T2DM through
lifestyle and/or pharmacological interventions.26–30 Lifestyle interventions aim to reduce body weight
and dietary fat intake, in particular saturated fat, while increasing dietary fibre and moderate physical
activity, to ≈ 30 minutes a day. The UK has recently launched a National Diabetes Prevention Programme
to support at-risk individuals to implement these lifestyle changes through referral to a behaviour
change programme.31
Management of diabetes
For most people, diabetes is a lifelong condition. People will manage diabetes themselves (self-management)
for most of the time, with only a few hours per year spent in contact with health-care professionals.
Consequently, people must develop the skills to manage their condition effectively. Structured self-
management education programmes have been developed and are recommended by the National
Institute for Health and Care Excellence (NICE) as an integral component of diabetes management.32,33
Diabetes is managed through a combination of lifestyle changes and, when needed, treatment with
antidiabetes drugs or insulin. The latest guidance highlights the importance of certain foods and dietary
patterns.32 In common with the general population, people with diabetes should be encouraged to eat a
healthy diet. For individuals who are overweight, losing weight is important; loss of 10–15 kg of body weight
may trigger remission.32,34 Increased physical activity has profound benefits, including improved fitness,
reduced insulin requirement, better glycaemic control, lower cardiovascular risk and greater life expectancy.
Diabetes in people with severe mental illness
The prevalence of diabetes is two to three times higher in people with SMI, and around 10% of
people taking antipsychotic medications live with diabetes.35,36 A meta-analysis of 41 studies comprising
161,886 participants reported 9.0% (95% CI 7.3% to 11.1%) diabetes prevalence in SMI.36 In people
with multiple episodes of psychosis, the prevalence of diabetes was double that of the general population,
with earlier age at onset.37 The incidence rates of diabetes in SMI, however, are usually < 1%,
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meaning that the absolute risk for any one individual is small.38,39 Although diabetes is rare in
adolescents and young adults, the relative risk of diabetes in young people exposed to antipsychotic
drugs appears to be increased, compared with healthy controls and people with psychiatric disorders
but unexposed to antipsychotic drugs.40 These increased risks are for T2DM; there is no evidence that
the incidence of type 1 diabetes is increased in people with SMI.41
There are multiple potential reasons for the higher incidence of T2DM in people with SMI, including living
conditions, lifestyle and disease-specific factors, as well as the effect of antipsychotic medications on
insulin secretion and action.42–47 People with SMI tend to have a dietary pattern that includes increased
intake of energy-dense foods that are rich in fat and refined sugars, with low levels of fruit and vegetable
intake, and tend to have low levels of physical activity.42,43 Smoking and social deprivation are also
important risk factors for diabetes, and the risks of both are higher in people with SMI.
In the early 2000s, as the use of atypical antipsychotics rose, reports of substantial weight gain,
diabetes and dyslipidaemia began to emerge.48,49 It has now become apparent that rates of diabetes
are higher among people taking typical or atypical antipsychotics than among the general population.
Among people with SMI who have not yet started antipsychotic treatment, the prevalence of diabetes
is low, but it rises rapidly after treatment initiation, suggesting that antipsychotics are involved in the
aetiology of T2DM, with women and those with multiple episodes of psychosis being at higher risk.44
Studies, including randomised controlled trials comparing different antipsychotics, indicate that the risk
of developing diabetes differs between medications.35,44,49–51 A consistently higher risk of diabetes is
reported in people taking clozapine or olanzapine, with the lowest risks associated with aripiprazole,
although all antipsychotics have been associated with increased risk of diabetes.44 Clinical trial data
are supported by real-world comparisons between atypical antipsychotics.45,46 Diabetes risk also
increases with the number and dose of antipsychotics prescribed.47 Potential mechanisms mediating
this increased risk include weight gain, which increases insulin resistance, and the direct effects of
antipsychotics, which decrease insulin sensitivity of cells and also impair insulin secretory capacity.
There is debate about the magnitude of increased diabetes risk, with estimates varying widely up to a
33-fold increase; typically, however, the relative risks are < 2.52
Prevention of diabetes in people with severe mental illness
No diabetes prevention studies have been undertaken in people taking antipsychotics, but lifestyle
interventions have been used to prevent weight gain or manage obesity. Short-term studies with
follow-ups of < 6 months report weight loss of around 3.1 kg over a period of 8–24 weeks,53 but
the results of longer-term studies are less consistent.54 Similarly, there have been no studies of
pharmacological interventions, but the use of metformin leads to a modest 3.3-kg reduction in body
weight over 3–6 months, in association with improved insulin sensitivity.53,55
Screening and diagnosis of diabetes in people with severe mental illness
Although regular screening for diabetes is recommended for people with SMI,56–58 many people taking
antipsychotics are not screened regularly; further work is needed to understand why this simple
measure has not been embedded into routine clinical practice.59,60 In 2011, targets for monitoring blood
glucose were included in the national Quality and Outcomes Framework (QOF) to incentivise general
practices to screen patients with SMI for diabetes. However, these targets were removed in 2014.61
Management of diabetes in people with severe mental illness
Diabetes appears to have a greater impact on people with SMI than on the general population through
an increased incidence of acute metabolic emergencies and diabetes complications.62,63 Current NICE
guidance12 suggests that diabetes in people with SMI should be managed in a similar way to diabetes
in the general population.64 However, the guidelines do not take into account the implications of
antipsychotic use or the unique challenges people with SMI may face in managing their diabetes.
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Additional challenges faced by people with severe mental illness
Although the principles of diabetes management are the same as for the rest of the population, people
with SMI face additional challenges in achieving optimal diabetes outcomes. These include, but are not
limited to:
l health-care systems that separate diabetes and mental health
l overshadowing when physical health problems are considered to be caused by the mental illness
l excessive weight gain caused by antipsychotics and effects on insulin secretion
l psychotic symptoms
l poor cognition that interferes with decisions about self-management
l lack of social support.
Given the burden of illness, and health and health-care inequalities for this population, improving
diabetes care for people with SMI is a high priority for the NHS.65 Little is known, however, about
how SMI and other risk factors and challenges combine to generate high diabetes prevalence and poor
diabetes outcomes, and how the quality and quantity of health-care services and interventions can
influence these risk factors and outcomes in people with SMI.
Understanding this is a first step in developing health-care interventions to improve outcomes for
people with diabetes and SMI. Better prevention and management of diabetes have the potential to
significantly reduce the risk of diabetes complications, deliver large cost savings to the NHS and help
reduce health inequalities (including life expectancy and morbidity) experienced by people with SMI.
In this report, we have focused on T2DM, as it is the most common type of diabetes in people with
SMI. When the term ‘diabetes’ is used without specifying type, this refers to T2DM.
Social inequalities
Socioeconomic factors are powerful determinants of health outcomes, and a theoretical framework
based on socioeconomic conditions is, therefore, appropriate for this study, in which social inequalities
are likely to play a key role.66,67 Under this framework, health gaps in morbidity and mortality arise for
people living in disadvantaged circumstances, from reduced access to the material, financial, social or
structural resources that the advantaged population leverage to maintain or improve health. People
with SMI are more likely to be socially disadvantaged than people without SMI.20,68–73 For example, only
6% of people with SMI in England and Wales are employed, whereas 58% are on long-term sick leave
or are disabled and receiving benefits.73
There are three related explanations for this. First, there is evidence that social disparities, including
racism and the multifactorial stresses of urban living, are among the causative factors for incident
SMI.74–77 Second, the presence of severe and enduring illness patterns, and the physical and social
consequences of these, thwarts efforts to maximise and improve social conditions. For example, SMI
is diagnosed most often in early adulthood, and prodromal symptoms that interfere with functioning
can be present months or years prior to onset.78 This may disrupt secondary education and limit
educational progression, thus constraining the greater economic opportunities afforded by further and
higher education. Third, if poor social conditions are experienced, these are likely to compound over
time, for example due to individuals not having the resources to invest in social contact, high rates
of housing precarity that places individuals into increasingly deprived neighbourhoods, and further
restriction in income due to potential discrimination against mental illness in the benefits system.79–81
Deprived neighbourhoods are more likely to have environments that are obesogenic, where access
to safe physical activity is limited and accessibility of poor-quality, calorie-dense foods is greater,
increasing the risk of poor health.82,83 Stigma and discrimination, represented through labelling,
stereotyping, separating, emotional reactions and status loss, and enacted through behaviours, in public
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attitudes towards people with SMI, internally held beliefs about how one is viewed by others, and
structural barriers can thwart efforts to obtain health care and prevent illness, and can perpetuate
social disadvantage.84–87
Given these details, it is not surprising that there is evidence that social inequalities play a role in
driving poor mental and physical health outcomes for people with SMI.88–92 A complicating, and further
disadvantaging, factor is an increased risk of developing diabetes, which is itself socially patterned.93
These greater health-care needs, combined with socioeconomic disadvantage, create a vulnerability
that demands increased levels of care while simultaneously decreasing the likelihood of successful
navigation of the health-care system.94 Social disadvantage also reduces one’s capacity to take
advantage of health promotion opportunities, and creates more barriers to taking up interventions
designed to prevent or treat illness. Further details about how we applied this framework are
presented in Chapter 3, Theoretical framework.
Overview of routine health-care databases
This section describes the routine health-care databases used in this study; specific information about
how they were used is provided in Chapter 5.
Clinical Practice Research Datalink
The Clinical Practice Research Datalink (CPRD) GOLD is the world’s largest computerised database of
anonymised longitudinal medical records from primary care. The CPRD data set (originally the General
Practice Research Database) was established in 1987. CPRD data include records of clinical events
(medical diagnoses), referrals to specialists and secondary care settings, prescriptions issued in primary
care, records of immunisations/vaccinations, diagnostic testing, lifestyle information (such as smoking
and alcohol status), and all other types of care provided as part of routine general practice. Data have
been collected on > 17 million patients from a network of 718 general practices throughout the UK,
representing around 8% of the UK population registered with a GP.95 A cross-sectional study of the
regional distribution of clinical computer systems in primary care found that 9% (636/7526) of general
practices in England used Vision® (In Practice Systems Ltd, London, UK) software, from which the
CPRD primarily draws its data.95
Clinical information is captured in the CPRD database using ‘Read codes’, which are recorded by
primary care practice staff as part of routine data entry. Read codes96 are a comprehensive hierarchical
coding system of clinical terms used in primary care to classify diseases, history and symptoms, patient
characteristics, procedures and tests.97 The purpose of this coding system is to provide a standard
language to enable accurate recording of patient information and more efficient retrieval of information
for clinical or research purposes.97
The CPRD data set benefits from being a large, retrospective and prospective longitudinal primary
care record. Patient characteristics in the database are broadly representative of the general UK
population in terms of age, sex and ethnicity.98 Although other clinical computer reporting systems are
used more commonly across the UK than the Vision system, patterns of area deprivation (based on
the locations of general practices) have not been found to differ between these different systems.95
Practices using the Vision software system are, however, geographically concentrated in the south and
north-west of England – particularly around London and Manchester – with relatively few practices
based in Yorkshire and the Humber, and the north-east.95,98
Individual patient data in the CPRD can be linked electronically to external data sources, including
Hospital Episode Statistics (HES) data for hospital admissions, Office for National Statistics (ONS) data
for dates and causes of death, and the Index of Multiple Deprivation (IMD) to assess area deprivation
in the locality. The CPRD provides a single extract of linked HES/ONS/IMD anonymised data.
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Hospital Episode Statistics
The HES database contains patient records for inpatient admissions, outpatient appointments and
accident and emergency (A&E) attendances at NHS hospitals in England.99 Admissions recorded in HES
include those for physical and mental health problems where the patient was admitted to an acute
hospital (but admissions recorded do not include specialist mental health facility admissions). HES
Admitted Patient Care data contain information on patients’ demographics, admission sources and
methods, discharge methods and destination, and primary and secondary diagnoses, as well as
procedures conducted during the stay.
Diagnoses from hospital admissions are classified using the International Statistical Classification of
Diseases and Related Health Problems, Tenth Revision (ICD-10), codes. Procedures are classified using
the Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4
(OPCS-4) codes.
Office for National Statistics mortality data
The ONS mortality data include information from a person’s death certificate, such as cause of death,
and date and place of death, for all registered deaths in England and Wales.100 These data are the
most complete source of information on deaths based on information from medical practitioners
and/or coroners.
Index of Multiple Deprivation data
The English IMDs provide a relative measure of deprivation at the lower-layer super output area (LSOA)
level. There are around 35,000 LSOAs in England, each containing an average of 672 households.101
The IMD rank used for the linkage is from 2010, and is a combined index of seven domains: income,
employment, health and disability, education, crime, barriers to housing and services, and living
environment deprivation.102
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Chapter 2 Study aims and objectives
The overall aim of this study was to understand the determinants of diabetes and the variations indiabetes outcomes and care for people with SMI. We also aim to identify health-care interventions
that are associated with better outcomes, which can be tested further. The study feeds into a wider
research programme to improve diabetes outcomes for people with SMI.
Research questions
Our key research questions were as follows:
l What are the sociodemographic and illness-related risk factors associated with –
¢ diabetes developing in people with SMI?
¢ variations in diabetes and mental health outcomes in people with SMI and diabetes?
l How do physical and mental health outcomes differ between people with SMI and diabetes and
people with –
¢ SMI without diabetes?
¢ diabetes but no SMI?
l What factors are associated with access to and receipt of diabetes health care for people with SMI,
and how are diabetes health-care interventions experienced by people with SMI?
l How, and at what cost, is diabetes monitored and managed in people with SMI, compared with
people without SMI?
l What health-care interventions (e.g. medication, referrals and care pathways) are associated with
better diabetes outcomes for people with SMI and diabetes?
These questions are addressed in two studies, with seven objectives (see Study objectives). The
quantitative study (see Chapter 5) addresses objectives 1–4, 6 and 7; the qualitative study addresses
objective 5 and also contributes to objectives 2 and 7 (see Chapter 6).
Study objectives
1. In people with SMI: to identify which sociodemographic, illness, family history and lifestyle factors
are associated with the development of diabetes (see Chapter 5, Objective 1: factors associated with
the development of diabetes in people with severe mental illness).
2. In people with SMI and diabetes: to identify which sociodemographic, illness, family history and
lifestyle factors are associated with variations in diabetes and mental health outcomes (see Chapter 5,
Objective 2: factors associated with variation in diabetes and mental health outcomes in people with severe
mental illness and diabetes).
3. In people with SMI: to compare the health-care interventions and physical and mental health
outcomes of people with diabetes with those of people without diabetes (see Chapter 5, Objective 3:
comparing health-care interventions and health outcomes in people with severe mental illness with
diabetes with those in people with severe mental illness without diabetes).
4. In people with diabetes: to compare the health-care interventions and physical and mental health
outcomes of people with SMI with those of people without SMI (see Chapter 5, Objective 4:
comparing the health outcomes of people with diabetes and severe mental illness with the health outcomes
of people with diabetes without severe mental illness).
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5. To understand the factors that are associated with access to, and receipt of, diabetes care for
people with SMI, and to explore the experience of diabetes health care by people with SMI
(see Chapter 6).
6. To compare diabetes care provision for people with and people without SMI, and to estimate costs
for these (see Chapter 5, Objective 6: comparing diabetes care provision and estimating health-care costs
for people with and people without severe mental illness).
7. To identify which health-care interventions (e.g. medication, referrals and care pathways) may be
associated with better diabetes outcomes for people with SMI and diabetes (see Chapter 5, Objective 7:
identifying health-care interventions associated with better outcomes for people with diabetes and severe
mental illness).
Deviations from the study protocol
The protocols for the overall study and for the quantitative study (study reference: 17_161R) have
been published and are publicly available.103,104
There were some changes to the study protocol for the quantitative analyses.
First, we planned to stratify all analyses by ethnicity. However, the small numbers in minority ethnic
categories precluded doing this for some analyses.
Second, for objective 2 (see Chapter 5, Objective 2: factors associated with variation in diabetes and mental
health outcomes in people with severe mental illness and diabetes), the methods were changed from
repeated measures to patient-level analysis, as the former did not add value.
Third, for objective 7 (see Chapter 5, Objective 7: identifying health-care interventions associated with
better outcomes for people with diabetes and severe mental illness), following discussions with clinical
experts at a research team workshop, we had planned to look at several physical health checks
including blood pressure, cholesterol, HbA1c, body mass index (BMI), retinopathy screening, diabetes
education and influenza vaccination. However, we were unable to explore in detail all health-care
interventions that we originally planned as a result of inconsistencies in the recording of relevant
activities in patient records. We therefore prioritised investigating the most common physical health
checks, including blood pressure, cholesterol, HbA1c level and BMI, for which recording was more complete.
Fourth, we identified that a significant proportion of the study population had diabetes diagnosed
before the onset of SMI. Therefore, we needed to explore any potential order of diagnosis effects;
these investigations were added to the planned analyses.
Fifth, for the final integration of study findings, we did not develop a logic model as proposed in the
protocol, because of the tentative findings about how diabetes care provision may be associated with
outcomes in people with SMI and diabetes.
There were no deviations from the study protocol for the scoping of the literature or the qualitative study.
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Chapter 3 Study framework
Theoretical framework
This study sought to address important gaps in evidence about which people with SMI experience poor
diabetes outcomes and why, and how health-care services could be changed to improve physical and
mental health outcomes.
For our theoretical framework, we conceptualised socioeconomic conditions as a fundamental contributor
to health outcomes.66 As described in Chapter 1, Social inequalities, people with SMI are more likely to be
socially disadvantaged,68,69,74,79 leading to a reduced ability to take advantage of resources that improve
health, or prevent or treat illness, which ultimately contributes to the significant inequalities in health
outcomes seen in this population.We acknowledge that, as a ‘downstream’ determinant of health,67 the
health-care system cannot completely remediate the social causes of poor health. However, using a social
inequalities lens, we aimed to understand how health-care delivery could better respond to the physical
health needs of people with SMI and diabetes, and identify areas for action in which health care and its
organisation appear to generate further inequalities in this vulnerable population.
Study design
We used a concurrent triangulation mixed-methods design,105 comprising:
l A quantitative longitudinal observational study.
The quantitative study interrogated CPRD-linked primary care and hospital records, along with
linked HES, ONS and IMD data of a large sample of adults with SMI, adults with SMI and diabetes
and a sample of matched controls with diabetes but no SMI.
l A qualitative interview study.
The qualitative study sought to identify the health-care needs and health-care delivery concerns of
this population through thematic analysis of semistructured interviews exploring how diabetes is
managed alongside SMI, and how diabetes care is experienced by people with diabetes and SMI,
their family members and informal supporters, and health-care professionals. The study drew on
critical realism as a guiding methodological framework,106,107 which acknowledges that there is an
external reality to be observed (e.g. through interrogation of data such as CPRD), but that there is
also a lived reality that can be accessed only through the perspectives of individual actors who
make sense of, and interact with, the world in which they live.
The mixed-methods design was underpinned by a pragmatic paradigm, which acknowledges that each
data type provides a different, but equally important, worldview, and that, merged together, they will
enable us to develop a more complete understanding of health inequalities in this population than
would be possible from using either method alone.105 In particular, this approach allowed for an
exploration of how people with SMI and diabetes navigate the health-care system and the range of
factors that might influence their health and access to health care.
The definitive design for the study was informed by the results of an initial expert consultation and
scoping of the literature, which aimed to develop a better understanding of the potential factors that
could influence diabetes outcomes for people with SMI (see Chapter 4). This was used to determine
which variables were important to explore in both the quantitative and qualitative studies and consider
how to include them.
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In line with the concurrent triangulation model, the quantitative and qualitative studies were
conducted in parallel, and findings were merged at the interpretation stages to develop a fuller
understanding of the factors contributing to poor outcomes and the drivers of improved health
outcomes in SMI and diabetes. As part of the integration process, we conducted two co-design
workshops involving members of the patient and public involvement (PPI) panel and participants from
the qualitative interview study, and a final research team workshop, to iteratively make sense of and
interpret the study findings and translate findings into key messages and implications for research
and practice (see Chapter 7). Following Medical Research Council guidance for the development of
complex interventions,108 we also used the co-design workshops to assess the potential acceptability
and feasibility of potential interventions and service improvements into routine health care.
Figure 1 illustrates the four distinct components of the study and how they inter-relate. Each
component will be discussed in detail in the upcoming chapters of this report:
l scoping of the literature and expert consultation (see Chapter 4)
l CPRD patient record analysis (quantitative longitudinal observational study) (see Chapter 5)
l qualitative interview study with people with diabetes and SMI, their family members and
health-care staff (see Chapter 6)
l study integration, including co-design workshops (see Chapter 7).
Study organisation and governance
The study research team, comprising all co-applicants, was responsible for day-to-day management of
the project, and held bimonthly project management meetings. A Study Steering Committee (SSC) with
an independent chairperson and service user, and clinical, academic and commissioning representation
was established, meeting every 6 months. The study was sponsored by Bradford District Care NHS
Foundation Trust, which was also represented on the SSC.
Patient and public involvement
Overview of patient and public involvement
This study has been supported by DIAbetes and Mental illness: improving Outcomes aND Services
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FIGURE 1 The four components of this study and the relationships between them.
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aim of ensuring that the research remains relevant to people with SMI and that the outcomes of the
research have the potential to have a meaningful impact on care and services.
Established in 2015, DIAMONDS VOICE comprises service users living with SMI and diabetes, and
family members who provide support. The group is facilitated by a PPI co-ordinator and has 12 members
who have been involved throughout the study, and a further two who have joined more recently. Three
of these are family members or carers of people with diabetes and SMI. The group has met quarterly
to discuss study progress, to offer advice on challenges faced by the research team and to undertake
activities to support and inform the study. In addition, individual members of the group have contributed
beyond the regular meetings, attending the co-design workshops and helping to raise the profile of the
study through their networks and at local and regional dissemination events.
John Radford is a member of DIAMONDS VOICE and also a co-investigator on this study. He has
participated in study research team meetings and SSC meetings, as well as co-design workshops
(see Chapter 7, Co-design workshops).
Patient and public involvement activities
DIAMONDS VOICE has been engaged in project-related activities, starting from the grant application
stages and continuing throughout the study duration (described below). The group has led the write-up
of this section of the report.
Pre project
During the planning stages, the group assisted with the prioritisation of research questions, expressing
a need for a better understanding of how diabetes is prevented and managed in people with SMI.
The group suggested that it was important to understand the lived experience of comorbid SMI
and diabetes, which influenced the research team to integrate qualitative inquiry into the study.
DIAMONDS VOICE representatives were invited to join the study research team and the SSC
(see Study organisation and governance for study governance details) to ensure that the service user
perspective was incorporated into the management and governance of the study.
Year 1
Activities included reviewing patient- and public-facing documentation, providing advice on interview
topic guides and publicity materials, and suggesting ways to ask sensitive questions relating to finances
and health. One member acted as a practice interviewee, which enabled researchers to refine the
topic guide and to assess participant burden. In addition, members publicised the project across their
own networks and at NHS events, for example running a stall at the sponsoring trust’s research and
development conference in May 2018. Membership of DIAMONDS VOICE also expanded as a result of
these engagement activities.
Year 2
DIAMONDS VOICE was involved in advising on participant recruitment, interpreting findings and in
engagement activities. The research team had experienced difficulties engaging family members in the
study, and advice was sought from the group on how to overcome this challenge. Members increased
promotion of the study and expanded the stakeholder network, using their personal networks to
engage family members supporting people with SMI and diabetes. This resulted in the creation of an
ongoing connection with organisations such as Roshni Ghar, a local charity group that was able to
provide input into the research and raise the study’s profile in the Asian community.
DIAMONDS VOICE also participated in the study co-design workshops, which took place in May and
July 2019 (see Chapter 7, Co-design workshops). In advance of the workshops, members were asked to
review invitation documents sent to potential service user and family member participants to ensure
that they were clear and engaging. Group members also offered to support service user attendees with
DOI: 10.3310/hsdr09100 Health Services and Delivery Research 2021 Vol. 9 No. 10
Copyright © 2021 Lister et al. This work was produced by Lister et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
13
no previous experience of contributing to research workshops. During the sessions, members offered
valuable insights into the authenticity of the interpretation of the study findings.
Group members played an important role in dissemination and engagement activities. For example,
John Radford was a co-author on the protocol paper published in the Journal of Medical Internet
Research.103 In addition, members continued to play an active role in engaging varied audiences, for
example at a regional National Institute for Health Research (NIHR) event on multimorbidity research.
Ongoing patient and public involvement
DIAMONDS VOICE will continue to be involved after this study ends, for example through advising
on key events for dissemination, giving feedback on materials used in dissemination of research to the
public to ensure that they are effective and appropriate, and advising about future research priorities.
Impact of patient and public involvement on the research
Patient and public involvement has had a clear impact on the design, management and dissemination of
this study. Importantly, the DIAMONDS VOICE group influenced the choice of mixed methods through
their recommendation to explore the lived experience of SMI and diabetes in addition to conducting
analyses of longitudinal patient records.
The study has benefited from PPI representation at study research team and SSC levels of governance,
which has ensured that the research has continued to address questions that are meaningful to people
living with SMI and diabetes. For example, although sleep difficulties were not identified as an important
variable in the scoping of the literature, DIAMONDS VOICE representatives highlighted the significance
of the relationship between sleep and the day-to-day management of SMI and diabetes. As a result, and
in recognition that CPRD recording of sleep difficulties would be incomplete, a decision was taken to
explore this issue through the qualitative interviews.
Input from DIAMONDS VOICE has also had an impact at the operational level of the study. Group
members reviewed all patient- and public-facing project documentation, indicating ways to improve
clarity and readability. They also advised on ways to make promotional materials engaging and appealing
and have been instrumental in promoting the study across their mental health networks and expanding
the stakeholder network. Topic guides and recruitment strategies were refined in accordance with
advice from the group.
Reflections on the experience of participating in patient and public involvement
Researcher and member feedback on PPI involvement in this and other studies is collected annually
by the PPI co-ordinator (see Appendix 1, Reflections on the experience of participating in patient and
public involvement).
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Chapter 4 Identifying potential variables:
determinants, outcomes and health-care
interventions for diabetes in severe
mental illness
Introduction
In preparation for the quantitative and qualitative studies, we undertook an iterative expert
consultation and rapid scoping of the literature to identify the following: factors that might be
associated with the development of diabetes, diabetes outcomes and diabetes health-care
interventions for people with SMI.
The aim was to create a ‘longlist’ of the range of factors potentially relevant to our study and map
which explanatory factors had been theorised or empirically demonstrated to have a relationship with
the outcomes. From this longlist, we considered which factors were feasible to explore, for example
which variables were available in the CPRD or could be explored in an interview. We planned that this
approach would assist in the construction of key explanatory, outcome and health-care intervention
variables for the quantitative study, and shape the topic guides for qualitative interviews.
Methods
We iteratively searched and aggregated evidence from a range of sources between January and March
2018 using an inclusive approach to capture a broad range of potential factors. Systematic reviews
and meta-analyses known to the research team provided a starting point. We also drew on primary
quantitative studies, literature reviews, expert consultation and clinical guidelines, as well as results
from a pilot interrogation of CPRD data of around 1000 people with SMI and diabetes. The list of
sources was reviewed and added to by the study research team and the SSC. Additional sources were
identified through iterative targeted searches of specific variables in key databases [e.g. MEDLINE,
EMBASE™ (Elsevier, Amsterdam, the Netherlands), Cochrane Database of Systematic Reviews] for
systematic reviews in the first instance, and, when these were not available, other study types. Only
publications in the English language were considered.
Details of determinants (including social determinants), outcomes and interventions were extracted
from each source to generate a longlist of potential variables. This was reviewed by the research
team to ensure that relevant variables were included and appropriately labelled, and that duplicates
removed or merged. Quality appraisal of sources was not undertaken. All evidence sources were
imported into NVivo 12 (QSR International, Warrington, UK).
Tables containing each variable, type, titles and number of sources cited, and summary of justification
(theory, research findings) were produced to inform plans for the quantitative and qualitative studies
(see Appendix 2, Tables 28–31).
Under objective 7, we planned to explore which health-care interventions were associated with better
diabetes outcomes for people with SMI and diabetes, subject to data availability in the CPRD and
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completeness of recording by practices. As these interventions needed to be from the UK, we
identified candidate interventions from the following sources:
l Diabetes and SMI QOF indicators that could be identified in CPRD data. The QOF is a national
programme that offers financial incentives to general practices for meeting quality-of-care targets across
a range of conditions, including SMI and diabetes.109,110 These indicators include, for example, annual
monitoring for key biological measurements such as blood glucose and blood pressure, dietary review,
foot examination, retinal screening, and structured education and comprehensive care planning.111
l Diabetes interventions recommended by NICE.32
l Interventions identified from the systematic review and service user engagement completed in
NIHR study 13/54/40,112,113 which identified a number of diabetes-related indicators of primary care
quality (e.g. diabetes screening, monitoring concomitant antipsychotic medications, BMI and weight
loss, retinal and foot examination, and education about nutrition and physical activity).
l Interventions identified from the DIAMONDS systematic review114 and PPI consultation, and through
ongoing consultation with the study research team, collaborators and steering committee, and the
wider DIAMONDS research group, DIAMONDS VOICE panel, and virtual stakeholder network.
l Results of our pilot interrogation of CPRD data carried out by the DIAMONDS research group to
characterise the population and to develop and test clinical (Read code) lists in preparation for
the study.115
l Interventions identified from systematic reviews as being potentially effective in the UK for
reducing inequalities in diabetes or SMI care and outcomes.116–121
Results
Fifty-six sources were used to identify variables, as shown in Table 1. The full list can be found in
Appendix 2, Tables 28–31.
The list of variables (Table 2) was reviewed by the study research team to check for clinical significance,
duplication or missing variables, and to determine which variables could be investigated in CPRD data.
Any that could not be identified or that would potentially be biased were considered for inclusion in the
qualitative interview topic guides.
We used the variables list to construct explanatory (e.g. age, obesity, type and severity of SMI) and
outcome variables (e.g. complications, cardiovascular control, mental illness relapses) and to shape the
topic guides for qualitative interviews (see Report Supplementary Material 1). Although it was important
not to be constrained by preconceived notions about participants’ experiences, being aware of the
potential influence of, for example, social determinants of diabetes in people with SMI steered
researchers towards initiating discussion around topics such as financial constraints and barriers to
service access.
TABLE 1 Type of studies and number of related sources providing variables
Study type Number
Systematic review and meta-analysis 12
Meta-analysis 1
Systematic review 11
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sources Explored in quantitative study?
Factors associated with the development of diabetes in people with SMI
Sociodemographic variables
Age ≥ 20 Objectives 1–4, 6 and 7
Ethnicity 10–19 Objectives 1–4, 6 and 7
Sex ≥ 20 Objectives 1–3
Poverty and disadvantage 10–19 Objectives 1–4, 6 and 7
Regional variation/rurality and urbanicity < 10 Not explored (no linkage to
these data)
Medication use
Antidepressant use < 10 Objectives 1–4, 6 and 7
Antihypertensive use < 10 Objectives 1–4, 6 and 7
Antipsychotic use ≥ 20 Objectives 1–4, 6 and 7
Lipid-lowering medication < 10 Objectives 1–4, 6 and 7
Illness features/physiological characteristics
Comorbidity or multimorbidity (e.g. comorbid depression,
hypertension)
< 10 Objectives 1–4, 6 and 7
Cognitive functioning < 10 Objectives 1–4, 6 and 7
First-episode vs. multi-episode psychosis < 10 Not explored
Genetic link/family history 10–19 Objectives 1–4, 6 and 7
Gene–environment interaction < 10 Not explored
Hormonal imbalance, including HPA axis dysfunction and stress 10–19 Not explored
Immune dysfunction and chronic inflammatory state < 10 Not explored
Lipid dysregulation < 10 Objectives 1–4, 6 and 7
Obesity 10–19 As above
Sleep 10–19 Not explored
Lifestyle factors
Lifestyle factors (general) < 10 Not explored
Alcohol use < 10 Objectives 1–4, 6 and 7
Poor diet < 10 Not explored
Relational context < 10 Not explored
Sedentary lifestyle < 10 Not explored
Smoking < 10 Objectives 1–4, 6 and 7
Substance use < 10 As above
Additional factors that may influence diabetes outcomes in people with SMI
Service providers’ adherence to care guidelines and quality of care < 10 Not explored
Care ambiguity < 10 Not explored
Non-adherence to diabetes medication < 10 Not explored
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DOI: 10.3310/hsdr09100 Health Services and Delivery Research 2021 Vol. 9 No. 10
Copyright © 2021 Lister et al. This work was produced by Lister et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
17




sources Explored in quantitative study?
Non-treatment < 10 Not explored
Polypharmacy (antipsychotic or antidiabetes) < 10 Not explored
Underdiagnosis of metabolic dysfunction < 10 Not explored
Stigmatisation < 10 Not explored
Interventions that may influence diabetes outcomes in people with SMI
Medication
Antihypertensive medication < 10 Objectives 1–4, 6 and 7
Antipsychotic switching < 10 Not explored
Antidiabetes medication 10–19 Objectives 1–4, 6 and 7
Lipid-lowering treatment < 10 Objectives 1–4, 6 and 7
Mood stabilisers < 10 Not explored
Monitoring and examinations
Monitoring: blood pressure, HbA1c, lipid profile, BMI 10–19 Objectives 1–4, 6 and 7




Self-management and education (general) 10–19 Not explored
Outcome measures < 10 Not explored
Predictors of self-care behaviours < 10 Not explored
Social or family support < 10 Not explored
Theoretical frameworks of interventions < 10 Not explored
HPA, hypothalamic–pituitary–adrenal.
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Chapter 5 Interrogation of patient
health records
Introduction
The interrogation of patient health records study addressed the following research questions:
l What are the sociodemographic and illness-related risk factors associated with –
¢ diabetes developing in people with SMI?
¢ variation in diabetes and mental health outcomes in people with SMI and diabetes?
l How do physical and mental health outcomes differ between people with SMI and diabetes and
people with –
¢ SMI without diabetes?
¢ diabetes but no SMI?
l What factors are associated with access to, and receipt of, diabetes care for people with SMI?
l How and at what cost is diabetes monitored and managed in people with SMI, compared with those
without SMI?
l What health-care interventions (e.g. medication, referrals and care pathways) are associated with
better diabetes outcomes for people with SMI and diabetes?
These correspond to study objectives 1–4, 6 and 7 (see Chapter 2, and the objective sections later
in this chapter). For all objectives, we conducted analyses in line with the inequalities framework to
quantify the relative effect of social inequalities on quality of care and outcomes. Specifically, we used
deprivation and disadvantage markers, such as the IMD, as independent variables to estimate gap or
gradient effects. We planned to stratify analyses by ethnicity, but were limited by the small numbers of
people in minority ethnic categories for most analyses.
Data and methods
Ethics approval
A data-use agreement for CPRD records and linked HES and ONS mortality data was granted by the
International Scientific Advisory Committee (reference: 17_161R).
Data sets
Three data sets were extracted from the CPRD for the quantitative analyses; the relationships
between these data sets are shown in Figure 2. Data set A contains anonymised longitudinal health
records of a cohort of 32,759 people with SMI. Records were extracted from the CPRD GOLD
population cohort if they:
l had at least one clinical or referral event with a SMI diagnostic code in their medical history
(see Report Supplementary Material 2, Table S1, for the code list)
l were actively registered with one of the contributing general practices in England in the study
period from 1 April 2000 to 31 March 2016
l were eligible for the linkages required (HES, IMD and ONS death)
l were aged ≥ 18 years when SMI was diagnosed
l had continuous health data up to research standard [up to standard (UTS)] in the study period.98
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Data set B is a subset of data set A and contains records of 2761 people with SMI who also had
T2DM. T2DM was defined as the presence of at least one clinical diagnostic code in a patient’s clinical
or referral records (see Report Supplementary Material 2, Tables S2 and S3). We excluded people who
had a record of type 1 diabetes mellitus after their diagnosis of T2DM.
Data set C comprises a cohort of 9573 control patients with a diagnosis of T2DM and no record of
SMI who were matched to people in data set B (cases). These controls, with a diagnosis of T2DM and
no record of SMI, were matched to cases based on age, sex and practice in a ratio of 4 : 1.
Variables
Using the longlist identified, as described in Chapter 4, Results, we constructed a range of candidate variables
associated with the development of T2DM and with physical and mental health outcomes based on whether
or not (1) the risk factor could be measured using the information in the CPRD and its linked data sets,
(2) the data had been collected in the CPRD and its linked data sets and the quality of data recording
was systematic enough for analysis and (3) it was likely to have an impact on the outcomes of interest.
Table 3 summarises the data sources and construction methods for the candidate risk factors that were







A = all patients with SMI
B = all patients with SMI and diabetes
C = patients with diabetes and no history
         of SMI (controls matched to group B)
FIGURE 2 Venn diagram illustrating the relationship between CPRD data sets.
TABLE 3 Data sources and construction methods for the candidate risk factors used to measure patient baseline
characteristics
Candidate explanatory variable Type Data sources and description
Demographic
Age Continuous l CPRD year of birth






l White, Asian, black, mixed,
other, unknown
CPRD and HES ethnicity
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TABLE 3 Data sources and construction methods for the candidate risk factors used to measure patient baseline
characteristics (continued )
Candidate explanatory variable Type Data sources and description
Socioeconomic status
Deprivation (patient level) Categorical (by quintiles) 2010 English IMDs102 at LSOA level,
matched using patients’ residential
postcodes
Status of SMI
Type of SMI l Categorical
l Schizophrenia, schizoaffective
disorder, bipolar disorder, depression
and psychosis, other affective
disorder, mixed, missing
l CPRD and HES data
l The last diagnosis was used when
multiple diagnoses were recorded in
medical history
Duration of SMI Continuous (years) l CPRD data
l Number of years from first recorded
diagnosis of SMI to the start of
follow-up in each objective
Status of diabetes
Duration of T2DM Continuous (years) l CPRD data
l Number of years from first recorded
diagnosis of T2DM to the start of
follow-up in each objective
Family history of diabetes Binary l CPRD data
l To indicate, at least one relevant
Read code was recorded in clinical
events in patients’ medical history
Comorbidities
Cardiovascular disease Binary l CPRD data
l To indicate, at least one relevant
diagnostic Read code was recorded
in clinical events prior to the start of
follow-up in each objective
Hypertension Binary As above
Dementia Binary As above
Learning disability Binary As above
Number of Charlson Index
comorbidities
Count l CPRD data
l Number of Charlson Index
comorbidities diagnosed prior to the
start of follow-up in each objective
l ‘Diabetes’ and ‘diabetes with
complications’ were removed from
the total to enable comparisons
across objectives
Medication
Antidepressants Binary l CPRD data
l To indicate, at least one prescription
record was identified in the
15-month window prior to the
start of follow-up in each objective
Antipsychotics Binary (by typical and atypical) As above
Antidiabetes Binary As above
Antihypertensive Binary As above
Lipid-lowering drugs Binary As above
continued
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It should be noted that patients’ follow-up periods varied for each objective, depending on the patient
samples and research questions. We provide a detailed definition of follow-up period for each objective
in the sections that follow.
Table 4 summarises the outcome variables under examination, along with their associated data sources,
analysis methods and related objective(s).
Methods
To improve data quality, we developed and applied four common inclusion criteria to the extracted
data set before carrying out analyses. These criteria were designed to account for the nature of SMI
and diabetes, as well as for the features and limitations of this longitudinal data set:
l First, we identified the diagnosis dates of SMI and diabetes. Diagnosis date is commonly identified
as the date when the earliest diagnostic code was recorded in primary care. Because the first
contact for (and diagnosis of) SMI can be in secondary care, we identified the diagnosis date for
SMI as the earliest of the date of first GP diagnosis or the date of the first hospital admission for
the condition. We also applied this method to the identification of diabetes diagnosis, although
this condition is more commonly diagnosed in a primary care setting. This increased the number of
people with SMI (data set A) to 32,781 and people with both SMI and T2DM (data set B) to 3448.
Our matched controls (data set C), therefore, decreased in number to 9551 people.
TABLE 3 Data sources and construction methods for the candidate risk factors used to measure patient baseline
characteristics (continued )
Candidate explanatory variable Type Data sources and description
Lifestyle factor
Smoking status l Categorical
l Non-smoker, ex-smoker, current
smoker, missing
l CPRD data
l Categorised using the most recent
record in the 15-month window
prior to the start of follow-up in
each objective
Alcohol intake status l Categorical
l Non-drinker, ex-drinker, current
drinker, missing
As above
Substance use Binary l CPRD data
l Categorised using the most recent
record in the 15-month window
prior to the start of follow-up in
each objective
Biometric measure
BMI (kg/m2) l Categorical
l < 20, 20–24, 25–29, 30–40,
> 40, missing
l CPRD data
l Categorised using the most recent
record in the 15-month window
prior to the start of follow-up in
each objective
HbA1c (%) l Categorical
l ≤ 7.5, > 7.5, missing
l CPRD data
l Categorised using the most recent
test result in the 15-month window
prior to the start of follow-up in
each objective
Serum cholesterol (mmol/l) l Categorical
l ≤ 5, > 5, missing
As above
Blood pressure (mmHg) l Categorical
l Diastolic: ≤ 80, > 80, missing
l Systolic: ≤ 140, > 140, missing
As above
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l Second, we excluded patients whose diagnosis of SMI and diabetes was recorded in the 90 days
following registration with their current practice. As patients’ primary care records could be
transferred between practices, we used this step to exclude those patients whose earliest primary
care records of SMI and diabetes were likely to be updated from medical history because of
changes of practices, rather than a new diagnosis.
l Third, we excluded patients who were diagnosed with SMI and diabetes before the age of 18 years,
using our modified diagnosis dates.
l Fourth, we identified the patients with diagnosis codes of both type 1 diabetes and T2DM and
removed people with potential type 1. For the patients with codes of both types, we followed
an existing identification algorithm (from study NIHR 14_168R113), which categorised patients as
potentially having type 1 diabetes if (1) their first diagnostic code of diabetes was recorded before
18 years of age or (2) there was a diagnostic code of type 1 recorded before 18 years of age or
(3) they had been treated with insulin only.
TABLE 4 Description of the outcome variables used in the quantitative study, their data sources, analysis methods
and objective(s)
Outcome variables Data sources and description Type and analysis methods Objectives
Physical health outcomes
Diabetes status l CPRD and HES data
l Binary outcome to indicate






Time to onset of diabetes l CPRD and HES data
l Time to event outcome to
measure the time period between










l All test results of glycaemic and
cardiovascular control were
extracted in the follow-up of each
objective. Data cleaning was
applied in terms of duplicates,
impossible results and results
in different units. We then
calculated average values by
financial years for each control





l Binary outcome was constructed
separately for hyperglycaemia and
hypoglycaemia using clinical data.
To indicate, at least one relevant
Read code was recorded in the









l Time to event outcome to
measure the time period between
the index date and the date when
the first complication event was
recorded. Index date was defined
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TABLE 4 Description of the outcome variables used in the quantitative study, their data sources, analysis methods
and objective(s) (continued )







l Binary outcome to indicate the
presence of at least one clinical
event associated with these




random intercepts were applied
on unmatched patient-level data
2 and 3
Conditional logistic regressions
were applied on matched control









l Count outcome to measure the
number of hospital admissions for
macrovascular complications in








with fixed effects by case–control
clusters were applied on matched
control data to generate ‘within’
estimators
4
All-cause mortality l ONS death data
l Time to event outcome to
measure the time between the
index date and death due to any
cause. Index date was defined
differently in each objective
Cox proportional hazards





case–control clusters were applied




SMI relapses l CPRD and HES
l Binary outcome to indicate the
presence of at least one of the
following events in the follow-up
of each objective: (1) referrals to
mental health secondary care,
home treatment or community






Depression and anxiety l CPRD data
l Binary outcome to indicate
markers of depression and




random intercepts were applied
on unmatched patient-level data
2
Conditional logistic regressions
were applied on matched control







l Count outcome to measure the
number of consultations with test
results recorded for each health
check in the follow-up of
each objective
l Glucose, serum cholesterol, blood
pressure and BMI were analysed
for people with SMI, as
incentivised by the QOF
l HbA1c, serum cholesterol, blood
pressure and BMI were analysed
for people with diabetes, as








with fixed effects by case–control
clusters were applied on matched
control data to generate ‘within’
estimators
4 and 7
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Most analyses were conducted on patient-level data sets that typically had two levels of hierarchy:
(1) patient-level observations nested within (2) practices. We accounted for the data structure by
applying multilevel mixed-effects models with practice-level random intercepts.
Although a rich medical information source, these routine primary care data have been collected for
administrative purposes, and the data quality depends on various factors such as the accurate and
complete utilisation of the computerised recording system, standardised coding and the introduction
of financial incentive schemes (such as the QOF) that reward general practices for performing
incentivised Read-coded activities. We therefore identified an UTS follow-up period for each patient,
which included comprehensive medical records for research. The start of the UTS period was defined
as the later date between patient current registration and practice UTS dates; the end of this period
was identified as the earliest among patient death, transfer-out and practice last collection dates.
We took a step-by-step forward approach to build the models from the most basic form (including only
exposure variables) to expanded models with a wide range of adjustments. This approach was adopted
to detect the potential confounding effect one variable might have on another, such as the association
between SMI status and health outcomes attributed to older age. We adjusted for patient characteristics
and time in all the final models as reported in this report (see Variables and statistical methods and Report
Supplementary Material 3). Other candidate explanatory variables were included in the final models if
they had significant association (p < 0.1) with the outcome of interest or their inclusion had improved the
goodness of fit of models. We used c-statistics to compare logistic models and the Akaike information
criterion and Bayesian information criterion (BIC) for negative binomial and Cox proportional hazards
models. In the results tables (see Tables 6, 9, 13, 16, 22 and 23, and Report Supplementary Materials 4–12),
we report a core model including only risk factors with good data quality and an extended model that
also included covariates with less complete data, such as lifestyle and biometric measures.
Objective 1: factors associated with the development of diabetes in people
with severe mental illness
Objective
The objective was to identify which sociodemographic, illness, family history and lifestyle factors are
associated with the development of diabetes in people with SMI.
TABLE 4 Description of the outcome variables used in the quantitative study, their data sources, analysis methods
and objective(s) (continued )
Outcome variables Data sources and description Type and analysis methods Objectives




diagnostic tests in primary
care settings and inpatient
stays at general hospitals)
l CPRD and HES
l Count outcome to indicate the
numbers of consultations, drug
prescriptions and diagnostic tests
in primary care settings and
inpatient stays at general hospital
every year
Generalised linear regressions
with gamma distributions and log
link functions
6
Medical costs (costs of
consultations, drug
prescriptions and
diagnostic tests in primary
care settings and inpatient
stays at general hospitals)
l CPRD and HES
l Continuous outcome to indicate
the costs of consultations, drug
prescriptions and diagnostic tests
in primary care settings and
inpatient stays at general hospital
in 2017/18 prices
Generalised linear regressions
with gamma distributions and log
link functions
6
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Study population
We used data set A (see Figure 2) containing records of 32,781 adults with SMI and applied the four
common inclusion criteria, as outlined in Methods. From the remaining sample, people were included in
the analysis if they (1) were diagnosed with SMI in their UTS continuous data period, (2) either had
no record of T2DM in their medical history or had T2DM diagnosed only after SMI and (3) had a
follow-up period of at least 1 day.
The follow-up period of eligible patients started from the later date between SMI diagnosis and UTS
period start plus 15 months, to ensure that at least 15 months’ UTS continuous data were available for
extracting baseline patient characteristics. The end of the follow-up period was identified as the end of
the UTS continuous data period or the end of the study period, whichever was earlier. The final sample
eligible for analysis included 14,838 people with SMI and without T2DM at baseline.
Variables and statistical methods
Descriptions of the outcome and candidate explanatory variables used in analyses for this objective,
and their associated data sources and analysis methods, can be found in Tables 3 and 4. Further details
on the statistical model specification have been provided in Report Supplementary Material 3.
For the status of diabetes, we adjusted for the length of follow-up (in years) and financial years to
account for the effect of time in the multilevel logistic regressions. Robust standard errors for
correlations by practices were specified in these regressions.
Results
Descriptive statistics
The distribution of patient characteristics at baseline was summarised according to diabetes
diagnosis (Table 5).
Of the 14,838 people with SMI at baseline, 707 (4.8%) were diagnosed with T2DM in the follow-up
period. This rate is lower than estimates from previous studies,44,122 and led us to further explore the
sample characteristics.
The estimate above excludes those who developed diabetes before the onset of SMI. We found that,
if we removed the criterion to have the recorded T2DM diagnosis after the diagnosis of SMI, in the
15,984 eligible patients whose SMI diagnosis was within the UTS data period, 1452 (9.1%) had a
diagnosis of T2DM; of these, 782 (53.9%) had SMI diagnosed before T2DM and 670 (46.1%) had
SMI diagnosed after or on the same day as T2DM. These figures are comparable to findings from the
2016–17 National Diabetes Audit (NDA),123 which reported that 34.9% of people with SMI and T2DM
were diagnosed with SMI first, but are unexpected, as it is generally thought, from clinical experience,
that most people with comorbid SMI and diabetes develop SMI first.
In the total sample of 29,281 people with SMI (not restricted to the UTS period), we found that
2984 (10.2%) patients had T2DM, and that 2209 (74.0%) of these had SMI before T2DM, which is
more consistent with reported prevalence in the literature and with experience of diagnosis order
from clinical practice. This demonstrated that, by restricting SMI diagnosis within the UTS data period
in our initial analysis, we selectively excluded patients diagnosed with SMI at an earlier age; therefore,
the patients remaining in the sample were more likely to have late-onset SMI.
Using the restricted UTS sample of 14,838, people who developed T2DM were diagnosed with SMI
at an older age were more likely to be of Asian or black ethnicity and were more likely to live in the
most deprived neighbourhoods than patients with no record of T2DM. Furthermore, people with
T2DM had a higher baseline prevalence of cardiovascular disease and hypertension and were more
likely to have been prescribed the medications under investigation.
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TABLE 5 Objective 1: descriptive statistics for people with SMI, with and without T2DM
Patient characteristic
People with SMI (N= 14,838)
Without T2DM With T2DM
Patients, n (%) 14,131 (95.2) 707 (4.8)
Diagnosis age (years), mean (SD)
SMI 45.29 (19.38) 50.70 (15.06)
T2DM 55.56 (14.46)
SMI type, n (%)
Schizophrenia 7001 (49.5) 340 (48.1)
Schizoaffective disorder 429 (3.0) 34 (4.8)
Bipolar disorder 4893 (34.6) 233 (33.0)
Depression and psychosis 1433 (10.1) 89 (12.6)
Other affective disorder 337 (2.4) 9 (1.3)
Mixed 38 (0.3) 2 (0.3)
Missing 0 (0) 0 (0)
Age at follow-up start (years), mean (SD) 45.39 (19.36) 50.82 (15.04)
Sex, n (%)
Male 6794 (48.1) 342 (48.4)
Female 7337 (51.9) 365 (51.6)
Ethnicity, n (%)
White 11,907 (84.3) 596 (84.3)
Asian 469 (3.3) 44 (6.2)
Black 442 (3.1) 30 (4.2)
Mixed 168 (1.2) 5 (0.7)
Other 203 (1.4) 11 (1.6)
Unknown 942 (6.7) 21 (3.0)
Deprivation (IMD), n (%)
1st quintile (least deprived) 2253 (15.9) 79 (11.2)
2nd quintile 2595 (18.4) 122 (17.3)
3rd quintile 2745 (19.4) 124 (17.5)
4th quintile 3194 (22.6) 176 (24.5)
5th quintile (most deprived) 3319 (23.5) 206 (29.1)
Missing 25 (0.2) 0 (0)
Follow-up length (years)
Mean (SD) 5.03 (4.57) 9.17 (4.87)
Median (minimum–maximum) 3.63 (0.003–25.46) 8.85 (0.16–25.66)
continued
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TABLE 5 Objective 1: descriptive statistics for people with SMI, with and without T2DM (continued )
Patient characteristic
People with SMI (N= 14,838)
Without T2DM With T2DM
Family history of diabetes, n (%) 1105 (7.8) 100 (14.1)
Comorbidities
Cardiovascular disease, n (%) 823 (5.8) 61 (8.6)
Hypertension, n (%) 1617 (11.4) 146 (20.7)
Learning disability, n (%) 141 (1.0) 3 (0.4)
Dementia, n (%) 257 (1.8) 6 (0.9)
Charlson Index score, mean (SD) 0.36 (0.66) 0.38 (0.65)
Medications, n (%)
Antidepressants 7869 (55.7) 419 (59.3)
Antipsychotics
Typical 1530 (10.4) 135 (19.1)
Atypical 3976 (28.1) 224 (31.7)
Antihypertensive 2402 (17.0) 212 (30.0)
Lipid-lowering drugs 976 (6.9) 86 (12.2)
Statins 940 (6.7) 84 (11.9)
Lifestyle factors, n (%)
Smoking
Non-smoker 2355 (16.7) 119 (16.8)
Ex-smoker 1299 (9.2) 63 (8.9)
Current smoker 3423 (24.2) 145 (20.5)
Missing 7054 (49.9) 380 (53.8)
Drinking
Non-drinker 931 (6.6) 47 (6.7)
Ex-drinker 342 (2.4) 19 (2.7)
Current drinker 2717 (19.2) 108 (15.3)
Missing 10,141 (71.8) 533 (75.4)
Substance use 424 (3.0) 13 (1.8)
Biometric measures
BMI (kg/m2), mean (SD) 26.42 (6.24) 31.57 (7.30)
< 20, n (%) 594 (4.2) 8 (1.1)
20–24, n (%) 1727 (12.2) 42 (5.9)
25–29, n (%) 1426 (10.1) 88 (12.5)
30–40, n (%) 989 (7.0) 115 (16.3)
> 40, n (%) 180 (1.3) 39 (5.5)
Missing, n (%) 9215 (65.2) 415 (58.7)
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Table 5 also shows that a large proportion of the sample had no baseline records for lifestyle factors
and biometric measures. Based only on available data, the descriptive statistics showed that people
with T2DM were more likely to be overweight; to have higher baseline levels of blood pressure,
cholesterol and HbA1c; and to have a family history of diabetes.
Regression analyses results for the risk factors for development of type 2 diabetes
Regression results are summarised in Table 6, and Appendix 3, Figure 10, illustrates the non-linear
impact of age on the risk of diabetes.
The key risk factors for T2DM identified in the regression analyses were consistent across the four
models, as were their estimated associations with the risk of T2DM. In the core model, results showed
that older age appeared to be a risk factor for developing diabetes until around age 60 years [odds
ratio (OR) 1.17, 95% CI 1.14 to 1.21], after which this impact would decrease, as suggested by the
impact of quadratic age (see Appendix 3, Figure 10). For patients from an Asian minority background,
the risk of T2DM increased by 147% (OR 2.47, 95% CI 1.78 to 3.42); for those from a black minority
background, the risk of T2DM increased by 85% (OR 1.85, 95% CI 1.25 to 2.75). People who lived in
the most deprived neighbourhoods were more likely, by around 86%, to develop diabetes (OR 1.86,
95% CI 1.39 to 2.48) than people from the most affluent areas.
After adjusting for patient sociodemographic characteristics and SMI status (e.g. type and duration),
having comorbid hypertension and cardiovascular disease at baseline increased the risk of diabetes
by 80% (OR 1.80, 95% CI 1.42 to 2.28) and 41% (OR 1.41, 95% CI 1.03 to 1.93), respectively.
TABLE 5 Objective 1: descriptive statistics for people with SMI, with and without T2DM (continued )
Patient characteristic
People with SMI (N= 14,838)
Without T2DM With T2DM
HbA1c (%),
a mean (SD) 5.77 (1.19) 7.18 (1.86)
≤ 7.5, n (%) 520 (3.7) 41 (5.8)
> 7.5, n (%) 19 (0.1) 12 (1.7)
Missing 13,592 (96.2) 654 (92.5)
Cholesterol (mmol/l), mean (SD) 5.19 (1.16) 5.39 (1.36)
≤ 5, n (%) 1371 (9.7) 84 (11.9)
> 5, n (%) 1463 (10.4) 115 (16.3)
Missing 11,297 (79.9) 508 (71.9)
Diastolic blood pressure (mmHg), mean (SD) 77.39 (10.42) 81.24 (10.56)
≤ 80, n (%) 5117 (36.2) 239 (33.8)
> 80, n (%) 2394 (16.9) 188 (26.6)
Missing, n (%) 6620 (46.9) 280 (39.6)
Systolic blood pressure (mmHg), mean (SD) 128.05 (18.50) 134.59 (19.27)
≤ 140, n (%) 6054 (42.8) 298 (42.2)
> 140, n (%) 1457 (10.3) 129 (18.3)
Missing, n (%) 6620 (46.9) 280 (39.6)
SD, standard deviation.
a HbA1c of 7.5% = 58mmol/mol.
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TABLE 6 Objective 1: adjusted effects of risk factors for the diagnosis of T2DM
Adjusted risk factor
Logistic regression Cox proportional hazard regression
Core model Extended model Core model Extended model
OR 95% CI p-value OR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Age (years) (at follow-up
start)
1.171 1.135 to 1.207 < 0.001 1.150 1.114 to 1.187 < 0.001 1.159 1.125 to 1.194 < 0.001 1.141 1.107 to 1.177 < 0.001
Age squared 0.999 0.998 to 0.999 < 0.001 0.999 0.999 to 0.999 < 0.001 0.999 0.999 to 0.999 < 0.001 0.999 0.999 to 0.999 < 0.001
Sex, reference =male
Female 0.879 0.751 to 1.028 0.106 0.791 0.673 to 0.930 0.004 1.109 0.880 to 1.397 0.381 0.986 0.783 to 1.243 0.907
Ethnicity, reference =white
Asian 2.465 1.775 to 3.424 < 0.001 2.431 1.751 to 3.377 < 0.001 2.453 1.798 to 3.347 < 0.001 2.294 1.681 to 3.131 < 0.001
Black 1.853 1.247 to 2.753 0.002 1.850 1.203 to 2.844 0.005 1.828 1.282 to 2.605 0.001 1.735 1.189 to 2.531 0.004
Mix, other and unknown 0.767 0.553 to 1.065 0.113 0.781 0.563 to 1.084 0.140 0.778 0.569 to 1.063 0.115 0.770 0.565 to 1.050 0.099
Patient IMD 2010, reference = 1st quintile (least deprived)
2nd quintile 1.279 0.934 to 1.751 0.126 1.249 0.908 to 1.717 0.171 1.276 0.951 to 1.713 0.104 1.227 0.914 to 1.648 0.173
3rd quintile 1.321 0.958 to 1.821 0.090 1.262 0.910 to 1.752 0.163 1.281 0.949 to 1.729 0.106 1.199 0.885 to 1.624 0.242
4th quintile 1.602 1.182 to 2.173 0.002 1.507 1.105 to 2.054 0.010 1.550 1.167 to 2.058 0.002 1.441 1.084 to 1.915 0.012
5th quintile
(most deprived)
1.858 1.393 to 2.478 < 0.001 1.677 1.247 to 2.254 0.001 1.782 1.364 to 2.329 < 0.001 1.591 1.211 to 2.091 0.001






















































Logistic regression Cox proportional hazard regression
Core model Extended model Core model Extended model
OR 95% CI p-value OR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
SMI status
Duration (years) 1.212 0.911 to 1.612 0.187 1.126 0.828 to 1.533 0.450
Type of SMI, reference = schizophrenia
Schizoaffective disorder 1.374 0.956 to 1.975 0.086 1.364 0.951 to 1.956 0.092 1.282 0.918 to 1.791 0.144 1.316 0.946 to 1.831 0.103
Bipolar disorder 0.917 0.764 to 1.101 0.355 0.869 0.722 to 1.046 0.137 0.904 0.759 to 1.076 0.256 0.866 0.729 to 1.029 0.103
Depression and
psychosis




0.515 0.300 to 0.886 0.017 0.437 0.240 to 0.795 0.007 0.532 0.315 to 0.899 0.018 0.429 0.243 to 0.759 0.004
Comorbidities
Cardiovascular disease 1.410 1.028 to 1.934 0.033 1.360 0.985 to 1.877 0.062 1.376 1.024 to 1.848 0.034 1.250 0.927 to 1.684 0.143
Hypertension 1.800 1.422 to 2.278 < 0.001 1.394 1.086 to 1.789 0.009 1.749 1.409 to 2.170 < 0.001 1.415 1.133 to 1.767 0.002
Medications
Antipsychotics – typical 1.215 0.984 to 1.499 0.070 1.209 0.973 to 1.503 0.087 1.055 0.831 to 1.339 0.662 1.030 0.814 to 1.304 0.804
Antipsychotics – atypical 1.391 1.162 to 1.666 < 0.001 1.242 1.030 to 1.497 0.023 1.373 1.161 to 1.623 < 0.001 1.238 1.043 to 1.471 0.015
Family history of diabetes 1.728 1.362 to 2.192 < 0.001 1.708 1.378 to 2.118 < 0.001
Biometric measures
BMI (kg/m2), reference = 20–25, normal
< 20, underweight 0.704 0.324 to 1.531 0.376 0.708 0.330 to 1.516 0.374
25–29, overweight 2.268 1.526 to 3.372 < 0.001 2.248 1.540 to 3.280 < 0.001
30–40, obesity 4.215 2.864 to 6.202 < 0.001 3.781 2.628 to 5.440 < 0.001
> 40, severely obese 10.936 6.608 to 18.098 < 0.001 9.817 6.371 to 15.127 < 0.001






















































































































































































































































































TABLE 6 Objective 1: adjusted effects of risk factors for the diagnosis of T2DM (continued )
Adjusted risk factor
Logistic regression Cox proportional hazard regression
Core model Extended model Core model Extended model
OR 95% CI p-value OR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Blood pressure (diastolic) (mmHg), reference =≤ 80
> 80 1.247 0.988 to 1.573 0.063
Missing 0.988 0.804 to 1.214 0.905
HbA1c (%),
a reference =≤ 7.5
> 7.5 4.188 1.242 to 14.126 0.021 3.502 1.436 to 8.536 0.006
Missing 0.387 0.267 to 0.560 < 0.001 0.363 0.255 to 0.518 < 0.001
Length of follow-up (years) 1.221 1.190 to 1.254 < 0.001 1.230 1.198 to 1.263 < 0.001
Financial year dummies Yes Yes Yes Yes
Time-varying covariates 0.020 0.034
Sex – female 0.956 0.921 to 0.993 0.051 0.960 0.925 to 0.997 0.058
Medication –
antipsychotics (typical)
1.030 1.000 to 1.060 1.029 0.999 to 1.059




Time at risk (years) < 0.001 < 0.001 74,328.397 < 0.001 74,328.397 < 0.001
HR, hazard ratio; OR, odds ratio.
a HbA1c of 7.5%= 58 mmol/mol.
Note





















































Patients who had been prescribed antipsychotics, particularly atypical antipsychotics, were more
likely to have diabetes than people without these medications. All of these findings are consistent
with expectations.
The extended model contained variables with higher proportions of missing values. The estimated
results of this model, therefore, should be interpreted with caution. There seemed to be a strong
association between BMI above the normal range and increased diabetes risk. This risk was doubled
for patients who were overweight (OR 2.27, 95% CI 1.53 to 3.37), four times higher for those who
were obese (OR 4.22, 95% CI 2.86 to 6.20) and 10 times higher for those who were severely obese
(OR 10.94, 95% CI 6.61 to 18.10). Results from the Cox proportional hazards regressions generated a
similar set of predictors for T2DM, the estimated impact of which was also comparable to that of the
multilevel logistic regressions (see Table 6).
Summary of findings
Type 2 diabetes prevalence was 10.2% in the total sample of 29,281 people with SMI and 9.1% in
the UTS-restricted sample (n = 15,984). The key predictors for developing T2DM in people with SMI
included older age, ethnicity (Asian and black), socioeconomic deprivation, physical comorbidities
(hypertension and cardiovascular disease) and antipsychotics. Potential risk factors may also include
being overweight or obese, and glucose dysregulation.
Objective 2: factors associated with variation in diabetes and mental health
outcomes in people with severe mental illness and diabetes
Objective
The objective was to identify which sociodemographic, illness, family history and lifestyle factors
are associated with variations in diabetes and mental health outcomes among people with SMI
and diabetes.
Study population
We used data set B containing records of 3448 patients with a clinical diagnosis of both SMI and
T2DM, identified from either primary care records or hospital admissions (see Figure 2 for details of
relationships between data sets). After applying the common eligibility criteria regarding registration,
diagnosis age and diabetes type, there were 2984 patients in the sample.
The start of the follow-up period was identified as the latest date of the recorded SMI diagnosis,
T2DM diagnosis or the start of UTS data period plus 15 months, so that patients were followed up
after the second diagnosis and there was a 15-month window to obtain their baseline characteristics.
The end of follow-up was identified as the end of the UTS data period or the end of the study period
date, whichever was earlier. A total of 2754 patients with a follow-up length of at least 1 day were
included for analysis.
Variables and statistical methods
Candidate risk factors are summarised in Table 3. The physical and mental health outcomes under
examination included:
l glycaemic and cardiovascular control (HbA1c, blood pressure and cholesterol levels)
l diabetes complications (hyperglycaemia, hypoglycaemia, microvascular complications and
macrovascular complications)
l hospital admissions for macrovascular complications
l mental health outcomes (SMI relapses and depression and anxiety)
l mortality.
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Details on the construction and statistical methods of these outcome variables are provided in Table 4,
and further details on the methodology can be found in Report Supplementary Material 1.
Results
Descriptive statistics
Patient baseline characteristics are summarised in Table 7 and health outcomes are summarised in
Figures 3 and 4, and Table 8. These descriptive statistics are reported for the whole eligible sample,
as well as by diagnosis order.
Table 7 shows that 73.3% (2019/2754) of eligible patients had SMI diagnosed before T2DM, and 26.7%
had T2DM diagnosed first (including same-day diagnosis). Patient characteristics differed between the
two groups. Patients who had SMI before T2DM were diagnosed at an earlier age for both conditions:
average diagnosis age was 41.9 years for SMI and 55.0 years for T2DM. In comparison, patients who
had T2DM first were diagnosed with T2DM at around 57.1 years of age and with SMI at around
63.3 years of age. Patients who had SMI before T2DM were also more likely to be male and to live in
the most deprived neighbourhoods.
Patients who had T2DM before SMI were more likely to have depression and psychosis as the type
of SMI. The prevalence in this group was more than double the prevalence in people diagnosed with
SMI first. These patients also had a higher prevalence of comorbidities and were more likely to be
prescribed medications other than antipsychotics.
TABLE 7 Objective 2: patient baseline characteristics for people with SMI and T2DM for the total sample and stratified
by diagnosis order
Characteristic
People with SMI and T2DM
Total SMI before T2DM
SMI after T2DM
(including same day)
Patients, n (%) 2754 (100) 2019 (73.3) 735 (26.7)
Diagnosis age (years), mean (SD)
SMI 47.60 (17.76) 41.88 (15.01) 63.30 (15.05)
T2DM 55.54 (13.75) 54.98 (13.48) 57.06 (14.37)
SMI type, n (%)
Schizophrenia 1469 (53.3) 1120 (55.5) 349 (47.5)
Schizoaffective disorder 150 (5.5) 130 (6.4) 20 (2.7)
Bipolar disorder 862 (31.3) 619 (30.7) 243 (33.1)
Depression and psychosis 228 (8.3) 126 (6.2) 102 (13.9)
Other affective disorder 34 (1.2) 18 (0.9) 16 (2.2)
Mixed 10 (0.4) 5 (0.3) 5 (0.7)
Missing 1 (0.0) 1 (0.1) 0 (0)
Age at follow-up start (years), mean (SD) 58.19 (14.26) 56.08 (13.45) 63.99 (14.81)
Duration (years), mean (SD)
SMI 10.70 (12.05) 14.33 (12.08) 0.72 (2.63)
T2DM 2.70 (5.05) 1.12 (3.12) 7.02 (6.60)
Sex, n (%)
Male 1301 (47.2) 993 (49.2) 308 (41.9)
Female 1453 (52.8) 1026 (50.8) 427 (58.1)
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TABLE 7 Objective 2: patient baseline characteristics for people with SMI and T2DM for the total sample and stratified
by diagnosis order (continued )
Characteristic
People with SMI and T2DM




White 2259 (82.0) 1650 (81.7) 609 (82.9)
Asian 197 (7.2) 140 (6.9) 57 (7.8)
Black 150 (5.5) 116 (5.8) 34 (4.6)
Mixed 26 (0.9) 18 (0.9) 8 (1.1)
Other 51 (1.9) 42 (2.1) 9 (1.2)
Unknown 71 (2.6) 53 (2.6) 18 (2.5)
Deprivation (IMD 2010), n (%)
1st quintile (least deprived) 344 (12.5) 235 (11.6) 109 (14.8)
2nd quintile 438 (15.9) 317 (15.7) 121 (16.5)
3rd quintile 525 (19.1) 382 (18.9) 143 (19.5)
4th quintile 690 (25.1) 514 (25.5) 176 (24.0)
5th quintile 754 (27.4) 570 (28.2) 184 (25.0)
Missing 3 (0.1) 1 (0.1) 2 (0.3)
Follow-up length (years)
Mean (SD) 4.84 (4.09) 5.16 (4.21) 3.96 (3.62)
Median (minimum, maximum) 3.78 (0.003, 23.80) 4.14 (0.003, 23.80) 2.84 (0.005, 18.78)
Comorbidities
Cardiovascular disease, n (%) 396 (14.4) 223 (11.1) 173 (23.5)
Hypertension, n (%) 978 (35.5) 629 (31.2) 349 (47.5)
Learning disability, n (%) 33 (1.2) 22 (1.1) 11 (1.5)
Dementia, n (%) 67 (2.4) 33 (1.6) 34 (4.6)
Charlson Index score, mean (SD) 0.55 (0.80) 0.48 (0.70) 0.79 (1.00)
Medications, n (%)
Antidepressants 1455 (52.8) 992 (49.1) 463 (63.0)
Antipsychotics
Typical 553 (20.1) 455 (22.5) 98 (13.3)
Atypical 1293 (47.0) 1049 (52.0) 244 (33.2)
Antihypertensive 1347 (48.9) 877 (43.4) 470 (64.0)
Antidiabetics 1098 (39.9) 561 (27.8) 537 (73.1)
Lipid-lowering drugs 1114 (40.5) 668 (33.1) 446 (60.7)
Statins 1083 (39.3) 647 (32.1) 436 (59.3)
Lifestyle factors, n (%)
Smoking
Non-smoker 770 (28.0) 512 (25.4) 258 (35.1)
Ex-smoker 508 (18.5) 349 (17.3) 159 (21.6)
Current smoker 860 (31.2) 699 (34.6) 161 (21.9)
Missing 616 (22.4) 459 (22.7) 157 (21.4)
continued
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TABLE 7 Objective 2: patient baseline characteristics for people with SMI and T2DM for the total sample and stratified
by diagnosis order (continued )
Characteristic
People with SMI and T2DM




Non-drinker 566 (20.6) 420 (20.8) 146 (19.9)
Ex-drinker 187 (6.8) 137 (6.8) 50 (6.8)
Current drinker 847 (30.8) 648 (32.1) 199 (27.1)
Missing 1154 (41.9) 814 (40.3) 340 (46.3)
Substance use 55 (2.0) 41 (2.0) 14 (1.9)
Biometric measures
BMI (kg/m2), mean (SD) 32.40 (7.17) 33.24 (7.31) 30.41 (6.39)
< 20, n (%) 29 (1.1) 12 (0.6) 17 (2.3)
20–24, n (%) 238 (8.6) 138 (6.8) 100 (13.6)
25–29, n (%) 574 (20.8) 375 (18.6) 199 (27.1)
30–40, n (%) 946 (34.4) 707 (35.0) 239 (32.5)
> 40, n (%) 289 (10.5) 233 (11.5) 56 (7.6)
Missing, n (%) 678 (24.6) 554 (27.4) 124 (16.9)
HbA1c (%),
a mean (SD) 7.67 (1.94) 7.77 (2.00) 7.49 (1.83)
≤ 7.5, n (%) 1094 (39.7) 681 (33.7) 413 (56.2)
> 7.5, n (%) 678 (24.6) 443 (21.9) 235 (32.0)
Missing, n (%) 982 (35.7) 895 (44.3) 87 (11.8)
Cholesterol (mmol/l), mean (SD) 5.13 (1.41) 5.32 (1.44) 4.66 (1.19)
≤ 5, n (%) 1130 (41.0) 725 (35.9) 405 (55.1)
> 5, n (%) 1044 (37.9) 828 (41.0) 216 (29.4)
Missing 580 (21.1) 466 (23.1) 114 (15.5)
Diastolic blood pressure (mmHg),
mean (SD)
80.09 (10.61) 81.37 (10.74) 76.80 (9.54)
≤ 80, n (%) 1427 (51.8) 929 (46.0) 498 (67.8)
> 80, n (%) 1013 (36.8) 830 (41.1) 183 (24.9)
Missing 314 (11.4) 260 (12.9) 54 (7.4)
Systolic blood pressure (mmHg),
mean (SD)
134.44 (17.76) 134.47 (17.72) 134.36 (17.90)
≤ 140, n (%) 1748 (63.5) 1262 (62.5) 486 (66.1)
> 140, n (%) 692 (25.1) 497 (24.6) 195 (26.5)
Missing, n (%) 314 (11.4) 260 (12.9) 54 (7.4)
Family history of diabetes, n (%) 430 (15.6) 316 (15.7) 114 (15.5)
SD, standard deviation.
a HbA1c of 7.5% = 58mmol/mol.
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FIGURE 3 Average cholesterol and HbA1c, 2000/1–2015/16. (a) Average cholesterol (mmol/l) and 95% CI; and
(b) average HbA1c (%) and 95% CI.
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FIGURE 4 Average blood pressure (mmHg), 2000/1–2015/16. (a) Systolic blood pressure and 95% CIs; and (b) diastolic
blood pressure and 95% CIs.
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There were fewer missing data for baseline lifestyle factors and biometric measures in patients who had
T2DM diagnosed first than in people diagnosed with SMI first. The latter were more likely to smoke
cigarettes (although there were a large number of missing data in both groups, limiting definitive
conclusions). People diagnosed with SMI first also had higher levels of HbA1c, cholesterol and blood
pressure at baseline, and were more likely to be obese than people diagnosed with T2DM first.
TABLE 8 Objective 2: physical and mental health outcomes for people with SMI and T2DM, by diagnosis order
Health outcome
People with SMI and T2DM
Total SMI before T2DM
SMI after T2DM
(including same day)
Diabetes complications: primary care diagnosis, n (%)
Hyperglycaemia 89 (3.2) 67 (3.3) 22 (3.0)
Hypoglycaemia 115 (4.2) 75 (3.7) 40 (5.4)
Macrovascular complications (combined) 187 (6.8) 123 (6.1) 64 (8.7)
Myocardial infarction 74 (2.7) 44 (2.2) 30 (4.1)
Peripheral vascular disease 55 (2.0) 43 (2.1) 12 (1.6)
Stroke 73 (2.7) 47 (2.3) 26 (3.5)
Microvascular complications (combined)
Baseline 229 (8.3) 81 (4.0) 148 (20.1)
New complications at follow-up 461 (16.7) 365 (18.1) 96 (13.1)
Nephropathy
Baseline 28 (1.0) 12 (0.6) 16 (2.2)
New nephropathy at follow-up 62 (2.3) 45 (2.2) 17 (2.3)
Neuropathy
Baseline 72 (2.6) 26 (1.3) 46 (6.3)
New neuropathy at follow-up 82 (3.0) 62 (3.1) 20 (2.7)
Retinopathy
Baseline 156 (5.7) 48 (2.4) 108 (14.7)
New retinopathy at follow-up 385 (14.0) 303 (15.0) 82 (11.2)
Diabetes complications: admissions, mean (SD)
Macrovascular complications (combined) 0.14 (0.58) 0.13 (0.55) 0.17 (0.67)
Ischaemic heart disease 0.09 (0.50) 0.09 (0.46) 0.12 (0.58)
Peripheral vascular disease 0.01 (0.17) 0.01 (0.19) 0.01 (0.10)
Cerebrovascular disease 0.04 (0.22) 0.03 (0.21) 0.05 (0.26)
Mental health outcomes, n (%)
SMI relapses 782 (28.4) 559 (27.7) 223 (30.3)
Depression and anxiety 580 (21.1) 413 (20.5) 167 (22.7)
All-cause mortality, n (%) 458 (16.6) 296 (14.7) 162 (2.0)
SD, standard deviation.
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For physical health outcomes, we examined the variations in glycaemic and cardiovascular control
by plotting time trends against financial years (see Figures 3 and 4). There was a general trend for
improved control among patients in both groups between 2000 and 2016. On average, people who
had T2DM before SMI had better baseline control, and continued to have similar, or better, control for
cholesterol and blood pressure in their follow-up periods. However, the average levels of HbA1c in this
group were consistently above the NICE-recommended threshold of 58 mmol/mol (7.5%) in this period,
whereas the average levels of HbA1c among people diagnosed with SMI first dropped (and remained)
below this threshold from around 2004/5.
The apparent improvements in cholesterol, HbA1c and blood pressure might reflect improvements
in care and control over time, but they might also reflect changes in the composition of the study
population. Recorded prevalence of diabetes increased throughout the period and practices were
financially incentivised for case-finding from 2004 onwards. As case-finding improved, less severe
cases at earlier stages of the condition may have constituted an increasing proportion of the study
population over time.
As summarised in Table 8, people who had SMI before T2DM had, in general, better physical and
mental health outcomes. Patients in this group were less likely to develop macrovascular complications
and had fewer hospital admissions for these complications in the follow-up period. These patients also
had lower rates of SMI relapses and depression and anxiety, and had a lower mortality rate. The SMI
before T2DM group had a lower baseline prevalence of microvascular complications, but were more
likely to develop these conditions during the follow-up period than the other group. Those diagnosed
with diabetes before SMI will have had diabetes for 5 or 6 years before entering the data set for this
analysis; therefore, they would have had the ‘opportunity’ to develop complications in the pre-baseline
period. As a result, they would be expected to have a higher baseline prevalence of microvascular
complications (and fewer new microvascular complications during follow-up) than those diagnosed
with SMI first.
Regression analyses results
The adjusted risk factors for physical health outcomes are reported in Table 9. Among the patient
sociodemographic characteristics, older age was a significant predictor of macrovascular complications
and more deprived socioeconomic status was also weakly associated with a higher risk of complications.
Diabetes duration of 1 additional year increased the odds for primary care diagnosis of macrovascular
complications by around 3% (OR 1.03, 95% CI 1.00 to 1.06) and for hospital admissions by 4% [incidence
rate ratio (IRR) 1.04, 95% CI 1.01 to 1.07]. The risk of these complications in patients with cardiovascular
disease at baseline was more than double the risk in patients without this comorbidity; this increased by
198% (OR 2.98, 95% CI 1.97 to 4.49) for primary care diagnosis and by 171% (IRR 2.71, 95% CI 1.87 to
3.92) for hospital admissions. Risk predictors of macrovascular complications also include comorbid
hypertension and the baseline prescription of antihypertensives. These two predictors are correlated
because of their nature, and we included them separately in our regressions. We chose between
alternative models using the c-statistic for the logistic regressions and BIC for negative binomial
regressions. Furthermore, there was evidence suggesting that the presence of additional Charlson
Index comorbidities was associated with increased hospital admissions.
The adjusted risk of microvascular complications was predicted by older age and baseline
cardiovascular disease. There was also weak evidence that more deprived socioeconomic status, longer
duration of SMI and baseline prescription of antidiabetes medications may also be associated with
an increased risk of developing these complications. Ethnicity was not associated with risk of either
macrovascular or microvascular complications.
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TABLE 9 Objective 2: adjusted risk factors for physical health outcomes for people with SMI and T2DM (core models)
Adjusted risk factor
Macrovascular complications
Microvascular complications All-cause mortalityPrimary care diagnosis Hospital admissions
OR 95% CI p-value IRR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Age at follow-up
start (years)
1.034 1.018 to 1.050 < 0.001 1.211 1.108 to 1.324 < 0.001 1.061 1.004 to 1.121 0.035 1.074 1.064 to 1.084 < 0.001
Age squared 0.999 0.998 to 0.999 < 0.001 0.999 0.999 to 1.000 0.041
Sex, reference =male
Female 0.905 0.654 to 1.251 0.544 0.864 0.621 to 1.203 0.387 0.964 0.786 to 1.183 0.728 0.825 0.683 to 0.997 0.046
Ethnicity, reference =white
Asian 0.703 0.365 to 1.354 0.292 1.168 0.645 to 2.114 0.608 1.075 0.769 to 1.503 0.673 0.477 0.299 to 0.762 0.002
Black 1.557 0.749 to 3.237 0.235 1.452 0.814 to 2.590 0.206 1.067 0.613 to 1.858 0.818 0.887 0.527 to 1.493 0.651
Mix, other and
unknown
0.728 0.315 to 1.683 0.458 0.424 0.162 to 1.112 0.081 1.031 0.626 to 1.700 0.904 1.845 1.289 to 2.641 0.001
Patient IMD 2010, reference = 1st quintile (least deprived)
2nd quintile 1.094 0.566 to 2.116 0.790 1.122 0.624 to 2.017 0.700 1.376 0.967 to 1.959 0.076 1.184 0.827 to 1.695 0.357
3rd quintile 1.594 0.920 to 2.761 0.097 1.587 0.909 to 2.771 0.104 1.153 0.815 to 1.632 0.422 0.959 0.663 to 1.387 0.824
4th quintile 1.571 0.922 to 2.675 0.096 1.664 0.991 to 2.795 0.054 1.371 0.974 to 1.930 0.070 1.493 1.087 to 2.051 0.013
5th quintile
(most deprived)
1.346 0.761 to 2.379 0.307 1.589 0.913 to 2.764 0.101 1.154 0.787 to 1.694 0.463 1.377 0.992 to 1.911 0.056






















































































































































































































































































TABLE 9 Objective 2: adjusted risk factors for physical health outcomes for people with SMI and T2DM (core models) (continued )
Adjusted risk factor
Macrovascular complications
Microvascular complications All-cause mortalityPrimary care diagnosis Hospital admissions
OR 95% CI p-value IRR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
SMI status
Duration (years) 0.989 0.977 to 1.002 0.087 1.008 0.999 to 1.016 0.068 0.990 0.983 to 0.998 0.017
Type, reference = schizophrenia
Schizoaffective
disorder
1.501 1.021 to 2.205 0.039
Bipolar disorder 0.882 0.708 to 1.100 0.267
Depression and
psychosis




1.563 0.822 to 2.972 0.173




2.976 1.973 to 4.490 < 0.001 2.706 1.868 to 3.920 < 0.001 1.313 1.000 to 1.724 0.050






























































Microvascular complications All-cause mortalityPrimary care diagnosis Hospital admissions





1.272 1.018 to 1.590 0.034
Antipsychotics –
atypical
1.314 1.080 to 1.599 0.006
Antihypertensive 1.529 1.103 to 2.119 0.011
Antidiabetics 1.218 0.997 to 1.487 0.054 1.351 1.103 to 1.654 0.004
Length of follow-up
(years)
1.158 1.102 to 1.217 < 0.001 1.169 1.121 to 1.220 < 0.001
Constant 0.004 0.001 to 0.016 0.000 0.000 to 0.001 < 0.001
Financial year
dummies
Yes Yes Yes Yes
Patients (n) 2628 2754 2524 2754
Practices (n) 349 354
c-statistic 0.805
Failures (n) 460 458
Time at risk (years) 10,356.178 13,334.804
HR, hazard ratio; IRR, incidence rate ratio.
Note





















































































































































































































































































All-cause mortality increased with demographic characteristics, including older age, male sex, white
ethnicity and socioeconomic deprivation. Longer duration of SMI was associated with slightly reduced
risk of mortality, and certain types of SMI, such as schizoaffective disorder, were associated with an
increased risk of mortality, compared with having schizophrenia. One additional comorbidity of the
Charlson Index increased the risk by 16% [hazard ratio (HR) 1.16, 95% CI 1.04 to 1.28]. Antipsychotics
were associated with higher risk of mortality: those on typical antipsychotics had an increased risk of
mortality of 27% (HR 1.27, 95% CI 1.02 to 1.59) and those on atypical antipsychotics had an increased
risk of mortality of 31% (HR 1.31, 95% CI 1.08 to 1.60). The baseline prescription of antidiabetes
medications also increased the risk by 35% (HR 1.35, 95% CI 1.10 to 1.65). We were not able to
control for severity of mental illness or diabetes.
The regression results for mental health outcomes (SMI relapse and depression or anxiety) are
summarised in Table 10. After adjustment, older age had a small but statistically significant impact on
mental health outcomes; the risk reduced by ≈ 2% for each additional year of age [OR 0.98 (95% CI
0.98 to 0.99) for SMI relapses and OR 0.98 (95% CI 0.97 to 0.99) for depression and anxiety]. Female
patients were more likely to have depression and anxiety (OR 1.27, 95% CI 1.03 to 1.58). Both SMI
relapse and diagnosis of depression or anxiety were affected by SMI type. Patients with bipolar disorder
were more likely to have a relapse of SMI in the follow-up period than patients with schizophrenia
(OR 1.36, 95% CI 1.12 to 1.66) and had a similar increased risk for depression and anxiety (OR 1.37,
95% CI 1.07 to 1.77). Patients with a clinical diagnosis of depression and psychosis had an increased risk
of depression and anxiety (OR 2.89, 95% CI 2.03 to 4.13) during follow-up. In terms of comorbidities,
we found that the presence of dementia and learning disability was associated with reduced risk of SMI
relapses. An additional Charlson Index comorbidity was associated with a lower risk of SMI relapses
(OR 0.85, 95% CI 0.75 to 0.95) but a higher risk of clinical events of depression and anxiety (OR 1.20,
95% CI 1.05 to 1.37). Furthermore, baseline prescription of antidiabetes medications was a significant
predictor for SMI relapses (OR 1.34, 95% CI 1.08 to 1.66).
In sensitivity analyses to investigate whether or not health outcomes and their association with
risk factors differed by diagnosis order, we included diagnosis order in the regression models as an
explanatory variable and tested its impact on outcomes as well as its interacting relationship with
other risk factors. Adjusting for diagnosis order had a similar effect to adjustment for the duration of
conditions. For instance, macrovascular complications were associated with longer duration and T2DM.
When conducting regression analyses on a restricted sample that included only those patients who had
SMI diagnosed first, the results were consistent with those obtained from the unrestricted models.
Results of the extended models can be found in Report Supplementary Material 4. In these models,
we investigated the impact of potential risk factors, such as lifestyle, biometric measures and family
history, on physical and mental health outcomes. The data on these variables were less complete and the
patterns of missing data were unlikely to be random, meaning that these results should be interpreted
with caution. The results showed that current smoker status increased the risk of macrovascular
complications (primary care diagnosis), compared with non-smokers (OR 1.91, 95% CI 1.19 to 3.06);
the risk of mortality was more than three times higher for patients who used substances at baseline
(HR 3.30, 95% CI 1.58 to 6.90); and a baseline HbA1c level exceeding the recommended threshold was
associated with a higher risk of developing microvascular complications (HR 1.66, 95% CI 1.33 to 2.08).
Summary of findings
The descriptive statistics showed that people diagnosed with SMI before T2DM differed from those
diagnosed with T2DM first in characteristics including diagnosis age, types of SMI, socioeconomic
status, comorbidities, medication and lifestyle, as well as baseline diabetes and cardiovascular controls.
After adjustment using regression analyses, we found that older age, socioeconomic deprivation and
the presence of multimorbidity were the common risk predictors for physical health outcomes. The
duration of T2DM and the use of medications were also associated with poorer status of some of
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TABLE 10 Objective 2: adjusted risk factors for mental health outcomes for people with SMI and T2DM (core models)
Adjusted risk factor
SMI relapses Depression and anxiety
OR 95% CI p-value OR 95% CI p-value
Age at follow-up start (years) 0.984 0.977 to 0.992 < 0.001 0.978 0.969 to 0.987 < 0.001
Sex, reference =male
Female 1.125 0.943 to 1.343 0.192 1.272 1.025 to 1.578 0.029
Ethnicity, reference =white
Asian 1.073 0.731 to 1.575 0.718 1.421 0.960 to 2.104 0.079
Black 1.143 0.795 to 1.645 0.471 0.784 0.462 to 1.330 0.366
Mix, other and unknown 0.591 0.386 to 0.906 0.016 0.679 0.389 to 1.185 0.173
Patient IMD 2010, reference = 1st quintile (least deprived)
2nd quintile 0.727 0.517 to 1.023 0.067 0.782 0.533 to 1.147 0.209
3rd quintile 1.048 0.754 to 1.457 0.780 1.092 0.725 to 1.643 0.674
4th quintile 0.863 0.617 to 1.208 0.390 0.732 0.497 to 1.079 0.115
5th quintile (most deprived) 1.013 0.726 to 1.413 0.939 1.185 0.816 to 1.722 0.373
Missing 10.905 0.214 to 556.451 0.234
SMI status
Type, reference = schizophrenia
Schizoaffective disorder 1.017 0.681 to 1.519 0.934 1.110 0.697 to 1.767 0.660
Bipolar disorder 1.361 1.116 to 1.660 0.002 1.373 1.066 to 1.768 0.014
Depression and psychosis 1.019 0.710 to 1.461 0.920 2.893 2.029 to 4.125 < 0.001
Other affective disorder,
mixed and missing
0.502 0.201 to 1.249 0.138 2.165 1.157 to 4.051 0.016
T2DM duration 1.036 1.014 to 1.059 0.001
Comorbidities
Dementia 0.381 0.148 to 0.981 0.046
Learning disability 0.313 0.123 to 0.801 0.015
Charlson Index comorbidities
(count variable)
0.845 0.749 to 0.953 0.006 1.197 1.048 to 1.366 0.008
Medications
Antidepressants 2.453 1.919 to 3.135 < 0.001
Antidiabetics 1.336 1.076 to 1.658 0.009
Length of follow-up (years) 1.091 1.057 to 1.127 < 0.001 1.158 1.114 to 1.203 < 0.001
Constant 0.648 0.274 to 1.532 0.264 0.097 to 0.716
Financial year dummies Yes Yes
Patients (n) 2751 2754
Practices (n) 354 354
c-statistic 0.738 < 0.001 0.826 < 0.001
Note
All 95% CIs are robust.
DOI: 10.3310/hsdr09100 Health Services and Delivery Research 2021 Vol. 9 No. 10
Copyright © 2021 Lister et al. This work was produced by Lister et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
45
these physical health outcomes. All-cause mortality risk increased with older age, male sex, white
ethnicity and socioeconomic deprivation. The risk of poorer mental health outcomes, however, was
primarily predicted by younger age, type of SMI and comorbidities.
Objective 3: comparing health-care interventions and health outcomes in
people with severe mental illness and diabetes with those in people with
severe mental illness without diabetes
Objective
The objective was to compare health-care interventions and physical and mental health outcomes in
people with SMI and diabetes with those of people with SMI without diabetes.
Study population
We used data set A, containing records of 32,781 people with a clinical diagnosis of SMI (see Figure 2).
After applying the common inclusion criteria regarding diagnosis date and age, practice registration,
and type, 29,281 patients remained in the sample.
The start of follow-up was calculated as the later date of SMI diagnosis or the start of UTS data plus
15 months, so that each patient was followed up from (or after) the diagnosis of SMI, with a 15-month
window for collecting baseline characteristics. The end of follow-up was identified as either the end of
UTS data or the end of the study period, whichever occurred first. A total of 26,977 patients with a
follow-up length of at least 1 day were included in the analyses.
Variables and statistical methods
The exposure variable for this objective was the status of T2DM. The other candidate explanatory
variables are summarised in Table 3. The outcome variables under investigation were as follows
(see Table 4 for further details):
l glycaemic and cardiovascular control (HbA1c, blood pressure and cholesterol levels)
l diabetes complications (hyperglycaemia, hypoglycaemia, microvascular complications and
macrovascular complications)
l hospital admissions for macrovascular complications
l mental health outcomes (SMI relapses)
l all-cause mortality
l health checks (glucose, cholesterol, blood pressure and BMI).
For this objective, we used SMI relapse as the mental health outcome. Markers of depression and
anxiety were not examined as the clinical Read codes for these overlapped with the diagnostic codes
of depression and psychosis (a type of SMI).
Variation in receiving health-care interventions was explored using levels of health checks. The QOF61
rewards primary care providers for performing regular health checks and monitoring the physical
health status for people with a wide range of long-term conditions, including SMI. We therefore
selected four QOF-incentivised physical health checks (glucose, cholesterol, blood pressure and BMI)
to examine their provision and association with T2DM status. For further details on the methodology,
see Report Supplementary Material 3.
Results
Descriptive statistics
The baseline characteristics for eligible patients are summarised in Table 11. Of the 26,977 people with
SMI, 2755 (10.2%) also had a diagnosis of T2DM. Patients with T2DM were diagnosed with SMI at an
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TABLE 11 Objective 3: baseline characteristics for people with SMI, with and without T2DM
Characteristic
People with SMI
Total Without T2DM With T2DM
Patients, n (%) 26,977 (100) 24,222 (89.8) 2755 (10.2)
Age at diagnosis (years), mean (SD)
SMI 41.41 (18.06) 40.71 (17.97) 47.60 (17.75)
T2DM 55.55 (13.77)
SMI type, n (%)
Schizophrenia 14,166 (52.5) 12,696 (52.4) 1470 (53.4)
Schizoaffective disorder 1213 (4.5) 1063 (4.4) 150 (5.4)
Bipolar disorder 9264 (34.3) 8402 (34.7) 862 (31.3)
Depression and psychosis 1837 (6.8) 1609 (6.6) 228 (8.3)
Other affective disorder 424 (1.6) 390 (1.6) 34 (1.2)
Mixed 72 (0.3) 62 (0.3) 10 (0.4)
Missing 1 (0.0) 0 (0) 1 (0.0)
Age at follow-up start (years), mean (SD) 46.71 (17.77) 45.76 (17.79) 55.02 (15.19)
Duration of SMI (years), mean (SD) 5.38 (9.33) 5.14 (9.08) 7.54 (11.10)
Sex, n (%)
Male 13,349 (49.5) 12,048 (49.7) 1301 (47.2)
Female 13,628 (50.5) 12,174 (50.3) 1454 (52.8)
Ethnicity, n (%)
White 22,790 (84.5) 20,531 (84.8) 2259 (82.0)
Asian 982 (3.6) 785 (3.2) 197 (7.2)
Black 1094 (4.1) 943 (3.9) 151 (5.5)
Mixed 320 (1.2) 294 (1.2) 26 (0.9)
Other 386 (1.4) 335 (1.4) 51 (1.9)
Unknown 1405 (5.2) 1334 (5.5) 71 (2.6)
Deprivation (IMD 2010), n (%)
1st quintile (least deprived) 3912 (14.5) 3568 (14.7) 344 (12.5)
2nd quintile 4709 (17.5) 4271 (17.6) 438 (15.9)
3rd quintile 5249 (19.5) 4724 (19.5) 525 (19.1)
4th quintile 6333 (23.5) 5643 (23.3) 690 (25.1)
5th quintile (most deprived) 6733 (25.0) 5978 (24.7) 755 (27.4)
Missing 41 (0.2) 38 (0.2) 3 (0.1)
Follow-up length (years)
Mean (SD) 6.14 (5.35) 5.93 (5.25) 8.02 (5.83)
Median (minimum, maximum) 4.58 (0.003, 26.21) 4.33 (0.003, 26.21) 7.10 (0.003, 25.91)
Family history of diabetes, n (%) 2446 (9.1) 2015 (8.3) 431 (15.6)
continued
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TABLE 11 Objective 3: baseline characteristics for people with SMI, with and without T2DM (continued )
Characteristic
People with SMI
Total Without T2DM With T2DM
Comorbidities
Cardiovascular disease, n (%) 1550 (5.8) 1212 (5.0) 338 (12.3)
Hypertension, n (%) 3199 (11.9) 2423 (10.0) 776 (28.2)
Dementia, n (%) 424 (1.6) 369 (1.5) 55 (2.0)
Learning disability, n (%) 252 (0.9) 229 (1.0) 23 (0.8)
Charlson Index score, mean (SD) 0.33 (0.63) 0.31 (0.61) 0.45 (0.76)
Medications, n (%)
Antidepressants 13,046 (48.4) 11,603 (47.9) 1443 (52.4)
Antipsychotics
Typical 4637 (17.2) 3970 (16.4) 667 (24.2)
Atypical 9088 (33.7) 8143 (33.6) 945 (34.3)
Antihypertensive 4775 (17.7) 3660 (15.1) 1115 (40.5)
Antidiabetics 1055 (3.9) 86 (0.4) 969 (35.2)
Lipid-lowering drugs 2391 (8.9) 1564 (6.5) 827 (30.0)
Statins 2304 (8.5) 1502 (6.2) 802 (29.1)
Lifestyle factors, n (%)
Smoking
Non-smoker 4898 (18.2) 4259 (17.6) 639 (23.2)
Ex-smoker 2555 (9.5) 2211 (9.1) 344 (12.5)
Current smoker 7748 (28.7) 7031 (29.0) 717 (26.0)
Missing 11,776 (43.7) 10,721 (44.3) 1055 (38.3)
Drinking alcohol
Non-drinker 2733 (10.1) 2321 (9.6) 412 (15.0)
Ex-drinker 938 (3.5) 803 (3.3) 135 (4.9)
Current drinker 6862 (25.4) 6182 (25.5) 680 (24.7)
Missing 16,444 (61.0) 14,916 (61.6) 1528 (55.5)
Substance use 2551 (9.5) 2354 (9.7) 197 (7.2)
Biometric measures
BMI (kg/m2), mean (SD) 27.59 (6.36) 26.98 (6.05) 31.36 (6.91)
< 20, n (%) 969 (3.6) 932 (3.9) 37 (1.3)
20–24, n (%) 3662 (13.6) 3434 (14.2) 228 (8.3)
25–29, n (%) 3852 (14.3) 3336 (13.8) 516 (18.7)
30–40, n (%) 3098 (11.5) 2372 (9.8) 726 (26.4)
> 40, n (%) 530 (2.0) 351 (1.5) 179 (6.5)
Missing, n (%) 14,866 (55.1) 13,797 (57.0) 1069 (38.8)
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older age; the mean diagnosis age was 40.7 years for people without T2DM and 47.6 years for people
with T2DM. People with T2DM were more likely to be female, to be of Asian or black ethnicity and to
live in socioeconomically deprived neighbourhoods than people without T2DM. Furthermore, there
was a higher probability of having a family history of diabetes in people with T2DM.
The baseline prevalence of cardiovascular disease and hypertension was substantially higher in people with
both SMI and T2DM than in people without T2DM, consistent with the patterns of baseline prescriptions;
the proportions of people receiving antihypertensive and lipid-lowering drugs were much higher in those
with T2DM than in those without T2DM. People with both diagnoses were also more likely to receive
other medications, including antidepressants, antipsychotics and antidiabetes medications.
People with T2DM, on average, had a higher baseline BMI and poorer glycaemic and blood pressure
controls. The average cholesterol level, however, was lower in people with T2DM than in people
without T2DM. In general, there were large numbers of missing data for lifestyle factors and biometric
measures in people without T2DM, and the patterns of missing values for these variables differed
between the two groups. Therefore, these comparisons should be interpreted with caution.
The patterns for the health outcomes of diabetes and cardiovascular control are shown in Figures 5 and 6.
These figures show a common trend: that diabetes and cardiovascular control measures improved from
2000/1 through to 2015/16 for both people with and people without T2DM. The gap between these
two groups, however, widened for average cholesterol and HbA1c levels.
TABLE 11 Objective 3: baseline characteristics for people with SMI, with and without T2DM (continued )
Characteristic
People with SMI
Total Without T2DM With T2DM
HbA1c (%),
a mean (SD) 6.71 (1.85) 5.78 (1.30) 7.47 (1.88)
≤ 7.5 1629 (6.0) 894 (3.7) 735 (26.7)
> 7.5 448 (1.7) 35 (0.1) 413 (15.0)
Missing 24,900 (92.3) 23,293 (96.2) 1607 (58.3)
Cholesterol (mmol/l), mean (SD) 5.16 (1.20) 5.23 (1.15) 4.92 (1.33)
≤ 5, n (%) 3160 (11.7) 2372 (9.8) 788 (28.6)
> 5, n (%) 3283 (12.2) 2681 (11.1) 602 (21.9)
Missing, n (%) 20,534 (76.1) 19,169 (79.1) 1365 (49.6)
Diastolic blood pressure (mmHg),
mean (SD)
77.68 (10.34) 77.41 (10.30) 79.50 (10.40)
≤ 80, n (%) 10,760 (39.9) 9494 (39.2) 1266 (46.0)
> 80, n (%) 5216 (19.3) 4458 (18.4) 758 (27.5)
Missing, n (%) 11,001 (40.8) 10,270 (42.4) 731 (26.5)
Systolic blood pressure (mmHg),
mean (SD)
127.82 (18.07) 126.95 (17.88) 133.79 (18.28)
≤ 140, n (%) 12,996 (48.2) 11,521 (47.6) 1475 (53.5)
> 140, n (%) 2980 (11.1) 2431 (10.0) 549 (19.9)
Missing, n (%) 11,001 (40.8) 10,270 (42.4) 731 (26.5)
SD, standard deviation.
a HbA1c of 7.5% = 58mmol/mol.
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FIGURE 5 Objective 3: average cholesterol and HbA1c, 2000/1–2015/16 for people with SMI with T2DM and for people
with SMI without T2DM. (a) Average cholesterol (mmol/l) and 95% CIs; and (b) average HbA1c (%) and 95% CIs.
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FIGURE 6 Objective 3: average blood pressure (mmHg) and 95% CI, 2000/1–2015/16 for people with SMI with T2DM
and for people with SMI without T2DM. (a) Systolic blood pressure and 95% CIs; and (b) diastolic blood pressure and
95% CIs.
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People with T2DM who had a lower cholesterol level at baseline continued to have better cholesterol
control in the follow-up period than people without T2DM. The average level dropped below 5 mmol/l,
the NICE-recommended threshold, after 2003/4 for people with T2DM, whereas the average level for
people without T2DM remained above this threshold in this period.
The average level of HbA1c for people with T2DM was consistently higher than the average level for
people without T2DM. There was a decreasing trend in people without T2DM, a pattern that might
suggest that an increased number of T2DM patients had been identified among people with SMI
through regular physical health checks, as incentivised under QOF.
For blood pressure, the gap between people with and people without T2DM remained constant over
time. Systolic blood pressure was higher in people with T2DM throughout this period, a pattern
consistent with the baseline measures of these two groups. Although diastolic blood pressure
was higher in people with T2DM at baseline, results suggested better control for these patients
during follow-up.
Descriptive statistics for the other health outcomes and physical health checks are summarised
in Table 12. There was a general pattern that people with T2DM had higher crude risks for poorer
physical and mental health outcomes, and received more frequent physical health checks, than people
without T2DM.
Regression analysis results for the impact of type 2 diabetes on health outcomes and
health-care interventions
The impact of the exposure variable, the status of T2DM, on health outcomes and health-care
interventions is summarised in Table 13 using results from the core models. The diagnosis of T2DM
was associated with increased risk of poorer physical and mental health outcomes, as well as increased
levels of physical health checks. After adjusting for patients’ sociodemographic characteristics, baseline
comorbidities and medication use, people with T2DM had an increased risk of macrovascular complications
compared with people without T2DM; clinical events recorded in primary care increased by 36% (OR 1.36,
95% CI 1.11 to 1.67) and hospital admissions increased by 62% (IRR 1.62, 95% CI 1.31 to 2.01). The risk of
microvascular complications was more than 22 times higher (HR 22.23, 95% CI 17.79 to 27.77) in people
with T2DM than in people without T2DM; the increased risk associated with T2DM was 24% for all-cause
mortality (HR 1.24, 95% CI 1.12 to 1.38) and 10% for SMI relapses (OR 1.10, 95% CI 1.00 to 1.20).
The results also suggested that levels of physical health checks were associated with T2DM status.
Compared with people without T2DM, people with T2DM received increased health checks by 103%
for glucose (IRR 2.03, 95% CI 1.91 to 2.16), by 128% for cholesterol (IRR 2.28, 95% CI 2.20 to 2.38),
by 62% for blood pressure (IRR 1.62%, 95% CI 1.57 to 1.68) and by 103% for BMI (IRR 2.03, 95% CI
1.93 to 2.15).
For full results of the core models, see Report Supplementary Material 5 and 6, and results of the
extended models in Report Supplementary Material 7 and 8. Of the candidate explanatory variables,
we found that older age was a significant predictor for poorer physical health outcomes and increased
physical health checks, but was associated with a lower risk of SMI relapses. Female patients had
reduced risk of poor physical health outcomes and increased risk of SMI relapse. They were also more
likely to receive health checks (except for cholesterol tests) than males. People of Asian ethnicity
had a reduced mortality rate and increased health checks. There was also a gradient in the impact of
socioeconomic deprivation on health outcomes; people who lived in more deprived neighbourhoods
had an elevated risk of macrovascular complications and mortality.
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TABLE 12 Objective 3: descriptive statistics for physical and mental health outcomes, and physical health checks for
people with SMI with T2DM and for people with SMI without T2DM
Descriptive statistic
People with SMI
Total Without T2DM With T2DM
Diabetes complications: primary care diagnosis, n (%)
Hyperglycaemia 147 (0.5) 23 (0.1) 124 (4.5)
Hypoglycaemia 138 (0.5) 18 (0.1) 120 (4.4)
Macrovascular complications (combined) 942 (3.5) 717 (3.0) 225 (8.2)
Myocardial infarction 378 (1.4) 292 (1.2) 86 (3.1)
Peripheral vascular disease 192 (0.7) 123 (0.5) 69 (2.5)
Stroke 414 (1.5) 323 (1.3) 91 (3.3)
Microvascular complications (combined)
Baseline 332 (1.2) 122 (0.5) 210 (7.6)
Follow-up 690 (2.6) 210 (0.9) 480 (17.4)
Nephropathy
Baseline 53 (0.2) 31 (0.1) 22 (0.8)
Follow-up 171 (0.6) 103 (0.4) 68 (2.5)
Neuropathy
Baseline 149 (0.6) 82 (0.3) 67 (2.4)
Follow-up 192 (0.7) 105 (0.4) 87 (3.2)
Retinopathy
Baseline 158 (0.6) 11 (0.1) 147 (5.3)
Follow-up 398 (1.5) 4 (0.0) 394 (14.3)
Diabetes complications: admissions, mean (SD)
Macrovascular complications (combined) 0.07 (0.40) 0.05 (0.34) 0.18 (0.76)
Ischaemic heart disease 0.04 (0.35) 0.03 (0.28) 0.12 (0.68)
Peripheral vascular disease 0.00 (0.05) 0 (0) 0.01 (0.17)
Cerebrovascular disease 0.02 (0.18) 0.02 (0.18) 0.04 (0.24)
Mental health outcomes, n (%)
SMI relapses 10,665 (39.5) 9458 (39.1) 1207 (43.8)
All-cause mortality, n (%) 3038 (11.3) 2580 (10.7) 458 (16.6)
Number of health checks per year, mean (SD)
Glucose 0.50 (0.81) 0.44 (0.72) 1.04 (1.27)
Cholesterol 0.46 (0.65) 0.38 (0.60) 1.10 (0.74)
Blood pressure 1.26 (2.85) 1.14 (2.91) 2.37 (2.02)
BMI 0.77 (2.52) 0.69 (2.60) 1.53 (1.41)
SD, standard deviation.
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The core models also showed that physical comorbidities were generally associated with increased levels
of physical health checks and poorer physical health outcomes. For instance, people with cardiovascular
disease at baseline had an increased risk of both macro- and microvascular complications, and all-cause
mortality. They also received more frequent health checks for diabetes and cardiovascular controls.
Cardiovascular disease showed no impact on the risk of mental health outcomes. Dementia was associated
with reduced risk of SMI relapse, as well as with receiving fewer physical health checks.
Of the medications we examined, antidepressants were associated with increased risk of macrovascular
complications and a lower risk of SMI relapse. Typical antipsychotics were identified as a risk factor for
SMI relapse and mortality. Furthermore, there was a general tendency towards physical health checks
increasing with baseline medication uptake.
The results of the extended models were consistent with the results of the core models. Using
additional information, we found that patients with a higher than normal BMI were more likely to
receive physical health checks. Current smokers had a higher risk of macrovascular complications and
SMI relapse. There was also evidence suggesting that poor diabetes and cardiovascular controls at
baseline were not only risk factors of poorer health outcomes, but also predictors of more frequent
physical health checks.
Summary of findings
A key finding is that, after adjustment, having diabetes increases the probability of receiving physical
health checks and is a significant risk factor for both poorer physical and mental health outcomes.
The physical and mental health outcomes examined responded differently to variations in patient
characteristics. For instance, advancing age was associated with increased risk of poorer physical
health outcomes, but with reduced risk of mental health outcomes (SMI relapses); female sex was




Coefficient 95% CI p-value
Physical health outcomes
Macrovascular complications: primary care diagnosis OR 1.361 1.108 to 1.671 0.003
Macrovascular complications: hospital admissions IRR 1.624 1.314 to 2.007 < 0.001
Microvascular complications: primary care diagnosis HR 22.229 17.792 to 27.772 < 0.001
All-cause mortality HR 1.243 1.122 to 1.378 < 0.001
Mental health outcomes
SMI relapses OR 1.096 1.002 to 1.199 0.045
Health checks
Glucose IRR 2.032 1.909 to 2.163 < 0.001
Cholesterol IRR 2.284 2.195 to 2.376 < 0.001
Blood pressure IRR 1.624 1.566 to 1.684 < 0.001
BMI IRR 2.033 1.926 to 2.146 < 0.001
Notes
All 95% CIs are robust. These impacts were estimated using the core model adjusting for demographics, deprivation,
duration of SMI and T2DM, comorbidities, medications and time effects.
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associated with a lower risk of diabetes complications and mortality, but a higher risk of SMI relapses.
Type of SMI was a significant predictor for poorer mental health status, but had less influence on
physical health outcomes, and antidepressant uptake reduced the risk of SMI relapses, but increased
the risk of macrovascular complications.
The analyses also showed that receipt of the four physical health checks under investigation was
affected by a wide range of factors, including older age, female sex, ethnicity, type of SMI, the presence
of comorbidities and the use of various medications.
Objective 4: comparing the health outcomes of people with diabetes and
severe mental illness with the health outcomes of people with diabetes
without severe mental illness
Objective
The objective was to compare health-care interventions and physical and mental health outcomes in
people with diabetes and SMI with those of people with diabetes without SMI.
Study population
There was a cohort of 12,999 patients in the CPRD data who had a clinical diagnosis of diabetes. This
cohort included 3448 patients in data set B who had been identified as ‘cases’ for having both SMI and
T2DM. A total of 9551 patients in data set C (see Figure 2) had been identified as matched ‘controls’
based on age, sex and general practice. For this objective, we used data sets B and C so that patients
with both SMI and T2DM (cases) could be compared with non-SMI patients with T2DM (controls) of
the same age band, sex and general practice.
Patients with T2DM were included if (1) they satisfied the four common inclusion criteria regarding
diagnosis date and age, practice registration and type of diabetes; (2) they had a follow-up length of at
least 1 day, in which the start of follow-up was identified as the later date of T2DM diagnosis or the
start of UTS data plus 15 months, and the end of follow-up was defined as the earlier of the end of
UTS data or the end of study period date; and (3) they were nested within a matched case–control
cluster. A total of 9965 patients remained in the final sample for analyses.
Variables and statistical methods
The exposure variable was SMI status. The candidate explanatory variables are listed in Table 3, with
detailed descriptions. The outcome variables under examination were as described in Objective 3:
comparing health-care interventions and health outcomes in people with severe mental illness and diabetes
with those in people with severe mental illness without diabetes, Variables and statistical methods.
The description and analysis methods for physical and mental health outcomes are provided in Table 4.
The outcome, mental health status, was identified by the markers of depression and anxiety only,
because we were unable to include SMI relapse owing to its perfect correlation with SMI status. The
four physical health checks were chosen using the QOF indicators for people with diabetes. We
therefore examined the level of health checks for HbA1c, cholesterol, blood pressure and BMI.
The patient-level observations for this objective were nested within matched case–control clusters,
an additional data hierarchy to the data used in previous objectives. We adopted statistical methods
that examine variations within case–control clusters, ‘within’ estimators, to compare cases only with
controls of the same age, sex and registered with the same practice. For further details on the
methodology, see Report Supplementary Material 3.
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The comparison of baseline characteristics between cases and controls, and by diagnosis order, are
summarised in Table 14. In our sample of 9965 patients, 2192 (22%) cases were matched to 7773
(78%) controls. Just under 90% of cases had been matched to at least three controls. Cases had similar
distribution in age and sex to controls. However, they differed for a range of other characteristics, and
by diagnosis orders.
TABLE 14 Objective 4: baseline characteristics for people with T2DM with SMI and people with T2DM without SMI,













Patients (n) 1666 5883 526 1890
Number of controls, n (%)
4 controls 1200 (72.0) 399 (75.9)
3 controls 255 (15.3) 68 (12.9)
2 controls 107 (6.4) 31 (5.9)
1 control 104 (6.2) 28 (5.3)
Diagnosis age (years), mean (SD)
SMI 43.02 (15.09) 63.70 (14.69)
T2DM 56.36 (12.86) 56.84 (12.47) 58.22 (14.11) 62.12 (13.36)
SMI type, n (%)
Schizophrenia 913 (54.8) 248 (47.2)
Schizoaffective disorder 96 (5.8) 17 (3.2)
Bipolar disorder 528 (31.7) 173 (32.9)
Depression and psychosis 110 (6.6) 74 (14.1)
Other affective disorder 15 (0.9) 11 (2.1)
Mixed 4 (0.2) 3 (0.6)
Age at follow-up start (years), mean (SD) 56.86 (12.81) 57.55 (12.32) 60.25 (13.73) 63.08 (13.10)
Duration of T2DM (years), mean (SD) 0.52 (2.13) 0.74 (2.66) 2.09 (4.65) 0.99 (3.19)
Follow-up duration (years), mean (SD) 5.39 (4.22) 6.14 (4.39) 8.02 (4.57) 6.53 (4.52)
Family history of diabetes, n (%) 245 (14.7) 1123 (19.1) 79 (15.0) 319 (16.9)
Sex, n (%)
Male 822 (49.3) 2861 (48.6) 229 (43.5) 846 (44.8)
Female 844 (50.7) 3022 (51.4) 297 (56.5) 1044 (55.2)
Ethnicity, n (%)
White 1376 (82.6) 4657 (79.2) 450 (85.6) 1612 (85.3)
Asian 108 (6.5) 413 (7.0) 31 (5.9) 86 (4.6)
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TABLE 14 Objective 4: baseline characteristics for people with T2DM with SMI and people with T2DM without SMI,













Black 86 (5.2) 213 (3.6) 20 (3.8) 44 (2.3)
Mixed 16 (1.0) 39 (0.7) 5 (1.0) 9 (0.5)
Other 35 (2.1) 118 (2.0) 6 (1.1) 29 (1.5)
Not stated/unknown 45 (2.7) 443 (7.5) 14 (2.7) 110 (5.8)
Deprivation (IMD 2010), n (%)
1st quintile (least deprived) 195 (11.7) 900 (15.3) 84 (16.0) 311 (16.5)
2nd quintile 271 (16.3) 1101 (18.7) 87 (16.5) 401 (21.2)
3rd quintile 310 (18.6) 1217 (20.7) 105 (20.0) 352 (18.6)
4th quintile 423 (25.4) 1340 (22.8) 119 (22.6) 405 (21.4)
5th quintile (most deprived) 466 (28.0) 1319 (22.4) 129 (24.5) 420 (22.2)
Missing 1 (0.1) 6 (0.1) 2 (0.4) 1 (0.1)
Comorbidities
Cardiovascular disease, n (%) 193 (11.6) 922 (15.7) 92 (17.5) 384 (20.3)
Hypertension, n (%) 521 (31.3) 2655 (45.1) 213 (40.5) 929 (49.2)
Dementia, n (%) 25 (1.5) 19 (0.3) 7 (1.3) 13 (0.7)
Learning disability, n (%) 18 (1.1) 17 (0.3) 1 (0.2) 4 (0.2)
Charlson Index score, mean (SD) 0.48 (0.71) 0.51 (0.77) 0.55 (0.78) 0.62 (0.85)
Medications, n (%)
Antidepressants 817 (49.0) 1156 (19.7) 245 (46.6) 367 (19.4)
Antipsychotics
Typical 361 (21.7) 63 (1.1) 73 (13.9) 27 (1.4)
Atypical 870 (52.2) 41 (0.7) 87 (16.5) 11 (0.6)
Antidiabetics 353 (21.2) 1218 (20.7) 168 (31.9) 425 (22.5)
Antihypertensive 723 (43.4) 3200 (54.4) 277 (52.7) 1149 (60.8)
Lipid-lowering drugs 517 (31.0) 1981 (33.7) 167 (31.8) 696 (36.8)
Statins 501 (30.1) 1921 (32.7) 164 (31.2) 679 (35.9)
Lifestyle factors, n (%)
Smoking
Non-smoker 410 (24.6) 1691 (28.7) 134 (25.5) 540 (28.6)
Ex-smoker 299 (18.0) 1248 (21.2) 91 (17.3) 411 (21.8)
Current smoker 550 (33.0) 924 (15.7) 100 (19.0) 299 (15.8)
Missing 407 (24.4) 2020 (34.3) 201 (38.2) 640 (33.9)
continued
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TABLE 14 Objective 4: baseline characteristics for people with T2DM with SMI and people with T2DM without SMI,














Non-drinker 325 (19.5) 565 (9.6) 64 (12.2) 197 (10.4)
Ex-drinker 112 (6.7) 111 (1.9) 16 (3.0) 30 (1.6)
Current drinker 519 (31.2) 1549 (26.3) 137 (26.1) 511 (27.0)
Missing 710 (42.6) 3658 (62.2) 309 (58.8) 1152 (61.0)
Substance use 31 (1.9) 28 (0.5) 8 (1.5) 7 (0.4)
Biometric measures
BMI (kg/m2), mean (SD) 33.28 (7.08) 32.77 (6.92) 31.89 (6.57) 31.91 (6.95)
< 20, n (%) 8 (0.5) 35 (0.6) 4 (0.8) 15 (0.8)
20–24, n (%) 102 (6.1) 344 (5.9) 43 (8.2) 128 (6.8)
25–29, n (%) 303 (18.2) 983 (16.7) 98 (18.6) 368 (19.5)
30–40, n (%) 582 (34.9) 1770 (30.1) 151 (28.7) 501 (26.5)
> 40, n (%) 181 (10.9) 511 (8.7) 40 (7.6) 139 (7.4)
Missing, n (%) 490 (29.4) 2240 (38.1) 190 (36.1) 739 (39.1)
HbA1c (%),
a mean (SD) 7.85 (2.03) 7.92 (1.96) 7.71 (1.84) 7.82 (1.89)
≤ 7.5, n (%) 506 (30.4) 1758 (29.9) 166 (31.6) 568 (30.1)
> 7.5, n (%) 350 (21.0) 1335 (22.7) 110 (20.9) 393 (20.8)
Missing, n (%) 810 (48.6) 2790 (47.4) 250 (47.5) 929 (49.2)
Cholesterol (mmol/l), mean (SD) 5.39 (1.42) 5.30 (1.29) 5.24 (1.42) 5.22 (1.25)
≤ 5, n (%) 563 (33.8) 2071 (35.2) 159 (30.2) 684 (36.2)
> 5, n (%) 703 (42.2) 2457 (41.8) 189 (35.9) 756 (40.0)
Missing, n (%) 400 (24.0) 1355 (23.0) 178 (33.8) 450 (23.8)
Diastolic blood pressure (mmHg), mean (SD) 81.58 (10.59) 82.20 (10.70) 81.07 (11.16) 81.36 (10.71)
≤ 80, n (%) 761 (45.7) 2484 (42.2) 250 (47.5) 896 (47.4)
> 80, n (%) 690 (41.4) 2453 (41.7) 184 (35.0) 742 (39.3)
Missing, n (%) 215 (12.9) 946 (16.1) 92 (17.5) 252 (13.3)
Systolic blood pressure (mmHg), mean (SD) 134.79 (17.48) 139.59 (18.11) 139.27 (19.91) 141.75 (18.41)
≤ 140, n (%) 1026 (61.6) 2973 (50.5) 254 (48.3) 901 (47.7)
> 140, n (%) 425 (25.5) 1964 (33.4) 180 (34.2) 737 (39.0)
Missing, n (%) 215 (12.9) 946 (16.1) 92 (17.5) 252 (13.3)
SD, standard deviation.
a HbA1c of 7.5% = 58mmol/mol.
Note
Total, N = 9965 patients [cases, n= 2192 (22.0%); controls, n= 7773 (78.0%)].
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In general, people with SMI were more likely to come from the most deprived neighbourhoods than
people without SMI. This socioeconomic disadvantage was further increased if SMI was diagnosed
before T2DM. We observed a similar pattern in the baseline prevalence of dementia and learning
disability, which were more common in people with SMI than in people without SMI; people with
SMI diagnosed before T2DM were most likely to be affected.
Recorded physical health status, including cardiovascular disease, hypertension and Charlson Index
diseases, showed opposite patterns. People with SMI were less likely to have a recorded diagnosis
of these physical comorbidities than people without SMI; prevalence of these diseases was lower in
people with SMI diagnosed before T2DM than in people who had T2DM first. As expected, larger
proportions of people with SMI had been prescribed antidepressants and antipsychotics than people
without SMI. The prescription rates of antihypertensive and lipid-lowering drugs were lower in people
with SMI than in controls, a pattern consistent with the lower prevalence of recorded hypertension
and cardiovascular disease in people with SMI.
Factors including BMI, smoking status and alcohol use were better recorded for people who had SMI
before T2DM than for the rest of the sample. Although results should be interpreted with caution,
we found that people with SMI had a higher BMI and were more likely to have substance misuse at
baseline. Furthermore, people with SMI tended to have better diabetes and blood pressure controls,
but a higher cholesterol level, at baseline than people without SMI.
The health outcomes of diabetes and cardiovascular control were compared between people with and
people without SMI (see Figures 7 and 8), and were analysed separately for people diagnosed with SMI
first and diagnosed with T2DM first. These analyses showed a common decreasing trend in the average
levels of cholesterol and blood pressure during the study period. The mean values of HbA1c remained
stable and around the 7.5% (58 mmol/mol) threshold for both groups. People with SMI had lower
HbA1c and blood pressure levels than people without SMI, a pattern consistent with the comparison of
baseline levels. The cholesterol levels of people with SMI, particularly those with SMI diagnosed before
T2DM, remained above the cholesterol levels of controls.
Descriptive statistics for the other outcome variables are provided in Table 15 and show that the
pattern of diabetes complications differed between people with SMI and people without SMI, and
that complications were also affected by diagnosis order. In general, the crude risks of both recorded
macro- and microvascular complications were lower in people with SMI than in people without SMI,
if SMI was diagnosed before T2DM. These crude risks were higher in people with SMI than in controls
if T2DM was diagnosed first. Depression and anxiety were also more likely to be diagnosed in people
with SMI than in people without SMI, and the crude mortality rate was higher in the SMI population.
For the four physical health checks, we found that people with SMI tended to have more frequent
checks than controls if SMI was diagnosed first, and less frequent checks if T2DM was diagnosed first.
Regression results for the impact of severe mental illness status on physical and
mental health outcomes, mortality and health checks
The adjusted impact of SMI status on outcome variables based on our core models is summarised in
Table 16. After adjustment, SMI status was not associated with macrovascular complications recorded
in primary care data. However, we found a complex association with hospital admissions: having SMI
was associated with an increased risk of emergency admissions for macrovascular complications (IRR
1.14, 95% CI 0.96 to 1.36) and with a reduced risk, by 36%, of elective admissions for macrovascular
complications (IRR 0.64, 95% CI 0.47 to 0.88). Compared with controls, people with SMI were more
likely to be diagnosed with depression and anxiety (OR 1.86%, 95% CI 1.63 to 2.12) and had an almost
90% increased risk of mortality (HR 1.89, 95% CI 1.59 to 2.26).
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FIGURE 7 Objective 4: average cholesterol and HbA1c, 2000/1–2015/16, for people with T2DM and SMI and people with
T2DM without SMI. Average cholesterol (mmol/l) and 95% CIs for (a) SMI diagnosed before T2DM; (b) SMI diagnosed
after T2DM (including same day); average HbA1c (%) and 95% CIs for (c) SMI diagnosed before T2DM; and (d) SMI
diagnosed after T2DM (including same day).
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FIGURE 8 Objective 4: average blood pressure, 2000/1–2015/16, for people with T2DM and SMI and people with
T2DM without SMI. Systolic blood pressure (mmHg) and 95% CIs for (a) SMI diagnosed before T2DM; (b) SMI diagnosed
after T2DM (including same day); diastolic blood pressure (mmHg) and 95% CIs for (c) SMI diagnosed before T2DM; and
(d) SMI diagnosed after T2DM (including same day).
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TABLE 15 Objective 4: descriptive statistics for diabetes complications, mental health outcomes, mortality and health
checks for people with T2DM with SMI and people with T2DM without SMI
Descriptive statistic
SMI diagnosed before T2DM










Patients (n) 1666 5883 526 1890
Diabetes complications: primary care diagnosis, n (%)
Hyperglycaemia 52 (3.1) 155 (2.6) 31 (5.9) 49 (2.6)
Hypoglycaemia 60 (3.6) 253 (4.3) 41 (7.8) 85 (4.5)
Macrovascular complications (combined) 102 (6.1) 481 (8.2) 82 (15.6) 203 (10.7)
Myocardial infarction 37 (2.2) 196 (3.3) 33 (6.3) 78 (4.1)
Peripheral vascular disease 36 (2.2) 183 (3.1) 22 (4.2) 64 (3.4)
Stroke 38 (2.3) 142 (2.4) 34 (6.5) 79 (4.2)
Microvascular complications (combined)
Baseline 45 (2.7) 253 (4.3) 39 (7.4) 69 (3.7)
Follow-up 310 (18.6) 1416 (24.1) 141 (26.8) 514 (27.2)
Nephropathy
Baseline 6 (0.4) 32 (0.5) 4 (0.8) 8 (0.4)
Follow-up 35 (2.1) 121 (2.1) 24 (4.6) 55 (2.9)
Neuropathy
Baseline 17 (1.0) 88 (1.5) 13 (2.5) 24 (1.3)
Follow-up 54 (3.2) 251 (4.3) 35 (6.7) 103 (5.5)
Retinopathy
Baseline 25 (1.5) 161 (2.7) 28 (5.3) 42 (2.2)
Follow-up 257 (15.4) 1227 (20.9) 112 (21.3) 433 (22.9)
Diabetes complications: admissions, mean (SD)
Macrovascular complications (combined) 0.13 (0.54) 0.20 (1.12) 0.32 (0.99) 0.23 (0.74)
Ischaemic heart disease 0.09 (0.45) 0.15 (1.07) 0.23 (0.90) 0.17 (0.66)
Peripheral vascular disease 0.01 (0.20) 0.01 (0.16) 0.02 (0.17) 0.01 (0.11)
Cerebrovascular disease 0.03 (0.19) 0.03 (0.24) 0.08 (0.33) 0.05 (0.26)
Emergency 0.09 (0.41) 0.10 (0.45) 0.21 (0.71) 0.14 (0.52)
Elective 0.03 (0.21) 0.08 (0.93) 0.07 (0.35) 0.07 (0.37)
Mental health outcomes, n (%)
Depression and anxiety 343 (20.6) 993 (16.9) 232 (44.1) 297 (15.7)
All-cause mortality, n (%) 248 (14.9) 672 (11.4) 116 (22.1) 348 (18.4)
Number of health checks per year, mean (SD)
HbA1c 1.94 (1.35) 1.90 (1.07) 1.73 (0.70) 1.94 (1.08)
Cholesterol 1.40 (1.07) 1.34 (0.79) 1.31 (0.58) 1.38 (0.91)
Blood pressure 2.94 (2.70) 2.96 (2.21) 2.92 (1.69) 3.25 (8.60)
BMI 2.16 (2.11) 1.91 (1.74) 1.80 (1.30) 2.07 (8.57)
SD, standard deviation.
Note
Total, N = 9965 [cases, n= 2192 (22.0%); controls, n= 7773 (78.0%)].
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For physical health checks, people with SMI were more likely to receive tests for cholesterol (IRR 1.05,
95% CI 1.03 to 1.08), blood pressure (IRR 1.03, 95% CI 1.01 to 1.06) and BMI (IRR 1.09, 95% CI 1.06
to 1.11) than people without SMI. There was no difference between cases and controls in the chance
of receiving a HbA1c test.
As suggested by the descriptive statistics, people who had SMI diagnosed before T2DM differed in many
aspects from people with T2DM diagnosed first. We therefore included interactions in the regressions
to investigate whether or not the impact of SMI could be modified by this diagnosis order. The impact
of SMI was not significantly modified by diagnosis order for hospital admissions for macrovascular
complications or physical health checks. For macrovascular complications recorded in primary care data,
however, the risk of this outcome was reduced for people with SMI if SMI was diagnosed before T2DM,
and increased with the presence of SMI if T2DM was diagnosed first. The risk of depression and anxiety
was higher in people with SMI than in people without SMI; this risk increased by around 41% for people
diagnosed with SMI first and by 245% for people diagnosed with T2DM first (results available on request).
For full results of the core models, see Report Supplementary Materials 9 and 10. These suggest that older
age is associated with higher rates of emergency admissions and physical health checks. Socioeconomic
disadvantage is associated with higher risk of depression and mortality and reduced chances of receiving
regular health checks. The presence of physical comorbidities, particularly cardiovascular disease and
high blood pressure, was found to be a risk factor for poorer physical health outcomes. The number of
Charlson Index diseases was associated with increased risks of mortality and depression. People who had
dementia were less likely to be identified for physical health checks, whereas people on lipid-lowering
medications were more likely to receive checks for cholesterol, HbA1c and BMI. The results of the extended
models confirmed these findings (see Report Supplementary Material 11 and 12). Furthermore, there is
evidence suggesting that current smoker status and poor diabetes and blood pressure controls might be
associated with poorer physical health outcomes. Obesity and abnormal diabetes and cardiovascular
controls might increase levels of physical health checks.




Coefficient 95% CI p-value
Physical health outcomes
Macrovascular complications: primary care diagnosis OR 0.999 0.824 to 1.210 0.988
Macrovascular complications: emergency admissions IRR 1.141 0.956 to 1.362 0.143
Macrovascular complications: elective admissions IRR 0.644 0.470 to 0.881 0.006
All-cause mortality HR 1.893 1.589 to 2.256 < 0.001
Mental health outcomes
Depression and anxiety OR 1.858 1.629 to 2.119 < 0.001
Health checks
HbA1c IRR 0.997 0.978 to 1.016 0.762
Cholesterol IRR 1.054 1.033 to 1.075 < 0.001
Blood pressure IRR 1.032 1.008 to 1.057 0.009
BMI IRR 1.085 1.058 to 1.113 < 0.001
Notes
All 95% CIs are robust. These impacts were estimated using the core models, adjusting for demographics, deprivation,
duration of T2DM, comorbidities, medications and time effects.
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Summary of findings
For this objective, we investigated the impact of SMI status on physical and mental health outcomes, as
well as the utilisation of health-care interventions. We also explored whether or not health inequalities
among people with SMI were associated with the order of diagnosis of SMI and diabetes.
People with SMI had tighter diabetes and blood pressure controls and better chances of receiving
physical health checks than people without SMI. Despite this, for health outcomes, we found significant
associations between SMI and increased risk for all-cause mortality and depression.
The results also suggested that elective admissions for macrovascular complications were significantly
lower for people with SMI, whereas the rate of emergency admissions was elevated for this group
(although the difference was not statistically significant). Further investigations indicated that most
of these elective admissions had chronic ischaemic heart disease as the main diagnosis, and most
emergency patients had been admitted for angina. These admission patterns might suggest a service
gap; people with SMI are less likely to be referred by their GPs to specialist care for their cardiovascular
disease and, when their symptoms deteriorate, they are more likely to be admitted as emergencies than
people without SMI.
The analyses of the primary care data also supported this suggestion. Although the rate for recorded
macrovascular complications was similar in people with and people without SMI, people with SMI were
less likely to have a primary care record of chronic heart conditions, such as angina and chronic heart
disease. This under-reporting/diagnosis pattern for people with SMI, which has been mentioned in the
literature,124 could help explain the inequalities in specialist and hospital care experienced by people
with SMI.
Objective 6: comparing diabetes care provision and estimating health-care
costs for people with and people without severe mental illness
Objective
The objective was to provide a comparison of, and cost estimation for, diabetes health-care provision
for people with and people without SMI.
Study population
We used the patient sample identified for objective 4 (see Objective 4: comparing the health outcomes of
people with diabetes and severe mental illness with the health outcomes of people with diabetes without severe
mental illness, Study population) to compare health-care use and associated costs between people with
SMI and T2DM (cases) and their matched controls (non-SMI, T2DM). These patients were included
for the analyses of this objective if they (1) had a length of follow-up of at least 1 year and (2) belonged
to a case–control cluster. The start and end of follow-up were identified using the same method as for
objective 4.
Variables and statistical methods
The exposure variable in this objective was the status of SMI. The candidate explanatory variables are
summarised in Table 3.
The outcome variables were health-care use and the associated costs, including:
l primary care service use (consultations, prescriptions and diagnostic tests)
l hospital admissions for physical conditions (number of admissions and length of stay)
l hospital admissions for mental health problems
l associated costs for this service use.
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The data construction and analysis methods are provided in Table 4. Mental health-related hospital
admissions were identified using Healthcare Resource Group (HRG) codes.125 Primary care service use
and hospital admissions were costed using a bottom-up approach. A&E attendance and the use of
community mental health services were not included in the analyses, as linkages to these data sources
were not available in the CPRD data set. For an overview of all sources of health-care utilisation data
and unit costs (both primary and secondary care), see Report Supplementary Material 13. Health-care
use and associated costs were aggregated on an annual basis.
For the consultation costs, we followed the approach adopted in Ride et al.126 and multiplied the
duration of consultations by the costs of 1 minute of staff time, which were extracted from Unit Costs
of Health and Social Care 2018.127 Multiple visits to the same staff on the same day were considered as
duplicates, whereas visits to different staff in a day were counted as different visits. For details on the
categorising of consultations, see Report Supplementary Material 14.
The costs of prescriptions were calculated as the number of prescriptions multiplied by unit costs
in 2018, as extracted from the prescription cost analysis for 2018.128 Prescription records were
aggregated at British National Formulary subparagraph level; higher hierarchy levels (paragraph, section
or chapter) levels were used if subparagraph codes were unavailable.
For diagnostic tests, we followed Ride et al.126 and grouped the test records into the categories as set
out in the NHS reference costs. Costs were then estimated using the levels of tests and the unit costs
extracted from the NHS Reference Costs 2017/18.129 For details of this approach, see Report
Supplementary Material 15.
The use and cost of hospital care were calculated for admissions to general hospitals only (including
non-specialist mental health providers), but not admission to specialist mental health facilities. Hospital
activities, such as diagnoses and procedures, were firstly grouped into HRGs using the costing grouper
that corresponds to the NHS Reference Costs 2017/18. The generated HRG codes were then used to
link the inpatient episodes to the national average costs from NHS Reference Costs 2017/18.129 The
calculated costs were therefore expressed in 2018 prices. To compare people with SMI with people
without SMI, we separated hospital admissions and associated costs by mental health- and physical
health-related admissions using HRG codes.
We conducted generalised linear regression models to explore the impact of SMI status and other
explanatory variables on health-care resource use and health-care costs, and to take into account the
non-negative, highly skewed and leptokurtic characteristics of cost data. The choice of distributional
family and link function were informed by the Park test130 and the Pregibon link test.131
Results
Descriptive statistics
A total of 6383 patients were included in the analysis sample with 1,023,257 primary care and 22,253
hospital admission records. Table 17 shows the distribution of baseline characteristics in the sample.
The mean age of the sample was 57.9 years, 48.3% were male, the majority (82.5%) were white, the
most common physical comorbidity was hypertension (55%), 26.6% were on antidepressants and 39.8%
were current or ex-smokers. Cases had distribution in baseline characteristics that was similar to that
of controls, such as age, sex, ethnicity and deprivation. However, people with SMI were more likely to
be prescribed medications, such as antidepressants, antipsychotics and antidiabetics. They were also
more likely to have lifestyles including smoking and substance use, although this finding is limited by
the quality of data recording and number of missing values.
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TABLE 17 Objective 6: baseline characteristics for people with SMI and T2DM (cases) and matched people with T2DM






People, N (%) 6383 (100) 1620 (100) 4763 (100)





Age at T2DM diagnosis (years), mean (SD)
T2DM 57.9 (12.6) 57.4 (12.9) 58.0 (12.5)
SMI 47.8 (17.2)
Sex, n (%)
Male 3080 (48.3) 780 (48.1) 2300 (48.3)
Female 3303 (51.7) 840 (51.9) 2463 (51.7)
SMI diagnosis, n (%)
Schizophrenia 850 (52.5)
Schizoaffective disorder 83 (5.1)
Bipolar disorder 524 (32.4)
Depression and psychosis 140 (8.6)
Other affective disorder 18 (1.1)
Mixed 5 (0.3)
Ethnicity, n (%)
White 5264 (82.5) 1375 (84.9) 3889 (81.6)
Non-white 726 (11.4) 203 (12.5) 523 (11.0)
Unknown 393 (6.2) 42 (2.6) 351 (7.4)
Deprivation (IMD 2010), n (%)
1st quintile (least deprived) 972 (15.2) 217 (13.4) 755 (15.8)
2nd quintile 1210 (19.0) 275 (17.0) 935 (19.6)
3rd quintile 1215 (19.0) 281 (17.3) 934 (19.6)
4th quintile 1475 (23.1) 401 (24.7) 1074 (22.6)
5th quintile (most deprived) 1505 (23.6) 445 (27.5) 1060 (22.3)
Missing 6 (0.1) 1 (0.1) 5 (0.1)
Comorbidities
Cardiovascular disease,a n (%) 2141 (33.5) 510 (31.5) 1631 (34.2)
Hypertension,a n (%) 3513 (55.0) 777 (48.0) 2736 (57.4)
Dementia, n (%) 27 (0.4) 20 (1.2) 7 (0.2)
Learning disability, n (%) 29 (0.5) 16 (1.0) 13 (0.3)
Charlson Index diseases, mean (SD) 0.51 (0.75) 0.49 (0.73) 0.51 (0.76)
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TABLE 17 Objective 6: baseline characteristics for people with SMI and T2DM (cases) and matched people with T2DM







Antidepressants 1696 (26.6) 792 (48.9) 904 (19.0)
Antipsychotics
Typical 360 (5.6) 307 (19.0) 53 (1.1)
Atypical 760 (11.9) 733 (45.3) 27 (0.6)
Antidiabetics 893 (14.0) 251 (15.5) 642 (13.5)
Lifestyle, n (%)
Smoking
Non-smoker 1764 (27.6) 406 (25.0) 1358 (28.5)
Ex-smoker 1308 (20.5) 285 (17.6) 1023 (21.5)
Current smoker 1234 (19.3) 479 (29.6) 755 (15.8)
Missing 2077 (32.6) 450 (27.8) 1627 (34.2)
Drinking
Non-drinker 673 (10.6) 258 (15.9) 415 (8.7)
Ex-drinker 175 (2.7) 95 (5.9) 80 (1.7)
Current drinker 1724 (27.0) 484 (29.9) 1240 (26.0)
Missing 3811 (59.7) 783 (48.3) 3028 (63.6)
Substance use 41 (0.6) 24 (1.5) 17 (0.4)
Biometric measures
BMI (kg/m2), mean (SD) 33.0 (6.8) 33.3 (7.1) 32.9 (6.7)
< 20 (underweight), n (%) 32 (0.5) 7 (0.4) 25 (0.5)
20–24 (normal), n (%) 328 (5.1) 98 (6.0) 230 (4.8)
25–29 (overweight), n (%) 1065 (16.7) 286 (17.7) 779 (16.4)
30–39 (obese), n (%) 1931 (30.3) 532 (32.8) 1399 (29.4)
≥ 40 (severely obese) 575 (9.0) 171 (10.6) 404 (8.5)
Missing, n (%) 2452 (38.4) 526 (32.5) 1926 (40.4)
Family history of diabetes, n (%) 1092 (17.1) 222 (13.7) 870 (18.3)
Average follow-up time (years)b
Mean (SD) 7.0 (4.0) 6.9 (4.0) 7.1 (4.0)
Median (minimum, maximum) 6.5 (1, 18) 6.4 (1, 18) 6.6 (1, 17.9)
Financial year at T2DM diagnosis, n (%)
1998–9 51 (0.8) 17 (1.1) 34 (0.7)
1999–2000 80 (1.3) 19 (1.2) 61 (1.3)
2000–1 229 (3.6) 55 (3.4) 174 (3.7)
continued
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Primary care costs results
Table 18 shows annual resource use and costs for people with diabetes and SMI (cases) and people
with diabetes alone (controls). The crude results demonstrate that, on average, people with diabetes
and SMI used significantly more primary care services every year than people with diabetes alone.
The main driver of this difference was the number of consultations (12.140 and 8.657 contacts per
year for cases and controls, respectively); drug prescription and test-related contacts were similar
between the two groups.
Hospital costs results
A similar trend was found for hospitalisation. People with diabetes and SMI had more hospital
admissions every year and stayed in hospital longer than those with diabetes only (controls).
This was regardless of whether or not the admissions were mental health related. As expected,
people with SMI had more mental health-related admissions and stayed in hospital longer following
those admissions. However, we also found that, for admissions related to physical health conditions,
people with SMI and diabetes spent significantly more days in hospital per year (p < 0.0001) than
people with diabetes alone. The difference in the number of admissions every year was small
(0.679 and 0.556 admissions per year for cases and controls, respectively), but statistically
significant (p = 0.018).
We also found that people with SMI incurred more costs than those without SMI. This difference was
observed across both primary and secondary care. The main cost driver was secondary care and
hospitalisation, which accounted for 83.3% and 72.5% of overall health-care expenditure for people
with diabetes and SMI and for people with diabetes alone, respectively.
TABLE 17 Objective 6: baseline characteristics for people with SMI and T2DM (cases) and matched people with T2DM






2001–2 268 (4.2) 70 (4.3) 198 (4.2)
2002–3 417 (6.5) 97 (6.0) 320 (6.7)
2003–4 470 (7.4) 118 (7.3) 352 (7.4)
2004–5 461 (7.2) 119 (7.4) 342 (7.2)
2005–6 464 (7.3) 127 (7.8) 337 (7.1)
2006–7 603 (9.4) 149 (9.2) 454 (9.5)
2007–8 463 (7.3) 139 (8.6) 324 (6.8)
2008–9 464 (7.3) 115 (7.1) 349 (7.3)
2009–10 496 (7.8) 106 (6.5) 390 (8.2)
2010–11 477 (7.5) 119 (7.4) 358 (7.5)
2011–12 444 (7.0) 117 (7.2) 327 (6.9)
2012–13 429 (6.7) 113 (7.0) 316 (6.6)
2013–14 336 (5.3) 84 (5.2) 252 (5.3)
2014–15 231 (3.6) 56 (3.5) 175 (3.7)
SD, standard deviation.
a Including those diagnosed by a GP and those having relevant medication.
b From date of T2DM diagnosis to study end date, transfer-out date or last collection date, whichever occurred first.
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TABLE 18 Objective 6: average resource use per person per year for people with SMI and T2DM (cases) and matched people with T2DM but no SMI (controls)
Resource use and cost
Crude Adjusted
p-valueTotal Cases (T2DM+ SMI) Control (T2DM only) Total Cases (T2DM+ SMI) Control (T2DM only)
N (people) 6383 1620 4763 6383 1620 4763
Resource use, mean (SD)
Primary care contacts 16.27 (10.64) 20.07 (12.27) 14.98 (9.69) 16.75 (6.50) 20.94 (7.76) 15.33 (5.31) < 0.0001
Consultation only 9.54 (7.12) 12.14 (8.36) 8.66 (6.41) 9.81 (3.75) 12.68 (4.39) 8.84 (2.91) < 0.0001
Medicine/prescription related 5.74 (4.63) 6.88 (5.73) 5.35 (4.12) 5.92 (2.62) 7.18 (3.20) 5.49 (2.23) 0.245
Test related 1.25 (1.48) 1.31 (1.49) 1.23 (1.48) 1.29 (0.51) 1.35 (0.52) 1.27 (0.50) 0.491
Inpatient stays
Annual number of admissionsa 0.61 (1.72) 0.75 (2.00) 0.56 (1.61) 0.64 (0.58) 0.87 (0.71) 0.57 (0.51) 0.001
Mental health relatedb 0.20 (0.14) 0.07 (0.25) 0.003 (0.05) 0.04 (0.13) 0.14 (0.22) 0.0004 (0.01) < 0.0001
Non-mental health related 0.59 (1.71) 0.68 (1.96) 0.56 (1.61) 0.62 (0.40) 0.74 (0.44) 0.58 (0.38) 0.018
Annual number of inpatient days 5.11 (24.63) 11.60 (44.96) 2.91 (10.33) 6.46 (16.00) 16.98 (28.01) 2.89 (5.08) < 0.0001
Mental health related 0.96 (9.50) 3.36 (16.88) 0.134 (4.63) 2.34 (10.46) 8.93 (19.30) 0.10 (0.34) < 0.0001
Non-mental health related 4.16 (22.41) 8.24 (41.39) 2.77 (9.10) 4.72 (6.46) 10.66 (9.60) 2.70 (2.90) < 0.0001
Cost (£), mean (SD)
Total 2618.7 (7214.8) 4059.0 (12,230.8) 2128.8 (4237.5) 2708.6 (2705.2) 4472.5 (3767.4) 2108.6 (1887.8) < 0.0001
Primary care contacts 618.0 (614.2) 804.0 (785.5) 554.8 (529.2) 637.0 (331.1) 849.2 (411.1) 564.8 (263.1) < 0.0001
Inpatient stays 2000.6 (7100.0) 3255.0 (12,180.6) 1574.0 (4049.7) 2170.6 (3033.8) 3883.3 (4543.6) 1588.0 (1944.8) < 0.0001
Mental health related 156.2 (1672.0) 510.5 (2770.9) 35.7 (1038.7) 342.5 (1474.8) 1271.0 (2719.9) 26.7 (82.5) < 0.0001
Non-mental health related 1844.4 (6834.3) 2744.6 (11,770.5) 1538.3 (3889.1) 1982.4 (2561.6) 3154.4 (3577.8) 1583.8 (1953.5) < 0.0001
SD, standard deviation.
a Number of admissions is at the spell level. Hence, if a person transfers to another hospital, it will count as two admissions.





















































































































































































































































































Regression analysis results for adjusted health-care resource utilisation and costs based
on baseline characteristics
To take sample heterogeneity into account, we conducted a series of generalised linear regressions to
adjust resource use and cost results by people’s baseline characteristics. These results can be found in
the ‘adjusted’ section in Table 18. Baseline characteristics that were controlled for included age at diabetes
diagnosis, sex, ethnicity, deprivation, comorbidities, medication use, time since diabetes diagnosis
and financial year of diabetes diagnosis. Generalised linear regression with gamma distribution and
log-link function was chosen, based on the Park and Pregibon tests, because of the non-normality of
the data. After adjustment, the differences in resource use and costs between people with and people
without SMI remained significant, except for differences in numbers of prescription-related and
test-related consultations.
Figure 9 demonstrates the 10-year trend of annual health-care cost per person for people with diabetes
and SMI and people with diabetes but no SMI. As shown, people with SMI incurred significantly higher
annual health-care costs across this 10-year horizon. Cases and controls followed a similar trend: higher
costs were incurred in the first year after diagnosis, followed by a cost reduction in the second year;
thereafter, the annual costs slowly increased year on year. This trend was more prominent in people
with SMI and diabetes than in those with diabetes alone.
Table 19 shows the impact of SMI on total costs among people with diabetes. SMI increased the total
costs by 82.6% (exp0.602 – 1), increased the primary care costs by 70.9% and increased secondary care
costs by 110.9%.
Summary of findings
People with SMI and diabetes had higher costs than people with diabetes alone. We found that the
main cost driver was secondary care, which accounted for 83.3% of overall health-care costs for
those with diabetes and SMI and for 72.5% of overall health-care costs for people with diabetes alone.
On average, people with diabetes and SMI use more primary care services every year than people with
diabetes alone. The same trend applied to hospitalisation: people with diabetes and SMI tended to
have more hospital admissions every year and to stay in hospital longer than those with diabetes only.





























FIGURE 9 Objective 6: trend for annual health-care cost per person with SMI and T2DM (cases) and matched person
with T2DM but no SMI (controls).
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TABLE 19 Objective 6: generalised linear regression results showing the impact of SMI on costs among people with T2DM
Adjusted risk factors
Total (n= 6383) Primary care (n= 6383) Secondary care (n= 6383)
Coefficient p-value 95% CI Coefficient p-value 95% CI Coefficient p-value 95% CI
Intercept 7.848 < 0.0001 7.450 to 8.247 6.281 < 0.0001 6.090 to 6.474 7.619 < 0.0001 7.004 to 8.234
Age (years) at T2DM diagnosis 0.013 < 0.0001 0.010 to 0.017 –0.001 0.357 –0.003 to 0.001 0.020 < 0.0001 0.015 to 0.026
Sex
Male Reference Reference Reference Reference Reference Reference Reference Reference Reference
Female 0.043 0.0325 –0.042 to 0.127 0.178 < 0.0001 0.137 to 0.219 0.027 0.678 –0.102 to 0.156
Case
With SMI (case) 0.602 < 0.0001 0.502 to 0.702 0.253 < 0.0001 0.204 to 0.301 0.746 < 0.0001 0.594 to 0.899
Without SMI (control) Reference Reference Reference Reference Reference Reference Reference Reference Reference
Ethnicity
White Reference Reference Reference Reference Reference Reference Reference Reference Reference
Non-white (Asian, black,
other, mixed)
0.151 0.031 0.014 to 0.289 0.062 0.064 –0.004 to 0.128 0.180 0.094 –0.031 to 0.390
Unknown < 0.0001 –1.524 to –1.172 –0.425 < 0.0001 –0.511 to –0.339 –2.544 < 0.0001 –2.823 to –2.265
Deprivation (IMD 2010)
1st quintile (least deprived) Reference Reference Reference Reference Reference Reference Reference Reference Reference
2nd quintile 0.175 0.017 0.032 to 0.319 0.107 0.003 0.037 to 0.177 0.135 0.228 –0.084 to 0.354
3rd quintile 0.143 0.050 0.000 to 0.286 0.164 < 0.0001 0.095 to 0.234 0.105 0.344 –0.113 to 0.324
4th quintile 0.157 0.025 0.020 to 0.295 0.141 < 0.0001 0.073 to 0.208 0.101 0.350 –0.111 to 0.312
5th quintile (most deprived) 0.136 0.054 –0.002 to 0.275 0.155 < 0.0001 0.088 to 0.223 0.059 0.589 –0.155 to 0.273
Missing 0.233 0.736 –1.121 to 1.588 0.462 0.170 –0.199 to 1.123 0.009 0.993 –2.052 to 2.070
Comorbidities
Hypertension 0.126 0.007 0.034 to 0.218 0.126 < 0.0001 0.082 to 0.170 0.132 0.066 –0.008 to 0.272
Charlson Index diseases,
mean (SD)






















































































































































































































































































TABLE 19 Objective 6: generalised linear regression results showing the impact of SMI on costs among people with T2DM (continued )
Adjusted risk factors
Total (n= 6383) Primary care (n= 6383) Secondary care (n= 6383)
Coefficient p-value 95% CI Coefficient p-value 95% CI Coefficient p-value 95% CI
Medications within 15-month window
Antidepressants 0.260 < 0.0001 0.161 to 0.359 0.423 < 0.0001 0.374 to 0.472 0.202 0.008 0.052 to 0.352
Antidiabetes 0.152 0.017 0.027 to 0.278 0.144 < 0.0001 0.084 to 0.205 0.142 0.143 –0.048 to 0.333
T2DM duration 0.062 < 0.0001 0.045 to 0.079 0.158 < 0.0001 0.149 to 0.166 0.024 0.074 –0.002 to 0.050
Financial year at T2DM diagnosis
1998–9 0.270 0.303 –0.244 to 0.785 –0.168 0.188 –0.419 to 0.082 0.384 0.335 –0.397 to 1.165
1999–2000 0.352 0.108 –0.077 to 0.781 0.161 0.133 –0.049 to 0.370 0.382 0.249 –0.268 to 1.031
2000–1 Reference Reference Reference Reference Reference Reference Reference Reference Reference
2001–2 0.121 0.427 –0.177 to 0.418 0.194 0.009 0.048 to 0.339 0.042 0.854 –0.409 to 0.493
2002–3 0.094 0.499 –0.179 to 0.368 0.124 0.067 –0.009 to 0.257 –0.004 0.984 –0.421 to 0.412
2003–4 0.034 0.805 –0.234 to 0.301 0.159 0.017 0.029 to 0.290 –0.087 0.677 –0.494 to 0.320
2004–5 0.019 0.891 –0.252 to 0.289 0.215 0.001 0.084 to 0.347 –0.071 0.736 –0.483 to 0.341
2005–6 –0.044 0.755 –0.318 to 0.231 0.283 < 0.0001 0.149 to 0.416 –0.255 0.232 –0.674 to 0.164
2006–7 –0.150 0.262 –0.413 to 0.112 0.300 < 0.0001 0.172 to 0.427 –0.401 0.051 –0.804 to 0.002
2007–8 –0.101 0.481 –0.382 to 0.180 0.329 < 0.0001 0.194 to 0.465 –0.356 0.106 –0.787 to 0.076
2008–9 –0.349 0.015 –0.631 to –0.068 0.316 < 0.0001 0.179 to 0.453 –0.646 0.003 –1.075 to –0.217
2009–10 –0.351 0.015 –0.634 to –0.067 0.302 < 0.0001 0.165 to 0.440 –0.634 0.004 –1.067 to –0.201
2010–11 –0.442 0.003 –0.734 to –0.150 0.250 < 0.0001 0.110 to 0.391 –0.807 < 0.0001 –1.257 to –0.357
2011–12 –0.434 0.005 –0.735 to –0.134 0.229 0.002 0.086 to 0.373 –0.775 0.001 –1.238 to –0.312
2012–13 –0.928 < 0.0001 –1.231 to –0.625 0.163 0.029 0.016 to 0.310 –1.460 < 0.0001 –1.927 to –0.993
2013–14 –1.143 < 0.0001 –1.466 to –0.821 –0.029 0.710 –0.185 to 0.126 –1.506 < 0.0001 –2.001 to –1.012






















































Objective 7: identifying health-care interventions associated with better
outcomes for people with diabetes and severe mental illness
Objective
The objective was to identify which health-care interventions may be associated with better health
outcomes for people with SMI and diabetes.
Study population
For objective 4, we combined data sets B and C (see Figure 2) and used comparisons between people
with SMI (cases) and people without SMI (controls) to estimate the association between SMI status and
the provision of physical health checks. For objective 7, we conducted further investigations to explore
the association between SMI and health checks in the presence of macrovascular complications.
The development of macrovascular complications as a physical health outcome was defined as the
presence of myocardial infarction, peripheral vascular disease or stroke during patients’ follow-up
periods. Although under constant review, the QOF has been incentivising primary care providers
to perform physical health checks as ongoing management for patients on the register for these
conditions. For instance, regular checks of blood pressure and cholesterol levels were included as QOF
indicators for patients with coronary heart disease (CHD) and stroke before 2011/12. These indicators
were also incentivised by the QOF for patients with CHD, stroke and peripheral arterial disease in
2012/13 and 2013/14. Since 2014/15, however, only checks on blood pressure remain incentivised for
patients with CHD, stroke or peripheral arterial disease, and regular checks for cholesterol levels are
no longer required.111 We hypothesised that physical health checks for blood pressure and cholesterol
could influence people’s health outcomes, and would also be affected by the presence of macrovascular
complications.
For this objective, we therefore applied restrictions on the patient sample used in objective 4 (see
Objective 4: comparing the health outcomes of people with diabetes and severe mental illness with the health
outcomes of people with diabetes without severe mental illness, Study population) and compared only cases
and controls with the same status of macrovascular complications (as a health outcome), so that the
impact of these complications on health checks was equal within case–control clusters. A total of 8724
patients remained in this restricted sample after controls with a macrovascular complication status
different from that of cases were excluded.
Variables and statistical methods
The exposure and explanatory variables and statistical methods for this objective were primarily based
on the core and extended models, as reported in objective 4 (see Objective 4: comparing the health
outcomes of people with diabetes and severe mental illness with the health outcomes of people with diabetes
without severe mental illness).
We explored the suitability of the CPRD data set for assessing individual interventions in terms of
quality and consistency of recording by practices. Recording was not sufficiently comprehensive to
allow detailed measurement of frequent and often complex interventions such as medication history
and comprehensive care pathways. For referrals, we were not able to confirm attendance as we did not
have linkage to outpatient data. However, we were able to ascertain whether or not lower frequency
interventions such as health checks, diabetes education and influenza vaccination had been performed
and we used these as the basis of our analysis.
For the impact of SMI on receipt of health checks, we re-estimated the core and extended models of
blood pressure, cholesterol, HbA1c and BMI, as reported in objective 4. An interaction term between
the status of SMI and macrovascular complications was added to these models to explore whether or
not the impact of SMI could be modified by the status of complications.
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For the impact of health checks on health outcomes, we separately estimated the association between
the level of each health check, measured as the mean number per year, and markers of depression and
anxiety using the core model reported in objective 4 (see Objective 4: comparing the health outcomes of
people with diabetes and severe mental illness with the health outcomes of people with diabetes without
severe mental illness). We then added an interaction term between the level of health checks and SMI
status to explore whether or not the association between health checks and depression could be
modified by this.
We did not investigate the impact of health checks on physical health outcomes because of the
confounding relationship between the two. We expected that the level of health checks would
potentially be affected by the other physical health outcomes for reasons similar to why these health
checks would be affected by macrovascular complications status. For instance, patients with poorer
diabetes and cardiovascular control could potentially receive more frequent physical checks; death in
the follow-up period would reduce health checks received, but deteriorated health status prior to death
would increase physical health checks. Owing to this two-way causality, the estimated association
between health checks and physical health outcomes would be biased using these patient-level data.
After initial investigation, we were unable to proceed with investigating the impact of retinopathy
screening, diabetes education and influenza vaccination on health outcomes because of limitations
in the overall data quality and the under-recording issue in primary care data for people with
SMI. A descriptive summary of the provision of these health-care interventions can be found in
Appendix 4, Table 32.
Results
Descriptive statistics
The baseline characteristics of the restricted sample are summarised in Table 20. Separating patients
by macrovascular complication status, we found that patients without complications were diagnosed
with SMI and T2DM at a younger age than patients with complications. The mean diagnosis age
was 47.0 years for SMI and 56.2 years for T2DM for patients with SMI and without complications.
TABLE 20 Objective 7: baseline characteristics for cases (people with T2DM and SMI) and controls (people with T2DM)
by macrovascular complications status
Characteristic









Patients (n) 2000 6517 89 118
Number of controls, n (%)
4 1031 (51.6) 0 (0)
3 595 (29.8) 5 (5.6)
2 234 (11.7) 19 (21.4)
1 140 (7.0) 65 (73.0)
Diagnosis age (years), mean (SD)
SMI 46.99 (16.98) 59.75 (19.94)
T2DM 56.24 (13.12) 56.90 (12.67) 67.01 (11.28) 68.72 (11.46)
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TABLE 20 Objective 7: baseline characteristics for cases (people with T2DM and SMI) and controls (people with T2DM)
by macrovascular complications status (continued )
Characteristic









SMI type, n (%)
Schizophrenia 1055 (52.8) 50 (56.2)
Schizoaffective
disorder
105 (5.3) 2 (2.3)
Bipolar disorder 644 (32.2) 29 (32.6)
Depression and
psychosis
168 (8.4) 7 (7.9)
Other affective
disorder
21 (1.1) 1 (1.1)
Mixed 7 (0.4) 0 (0)
Age at follow-up start
(years), mean (SD)
57.03 (13.05) 57.63 (12.53) 68.22 (10.57) 69.98 (10.83)
Duration of T2DM
(years), mean (SD)
0.82 (2.91) 0.74 (2.69) 1.23 (2.96) 1.33 (3.41)
Duration of follow-up (years)
Mean (SD) 5.76 (4.32) 5.97 (4.33) 8.91 (5.21) 8.86 (5.06)
Median (minimum,
maximum)
4.88 (0.02, 24.25) 5.25 (0.003, 24.81) 8.92 (0.09, 25.84) 8.54 (0.21, 21.67)
Family history of
diabetes, n (%)
297 (14.9) 1253 (19.2) 13 (14.6) 19 (16.1)
Sex, n (%)
Male 963 (48.2) 3114 (47.8) 41 (46.1) 51 (43.3)
Female 1037 (51.9) 3403 (52.2) 48 (53.9) 67 (56.9)
Ethnicity, n (%)
White 1657 (82.9) 5164 (79.2) 80 (89.9) 103 (87.3)
Asian 131 (6.6) 443 (6.8) 5 (5.6) 8 (6.8)
Black 98 (4.9) 234 (3.6) 3 (3.4) 0 (0)
Mixed 21 (1.1) 43 (0.7) 0 (0) 0 (0)
Other 38 (1.9) 135 (2.1) 0 (0) 0 (0)
Not stated/unknown 55 (2.8) 498 (7.6) 1 (1.1) 7 (5.9)
Deprivation (IMD 2010), n (%)
1st quintile (least
deprived)
261 (13.1) 1007 (15.5) 7 (7.9) 19 (16.1)
2nd quintile 330 (16.5) 1278 (19.6) 15 (16.9) 18 (15.3)
3rd quintile 371 (18.6) 1299 (19.9) 20 (22.5) 30 (25.4)
4th quintile 485 (24.3) 1468 (22.5) 25 (28.1) 28 (23.7)
5th quintile
(most deprived)
550 (27.5) 1460 (22.4) 22 (24.7) 23 (19.5)
Missing 3 (0.2) 5 (0.1) 0 (0) 0 (0)
continued
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TABLE 20 Objective 7: baseline characteristics for cases (people with T2DM and SMI) and controls (people with T2DM)
by macrovascular complications status (continued )
Characteristic












227 (11.4) 895 (13.7) 29 (32.6) 47 (39.8)
Hypertension, n (%) 645 (32.3) 2890 (44.4) 44 (49.4) 64 (54.2)
Dementia, n (%) 28 (1.4) 24 (0.4) 1 (1.1) 0 (0)
Learning disability,
n (%)
19 (1.0) 20 (0.3) 0 (0) 0 (0)
Charlson Index score,
mean (SD)
0.47 (0.69) 0.50 (0.75) 0.76 (1.09) 0.86 (1.02)
Medications, n (%)
Antidepressants 982 (49.1) 1256 (19.3) 32 (36.0) 21 (17.8)
Antipsychotics
Typical 393 (19.7) 61 (0.9) 15 (16.9) 9 (7.6)
Atypical 908 (45.4) 43 (0.7) 20 (22.5) 0 (0)
Antidiabetics 451 (22.6) 1316 (20.2) 34 (38.2) 42 (35.6)
Antihypertensives 887 (44.4) 3505 (53.8) 54 (60.7) 86 (72.9)
Lipid-lowering drugs 621 (31.1) 2145 (32.9) 32 (36.0) 47 (39.8)
Statins 604 (30.2) 2089 (32.1) 32 (36.0) 44 (37.3)
Lifestyle factors, n (%)
Smoking
Non-smoker 505 (25.3) 1942 (29.8) 17 (19.1) 28 (23.7)
Ex-smoker 361 (18.1) 1342 (20.6) 13 (14.6) 34 (28.8)
Current smoker 608 (30.4) 1018 (15.6) 13 (14.6) 9 (7.6)
Missing 526 (26.3) 2215 (34.0) 46 (51.7) 47 (39.8)
Drinking
Non-drinker 365 (18.3) 634 (9.7) 7 (7.9) 10 (8.5)
Ex-drinker 118 (5.9) 114 (1.8) 3 (3.4) 1 (0.9)
Current drinker 610 (30.5) 1736 (26.6) 17 (19.1) 32 (27.1)
Missing 907 (45.4) 4033 (61.9) 62 (69.7) 75 (63.6)




33.15 (7.07) 32.88 (6.98) 29.94 (4.78) 29.34 (4.61)
< 20, n (%) 10 (0.5) 42 (0.6) 1 (1.1) 1 (0.9)
20–24, n (%) 133 (6.7) 359 (5.5) 5 (5.6) 14 (11.9)
25–29, n (%) 359 (18.0) 1105 (17.0) 22 (24.7) 26 (22.0)
30–39, n (%) 688 (34.4) 1947 (29.9) 17 (19.1) 34 (28.8)
> 40, n (%) 215 (10.8) 591 (9.1) 2 (2.3) 1 (0.9)
Missing, n (%) 595 (29.8) 2473 (38.0) 42 (47.2) 42 (35.6)
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Diagnosis ages were increased by > 10 years for patients with complications. In both groups, controls
were closely matched to case patients in terms of age. There were more female patients in the group
with complications. Socioeconomic deprivation was more common in people with SMI than in people
without SMI.
Physical comorbidities, such as cardiovascular disease, hypertension and Charlson Index comorbidities,
were more likely to be diagnosed in the group with macrovascular complications than in the group without
complications, consistent with the pattern of prescription rates of antidiabetes, antihypertensive and
lipid-lowering drugs. In these groups, patients with SMI had lower prevalence of physical comorbidities
and lower prescription rates for antihypertensive and lipid-lowering drugs than people without SMI.
This finding, however, may not suggest better baseline health status for people with SMI, but may
reflect under-reporting or underdetection for this population (as previously discussed in Objective 4:
comparing the health outcomes of people with diabetes and severe mental illness with the health outcomes of
people with diabetes without severe mental illness).
TABLE 20 Objective 7: baseline characteristics for cases (people with T2DM and SMI) and controls (people with T2DM)
by macrovascular complications status (continued )
Characteristic












7.84 (1.99) 7.91 (1.96) 7.38 (2.09) 7.80 (1.90)
≤ 7.5, n (%) 617 (30.9) 1991 (30.6) 29 (32.6) 26 (22.0)
> 7.5, n (%) 427 (21.4) 1468 (22.5) 13 (14.6) 23 (19.5)
Missing, n (%) 956 (47.8) 3058 (46.9) 47 (52.8) 69 (58.5)
Cholesterol (mmol/l),
mean (SD)
5.35 (1.39) 5.28 (1.28) 5.35 (1.35) 5.11 (1.29)
≤ 5, n (%) 668 (33.4) 2317 (35.6) 25 (28.1) 40 (33.9)
> 5, n (%) 820 (41.0) 2754 (42.3) 30 (33.7) 32 (27.1)




81.30 (10.47) 82.23 (10.58) 84.03 (14.76) 79.75 (11.24)
≤ 80, n (%) 928 (46.4) 2766 (42.4) 38 (42.7) 62 (52.5)
> 80, n (%) 794 (39.7) 2732 (41.9) 38 (42.7) 41 (34.8)




135.07 (17.59) 139.46 (17.81) 145.71 (24.58) 146.72 (22.71)
≤ 140, n (%) 1187 (59.4) 3294 (50.5) 41 (46.1) 54 (45.8)
> 140, n (%) 535 (26.8) 2204 (33.8) 35 (39.3) 49 (41.5)
Missing, n (%) 278 (13.9) 1019 (15.6) 13 (14.6) 15 (12.7)
SD, standard deviation.
a HbA1c of 7.5% = 58mmol/mol.
Note
Total, N = 8724 [cases, n= 2089 (24.0%); controls, n= 6635 (76.0%)].
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Lifestyle and BMI were better recorded in people with SMI and without macrovascular complications.
Although there were a high number of missing values, limiting interpretation, results suggest that the
group without macrovascular complications had greater BMI at baseline.
Table 21 shows descriptive statistics for the outcome variables. Without adjustment, the number of
health checks for HbA1c and BMI were higher in the group without macrovascular complications and
checks on blood pressure were higher in the group with complications. Within groups, people with SMI
were more likely to receive checks for cholesterol level and BMI in the group without complications,
and less likely to receive these checks in the group with complications, than people without SMI.
For blood pressure and HbA1c, the crude rates of health checks were lower in people with SMI than
in people without SMI in both groups. These statistics also showed that people with SMI were more
likely to have depression and anxiety recorded in their primary care records.
Regression analysis results for the adjusted impact of severe mental illness on levels
of physical health checks
The adjusted impact of SMI on levels of physical health checks is reported in Table 22. These results
suggest a significant association between SMI and health checks for blood pressure, cholesterol and
BMI. These relationships differ by whether or not macrovascular complications have been diagnosed.
Results from the core models show that people with SMI are more likely, by around 5%, to receive
checks on blood pressure than people without SMI in the group without complications (IRR 1.05,
95% CI 1.03 to 1.08). This IRR is diminished by around 20% (IRR 0.80, 95% CI 0.70 to 0.91) in the
group with complications; people with SMI are less likely, by around 16%, to receive this check
[calculation of interaction between diagnosis of SMI and macrovascular complications (IRR 1.05 × 0.80)]
than people without SMI in this group. A similar pattern was also found for the health checks for
cholesterol and BMI, with HbA1c showing no significant association with the status of either SMI or
macrovascular complications. Results from the extended models confirm these findings. The estimated
impact of the other explanatory variables is consistent with the results for objective 4.
The adjusted association between health checks and depression and anxiety is provided in Table 23.
These results suggest that health checks for blood pressure and BMI are associated with increased
recording of depression and anxiety after adjusting for SMI status and other risk factors. For instance,
an additional check on blood pressure per year increases the probability of depression and anxiety
TABLE 21 Objective 7: outcome variables by macrovascular complication status for cases (people with T2DM and SMI)
and controls (people with T2DM)
Outcome variable
Without macrovascular complications With macrovascular complications
Cases (T2DM+ SMI) Controls (T2DM) Cases (T2DM+ SMI) Controls (T2DM)
Patients (n) 2000 6517 89 118
Number of health checks per year, mean (SD)
HbA1c 1.80 (1.30) 1.81 (1.16) 1.56 (0.66) 1.76 (0.69)
Cholesterol 1.39 (1.00) 1.34 (0.84) 1.21 (0.57) 1.39 (0.61)
Blood pressure 2.92 (2.56) 2.97 (4.99) 3.01 (1.79) 3.70 (2.00)
BMI 2.10 (1.99) 1.98 (4.84) 1.56 (1.24) 1.68 (1.15)
Mental health outcome, n (%)
Depression and anxiety 506 (25.3) 1032 (15.8) 31 (34.8) 30 (25.4)
SD, standard deviation.
Note
Total, N = 8724 [cases, n = 2089 (24.0%); controls, n = 6635 (76.0%)].
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TABLE 22 Objective 7: adjusted impact of SMI on physical health checks, modified by macrovascular complication status
Model
Health checks
Blood pressure Cholesterol HbA1c BMI
IRR 95% CI p-value IRR 95% CI p-value IRR 95% CI p-value IRR 95% CI p-value
Core modelsa
Diagnosis of SMI 1.054 1.028 to 1.081 < 0.001 1.069 1.047 to 1.092 < 0.001 1.013 0.991 to 1.036 0.244 1.104 1.074 to 1.134 < 0.001
Macrovascular complications
(outcome)
0.969 0.703 to 1.334 0.847 0.523 0.245 to 1.118 0.094 1.055 0.574 to 1.937 0.864 0.804 0.547 to 1.182 0.267
SMI*macrovascular
complications
0.796 0.700 to 0.905 < 0.001 0.843 0.753 to 0.945 0.003 0.918 0.825 to 1.021 0.115 0.790 0.682 to 0.915 0.002
Patients 8697 8710 8706 8720
Case–control clusters 2081 2082 2084 2087
Extended modelsb
Diagnosis of SMI 1.060 1.034 to 1.087 < 0.001 1.070 1.048 to 1.093 < 0.001 1.014 0.992 to 1.037 0.222 1.099 1.070 to 1.129 < 0.001
Macrovascular complications
(outcome)
0.983 0.710 to 1.362 0.918 0.579 0.254 to 1.318 0.193 1.047 0.568 to 1.930 0.883 0.765 0.521 to 1.122 0.170
SMI*macrovascular
complications
0.802 0.706 to 0.910 0.001 0.840 0.752 to 0.940 0.002 0.921 0.828 to 1.024 0.129 0.811 0.700 to 0.939 0.005
Patients 8697 8710 8706 8720
Case–control clusters 2081 2082 2084 2087
* Interaction between terms.
a Core models were adjusted for demographics, deprivation, comorbidities, medications and time effects.
b Extended models were adjusted for demographics, deprivation, comorbidities, medications, family history, lifestyle, biometric measures and time effects.
Note





















































































































































































































































































TABLE 23 Objective 7: adjusted impact of physical health checks on depression and anxiety, modified by the status of SMI
Interaction
1 2 3 4
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Without interactiona
Diagnosis of SMI 1.865 1.620 to 2.147 < 0.001 1.858 1.612 to 2.141 < 0.001 1.864 1.618 to 2.147 < 0.001 1.860 1.616 to 2.142 < 0.001
Health checks (per year)
Blood pressure 1.016 1.005 to 1.026 0.004
Cholesterol 1.031 0.908 to 1.170 0.637
HbA1c 1.054 0.986 to 1.125 0.121
BMI 1.010 1.002 to 1.018 0.014
Patients 4912 4912 4912 4912
Case–control clusters 1134 1134 1134 1134






















































1 2 3 4
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
With interactiona
Diagnosis of SMI 1.598 1.254 to 2.037 < 0.001 2.004 1.502 to 2.674 < 0.001 1.939 1.373 to 2.737 < 0.001 2.042 1.684 to 2.476 < 0.001
Health checks (per year)
Blood pressure 1.014 1.005 to 1.023 0.002
Blood
pressure*SMI
1.053 0.992 to 1.118 0.091
Cholesterol 1.061 0.930 to 1.212 0.377
Cholesterol*SMI 0.947 0.786 to 1.140 0.563
HbA1c 1.059 0.999 to 1.123 0.054
HbA1c*SMI 0.978 0.820 to 1.167 0.807
BMI 1.012 1.004 to 1.020 0.002
BMI*SMI 0.957 0.901 to 1.015 0.142
Patients 4912 4912 4912 4912
Case–control clusters 1134 1134 1134 1134
c-statistic 0.689 0.688 0.688 0.688
* Interaction between terms.
a These are based on the core model of depression and anxiety, adjusting for demographics, deprivation, comorbidities, medications and time effects.
Note





















































































































































































































































































being recorded by around 2% (OR 1.02, 95% CI 1.01 to 1.03); and one additional check on BMI
increases this probability by around 1% (OR 1.01, 95% CI 1.00 to 1.02). The regressions with interaction
terms show weak evidence that, in people with SMI, health checks for blood pressure have a bigger
effect on the probability of depression and anxiety being classified than in people without SMI. An
additional check per year increases this probability by around 1% for people without SMI (OR 1.01,
95% CI 1.01 to 1.02) and by around 6% [calculation of interaction effect (IRR 1.01 × 1.05)] for people
with SMI. The impact of other health checks does not appear to be modified by the SMI status. The
estimated impact of the other explanatory variables is consistent with the results for objective 4.
Summary of findings
We found that the association between SMI and physical health checks was influenced by the
diagnosis of macrovascular complications. In the group without complications, people with SMI were
more likely to receive health checks than people without SMI, whereas SMI was associated with
reduced chances for receiving health checks in the group with complications.
The results also suggest that, in general, there is a positive association between the frequency of
physical health checks and the likelihood that patients had depression and anxiety recorded. It is
important to note that this finding is evidence of an association, rather than establishing causality;
patients who saw their GPs more often would be more likely to have their depression and anxiety
detected and recorded. This association, however, did not seem to differ between people with and
without SMI.
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Chapter 6 Qualitative interview study with
people with diabetes and severe mental illness,
family members and supporters, and
health-care staff (objective 5)
Introduction
The qualitative study aimed to explore the experiences of people living with and managing diabetes
alongside SMI. An overarching topic was the extent to which social circumstances (e.g. money for
transportation, type of neighbourhood, carer role) enabled or hindered people’s ability to receive
effective health care and to action preventative measures for diabetes and mental illness – eliciting
both actual experiences of people with diabetes and SMI and the perceptions of the influence of these
factors from health-care staff.
Objectives
This study focused on objective 5, to understand the factors that influence access to, and receipt of,
diabetes care for people with SMI. We also aimed to explore factors perceived to be associated with
variation in diabetes and mental health outcomes (objective 2) and perceived impacts of SMI on
diabetes management, and vice versa.
As the quantitative analyses of patient records were limited to investigation of variables recorded in
these data, we aimed to use the qualitative study to explore additional factors that may not be available
from health-care records. We intended to develop a more in-depth understanding of the reasons for
differences in diabetes care provision between people with and people without SMI observed in the
observational study and to explore how health services may be supporting diabetes management. We
also aimed to understand how people interacted with various health-care interventions for their diabetes
and to explore perceived benefits associated with these interventions (objective 7). Insights were
expected to also feed back into the quantitative study of health-care interventions (objective 7 analyses).
Methods
Ethics approval
Approval for this element of the study was given by the Greater Manchester West Research Ethics
Committee (reference number 18/NW/0005).
Sample
We included people living with both SMI and diabetes; those providing informal care, such as family
members and close friends; and health-care staff. Eligibility criteria and the sampling strategy for each
of these participant groups were as follows.
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People with diabetes and severe mental illness
l Aged ≥ 18 years.
l Recorded diagnosis of SMI (schizophrenia, schizoaffective disorder, bipolar disorder and manic
episodes, or non-organic psychoses), excluding those experiencing an acute relapse.
l Diagnosis of diabetes (excluding gestational diabetes).
l Living in the community (including supported housing, but not admitted to acute hospital settings).
l Had the capacity to provide informed consent to participate in the study.
We employed a maximum variation sampling strategy132 to include participants whose experiences
were likely to differ, enabling us to explore the range of factors potentially affecting diabetes
management, and to capture variations in diabetes care experiences.
From the expert consultation and scoping of the literature (see Chapter 4), we identified the following
participant characteristics that were expected to affect diabetes experiences and management:
l demographic (age, sex) and geographical (deprivation, region) characteristics
l family composition and presence of carer/supporter
l mental health and diabetes diagnoses
l diabetes medication
l diabetes control (determined by data obtained from health record)
l presence of other comorbidities
l provider of mental health care (e.g. primary or secondary mental health)
l provider of diabetes health care (e.g. primary care, secondary care).
We initially adopted a convenience sampling strategy in recruitment sites because of recognised
challenges to identifying and recruiting this patient population.133 We continuously monitored
variations in the sample, and worked with recruiting sites to increase diversity and include particular
characteristics that were not represented. For example, we sought to target people with a history of
diabetes complications to increase the sample variation. Our sampling strategy could not be informed
by preliminary analysis of CPRD data, as originally planned, owing to delays in obtaining CPRD data.
To achieve diversity across the relevant characteristics, we aimed to recruit a minimum of 30 patients.
In addition to adding participants who were under-represented in the study (e.g. those with poor
diabetes control), we also monitored data saturation in the later stages of recruitment, and continued
to recruit patients, with a stopping criteria of two, until we were satisfied that no new distinct ideas
relevant to the study objectives were emerging.134
Family members/supporters
We defined ‘family members/supporters’ as adults who were involved in the care of a person with
diabetes and SMI taking part in the study. We expected that this would include a spouse/partner,
parent or other family member, or close friend. They did not have to live with the person they
supported, but they had to be identified by a participating person with diabetes and SMI as providing
support for their health.
As people with SMI are more likely than the general diabetes population to have inadequate social
support,135 we anticipated that the total sample would be 15–20. To reach these numbers, we aimed
to monitor recruitment and adjust purposive sampling of people with diabetes and SMI accordingly
(i.e. to include more people with diabetes and SMI living with other adults).
Health-care staff
We defined health-care staff as commissioners, clinicians, nurses and other staff who are involved in
health-care services for SMI and diabetes. We used a purposive sampling strategy to ensure a mix of
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staff roles from differing organisations and services. We aimed to recruit a minimum of 15 staff to
achieve this variation and continued to recruit participants, with a stopping criterion of one, until we
achieved data saturation or a sufficient mix of staff roles (which we expected would affect perspectives
and experiences of supporting this population).
Recruitment
People with diabetes and severe mental illness
We identified and recruited potential participants with diabetes and SMI through three routes:
1. Community mental health teams in NHS mental health trusts, which conducted electronic searches
of registers or searched the case loads of psychiatrists and care co-ordinators. Learning from an
earlier study,133 we prioritised the second strategy because of limited recording of diabetes
diagnoses in patient records.
2. SMI and diabetes QOF registers61 in general practices. Practices identified patients who appeared
on both the SMI and diabetes QOF registers using a query in the electronic patient record system.
3. Networks at the University of York, such as participants from another study who had consented to
be contacted about taking part in future studies.136
Mental health trusts (n = 7) in two regions of England (North West, and Yorkshire and the Humber)
and general practices (n = 10) in Yorkshire and the Humber were chosen to include rural and urban
patient populations, areas of wealth and deprivation and areas where minority ethnic groups are well
represented. We expected that individual general practices would yield low participant numbers,
compared with mental health trusts. However, as previous research indicates that around 20–30%
of people with SMI are treated in primary care only and not in specialist mental health services,137
it was important to recruit from both settings as support for diabetes may differ.138
Care co-ordinators and practice staff were asked to check that potential participants met the inclusion
criteria for the study. Eligible participants were provided with an information pack about the study,
containing an invitation letter from participating sites, a participant information sheet and response
form (with prepaid envelope), and were asked to return a completed form to the research team if they
were interested in taking part. A researcher telephoned those who were interested to introduce the
study and answer any questions. Eligibility and capacity to consent were assessed during the telephone
call, and a suitable date and time for an interview was arranged.
Family members/supporters
All participants with diabetes and SMI were asked to identify a family member/supporter during their
interview. After the interview, the researcher explained that they would like to invite this person to
take part in an interview as well and gave participants an invitation pack to provide to their named
family member/supporter. Interested family member/supporter participants were asked to contact
the research team or to return a completed response form. This approach was used successfully in
the National Audit of Schizophrenia (involving the researcher DS) and avoids additional consent issues
for service user participants.139
We aimed to recruit 15 family members/supporters. However, many participants with diabetes and
SMI reported not having a family member or friend who provided support for their health, or the
family member was unwilling to participate in the study. Recruiting trusts were therefore encouraged
to renew recruitment efforts and we promoted the study more widely (including through the McPin
Foundation, an organisation dedicated to engaging people experiencing mental health difficulties to
participate in research), DIAMONDS VOICE members leveraged their networks, and we contacted
family member participants from another study who had consented to be contacted about taking part
in future studies.136
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Health-care staff
Eligible health-care staff participants were identified through University of York networks, or by asking
staff supporting the study in participating sites to identify people involved in diabetes care for people
with SMI, and invite them to the study. Potential participants were invited by e-mail and provided with
an information sheet about the study and asked to contact the study team if they wished to take part.
Written or audio-recorded verbal consent for all participants was taken at the time of interview. For
telephone interviews and for participants with a limited understanding of written English, the researcher
read out the statements contained in the study consent form to obtain verbal consent.
Data collection
We used in-depth semistructured interviews to explore individual experiences and perceptions of the
management of diabetes in people with diabetes and SMI. Participants were offered the choice of a
face-to-face or telephone interview; the former were conducted at home or another private venue,
according to participant preference. For health-care staff, it was expected that interviews would
be conducted at their workplace, although they were given the option of another suitable venue
if preferred.
A standardised semistructured interview format was used for all participants, tailored in length
to reflect the number of topics to be covered and to minimise participant burden. Key topics to
explore aligned with study objectives and were guided by a social inequalities framework (see Report
Supplementary Material 1). Separate interview guides for the three participant groups were developed
in partnership with study co-investigators and DIAMONDS VOICE members (see Chapter 3, Patient and
public involvement), following key principles outlined by Arthur and Nazroo.140 Interview guides were
also informed by the scoping of the literature and expert consultation process. This process led to the
inclusion of new topics to explore (e.g. sleep difficulties), and to the rephrasing of questions to aid
understanding and facilitate appropriate responses from participants. The patient topic guide was
piloted with a DIAMONDS VOICE member and feedback was used to refine the guide before
commencing data collection.
Topic guides were designed so that interviews with people with diabetes and SMI and with family
members/supporters would last approximately 45–60 minutes to allow for sufficient exploration while
minimising participant burden. This was particularly important for people with diabetes and SMI, some
of whom were likely to have cognitive and attention difficulties.2 To enable staff to take part during
working hours, interviews were designed to last approximately 30 minutes (fewer topics were included
in these). Interview guides were employed flexibly (e.g. ordering of topics and wording of specific
questions were tailored to individual participants), but ensured that key topics were covered.
Data were collected by Sue Bellass, an experienced qualitative researcher with experience of working
with people with cognitive and attentional difficulties and with people who may have fluctuating
mental capacity. Sue Bellass was supported by Najma Siddiqi and Jo Taylor throughout the data
collection period.
We planned to audio-record interviews, but allowed participants to consent separately to this. Two
participants with diabetes and SMI and four staff members declined audio-recording. Recorded
interviews were transcribed (intelligent verbatim) for analysis by a subcontractor with experience in
transcribing audio for academic research. For interviews that were not recorded, the researcher made
extensive field notes immediately after the interview. We sought to include non-English speakers (our
primary research sites include significant South Asian populations, who are at greater risk of diabetes
and SMI) and used a translator for one interview with a service user from the South Asian community.
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Data analysis
The framework method was used to analyse interview data, to allow for inductive analysis and analysis
of a priori themes and to enable us to move iteratively through the different stages in the analytical
process to develop explanatory accounts and facilitate mixed-methods integration.141,142
NVivo version 12 was used to manage and code anonymised interview transcripts, to test and apply
the coding frameworks, to identify and describe themes, and to explore potential differences between
participant groups.
Analysis involved two key stages (incorporating the five steps of framework analysis).141
Stage 1: developing and applying the coding frameworks [framework step 1
(‘conceptual scaffolding’), step 2 (‘indexing’) and step 3 (‘coding’)]
This involved identifying and extracting recurring ideas and concepts from across the data and
developing thematic coding frameworks (step 1), which incorporated a priori descriptive themes based
on the study objectives (including diabetes care experiences, and diabetes knowledge and education),
as well as those identified during analysis. To explore differences between participant groups, we
analysed these data separately, starting with people with diabetes and SMI and then applying and
refining the coding framework for the analysis of family members and health-care staff.
The coding frameworks were tested and modified as follows (step 2):
l The coding framework for people with diabetes and SMI was tested with eight interview transcripts,
chosen to represent a range of participants: two males and two females with bipolar disorder, and
two males and two females with schizophrenia.
l For family members, the diabetes and SMI participants’ framework was adapted and tested at the
same time because of the small number of participants.
l For staff, the diabetes and SMI participants’ framework was adapted and tested using four interviews,
drawn from different staff groups to ensure that the diversity of experiences was accounted for.
Once the frameworks were finalised, all interviews were coded using NVivo (step 3). A record of how
each framework was modified during development and testing was logged (manually for people with
diabetes and SMI and in NVivo for family members and staff). The final frameworks can be found in
Appendix 5, Boxes 1–3.
Stage 2: identifying cross-cutting themes and exploring relationships between
themes [framework step 4 (‘descriptive analysis’) and step 5 (‘explanatory analysis’)]
We then explored the coded data (by theme and subtheme) to identify thematic patterns and classify
findings into higher-order themes and to describe these with reference to relevant coded data (step 4).
Again, we started with the data from participants with diabetes and SMI to develop themes and
mapped the findings from family members and supporters onto these to explore similarities and
differences and to refine the meaning and descriptions of themes. This was an iterative process
involving regular discussion among the qualitative study team, using mind-mapping to explore links
between themes (step 5) and continuous checking against the coded data to ensure that themes
represented the accounts of all participants. Deviant cases were analysed to understand the variation
in managing diabetes in the sample of people with diabetes and SMI, and coding matrix queries were
used in NVivo to explore potential differences in diabetes experiences between people with
schizophrenia and bipolar disorder.
In a final step, a table with the main themes and subthemes mapped to coded data (see Appendix 6,
Tables 33–40) was shared with the wider research team for sense-checking and interpretation, and to
explore further the relationships between themes and the meaning of findings in the context of the
social inequalities framework that underpinned the study as a whole (step 5).
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Ensuring quality of data analysis
To ensure consistency, the key steps of the data analysis were carried out by the same person for each
group (participants with diabetes and SMI, and staff data: JL; family member data: Lyndsey Kramer, with
guidance from JL). To ensure reliability, coding was regularly discussed with Jo Taylor and Sue Bellass,
who also checked random samples of coded transcripts during the initial stages. To ensure credibility
and authenticity of findings, preliminary findings were discussed with people with diabetes and SMI,
family members and staff at co-design workshops (see Chapter 7, Co-design workshops) and at regular
meetings involving John Radford (service user co-investigator).
Results
In total, we interviewed 39 people with diabetes and SMI, nine family members and 30 health-care staff.
Participant characteristics
Of the 39 people with diabetes and SMI, 22 (56%) were men and 17 (44%) women (Table 24).
Schizophrenia was the most common SMI diagnosis (n= 22, 56%), followed by bipolar disorder (n= 13, 33%),
schizoaffective disorder (n= 2, 5%) and depressive psychosis (n= 2, 55%). Most participants (n= 36, 92%)
























SMI–DM T2 45 Male White Degree Employed
ES-G3-01 Schizophrenia Not clear T2 47 Male White No
qualifications
Unemployed
ES-G4-01 Schizophrenia SMI–DM T2 55 Male White GCSE/O levels Unemployed
ES-G4-02 Bipolar
disorder










SMI–DM T1 63 Male White Degree Retired

















Not clear T2 51 Male White Masters/PhD Unemployed





SMI–DM T2 59 Female White Masters/PhD Retired
ES-T2-06 Bipolar
disorder
Not clear T2 59 Female White GCSE/O levels Unemployed





ES-T2-09 Schizophrenia SMI–DM T2 44 Male White GCSE/O levels Unemployed
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ES-T2-16 Schizophrenia SMI–DM T2 65 Female White Degree Unemployed
ES-T2-18 Schizophrenia SMI–DM T2 48 Male White GCSE/O levels Unemployed
ES-T3-03 Bipolar
disorder





SMI–DM T2 67 Female White GCSE/O levels Retired
ES-T3-07 Bipolar
disorder
Not clear T2 71 Female White GCSE/O levels Unemployed
ES-T3-09 Schizophrenia Not clear T2 37 Female White GCSE/O levels Unemployed
ES-T3-11 Schizophrenia SMI–DM T2 60 Male White GCSE/O levels Unemployed
ES-T4-01 Schizophrenia Not clear T2 39 Female Mixed/
multiple
A levels Unemployed
ES-T4-02 Schizophrenia SMI–DM T2 53 Female White BTEC Unemployed
ES-T4-09 Depressive
psychosis
SMI–DM T2 60 Female White Degree Unemployed
ES-T4-10 Bipolar
disorder
SMI–DM T2 41 Male White No
qualifications
Unemployed
ES-T4-12 Schizophrenia SMI–DM T2 41 Female White GCSE/O levels Employed:
volunteer
ES-T4-13 Schizophrenia SMI–DM T2 53 Male White A levels Unemployed
ES-T5-05 Schizophrenia SMI–DM T2 35 Male Not
recorded
GCSE/O levels Unemployed
ES-T5-08 Schizophrenia SMI–DM T2 51 Male White No
qualifications
Unemployed





ES-T5-10 Schizophrenia SMI–DM T2 64 Male White GCSE/O levels Unemployed





Same time T2 39 Female Not
recorded
A levels Unemployed
ES-T6-07 Schizophrenia SMI–DM T2 60 Male White No
qualifications
Unemployed
ES-T7-02 Schizophrenia Not clear T2 28 Male Mixed/
multiple
Not recorded Unemployed












A level, Advanced level; BTEC, Business and Technology Education Council; DM, diabetes mellitus; ID, identifier;
NVQ, National Vocational Qualification; O level, Ordinary level; OND, Ordinary National Diploma; PhD, Doctor of
Philosophy; T, type.
This table has been reproduced with permission from Bellass et al.143 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
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had a diagnosis of T2DM; three (8%) had type 1 diabetes. Twenty-three (59%) participants had received a
diagnosis of SMI before their diabetes diagnosis, two (5%) had received the diabetes diagnosis first and two
(5%) had received it at the same time; for the remainder, diagnosis order was unknown (n= 12, 31%). The
mean age of participants was 53 years (range 28–71 years), with women being older than men (females,
mean 55 years; males, mean 52 years). Most participants identified as white (n = 27, 69%), with others
identifying as Asian/Asian British (n = 2, 5%), black/African/Caribbean/black British (n = 3, 8%) and
mixed/multiple (n = 2, 5%) ethnic groups. Information on ethnicity was missing for five (13%)
participants. The highest education level varied, with participants ranging from having no qualifications
(n = 9, 23%) to 10 (26%) having qualifications beyond General Certificate of Secondary Education
(GCSE) level. Data on education were missing for three (8%) participants. Only two (5%) participants
were working, whereas 32 (82%) were unemployed and the remainder (n = 5, 13%) were retired.
As shown in Table 25, among the nine family members in the final sample, six were female; ages
ranged from 37 to 73 years (mean 59 years) and all participants who identified an ethnic group
were white British (n = 8); one person’s ethnicity information was not recorded. All participants with
recorded education data were educated to GCSE level or above, with six educated beyond degree
level. Two participants had missing education data. Most family members were married to the person
they supported (n = 6); of the remainder, two were parents and one was the adult child of the
participant with diabetes and SMI.
As shown in Table 26, the 30 staff members were from a variety of disciplines and had varied training
and experience. Twelve (40%) participants in this group had their key training in mental health,
10 (33%) in physical health and five (17%) in a combination of the two. The remaining participants
had training in management (n = 2, 7%) and social work (n = 1, 3%). Four (13%) participants were GPs,
11 (37%) were mental health nurses, three (10%) were physical health nurses, two (7%) were dietitians,
two (7%) were pharmacists, four (13%) were psychiatrists and the remaining four staff members
comprised an NHS commissioner, a diabetologist, a practice manager and a recovery support worker.
Two (7%) of the nurse participants also worked as care co-ordinators.
The analysis of interviews identified eight key themes, which are described in the following sections,
accompanied by supporting quotations. A supplementary table containing further quotations for each
theme and subtheme can be found in Appendix 6, Tables 33–40.
TABLE 25 Participant characteristics for the family member sample
Participant ID Sex Age (years) Ethnic group Highest education
Relationship to person
with diabetes and SMI
ES-D1-02 Female 71 White British College certificate Parent
ES-D1-03 Female 73 White British GCSE/O levels Spouse
ES-T2-08 Female Not recorded Not recorded Not recorded Parent
ES-T2-17 Male 67 White British Not recorded Spouse
ES-T2-20 Female 47 White British Masters/PhD Spouse
ES-T2-21 Male 59 White British Masters/PhD Spouse
ES-T3-08 Female 37 White British Postgraduate degree Adult child
ES-T4-03 Male 61 White British Foundation degree Spouse
ES-T5-12 Female 56 White British Batchelor’s degree Spouse
ID, identifier; O level, Ordinary level; PhD, Doctor of Philosophy.
This table has been reproduced with permission from Bellass et al.143 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
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TABLE 26 Participant characteristics for the staff sample
Participant ID Role Key training
Areas of expertise/
experience/responsibility
ES-PC-01 GP Physical health Some psychiatry experience
ES-PC-02 GP Physical health Used to be diabetes lead
ES-PC-03 Practice manager Management –
ES-PC-04 Practice nurse Physical health –
ES-PC-05 GP Physical health Diabetes lead
ES-PC-06 GP Physical health –
ES-T1-01 Psychiatrist Mental health Diagnosis and management of SMI
ES-T1-02 Community mental health nurse Mental health –
ES-T1-03 Community mental health nurse Mental health –
ES-T1-04 Community mental health nurse Mental health –
ES-T1-05 Nurse prescriber/care co-ordinator Mental health Some previous training in diabetes
ES-T2-01 Mental health nurse Mental health Diabetes and physical health care
ES-T2-12 Psychiatrist Mental and
physical health
–
ES-T2-13 Pharmacist Physical health Training in psychiatric therapeutics
ES-T2-14 Dietitian Physical health Working in mental health
ES-T2-15 Psychiatrist Mental and
physical health
–
ES-T3-01 Pharmacist Physical health Training in psychiatric therapeutics
ES-T3-02 Community mental health nurse Mental health –
ES-T3-05 Psychiatrist Mental and
physical health
–
ES-T4-06 Recovery support worker Social work –
ES-T5-01 Mental health nurse Mental health –
ES-T5-02 Mental health nurse Mental and
physical health
Prescribing course
ES-T5-03 Nurse Mental and
physical health
Nurse prescriber
ES-T5-04 Mental health nurse – professional
lead for nursing
Mental health Previously ran team focused on
physical health for SMI
ES-T6-01 Mental health nurse Mental health Experience of work involving physical
health for SMI
ES-T6-02 Dietitian Physical health –
ES-T6-03 Care co-ordinator/psychiatric nurse Mental health Training in physical health
ES-T6-04 Commissioner Management –
ES-T7-01 Mental health nurse Mental health Senior practitioner for physical health
ES-X1-01 Diabetologist and endocrinologist Physical health –
ID, identifier.
This table has been reproduced with permission from Bellass et al.143 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://
creativecommons.org/licenses/by/4.0/. The table includes minor additions and formatting changes to the original table.
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Theme 1: mental illness affects everything
Some of the participant quotations in this section have been reproduced with permission from Bellass
et al.143 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The text below includes minor additions and formatting changes to the original text.
The pervasive effect of severe mental illness
Participants with diabetes and SMI described the pervasive effect of their mental health problems on
their daily lives, for example on their ability to make or maintain friendships, retain a driving licence,
engage in personal or household care, leave the house or keep appointments. SMI appeared to have a
withering effect on social worlds, as one participant described:
I’m just getting worse actually, not going out, putting myself off, not going to the shops or anything like
that. I make appointments and then I cancel them, I used to have friends, but I haven’t got any any more,
they’ve all deserted me.
ES-G7-01, female, aged 61 years, bipolar disorder
In addition, their mental illness affected their ability to work and many participants relied on state
benefits for financial support, a system that was perceived to disadvantage them through disregarding
the disabling effect of their enduring mental illness. Several staff described time-consuming attempts to
support service user applications for benefits, which were not always successful. When asked directly
about the impact of their financial situation on their health, however, many participants with diabetes
and SMI tended not to highlight their limited resources, perhaps normalising their constrained
circumstances. By contrast, the impact of lack of employment and reduced economic resources on
healthy dietary choices was discussed by several staff participants:
. . . patients with mental health . . . often are not in employment and are living on very very much reduced
resources, and when you are discussing what foods to buy and prepare, often it’s very difficult for them to
afford a lot of what you are asking them to [buy].
ES-PC-02, GP
Foregrounding mental illness
For all three participant groups, the effects of having SMI were perceived to overshadow the experience
of diabetes and other physical health conditions. Participants spoke of diabetes self-management as
being ‘governed’ by mental health (ES-T2-02, female, aged 63 years, bipolar disorder), or of mental
health problems being ‘more all-consuming’ (ES-T5-03, nurse). Similarly, a family member noted that:
I know you’re looking at diabetes and mental health . . . but, from my point of view, the issues are,
without a doubt, the mental health issues, not the diabetes.
ES-T2-17, male, aged 67 years, spouse
The foregrounding of SMI and associated overshadowing of physical health was particularly acute
when experiencing a SMI relapse, as the following service user explained:
. . . the sort of GP service had tried to do a diagnosis, tried to tell me it [diabetes] was important, which
was never going to have any impact, ‘cause when you’re mad as a hatter, you don’t take any notice.
They’re just noise in a corner.
ES-T2-03, male, aged 51 years, bipolar disorder
Being unwell with mental illness was perceived to be a significant barrier to diabetes self-management,
with some staff participants remarking that stable mental health was an important factor in physical health
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management. One participant suggested that, at times of poor mental health, successful self-management
needed to be redefined:
If someone is unwell with their mental health they are just trying to survive . . . they don’t want to hear
the advice on smoking and diet, they just need to get through the day, and if they are eating something,
it’s a victory, not necessarily eating a healthy meal, it’s just eating a meal.
ES-PC-01, GP
Persistence and powerlessness
A dominant feature of their mental health problems for many participants was the persisting,
unrelenting nature of their condition, which could leave them feeling powerless. One participant
reported that their SMI is:
. . . something actually inside of your head all the time, and it’s like you’re carrying around mental illness
. . . it’s just like having a cold, you want to get rid of it but you can’t. [. . .] it just keeps going round and
re-playing and re-playing . . . and when am I going to get off the circle? And you can’t because it’s mental . . .
I mean, it’s not like a diet . . . you can change your diet. You can’t change your mental illness.
ES-G3-01, male, aged 47 years, schizophrenia
Despite feelings of helplessness, participants described efforts to manage their mental illness, including
engaging in physical exercise and practising religion. Most participants described taking at least one
medication (often many more) for their SMI; for many, this was an unquestioned part of their lives.
For some, however, this represented an unpleasant aspect of their daily reality, adding to their feelings
of powerlessness as they disliked having to take medication but felt that they had no choice:
I mean, I take around 20 tablets a day . . . and I hate that, I hate that, I hate taking all of them,
but it’s got to be done.
ES-T2-05, female, aged 59 years, schizoaffective disorder
. . . you wouldn’t take them if you had the choice. I mean, I am desperate, so I take my medication.
ES-T2-16, female, aged 65 years, schizophrenia
Theme 2: not just two illnesses – multimorbidity and diabetes management
Poor physical health and everyday life
Many participants with diabetes and SMI described living with multiple health conditions and
problems, including cardiovascular and respiratory illnesses, such as angina, chronic obstructive
pulmonary disease (COPD) and asthma; musculoskeletal problems, such as osteoarthritis or
inflammatory arthritis; and other conditions, such as urinary incontinence, difficulties with eyesight,
sleep problems or gastrointestinal conditions. Staff participants described the complexity of
multimorbidity in terms of risk for the SMI and diabetes population:
I mean, definitely, the rates of the diabetic complications are higher in our group of SMI patients,
as they will often have cardiac disease or cardiovascular disease at an earlier onset, I would say,
than our non-SMI patients.
ES-PC-06, GP
This increased risk of multimorbidity could lead to polypharmacy, as one nurse noted:
. . . and normally if they are on diabetes tablets, they are on blood pressure tablets, and if they are on
blood pressure tablets, they are on cholesterol tablets, if they are on cholesterol tablets, you know,
they’ll be on something else . . .
ES-PC-04, practice nurse
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Rather than describing their health conditions in terms of associated risk, participants with diabetes
and SMI tended to illustrate how their health problems created limitations in their everyday lives.
For one person, the combination of their conditions placed significant restrictions on their freedom:
My COPD only allows me to go to the bottom there, and I’m coughing and weeing myself and everything
[. . .] I wear nappies now, I daren’t go out. I only go somewhere, where my scooter will take me.
ES-T2-02, female, aged 63 years, bipolar disorder
The constraints placed on people with diabetes and SMI by their poor physical health often affected their
ability to exercise, and hence manage their diabetes, even when motivated to do so, as one person explained:
I’m waiting for a knee operation, I can’t get about as well as I used to [. . .] they won’t do the operation
unless the leg muscle is strong. That is why I try and swim to keep the strength in the leg muscles. I walk
as well. But unfortunately, I can’t do as much as I would like.
ES-D1-05, male, aged 69 years, psychosis
Precedence-taking in the context of multimorbidity
One of the key challenges for participants managing SMI and diabetes alongside other chronic
conditions was deciding which to prioritise. Some staff described their patients as taking a ‘fire-fighting’
approach by attending to the problem that was causing the most difficulty at that moment:
The condition that’s causing the most immediate difficulty is going to be the one that gets the attention,
so somebody has daily pain, that pain is going to take more attention than the diabetes, which isn’t
causing any immediate pain but is a long-term complication and consequence. It’s a silent killer.
ES-T2-12, psychiatrist
Some participants described how they did not see immediate consequences when they did not manage
their diabetes well. One participant, for example, did not feel the need to improve their diabetes
management because they had ‘not had to hit that point yet’ (ES-G2-01, male, aged 45 years, bipolar
disorder), and another emphasised the lack of feedback from the condition:
It’s a funny one, diabetes, I mean, you just don’t know until it’s too late how it’s affecting you.
ES-T2-16, F, 65, schizophrenia
This lack of visibility of diabetes may explain why physical and mental health conditions that are having
a more salient effect on everyday life are prioritised.
Alternatively, having multiple health conditions may become so overwhelming that it feels easier not to
manage any of them, as one family member observed:
I also think she gets quite confused, because she’s got things going on, not just the diabetes but she’s got
other ailments, you know, [. . .] I think sometimes it will come as a bit overwhelming because she thinks,
‘well, there’s too many things that I’ve got to think about what I can and can’t eat. I’m just going to
ignore it’, if you know what I mean.
ES-T2-08, female, aged 37 years, daughter
Theme 3: interacting conditions, overlapping symptoms
Some of the participant quotations in this section have been reproduced with permission from Bellass
et al.143 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The text below includes minor additions and formatting changes to the original text.
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Many participants had noticed an overlap in their conditions. People described struggling to identify
whether their diabetes or their mental health was causing symptoms such as low mood, anxiety or
fatigue, and some suggested that it could be a combination of the two:
. . . if I go on a high, sometimes, they’ve got to check my blood sugars, because they don’t know if it’s the
blood sugars, that are causing me to go a bit loopy. Or it’s my mental illness.
ES-T4-10, male, aged 41 years, bipolar disorder
Many participants also stated that their conditions could affect each other, with one person describing
a ‘direct correlation between the two’ (ES-G2-01 male, aged 45 years, bipolar disorder). This close link
meant that poor diabetes control had a direct impact on participants’ mental health and vice versa:
Oh yeah, definitely, because you need to be careful what you eat, being overweight. I mean, that makes me
anxious. That does upset me. And knowing that I’m diabetic, knowing I’m overweight, I am. That upsets me
and that makes my anxiety worse and that makes the hallucinations worse. There’s definitely a connection.
ES-T3-09, female, aged 37 years, schizophrenia
One participant who had access to blood sugar monitoring equipment described seeing their blood
sugars increase as a result of anxiety:
When I’m hyper, I’m, like, showing the meter to my partner, and stuff, and he’s like, ‘well why is that high?’
But it’s how my body reacts. It’s like as if the anxiety makes it go up as well.
ES-T3-03, female, aged 34 years, bipolar disorder
Not all participants with diabetes and SMI agreed that there was a link between their conditions; those
who felt that there was no overlap or interaction mostly had a diagnosis of schizophrenia or psychosis.
One participant described being uncertain if a link existed:
I don’t know. If my blood sugar’s dodgy, I do feel ill. But I’m not quite sure if there’s a link to my mental
illness and diabetes really.
ES-T4-12, female, aged 41 years, schizophrenia
Staff participants had also noticed the interaction and overlap between diabetes and SMI, and
suggested that symptoms such as irritability or manic episodes could also be linked to poor diabetes
control, as one psychiatrist described:
And, on the other hand, if people are diabetic and they’re not maintaining their blood sugars right, it can
give rise to symptoms which are synonymous with anxiety and low mood, so there is a big interface
between diabetes and mental illness.
ES-T1-01, psychiatrist
A nurse also noted that behavioural symptoms could be interpreted by staff as a warning sign for poor
diabetes control:
When it’s not managed well, when they’re not taking their insulin or taking their metformin when they
should, when the blood sugars are high, they become more aggressive, argumentative, that’s often a sign
that they’re not managing it properly and it might not just be a sign of their mental health deteriorating,
because it could be a physical cause like diabetes.
ES-T1-02, community mental health nurse
This suggests that people with diabetes and SMI may be facing an additional barrier to effectively
managing their diabetes, in that they need to understand the underlying cause of their symptoms
before they are able to manage them, but this may be difficult or confusing. Most participants in our
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sample did not have access to blood sugar monitoring equipment, which could help to distinguish
between symptoms of diabetes and SMI. If this group interpret symptoms as being linked to mental
illness when they are actually physical, and vice versa, this could lead to conditions not being managed
appropriately and exacerbating each other in a vicious cycle.
Mental health medication and diabetes management
As outlined in theme 1 (see Theme 1: mental illness affects everything), many participants in this study
discussed the side effects of their antipsychotics and the impact that these had on their physical health
and diabetes management. Participants, especially those with schizophrenia and psychosis, described
extreme and rapid weight gain, as well as a constant hunger, as a consequence of their medication,
which caused difficulties in diabetes management. Some participants felt that medication had caused
their diabetes in the first place:
I got the schizophrenia and then I got the Clozaril [®; Mylan Products Ltd, Potters Bar, UK] and then I got
the weight gain and then I got the diabetes.
ES-T3-09, female, aged 37 years, schizophrenia
Participants also emphasised the lethargy caused by SMI medication, which could affect people’s ability
to manage diabetes:
It is and the medication that I’m taking. It makes me hungry and it makes me tired. Quite normal for me
to have a couple hours’ sleep during the day, but if I didn’t take the tablets, I wouldn’t be snoozing
like that.
ES-T2-18, male, aged 48 years, schizophrenia
Staff participants and family members also highlighted the issue of mental health medication and its
effects on physical health and well-being. As one nurse explained:
. . . the medication is a big thing, they might feel slowed down, the less they do, so that adds to the
weight gain.
ES-T1-02, community mental health nurse
A parent also described the extreme weight gain and ‘slowing down’ experienced by their son as a
result of his medication:
. . . [son] weighed 79 kg; at his largest he went up to 180 kg from being on the mental health drugs, which
is as a result of the type of medicine they give you. Because, you understand, the medicine slows down
your mind. But it slows down all parts of your body.
ES-T2-08, female, parent
Theme 4: the effect of mood on diabetes management
Some of the participant quotations in this section have been reproduced with permission from Bellass
et al.143 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The text below includes minor additions and formatting changes to the original text.
Fluctuating moods, fluctuating management
Participants described experiencing fluctuating moods that differed from SMI relapses, and were
often part of their daily life. Low mood could lead to poor motivation, low self-esteem and pessimism,
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which, as participants explained, could derail their efforts to manage their diabetes and their
health generally:
. . . it’s mostly the exercise, but it’s also diet as well. You just eat more poorly and put weight on, and it’s just
all those things that you associate with depression, are actually also associated with poor physical health.
ES-G2-01, male, aged 45 years, bipolar disorder
Participants linked low mood and anxiety to lethargy, not wanting to exercise or engage in self-care,
and a reluctance to leave the house, all of which affected diabetes management. Eating habits were
prominent in participants’ accounts, with many people describing ‘comfort eating’ foods that they knew
could negatively affect their diabetes when they felt anxious or had low mood:
I think definitely there is a link there, in if your blood sugar is low and you feel depressed or fat or you’re
anxious or feeling paranoid, then you want comfort and I find that in naughty foods like crisps and chocolate.
ES-T2-05, female, aged 59 years, schizoaffective disorder
Family member participants had also noticed the effects of low mood on diabetes management, as the
daughter of one participant with diabetes and SMI explained:
If she’s stressed or frustrated or angry or just not feeling 100%, she won’t be disciplined, especially with
diet and what [she] should be doing to help, I suppose, control the diabetes.
ES-T3-08, female, daughter
Staff also acknowledged these links, and described low mood leading to diabetes taking a ‘back seat’,
as one GP described:
I’ve seen patients who so, when their mental health deteriorates their eating deteriorates, so they may
start to comfort eat, make the wrong food choices and so they lose their diabetic control. I’ve got a
patient who, when her mother died, you know you can date things back, she said ‘I’ve got dreadful
glycaemic control’ and this dates back to the death of her mother and she is still in a bereavement
phase and the diabetes is just not important for her.
ES-PC-05, GP
More extreme drops in mood were also described, which could cause suicidal feelings and a sense of
total hopelessness. At these times, participants did not look after their physical health at all:
. . . when I’m depressed, there’s nothing that you could say that would, ‘cause you stop caring, it’s like,
if you stop caring about yourself, or what happens to you, it’s very difficult then, for someone to say,
‘well you need to stop eating these, these and these’. It’s very, very difficult.
ES-G2-01, male, aged 45 years, bipolar disorder
. . . so a lack of motivation, you know. ‘I don’t want to be here; therefore, why should I bother about this
because I don’t care’. I forget the complications because I might not be here long enough to get them.
ES-PC-05, GP
A psychiatrist also outlined the ongoing difficulties that this link between low mood and poor diabetes
management could cause further down the line:
They’re relapsing but they’re not risky. They’re like, well . . . just see your GP, would be the answer. In the
meantime, they’re not eating or they’re eating chocolate for five meals a day, because it’s easy and they’re
not sleeping any more. Their weight is ballooning or shrinking, they’re getting more physically unwell, their
blood sugars are raging. That person is 6 months down the line and they’re acutely psychotic. At that
point, they’ve got retinopathy, their blood sugars are all over the place, then you’ve given yourself two big
problems to manage, what would have been one small problem.
ES-T2-12, psychiatrist
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Worries about diabetes
Despite the foregrounding of SMI previously described, many participants with diabetes and SMI were
aware of the severity of diabetes, and some reported that this caused them anxiety and stress,
affecting their mental health more generally:
It does affect me badly because I worry. I worry about going to bed. I worry about sleeping because
I think, ‘am I going to wake up or am I not going to wake up?’
ES-T3-03, female, aged 34 years, bipolar disorder
The accumulation of these worries could have a negative effect on participants’ mental state. A family
member participant described the effect that the additional burden of diabetes had on the mental
health of the person they supported:
. . . being diagnosed with diabetes and it’s another thing that she’s got to think about and, you know, sort
of contend with. So, I do think it has affected her mental health in that it’s an additional thing for her to
worry about.
ES-T3-08, female, aged 37 years, daughter
Theme 5: ‘the most critical person in my care’ – the role of informal support networks
The importance of family, friends and others
Many people with diabetes and SMI highlighted the role of family, friends and other informal
supporters in helping them to manage their lives, emotionally and practically. Participants explained
how these supporters provided essential emotional support as well as helping with everyday activities
such as shopping, personal care and finances:
I go to church on a Sunday. My partner drives me to church and drops me and my daughter off while I’m
at church and then picks me up. On a Monday, my mam and sister take me to Asda and then we go and
have a coffee and then go and do our shopping. And then on a Tuesday and a Thursday, my mam’s now
started taking me to the gym.
ES-T3-09, female, aged 37 years, schizophrenia
This type of support affected participants in a variety of ways. For example, one person described how
their daughter could detect worsening mental health problems in their regular conversations and could
‘tell by my voice when I’m not right’ (ES-T3-04, female, aged 67 years, bipolar disorder), which would
prompt her to arrange for professional support. Another participant described how sharing their
difficulties helped them through a period of anxiety:
That’s what helped me through the anxiety a couple of years ago, was a girl at work who I was real close
friends with, had said that she used to suffer from depression and anxiety [. . .] And she’d had the same
thing, and talking to her, and I said, ‘how did you get through it?’
ES-G2-01, male, aged 45 years, bipolar disorder
Participants also described how their informal supporters were able to step in and support them with
their self-management. One participant described how their parent was able to ensure that they had
a ‘dosette box’ (a medication container with multiple compartments) to organise their medications:
I have a dosette box because, the second time being in hospital, they put me on all these tablets, I’m not
on as many now, but I couldn’t cope with the . . . and my dad was really good, he sorted that out for me.
ES-T3-03, female, aged 34 years, bipolar disorder
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The emotional support provided by family and friends was key for many people with diabetes and SMI.
One person described how visiting the mosque with friends gave them ‘another motivation, [to] carry
on’ (ES-G9-01, male, aged 38 years, schizophrenia). In extreme circumstances, this support could make
the difference to participants deciding whether or not to continue living. One person summed up the
huge impact and importance of this type of support:
Who helps me the most in continuing to be here at all? ‘Cause there’ve been occasions when that’s
definitely been a possibility not to be true. My wife. So my unpaid carer, a 24-hour-a-day, unpaid carer,
is the most critical person in my care.
ES-T2-03, male, aged 51 years, bipolar disorder
Family history of diabetes was also discussed by some participants, and family members with diabetes
were sometimes able to provide additional support and knowledge based on their own experiences,
as this participant described:
. . . my relatives are important as well because people with diabetes in my family, we discuss issues and
medication and the best way forward to manage it, so they are important connections.
ES-T2-05, female, aged 59 years, schizoaffective disorder
Health-care staff too highlighted the ongoing and permanent nature of family support, compared with
staff who ‘may think we’re very important but actually we may spend a couple of hours a week with
the service user’ (ES-T6-01, mental health nurse). The different nature of peer relationships, compared
with service user/staff relationships, was also acknowledged, with one staff member suggesting:
. . . they’re most probably more likely to listen to them [peers], than they would a professional.
ES-T1-02, community mental health nurse
Although many participants with diabetes and SMI highlighted the importance of informal support,
some also discussed a lack or loss of support and the impact this could have. Several participants had
relied on their parents for many years, for example, but, as their parents aged, they were now losing
that support as a result of illness or death, leaving them isolated:
I’ve got family, although my mum’s passed away and my dad’s getting on a bit and he’s had heart surgery,
so they can’t look after . . . they can’t help me any more, I’m on my own.
ES-T4-01, female, aged 29 years, schizophrenia
Participants also discussed losing support for other reasons, including the nature of their mental illness
making social relationships difficult, poor physical health being a barrier to socialising outside the
house and the loss of services they used to rely on such as day centres. One psychiatrist explained how
a lack of support can make life more difficult for people with diabetes and SMI:
If they are lacking in the understanding, both from the physical perspective, but also from the emotional
perspective, it makes it so much harder for the patient because the people immediately around them
don’t get it.
ES-T2-12, psychiatrist
Although staff members acknowledged the vital role informal support plays in the lives of people with
diabetes and SMI, they also discussed the potentially negative effects that family and friends can have
on diabetes management. Staff participants highlighted examples of family members bringing unhealthy
foods to hospital when visiting inpatients, or using food as a means of pacification when people
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became difficult. Staff and family member participants also identified the negative effect that a close
supporter can have on motivation to manage diabetes:
If you’ve got somebody who is dismissive of the attempt or knocks it down constantly, then that can be very
unhelpful. And if you’ve got somebody who’s encouraging them to get the takeaway or, ‘don’t bother with that,
it’s raining outside’. If your own motivation is a bit shaky to begin with, that’s probably not going to help.
ES-T7-01, mental health nurse
. . . it’s easier having both of us having to watch our diet. If I munch away at huge bits of cake and he’d
have to watch me – that would be awful.
ES-D1-02, female, aged 71 years, parent
The effects of being a supporter
Although the family members in our study made it clear that they loved the people they were
supporting, and relationships were usually seen as reciprocal (with the label of ‘carer’ being forcibly
rejected by two participants), interviews also demonstrated the toll that supporting someone with SMI
and diabetes can take.
Family member participants explained how their supporter role had negatively affected their
education, ability to work and their relationship with the person they supported. Some felt unable to
have a break from their role, as they were reluctant to leave the person with diabetes and SMI for
long periods. They also described times of crisis that had caused immense stress and upset:
I was waiting and waiting for a phone call back trying to calm him down, trying to stop him going out and,
sort of, trying to meet his attackers or whatever, you know, with a knife in hand or whatever. You just don’t
know what to do and you’re absolutely terrified for hours. And that shouldn’t happen, really.
ES-D1-02, female, aged 71 years, parent
Theme 6: diabetes health care
Some of the participant quotations in this section have been reproduced with permission from Bellass
et al.143 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The text below includes minor additions and formatting changes to the original text.
Diabetes health care was an a priori theme identified as being of interest at the beginning of this
study. Although nearly all participants reported receiving diabetes care, they tended to talk about it in
simple and descriptive terms and were much less concerned with discussing their diabetes care than
their mental health care. Most participants, when asked about diabetes care, talked about diabetes
checks, which were most commonly carried out every 6–12 months, although some participants
described having more regular appointments when necessary:
They’re 3 months at the moment, yeah. Three months at the moment, normally 6 months. [. . .] I do tend
to go for the eye tests every year, and I do all the things that they ask me to do, and I do all the blood
tests. And, if it’s more frequent, because they’re more worried, then I will go in.
ES-G2-01, male, aged 45 years, bipolar disorder
For participants in this study, diabetes care was predominantly carried out in primary care, with people
reporting attending their diabetes checks with diabetes nurses or doctors at their GP’s surgery. These
appointments were described as including a blood test, along with health checks such as weight and
height measurements. Some participants reported being asked questions about their health more
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generally, and being given advice about diet, weight and exercise in these appointments, but not all
received this. One participant described their experience of a typical appointment:
I have a blood test every 3 months, approximately, for the diabetes, specifically to look at my blood sugar
levels, and I also have my feet checked and a chat with the nurse about the results, about a couple of
weeks after the blood test, where we discuss the results and any changes that need doing vis-à-vis diet,
medication or exercise.
ES-T2-05, female, aged 59 years, schizoaffective disorder
Despite the limited discussion around diabetes care, participants with diabetes and SMI did highlight a
desire for more intensive diabetes management support, and explained how a lack of ongoing support
and large gaps between diabetes checks could negatively affect their diabetes management:
. . . in diabetes, what you’re missing is the physiological feedback, and a consultation can, to a degree,
give you some of the feedback that you lack on a minute-to-minute basis; even if it’s only three times a
year. [. . .] Because you can lose the plot over the course of a year, whereas I think if you have an horizon
of 4 months, that gives you an end point in sight.
ES-G8-01, male, aged 63 years, bipolar disorder
Another participant with diabetes and SMI described his desire for more support for people with
diabetes for financial budgeting and dietary planning to help with self-management:
It should be a lot more help. Not just from GPs and nurses, but there should be teams going out into
communities, and people what are really overweight and really obese, they should be sitting them down
and going over a budget plan and a plan to lose weight.
ES-G3-01, male, aged 47 years, schizophrenia
One GP described how this type of more intensive, ongoing support could lead to great successes in
diabetes management for people with SMI:
I think most of it, the credit will probably have to go to the health-care assistants that we’ve got who
often see these patients almost week in, week out, monitoring weight and blood pressures and that type
of thing, and just able to develop some really really nice relationships of, kind of, trust and really plugging
away at the health understanding behind, kind of, some of the lifestyle management with diabetes, and
we’ve had some really good successes in terms of really impressive weight loss.
ES-PC-06, GP
Theme 7: diabetes knowledge and education
Knowledge of diabetes
Knowledge of diabetes and diabetes management among participants with diabetes and SMI varied
widely; some were very knowledgeable, whereas others gave incorrect information or simply said that
they did not know about it:
I don’t know nowt about diabetes, and understand it.
ES-T2-02, female, aged 63 years, bipolar disorder
Staff participants also identified the variation in knowledge among the people with diabetes and SMI
that they worked with:
I think there is a huge variation, some people are very engaged in their health and will often know more
than you do about, you know, diet [. . .] but you always have this big group that know what they should
be doing, but just don’t do it for whatever reason, and, some people, they have so many other problems
that it is just a last thing on their minds.
ES-PC-01, GP
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Staff members highlighted a lack of knowledge about healthy diets among people with diabetes and
SMI whom they encountered, especially in relation to diabetes, for example those who ‘think that they
can eat as much fruit as they want’ (ES-T5-02, mental health nurse). Staff participants’ expectations of
knowledge among their patients also varied, with one nurse suggesting that:
. . . even with the people with mental health issues [. . .] People know what they should be eating and
what they shouldn’t be eating these days.
ES-T5-03, nurse
Another, however, acknowledged that these kinds of expectations may be too high for people with
SMI, and identified barriers to what may usually be considered general knowledge:
I thought [it] was general knowledge, but perhaps isn’t, perhaps, actually, it’s a lot to do with educational
opportunities, having family that eat healthily, whatever.
ES-T2-15, psychiatrist
Sources of information
Participants with diabetes and SMI reported that the information they had received about diabetes
came from various sources, both formal (e.g. from health-care professionals, NHS leaflets or education
courses) and informal (e.g. family members):
I’ve done my own research on YouTube and asking people who’s had diabetes, or people who know what
good food are [. . .].
ES-G3-01, male, aged 47 years, schizophrenia
[At diabetes appointments] They give me booklets about sugar diabetes and things like that. They tell me
what to eat.
ES-T2-04, female, aged 68 years, schizophrenia
Family members also provided participants with diabetes and SMI with information. Some participants,
for example, had family members with diabetes who shared their own tips on management, whereas
other family member participants reported educating themselves on diabetes to provide better support.
Although many participants with diabetes and SMI reported receiving information about their diabetes,
the varying quality of this information was identified as a concern by staff participants:
I mean one of my clients does use an online forum where she can kind of go for support, but the problem,
as I say, in some ways with online is who is monitoring that? Who is providing the information, you know?
How accurate is it?, and so forth.
ES-T1-05, nurse/care co-ordinator
Several participants reported receiving information about healthy diets and achieving weight loss from
commercial programmes such as Slimming World (Alfreton, UK):
I’ve done all sorts of diets in the past and if you’re on your own, you don’t lose well. So yes, they took me
[to Slimming World]. And I’ve lost nearly two stone.
ES-T3-07, female, aged 71 years, bipolar disorder
One nurse participant, however, highlighted how the dietary information given in these groups may be
misleading for people with diabetes:
. . . even, like, being at Slimming World, you know, you’ll get people that come in and they’ll say, they have,
like, a great big bowl of pasta with cheese on and it’s just like, ‘yeah you can have as much pasta as you
like’, no you can’t. There’s only certain amounts of pasta you should actually be eating.
ES-T5-03, nurse
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In contrast to many comments from staff participants about the types of information they provided
about diabetes, and the varying ways in which they attempted to educate people on diabetes
management, many participants with diabetes and SMI in our study reported receiving only
perfunctory information such as leaflets or links to websites that they had to navigate themselves,
rather than explanations that helped them understand their condition:
He [GP] never really sat me down and explained. I got all the leaflets and things, but I’m not one to read
such things.
ES-T2-06, female, aged 59 years, bipolar disorder
This discrepancy between staff and service user reports on the provision and usefulness of different
sources of information may indicate a need for a more considered approach to providing diabetes
management information.
Diabetes education courses
Participants with diabetes and SMI described a range of experiences of formal diabetes education:
some had attended formal courses; some had been offered a place on a course but were unable to
attend; and some reported that this had not been discussed, or offered to them. Participants who
had attended courses gave positive feedback, mentioning the valuable information they had gained
about diabetes and its effects, as well as how to better manage the condition, for example through
diet and exercise:
And that was by far and away the best thing and the most useful thing, in terms of management. [. . .]
it was the intervention of the community trust, with their education, that was provided by a dietitian,
that really, really, made a difference.
ES-T2-03, male, aged 51 years, bipolar disorder
[From interviewer notes] She reported having ‘zero knowledge’ before the course, it opened her eyes to
diabetes, what it is, what it can do, and how it can be controlled. It was really interesting, and was
successful because it was a friendly atmosphere where everyone wanted to join in.
ES-T6-05, female, aged 39 years, schizoaffective disorder
Despite this positive feedback, some specific barriers to attending education courses were identified
by staff participants, although very few participants with diabetes and SMI discussed these. One GP
suggested that the group-work element of diabetes education courses could cause difficulties for
people with SMI, for example:
. . . often, I think, a barrier to the structured education is the group work, so I don’t know if it would help
if the group was people with similar other comorbidity, so other mental health problems, or whether a bit
more one to one.
ES-PC-05, GP
This was echoed by a participant with diabetes and SMI, who explained that ‘the actual getting out
of the house and mixing, is a bit nerve-wracking’ and who had found they were ‘scared to death’ and
‘a shaking mess’ (ES-T3-09, female, aged 37 years, schizophrenia) when they did attend an education
class. One participant with diabetes and SMI also discussed the fact that he had been offered an
education course and was prevented from attending by his SMI symptoms:
Now, I was offered that by the GP service, and I went, ‘no thanks, I’m too busy being mad’.
ES-T2-03, male, aged 51 years, bipolar disorder
Staff participants suggested that the duration of sessions or complexity of content may be difficult
for some people with SMI as a result of literacy issues or problems with concentration, and one
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GP highlighted a lack of tolerance a person with diabetes and SMI had experienced at an
education class:
And our services users classically tell us that some of them have problems with literacy, so they go along,
they can’t read the information. The information is information overload. If you think that a lot of our
service users have problems with cognition, with attention, with cognitive deficit. They can’t take on board
the information; they don’t understand the information.
ES-T6-01, mental health nurse
I sent a chap on a DESMOND [Diabetes Education and Self Management for Ongoing and Newly
Diagnosed] course [T2DM education programmes provided by the NHS] recently, you know the diabetes
education course, and he got kicked off because they didn’t like his behaviour, well you know he’s a chap
with schizophrenia and actually even getting him there was massive.
ES-PC-06, GP
These findings suggest that there is a need for a more tailored approach to diabetes education for this
group, both for the provision of information and in structured education classes.
Getting everyone on board
Staff participants discussed the importance of diabetes management education for supporters and
family members of people with diabetes and SMI. Participants gave examples of family members who
were not aware of aspects of diabetes management, such as blood glucose monitoring or dietary
requirements, for example. One staff member highlighted a parent who said they ‘know nothing about
diabetes really’ (ES-T3-02, community mental health nurse), despite having diabetes themselves.
A GP participant highlighted the important role that informal supporters play in helping people with
diabetes and SMI to manage their diet, medication and lifestyle, and emphasised the need for this
group to be educated on the topic:
I think that it is important that they have the awareness and understanding of diabetes as well, for the
importance of it. The education as well, they might be the ones cooking, so just make the health choices,
understand if they are blood glucose testing you know the values, when to be worried, when to react,
sometimes teaching the family member to give insulin. They need as much education as the patient.
ES-PC-05, GP
Theme 8: person-centred care
Some of the participant quotations in this section have been reproduced with permission from Bellass
et al.143 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this
work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The text below includes minor additions and formatting changes to the original text.
The value of person-centred care
Participants with diabetes and SMI identified many different health-care professionals whom they saw for
their health conditions and expressed the most positivity when talking about professionals who focused
on them as a whole person, understood their life circumstances as well as their multiple conditions and
responded to emotional and social difficulties that fell outside their diagnosed condition management. This
type of care is referred to as ‘person-centred care’ in the findings that follow, although it encompasses
wider concepts such as continuity of care and relationships with staff who know people’s histories and the
multiple challenges they face, and have the time and knowledge to help navigate complex systems.
To illustrate the person-centred care they valued, participants tended to focus on the informal
conversations and relaxed interactions with these care providers, rather than the more practical or
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health-related aspects of their care. This emphasised the value they placed on having a relationship
with their health-care provider(s):
My care co-ordinator’s brilliant, she comes every fortnight and we’ll just out for a cup of coffee and walk
around the garden centre.
ES-T3-09, female, aged 37 years, schizophrenia
[About community psychiatric nurse (CPN)] We have a chat, see how I’m doing, she’s very supportive,
sometimes she tells us about her family to give us a bit of amusing gossip.
ES-T4-02, F, 63, schizophrenia
Continuity of care was also described as important by participants, as it allowed them to build these
relationships with health-care staff:
[About nurse] Yeah, she was great. [. . .] She was absolutely fantastic. She could tell . . . When we said hello
to each other, she could tell my mood straight away. [. . .] She asked me in depth about the problems, the
real problems and what was at the back of them. Sometimes she would recommend some medication to
the psychiatrist. And that was a big help. I knew she cared. I knew she was listening, because there was
a follow-up, so to speak.
ES-D1-05, male, aged 69 years, depressive psychosis
A family member participant described the difficulties they had experienced when there was a lack of
continuity of care:
We’ve got a whole team of doctors down here – you never get to see the same one twice, but you used to
just have one face, GP you knew really well [. . .] There is a lot of difference between somebody knowing
you and just seeing different people each time.
ES-D1-02, female, aged 71 years, parent
Participants with diabetes and SMI described the powerful impact that person-centred care, focused
around positive relationships, could have on their mental and physical health, as well as the support they
received from valued care providers for wider issues such as navigating the financial benefits system:
Most people over the years have always been supportive [. . .] And all these services are very good
because, without these people, we would be a lot worse than what I am now. [. . .] Without these people,
people wouldn’t be sane.
ES-T5-11, male, aged 59 years, schizophrenia
When it first came out, when they were first looking at benefit, it was looking like I would have to go for
interview. And whoever was my consultant psychiatrist at the time intervened, so I never went for an interview.
ES-T2-16, female, aged 65 years, schizophrenia
Although the importance of building relationships between health-care providers and people with
diabetes and SMI was emphasised by participants, the lack of time available to build these relationships
was also identified as a barrier to this type of person-centred care. Participants acknowledged the time
pressures health-care staff face and the limitations this puts on care, while expressing their
disappointment that this was the case:
Because when you go to your doctor you’ve got 10 minutes, and that’s what the problem is. Many of the
guys [people with SMI], by the time they’re reaching the stage, like, you’re talking, guys with diabetes,
they’ve got lots of things going on with them. And they’re trying to tell the doctor and it becomes like . . .
So the doctor doesn’t give them . . . he just says ‘come for your annual diabetes check, come for your
tablet, we have to check your liver and your kidneys. We’ll do that once a year’.
ES-T2-08, female, parent
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I think GPs and practice nurse haven’t got the time to give that support, and it’s nothing against them,
they just . . . their workload is so under pressure, do you know what I mean?
ES-T3-03, female, aged 34 years, bipolar disorder
These findings illustrated a difficult dichotomy in care for this group. People want and value person-
centred care from the professionals who treat them and the trust that this brings, but this may not
always be possible within the restrictions of the current health-care system.
Separation of mental and physical health care
Despite valuing person-centred health care, participants with diabetes and SMI often viewed
health-care professionals as having defined roles based in either physical or mental health and
described seeking help on this basis. Some participants chose to keep these areas separate, despite
acknowledging the links between the conditions. One participant, for example, felt that she would be
wasting her GP’s time discussing mental health:
I’m seeing my GP this Wednesday with physical things. And the two will interact, but I can’t go and sit in
a GP’s surgery and go on about my paranoia because it would take up an hour of a GP’s time and that’s
not fair, not fair on the GP, not fair on the other patients. So I don’t do that.
ES-T2-16, female, aged 65 years, schizophrenia
Other participants felt that mental health teams did not have the knowledge or understanding of their
physical conditions and vice versa, and that health-care professionals focused on their own areas:
Their focus is on diabetes, yeah. Whenever I do anything that’s specifically for diabetes, obviously,
on the blood tests through the GP, and the results go through the diabetic nurse at the GP’s surgery,
but when I go for the eye test and things like that, they never ask me about mental health problems,
it’s never considered.
ES-G2-01, male, aged 45 years, bipolar disorder
I don’t think the mental health side of things are necessarily that clued on diabetes.
ES-T3-09, female, aged 37 years, schizophrenia
Many staff member participants also recognised the separate nature of mental and physical health
services and the lack of joined-up care that they saw in their practice:
I suppose it’s everybody is managing a certain part of that person’s either physical or mental, you know,
needs but not really coming together to discuss it in a more holistic approach.
ES-PC-02, GP
I mean, we’re aware of the impacts of the comorbid conditions, but we don’t tend to actually deal with
those, other than via the GP.
ES-T3-05, psychiatrist
Some participants, however, did feel that there was crossover in their care. One participant, for
example, suggested that, although her doctor was just trying to find out the ‘one thing that’s wrong
with you’, her mental health team understood that ‘it is a big picture, that it is the diabetes and
everything’ (ES-T3-03, female, aged 34 years, bipolar disorder). Several people also suggested that
their GP had knowledge and understanding of their mental health conditions.
It was clear from many comments from staff and participants with diabetes and SMI that physical and
mental health-care systems were viewed and functioned, in the main, as separate entities.
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Co-ordinating care
All participant groups talked about poor co-ordination of care and limited information-sharing between
services as contributing to the separation of care for mental health and diabetes. Staff discussed
experiencing time delays in getting health information about people with diabetes and SMI, and the
difficulties of having to get access to information through GPs as they could not access it directly:
. . . if we are sending the bloods from our site, then they come to us, so can see blood sugars and we’ll
have access to that. But the diabetic plan, as such, we don’t have access to it and it goes to the GP.
ES-T1-01, psychiatrist
One community mental health nurse also highlighted how people with diabetes and SMI were often
the only source of information available on their own physical health treatments:
No, you just find out from the patient, you don’t get any information passed back to you. It’s when you
say to them ‘how comes you’ve come on metformin? When did this happen?’ that you find things out.
ES-T1-02, community mental health nurse
The lack of co-ordination between mental and physical health care was particularly highlighted by staff
participants, despite their awareness of the links between SMI and physical health. One member of
staff described the risk of health-care professionals becoming ‘blinkered’ by remaining ‘within their
own branch’ (ES-T1-05, nurse/care co-ordinator) and identified the importance of taking in all available
information to provide the best possible care. Another staff member described health providers’
responsibility to understand the nature of difficulties experienced by people with SMI and diabetes:
Everyone who’s involved with that has responsibility to understand both sides. The psychiatrist needs to
understand the physical impact of both the condition and the treatment. The GP needs to understand the
interactions between the two. Any physician, medical professional, acute hospital needs to understand
that having the two together is going to make things more complicated. There isn’t a uniform answer,
that one-size-fits-all approach.
ES-T2-12, psychiatrist
Family member participants also described experiencing difficulties during their involvement in the
care of people with diabetes and SMI and their frustrations at dealing with a system that they felt did
not always understand the links between the conditions:
And I’m saying why if psychiatry caused the diabetes, why must be the GP be doing it? Why is mental
health not interested enough to see what’s going on with the guys? Because very seldom does your GP
talk to your psychiatrist. Maybe once in a while. They don’t even share the same computer system.
ES-T2-08, female, parent
Now I remember saying to the hospital, ‘look, my wife has mental health issues. Please make sure there is
provision’. And you get the impression that . . . just in one ear and out of the other. No mental health
provision. No-one came to see her with regards to that issue.
ES-T2-17, male, aged 67 years, spouse
These findings suggest that the lack of co-ordination in health care for people with diabetes and SMI
may often occur at a systemic level, with many staff participants being aware of and frustrated by the
inability to deliver the person-centred care that was identified as being the most valued by all parties.
Training needs
Many staff member participants identified their own lack of knowledge as a barrier to delivering
person-centred care. Physical and mental health-care staff participants identified gaps in their training
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that would help them deliver care that accounted for the way conditions interacted and affected
each other.
Several mental health support staff in our sample, for example, suggested that they would benefit from
an improved understanding of diabetes care to better help people with diabetes and SMI to manage
their conditions:
A better understanding of the types of diabetes, how to look for sign and symptoms of diabetes because
it’s a bit ad hoc, what I remember and just generally managing it [. . .] So, it would be beneficial to all of
us to have some education on it even if they’re not nurses, anybody.
ES-T1-02, community mental health nurse
It was also suggested by some staff participants that physical health staff could benefit from having a
better understanding of mental health to improve care:
I think it’s very easy to focus on physical side of things, but the mental health is just a massive side of it
and [. . .] I think if we were more trained and more aware of the mental health of a patient, I think it
could probably alleviate a lot of the problems for both patients and the staff.
ES-PC-04, practice nurse
Examples of diagnostic overshadowing, whereby physical symptoms are attributed to a mental disorder
rather than a somatic one, were given by participants with diabetes and SMI and staff member
participants. These accounts highlight the consequences of diagnostic overshadowing and further
illustrated the need for an understanding of both mental and physical health among health-care staff:
I’ve had patients on the wards who have complained endlessly about abdominal pain and it’s put down
as delusional. When they actually collapse with a perforated bowel or ruptured appendix [. . .] or worse,
then it’s like ‘oops, we didn’t look at that’.
ES-T5-03, nurse
I don’t know, he [GP], probably thinks, because I’ve got a mental illness, I’m just making everything up.
Because I’ve faced that a lot over the years.
ES-T4-12, female, aged 41 years, schizophrenia
Finally, several staff participants noted the importance of any training that they did receive being
mandatory and encouraged by management, or it would be unlikely to be attended because of
time pressures.
Summary of findings
Themes from the qualitative enquiry, which were taken forward to the mixed synthesis (see Chapter 7)
can be summarised as follows:
l Mental illness affects everything.
l Managing mental illness and diabetes is not just about coping with two illnesses – there are
additional problems for diabetes management in multimorbidity.
l The conditions interact and have overlapping symptoms.
l Mood influences diabetes management.
l Informal support networks are important, and often lacking.
l There are gaps in diabetes health-care provision (a priori theme).
l Diabetes knowledge and education vary (a priori theme).
l Person-centred care and continuity of care are valued.
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Chapter 7 Integration of quantitative
and qualitative findings: understanding
the relationship between severe
mental illness and diabetes
Introduction
A key component of the mixed-methods concurrent triangulation study design involved the
convergence of results from the quantitative and qualitative studies. In this chapter, we present the
integrated themes that represent the study findings. First, the methods for integration are described,
and the challenges to achieving this are discussed.
Methods for integration
The primary method for integration was ‘convergence’, which involved bringing together the results
from each study to generate a more complete understanding of the relationship between SMI and
diabetes. Co-design workshops formed part of this process to ensure that study findings, and the
integration of these, were interpreted by service users and health-care providers, in addition to the
research team. ‘Embedding’ techniques were also used to ensure that, when possible, each study
informed the other throughout the research.
Embedding
Although we used a convergent design, in which the integration primarily occurs when the study
findings are brought together, we also considered how the studies could be integrated at the data
collection and analysis stages.
The following strategies were employed:
l The scoping of the literature and expert consultation (see Chapter 4) informed the selection of a
priori variables to explore quantitatively, qualitatively or in both studies when this was deemed
important and was possible. For example, sleep was identified as an important determinant of
diabetes self-management, but was not possible to explore reliably in CPRD data, and instead was
added as a topic for the qualitative study.
l We had anticipated that the sampling criteria and interview topic guides for the qualitative study
would be informed by the quantitative analysis for study objectives 1–3. However, this was not
possible because of delays in obtaining CPRD data and operationalising key variables. Instead, we
used preliminary analyses of a smaller CPRD data set carried out in preparation for the study to
explore population characteristics to inform the sampling criteria.115
l Emerging results and observations from each study were discussed at each project meeting to
identify opportunities for exploring these further; for quantitative results, using qualitative inquiry;
and for qualitative findings, using quantitative interrogation of health records.
Co-design workshops
Two multistakeholder co-design workshops were used to make sense of emerging findings, to explore
the potential for additional integration during analysis (e.g. re-analysing qualitative data to explain the
finding from a quantitative model) and to situate the findings in the context of policy and practice from
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the perspective of both service users and providers. Owing to time delays in the quantitative study,
the workshops primarily focused on emerging qualitative findings.
We invited study participants who had expressed an interest in the workshops and interested
stakeholders who received newsletters about the study and wider research programme. To ensure
service user engagement at the workshops, we also invited DIAMONDS VOICE members, who had
an existing relationship with the study team and who helped to facilitate small group discussions and
offered feedback during whole-group sessions.
Outputs from the workshops were used to help interpret the qualitative findings and were discussed
with the study team to ascertain whether or not we could explore key points raised in the workshops
in the quantitative study (e.g. the relationship between depression and diabetes outcomes). They also
formed part of the final integration of study findings (see Convergence).
Workshop 1
Workshop 1 was attended by six service users and focused on learning more about two qualitative
findings: (1) that mood affects diabetes management and (2) that it can be difficult to tell whether
symptoms are due to SMI or diabetes. To explore the first finding, we presented two personas
(David and Barbara; see Report Supplementary Material 16), based on findings from the qualitative
study. We used an empathy map (see Report Supplementary Material 17 for an example) to discuss
and record what the personas might think, do, say and feel when their mental illness affected them
and how this affected their diabetes. For the second finding, we presented quotations from the
study about the uncertainty regarding symptoms, and asked participants to write down feelings and
symptoms on sticky notes and place them on a board to indicate whether they were associated with
diabetes, mental illness or both.
Workshop 2
Workshop 2 was attended by nine service users, two informal supporters and seven staff (from services
that support people with SMI and diabetes). We wanted to learn more about care provision for people
with SMI and diabetes, in part to make sense of the passivity we had noted from participants about
diabetes care, but also because of the limited data for exploring diabetes care in the CPRD (due to the
unreliability of referrals data for diabetes education and specialist services).
We presented findings about care experiences and described the challenges to exploring the complexity
of care provision in the quantitative study. Using a large board that represented 11 different types of
health and social care professionals highlighted in the qualitative study, we asked participants to map
their expectations for care against these in relation to SMI, diabetes, and health and well-being, and then
to map their experiences (for an example, see Report Supplementary Material 18). In the final session, we
asked participants to draw on their discussions to identify three changes that would improve diabetes
care for people with SMI. In this workshop, service users and carers/informal supporters worked
separately from health-care staff to explore any differences in expectations and experiences, and to
enable service users to discuss their experiences together.
Convergence
To develop our understanding of the relationship between SMI and diabetes in this final phase of the
study, we used principles of both convergence, which involved comparing and contrasting the study
findings, and transformation, which involved translating the study findings into descriptive summaries
and merging these when possible.105 This final integration was underpinned by the study’s social
inequalities theoretical framework, which considered how social and economic disadvantage can
contribute to worse physical and mental health.
In practice, this process entailed a full-day workshop attended by the whole study team, and
subsequent analysis of workshop outputs and discussions. Specifically, this involved (1) producing
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narrative and tabular summaries of findings from both studies, which were reviewed by the whole
study team prior to the integration workshop; (2) mapping and synthesising study findings from
the quantitative and qualitative studies to the study objectives in the integration workshop and
subsequently into a table to allow for comparison (Table 27); (3) identifying key themes across the
study findings and discussing these within a social inequalities framework in the workshop; and
(4) developing the themes and writing integrated explanatory summaries for these to ensure that all
findings, including any contradictory or unusual findings, fit within this framework. Although themes
were derived through the integration process, they were not selected based on their potential for
integration, but rather on their importance for understanding the relationship between SMI and
diabetes, and the poor diabetes outcomes experienced in this population.
Results
Six themes were identified from the integration process. These are described in the following sections,
with reference to individual study findings when relevant.
Diagnostic overshadowing
From the analysis of patient records, we found that, despite people with SMI and diabetes having
more frequent contact with their GP and more diabetes checks (e.g. cholesterol, blood pressure, HbA1c,
BMI) than people with diabetes alone, they still have a much higher risk of mortality (see Chapter 5,
Objective 4: comparing the health outcomes of people with diabetes and severe mental illness with the health
outcomes of people with diabetes without severe mental illness, Results). We also found that, although the
rates of macrovascular and microvascular complications were similar in both groups (see Chapter 5,
Objective 4: comparing the health outcomes of people with diabetes and severe mental illness with the health
outcomes of people with diabetes without severe mental illness, Results), people with SMI are more likely to
present to A&E for treatment (i.e. to have unplanned care) than people with diabetes alone, who have
higher rates of elective care (see Chapter 5, Regression results for the impact of severe mental illness status
on physical and mental health outcomes, mortality and health checks). Both of these findings suggest that,
although there is a greater opportunity to detect and treat diabetes complications in people with SMI,
this is not happening. Findings from the qualitative study suggest that diagnostic overshadowing, which
occurs because of the foregrounding of SMI (see Chapter 6, Theme 1: mental illness affects everything)
in a health-care system that treats mental and physical illnesses in silos (see Chapter 6, Separation of
mental and physical health care), may help to explain this.
The qualitative study also found that diagnostic overshadowing is influencing patient, as well as staff,
behaviours. So, although participants in all three groups advocated for care that was person-centred
and co-ordinated (see Chapter 6, Theme 8: person-centred care), and described the separation of physical
and mental health services as a barrier to this, they also expressed beliefs that primary care treats
physical health and mental health services treat mental illness. Participants with SMI and diabetes
also described encounters with staff during which these beliefs influenced what they spoke about as
patients (see Chapter 6, Separation of mental and physical health care). Staff accounts reflected these
beliefs too: although they agreed that SMI and diabetes interact, limited time and resources tended to
restrict their focus according to these beliefs (see Chapter 6, Separation of mental and physical health
care). Lack of training in both conditions reinforced the practice of focusing on a single condition
(see Chapter 6, Training needs), and, in the co-design workshops, participants recommended that all
health-care staff be trained in multiple conditions and multimorbidity.
The foregrounding of SMI affected patient and staff behaviours further, as they focused on addressing
the greater impact of psychosis relative to diabetes (see Chapter 6, Foregrounding mental illness), which
included addressing social issues, such as housing and benefits (see Chapter 6, The pervasive effect of
severe mental illness). This, and the difficulties attributing symptoms to either illness (see Chapter 6,
Theme 3: interacting conditions, overlapping symptoms), resulted in the symptoms of diabetes being
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TABLE 27 Integration table mapping study findings from the quantitative and qualitative studies by study objective
Objective Description Quantitative data Qualitative data Conclusion
1 In people with SMI, to identify
which sociodemographic, illness,
family history and lifestyle
factors are associated with the
development of diabetes
l Older age, ethnic minority, higher
deprivation, presence of comorbidities,
antipsychotic use and family history
of diabetes were all predictors for
diabetes diagnosis and time to onset
l Higher than normal BMI and glucose
dysregulation were both identified as
potential risk factors for diabetes
l Many participants had several physical
comorbidities, which affected their
ability to manage diet and weight
(theme 2)
l Participants discussed the devastating
effect antipsychotic drugs had on their
physical health, but mental health had
to take priority (themes 1 and 3)
l Unhealthy food is cheaper, so those
with less money may be more likely to
have a poor diet
l Different dietary habits in ethnic
minority communities may contribute to
unhealthy diet
l The risk factors for developing diabetes
for people with SMI are similar to those
for the general population, but a
combination of increased levels of
deprivation and taking antipsychotic
medication increases the risk of diabetes
for a SMI population
l People with diabetes and SMI are
aware of the negative effects of their
medication, but feel that this is a price
they must pay for reduced SMI
symptoms. They also identify issues with
physical health that could contribute to
poor weight management and, therefore,
high BMI
2 In people with SMI and diabetes,
to identifywhich sociodemographic,
illness, family history and lifestyle
factors are associated with
variation in diabetes andmental
health outcomes
l 73.3% of eligible patients had a SMI
diagnosis before a T2DM diagnosis,
26.7% had T2DM diagnosed first or had
both diagnosed together
l Patient baseline characteristics differed
by diagnosis order. When included as a
risk predictor, diagnosis order had a
similar effect to T2DM duration
l Older age, lower socioeconomic
status, T2DM duration, presence
of comorbidities, being a smoker
and substance use predicted
macrovascular complications
l Most participants had a diagnosis of
SMI before diabetes, although not all.
Some participants, especially those with
bipolar disorder, discussed identifying
SMI symptoms long before their diagnosis
l Many participants had several physical
comorbidities, which affected their
ability to manage diet and weight
(theme 2)
l The effect of SMI type on diabetes
management was explored. Few
differences were found and both groups
identified barriers to their diabetes
l It is unclear if the findings relating to
diagnosis order are due to limitations of
the data set. Qualitative feedback from
people with diabetes and SMI suggests
that some people are experiencing SMI
long before diagnosis, which may
account for some of the group
diagnosed with T2DM before SMI or
concurrently. This is not conclusive, and
needs to be explored further
l People with diabetes and SMI in the
qualitative study identified comorbidities




























































Objective Description Quantitative data Qualitative data Conclusion
l Older age, comorbidities and high
baseline HbA1c level predicted
microvascular complications
l Older age, male sex, Asian ethnicity,
higher deprivation, SMI type, SMI
duration, number of comorbidities,
antidiabetic and antipsychotic
medication use and substance use were
predictors of all-cause mortality
l Younger age, SMI type, comorbidities,
antidiabetic and antidepressant
medication use were all predictors
for mental health relapse
management. People with schizophrenia
discussed the effect of antipsychotic
drugs on their physical health to a
greater extent than those with bipolar
disorder (theme 3)
l Links were identified between presence
and severity of mental health and
diabetes symptoms (themes 3 and 4)
Those with more comorbidities,
therefore, may be likely to have more
trouble managing diabetes and therefore
have worse outcomes
l Although all people with diabetes and
SMI discussed barriers to diabetes
management, the presence or absence of
which could affect diabetes outcomes,
people with schizophrenia were much
more likely to discuss the effects of
antipsychotic medication. This may
highlight a difference between
SMI types
l Links identified between mental health
and diabetes suggest that outcomes
could be linked, that is those with
poorer mental health may also have
poorer diabetes outcomes
3 In people with SMI, to compare
health-care interventions and
physical and mental health
outcomes in those with diabetes
with those of people without
diabetes
l T2DM prevalence in eligible patients
with SMI was 10.2%




l T2DM increased the chances of people
with SMI receiving health checks for
glucose, cholesterol and blood
pressure levels
l Note that all qualitative study
participants had a diagnosis of diabetes
l Relationships were identified between
diabetes and mental health symptoms
and severity (themes 3 and 4)
l People with diabetes and SMI describe
having regular diabetes health checks in
primary care (theme 6)
l A diagnosis of diabetes adds complexity
to a diagnosis of SMI alone, increasing
the risk of death, mental health relapses
and macro- and microvascular
complications. Relationships identified in
the qualitative study between SMI
symptoms and diabetes could help
explain the links between T2DM and
mental health relapse
l Having T2DM was associated with
increased physical health checks.
























































































































































































































































































TABLE 27 Integration table mapping study findings from the quantitative and qualitative studies by study objective (continued )
Objective Description Quantitative data Qualitative data Conclusion
4 In people with diabetes,
to compare health-care
interventions and physical and
mental health outcomes in
people with SMI with those of
people without SMI
l People with SMI had a higher risk of
emergency admissions and a lower
risk of elective admissions for
macrovascular complications
l People with SMI had higher all-cause
mortality, were more likely to die from
chronic ischaemic heart disease and had
increased chance of health checks for
HbA1c, blood pressure and cholesterol
l Note that all qualitative study
participants had a SMI diagnosis
l People with diabetes and SMI described
having regular diabetes health checks
in primary care. Some participants
suggested that these were not regular
enough, which may lead to loss of
diabetes control in between checks
(theme 6)
l Staff and people with diabetes and SMI
identified instances whereby somatic
symptoms were attributed to mental
health by health-care staff (diagnostic
overshadowing), sometimes leading
to much more serious health
problems later
l People with SMI receive more physical
health checks than those without SMI,
yet have higher rates of mortality and a
higher risk of emergency admission and
a lower risk of elective admission to
hospital for macrovascular complications.
This suggests that people with SMI are
not being referred to cardiovascular
specialist care, despite receiving health
checks in which health issues would be
expected to be identified
l Qualitative study participants discussed
incidences of diagnostic overshadowing,
which could help explain this finding. If
symptoms are being attributed to mental
rather than physical health, warning
signs of illness could be missed until
the point at which they become an
emergency and cannot be ignored when
patients are admitted to hospital
5 To understand the factors that
are associated with access to,
and receipt of, diabetes care for
people with SMI, and to explore
the experience of diabetes
health care by people with SMI
This was a qualitative research question
exploring personal experiences. The
quantitative research was not able to
address this objective
Key themes:
1. The pervasive effect of SMI – diabetes
cannot take priority
2. The effect of multimorbidity on
diabetes management
3. The interacting and overlapping nature
of diabetes and SMI symptoms
4. How mood affects
diabetes management
5. The importance and impact of informal
support networks
6. Experiences of diabetes health care
7. Diabetes knowledge and education and
impact on self-management
8. A desire for person-centred care with
an emphasis on continuity
Experiences differed between participants;
for some, having diabetes and a SMI is
linked to numerous mental and physical
barriers to self-care and diabetes
self-management. The importance of
personalised support from people who





























































Objective Description Quantitative data Qualitative data Conclusion
6 To compare diabetes care
provision for people with and
people without SMI, and to
estimate costs for these
l People with SMI and diabetes have
significantly more primary care
consultations and more mental health
inpatient stays (of a longer duration)
than people with diabetes alone
l They have a similar number of
non-mental health inpatient stays
but patients with SMI stay for
significantly longer
l People with SMI and diabetes use
consistently more health-care resources
than people with diabetes alone
l People with diabetes and SMI are
seeing many different health-care
professionals as a result of their two
primary conditions and often multiple
comorbidities. Mental and physical
health-care services are often seen as
separate entities and function in this
way (themes 2 and 8)
l Links between mental and physical
health symptoms and severity have
been highlighted (themes 3 and 4)
l People with diabetes and SMI are
understandably using more health-care
resources because of multiple conditions
and comorbidities
l The lack of joined-up care described in
the qualitative data may account for the
increased consultations for this group.
Links between mental and physical
health symptoms could mean that
physical health issues leading to
inpatient stays were exacerbating mental
health issues, resulting in extended
illness periods and longer hospital stays
7 To identify which health-care
interventions may be associated
with better diabetes outcomes
for people with SMI and diabetes
l People with SMI had increased chances
for health checks, compared with
controls, in people without
macrovascular complications
(as outcome)
l People with SMI had reduced chances
for health checks, compared with
controls, in people with macrovascular
complications (as outcome)
l The importance of support for diabetes
and mental health management, both
informal and from health-care services,
was emphasised. Ongoing support from
a familiar person was important to
people with diabetes and SMI.
Individualised care that focused on all
aspects of a person and their condition
was wanted (themes 5 and 8)
l Fluctuating nature of moods, and
therefore diabetes management, was
identified, which is unlikely to be
captured in 6- to 12-monthly checks
(themes 3, 4 and 6)
Ongoing, regular support and continuity of
care were discussed in the qualitative study
as being key to diabetes and mental health
management. The fluctuating nature of
mood (not just SMI symptoms) and the
close links between mental state and
diabetes management suggest that closer
monitoring of this group could help






















































































































































































































































































hidden, and, for many participants, becoming a lesser priority. This may explain why we obtained such
limited responses about diabetes care from service user participants (see Chapter 6, Theme 6: diabetes
health care), which contrasted significantly with the detailed accounts of mental health care.
Depression and anxiety
In the context of SMI, this study suggests that, like diabetes, depression and anxiety may be
overlooked because of the focus on managing and preventing psychotic symptoms, and living with the
experience of these symptoms (see Chapter 6, Theme 1: mental illness affects everything). Depression
and anxiety were highlighted by participants as being difficult to attribute to SMI or diabetes (see
Chapter 6, Theme 3: interacting conditions, overlapping symptoms), and this was confirmed by co-design
participants who consistently linked mood symptoms to both conditions. There was also a suggestion
that these symptoms may not be prioritised for treatment (see Chapter 6, Fluctuating moods, fluctuating
management); when we asked about this in the co-design workshop, service users reported generally
not seeking help for low mood, and clinicians agreed that depression is not always considered as a
potentially separate condition to manage.
This additional overshadowing is important, because many service user participants in the qualitative
study described low mood, anxiety and stress as recurring features in their lives (see Chapter 6, Theme 4:
the effect of mood on diabetes management), in addition to the symptoms of psychosis and mania that
were associated with a relapse. In the quantitative study, we found that people with SMI who took
antidepressant medications had an increased risk of macrovascular complications (see Chapter 5,
Regression analysis results for the impact of type 2 diabetes on health outcomes and health-care interventions),
even though having depression and anxiety was associated with better attendance for health checks that
could help to prevent such complications (see Chapter 5, Regression analysis results for the adjusted impact
of severe mental illness on levels of physical health checks). We also found that people with SMI and diabetes
had an increased risk of depression and anxiety, compared with people with diabetes alone (see Chapter 5,
Objective 4: comparing the health outcomes of people with diabetes and severe mental illness with the health
outcomes of people with diabetes without severe mental illness, Results). This risk was highest for those
diagnosed with diabetes before SMI; for these patients, their SMI diagnosis was more likely to be
depression and psychosis, rather than other types of SMI (see Chapter 5, Objective 2: factors associated
with variation in diabetes and mental health outcomes in people with severe mental illness and diabetes, Results).
Service user participants seemed to relate their anxiety and low mood to worries about diabetes (see
Chapter 6, Worries about diabetes) and the impact of poor physical health on their lives (see Chapter 6,
Theme 3: interacting conditions, overlapping symptoms). At the same time, depression and low mood were
perceived to contribute to worsening physical health, through lower motivation to manage diabetes
and other health problems (see Chapter 6, Fluctuating moods, fluctuating management).
This complex relationship between depression and anxiety, SMI and diabetes suggests that low mood
may result in poor diabetes outcomes in people with SMI and may help to explain why people with
both conditions are more likely to experience a SMI relapse. Low mood is more likely to occur in
people who are marginalised and less likely to be noticed in primary care, and people with SMI who
develop T2DM are more likely to live in the most deprived neighbourhoods than those with SMI who
do not develop T2DM (see Chapter 5, Objective 1: factors associated with the development of diabetes in
people with severe mental illness, Results). This relationship may form part of the mechanism linking poor
social conditions and worse physical and mental health.
Better diabetes control, or hidden fluctuation?
We found that, although people with SMI and diabetes have poorer outcomes, including increased risk
of mortality, than people with SMI alone and people with diabetes alone, they consistently have lower
HbA1c and blood pressure levels (see Chapter 5, Objective 4: comparing the health outcomes of people with
diabetes and severe mental illness with the health outcomes of people with diabetes without severe mental
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illness, Results), which are indicative of better diabetes management. Our integrated findings offer three
potential explanations.
The first explanation relates to diagnostic overshadowing (see Diagnostic overshadowing); despite there
being a greater opportunity to detect problems [through more testing and contact with GPs (see
Chapter 5, Objective 6: comparing diabetes care provision and estimating health-care costs for people with
and people without severe mental illness, Results)], there is disproportionately less action taken, with the
consequence of underdiagnosis of complications and delayed referral to specialist services for people
with SMI (see Chapter 5, Objective 4: comparing the health outcomes of people with diabetes and severe
mental illness with the health outcomes of people with diabetes without severe mental illness, Results). The
second explanation is that diabetes control may fluctuate more widely in people with SMI because of
the additional challenges to managing their diabetes. Such fluctuations would not be evident in primary
care records without more regular monitoring of glucose. Co-design participants recommended glucose
monitoring as a future intervention for people with SMI and diabetes to help increase awareness of
whether a symptom was due to diabetes or SMI, and to improve diabetes management. The third
explanation is that people with SMI who have the greatest risk of poor outcomes from diabetes may be
the least likely to attend diabetes checks and receive specialist diabetes care. For example, we found that,
among those with macrovascular complications, people with SMI were less likely to receive health checks
than people with diabetes and no SMI (see Chapter 5, Objective 7: identifying health-care interventions
associated with better outcomes for people with diabetes and severe mental illness, Results). Moreover, people
with SMI and diabetes had more psychotic relapses than those without diabetes (see Chapter 5, Regression
analysis results for the impact of type 2 diabetes on health outcomes and health-care interventions), and we
know from the qualitative study that psychotic symptoms can lead to a foregrounding of mental illness
and feelings of helplessness, and negatively affect self-care, engagement with services, social support and
health management (see Chapter 6, Theme 1: mental illness affects everything, and Theme 5: ‘the most critical
person in my care’ – the role of informal support networks).
Tied intimately to these potential explanations is that social and economic deprivation contribute to
the health gap. People with SMI living in deprived areas or who are of black or Asian ethnicity were
more likely to develop diabetes, and these factors were the strongest predictors of developing diabetes
(see Chapter 5, Objective 1: factors associated with the development of diabetes in people with severe mental
illness, Results). Compared with controls with diabetes only, people with SMI and diabetes lived in more
deprived areas, which was a significant predictor of worse health outcomes (see Chapter 5, Objective 4:
comparing the health outcomes of people with diabetes and severe mental illness with the health outcomes
of people with diabetes without severe mental illness, Results, Descriptive statistics). In addition, social
deprivation was associated with fewer health checks (see Chapter 5, Objective 4: comparing the health
outcomes of people with diabetes and severe mental illness with the health outcomes of people with diabetes
without severe mental illness, Results).
Multimorbidity
Both studies highlight the importance of situating comorbid SMI and diabetes within the framework
of multimorbidity. People with SMI and diabetes had more comorbidities than people with SMI and
no diabetes; this included depression and anxiety as well as physical illnesses such as cardiovascular
disease and hypertension (see Chapter 5, Objective 3: comparing health-care interventions and health
outcomes in people with severe mental illness and diabetes with those in people with severe mental illness
without diabetes, Study population). When controlling for other key variables, comorbidities were also
associated with both the onset of diabetes in people with SMI (see Chapter 5, Regression analyses results
for the risk factors for development of type 2 diabetes) and poor outcomes for people with diabetes,
whether or not they had SMI as well (see Chapter 5, Regression results for the impact of severe mental
illness status on physical and mental health outcomes, mortality and health checks).
Surprisingly, we found that, when comparing outcomes between people with diabetes with SMI and
people with diabetes without SMI, people with SMI had fewer physical comorbidities and similar rates
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of cardiovascular disease, even though they had a significantly increased mortality rate (see Chapter 5,
Regression results for the impact of severe mental illness status on physical and mental health outcomes,
mortality and health checks). Social deprivation may, in part, explain this, because people with SMI
were more likely to live in a deprived area, and this was associated with a higher risk of mortality
(see Chapter 5, Regression results for the impact of severe mental illness status on physical and mental health
outcomes, mortality and health checks). Diagnostic overshadowing (see Diagnostic overshadowing) may
also offer an explanation, with physical health problems being attributed to SMI; therefore, they are
not diagnosed or treated. The qualitative study sheds light on other potential reasons too, as many
service user participants talked about physical health problems such as poor sleep, musculoskeletal
problems and poor mobility, which we could not reliably explore in the CPRD data, but which affected
their ability and motivation to manage diabetes (see Chapter 6, Theme 2: not just two illnesses –
multimorbidity and diabetes management). The sense of being overwhelmed by poor health from multiple
conditions, each with their own treatment and management burdens (see Chapter 6, Theme 1: mental
illness affects everything, and Theme 2: not just two illnesses – multimorbidity and diabetes management),
led many participants to respond by prioritising SMI as their dominant concern, potentially to the
detriment of optimal diabetes outcomes.
In the context of multimorbidity, this study additionally highlights the importance of ordering of
diagnosis. Unexpectedly, we found some evidence that people who are diagnosed with diabetes first
may have poorer health outcomes (see Chapter 5, Objective 2: factors associated with variation in diabetes
and mental health outcomes in people with severe mental illness and diabetes, Results, and Objective 4:
comparing the health outcomes of people with diabetes and severe mental illness with the health outcomes
of people with diabetes without severe mental illness, Results). The qualitative study included very few
participants who received their diagnoses in this order and offers little insights into how different their
experiences are, but, considering the overwhelming nature of having SMI, it may be that the layering
of psychosis onto poor physical health has a greater impact on an individual’s ability to manage their
diabetes (see Chapter 6, Participant characteristics).
The role of antipsychotic medication
We found that, after controlling for other variables, treatment with antipsychotic medication increases
the risk of developing diabetes in people with SMI (see Chapter 5, Objective 1: factors associated with the
development of diabetes in people with severe mental illness, Results). For people with both conditions, use
of antipsychotic medication increases the risk of mortality (see Chapter 5, Regression analyses results),
and, for people with both conditions, atypical antipsychotics are associated with worse outcomes. The
qualitative study also highlights concerns about the side effects of antipsychotic medication, including
weight gain, increased appetite and lethargy (see Chapter 6, Mental health medication and diabetes
management). Some participants associated these with both the onset and management of diabetes,
and all three side effects were identified as barriers to eating healthily and being physically active (see
Chapter 6, Mental health medication and diabetes management). Fewer people with diabetes and SMI than
staff identified a link between antipsychotic medication and diabetes, and many expressed a resigned
acceptance that living with the side effects that came with such medication was a necessity (see
Chapter 6, Persistence and powerlessness). Very few participants talked about antipsychotic medications
in relation to diabetes treatment; for example, no participant talked about addressing the side effects
of antipsychotic medications to help their diabetes, or the possibility of switching medication as
potential solutions (see Chapter 6, Theme 6: diabetes health care).
The value of relationship-based care that supports management of both conditions
The quality and quantity of relationships with others, both friends and family, and health-care
providers, were identified as important resources for health management, and were also reported as
being deficient by many participants (see Chapter 6, Theme 5: ‘the most critical person in my care’ – the
role of informal support networks). When talking about person-centred care, the positive aspects that
participants highlighted were often about the relationships they had established with individual mental
health care co-ordinators, and the benefits of quite general support provided to help with their lives,
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such as getting out and about (see Chapter 6, The value of person-centred care). This mirrored the
narrative about the benefits of interactions from informal social networks (see Chapter 6, Theme 5:
‘the most critical person in my care’ – the role of informal support networks), which included a focus on
the whole person and help with navigating the care system.
In supporting people with SMI and diabetes, offering continuity and opportunities to build relationships
(see Chapter 6, Theme 8: person-centred care), and compensating for the lack of informal support we
observed among many participants, were highly valued by service users and staff in the qualitative
study, and also by the co-design participants as they discussed recommendations for future care.
Challenges to this were also identified, including lack of time and continuity to provide person-centred
care, and limited knowledge among staff about either diabetes or SMI, which limited their ability to
provide specialist advice or care for both conditions. Poor information-sharing between different
services was identified as a further barrier to accessing specialist care and navigating the health-care
system (see Chapter 6, Theme 8: person-centred care), and, although the unreliability of referral data
limited our investigation of diabetes and mental health care provision, we did find that frequency of
care alone (e.g. more GP contact, health checks, hospital stays) was not indicative of better care or
health outcomes (see Chapter 5, Objective 4: comparing the health outcomes of people with diabetes and
severe mental illness with the health outcomes of people with diabetes without severe mental illness, Results,
Objective 6: comparing diabetes care provision and estimating health-care costs for people with and people
without severe mental illness, Results, and Objective 7: identifying health-care interventions associated with
better outcomes for people with diabetes and severe mental illness, Results).
In the final co-design workshop, service users and health-care staff took forward the study findings to
make recommendations that they believed would improve outcomes for people with SMI and diabetes.
Although they worked independently, all groups proposed similar changes and agreed on three key
priorities: (1) relationship-based care that focuses on management of both conditions, (2) the sharing of
patient records between primary care, mental health care and diabetes services and (3) access to specialist
SMI and diabetes expertise for staff supporting patients, to increase knowledge of both conditions.
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We set out to identify the determinants of diabetes, to explore variation in health outcomes and
mortality, and to investigate access to, and experiences of, diabetes health care for people with SMI
and diabetes.
Underpinned by a social inequalities framework, we conducted a mixed-methods study, using a
concurrent triangulation design, comprising:
l a quantitative longitudinal observational study, using the health records of 32,781 people with SMI
(2761 of whom had diabetes) and of 9573 ‘controls’ with diabetes and no mental illness, matched
on age, sex and practice from the CPRD (GOLD) database, with individual linkages to HES, ONS
and IMD data
l a qualitative interview study with 39 adults with SMI and diabetes, nine family members and
30 health-care staff.
Emerging findings from each investigation iteratively informed the design and analysis of the other.
Quantitative and qualitative results were integrated using charting and co-design methods to develop
a more comprehensive and in-depth understanding of the relationship between SMI and diabetes.
Diabetes in people with severe mental illness
We found that the prevalence of T2DM was 10% in people with SMI. Sociodemographic factors
associated with increased risk of diabetes in SMI included older age, older age at diagnosis of SMI,
Asian or black ethnicity, living in areas of socioeconomic deprivation and family history of diabetes.
Baseline cardiometabolic risks of overweight, cardiovascular disease, hypertension and higher baseline
blood pressure, cholesterol and HbA1c levels were also associated with diabetes, as was being on
antipsychotic medication. People with SMI who were prescribed atypical antipsychotics were 40%
(OR 1.39) more likely to develop diabetes.
We observed a general trend of improved control of HbA1c, cholesterol and blood pressure from 2000
to 2016 in people with SMI and diabetes. These apparent improvements might reflect improvements in
care, influencing better control over time, but may also be a function of changes in the composition of
the study population. Recorded prevalence of diabetes increased throughout the period and practices
were financially incentivised for case-finding from 2004 onwards. Less severe cases at earlier stages
of disease may, therefore, have constituted an increasing proportion of the diabetes study population
over time, as detection (and therefore correct categorisation) of diabetes ‘caseness’ improved.
Diabetes and mental health outcomes in people with severe mental illness and diabetes
Factors associated with poorer physical or mental health outcomes were complex and differed by outcome.
For macrovascular complications, older age, longer diabetes duration, comorbidity, baseline cardiovascular
disease, hypertension and prescription of antihypertensive agents were all risk predictors. A more deprived
socioeconomic status was also weakly associated with a higher risk. Current smokers had almost double
the risk compared with non-smokers, although missing data limit confidence in this finding.
Microvascular complications were predicted by older age, baseline cardiovascular disease and baseline
HbA1c level exceeding the recommended threshold of 58 mmol/mol (7.5%). There was also weak
evidence that more deprived socioeconomic status, longer duration of SMI and baseline prescription of
antidiabetes medication increased the risk of developing these complications.
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In contrast to the association with diabetes risk, ethnicity was not identified as a risk predictor for
poor physical health outcomes in people with SMI and diabetes. This may be as a result of missing
ethnicity data and small numbers recorded as being from ethnic minority populations in our data set.
For mental health outcomes, older age had a small but statistically significant protective effect. Women
were more likely to have recorded depression and anxiety than men (which could indicate increased
risk and/or increased recognition). Asian ethnicity increased the risk of depression, even after adjustment
for baseline antidepressant prescriptions. People with bipolar disorder were more likely to have a relapse
of SMI in the follow-up period than people with schizophrenia, and also had an increased risk of depression
and anxiety. Clinical diagnosis of depression with psychosis, unsurprisingly, considerably increased the risk
of depression and anxiety. An additional Charlson Index comorbidity was associated with reduced risk of
SMI relapse but increased risk of depression and anxiety. Baseline prescription of antidiabetes medication
was a significant predictor for SMI relapse, increasing risk by 34%. A possible explanation may be that
being on such medication is associated with more severe/poorly controlled diabetes, which acts as a trigger
for SMI relapse.
All-cause mortality in SMI and diabetes increased with older age, male sex, white ethnicity, Charlson
Index comorbidity and socioeconomic deprivation; longer duration of SMI slightly reduced the effect
on mortality. Schizoaffective disorder was associated with an increased risk of all-cause mortality,
compared with schizophrenia. Baseline antidiabetes drug prescription increased all-cause mortality
by 35%. Antipsychotics were also associated with higher mortality. Typical antipsychotics increased
mortality risk by 27% and atypicals by 31%. These risks are likely to be confounded by higher severity
of conditions (diabetes and SMI) requiring medication. Although missing data preclude definitive
conclusions, people who used substances at baseline had a three times higher mortality risk than
people with no substance use.
The impact of having severe mental illness for people with diabetes
We were interested in understanding the impact of having SMI for people with diabetes, and the
impact of having diabetes for people with SMI.
We found evidence that people with SMI alongside diabetes had better control of diabetes and blood
pressure and were more likely to receive physical health checks than people with diabetes alone.
Despite this, we found that the risk of depression and all-cause mortality was increased, compared
with people without SMI. We think this may be because of ‘service gaps’ in accessing elective or
planned care that could improve health outcomes. This is supported by the findings on macrovascular
complications, for which elective admissions were lower but emergency admissions higher, for people
with SMI alongside diabetes than for people with diabetes alone. Similarly, as previously reported in
the literature,124 there are likely to be gaps in recognition and reporting of health problems for this
group. We found that the rate of macrovascular complications was similar in people with and people
without SMI, but people with SMI were less likely to have a record of less acute conditions, such as
chronic heart disease. Service gaps were also suggested by qualitative findings, which highlighted
the additional barriers to receiving physical health interventions, structural inequalities and the sense
of mental illness ‘overshadowing’ physical health needs from the perspective of both health-care
providers and people with SMI. Challenges distinguishing between mental and physical illness
symptoms, and the impact of low mood and anxiety on the importance given to, and the ability to
manage, physical health may compound these difficulties.
The impact of having diabetes for people with severe mental illness
Diabetes alongside SMI increased the probability of receiving physical health checks, but was a
significant risk factor for poorer physical and mental health outcomes than SMI alone. The risk
of depression and anxiety was increased. From interviews, we found that worries about diabetes
could make people feel depressed and anxious; this was also found to lower motivation and intentions
to manage diabetes and physical health more generally in SMI. It could be challenging to distinguish
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between symptoms of mental illness relapse and symptoms of poor glycaemic control. Multimorbidity
was common and posed a significant challenge; people with SMI frequently found it overwhelming to
deal with several long-term conditions.
Ordering of severe mental illness and type 2 diabetes diagnosis
A surprising initial finding was the larger than expected proportion of people who had been diagnosed
with T2DM before their SMI diagnosis. Although further investigation established that this was, in part,
a function of using the necessary cut-off points to include only more reliable quality data (which had
the unintended effect of selectively excluding people diagnosed with SMI at an earlier age), it was clear
that the population diagnosed with T2DM before SMI constituted a significant proportion of those
with comorbid diabetes and SMI. The NDA reported an even higher proportion of people with diabetes
diagnosed before SMI (65%).144
The approach to restrict analyses to UTS data is one that is widely used in studies interrogating large
health-care data sets. The findings about how this affected the make-up of the study population,
differentially excluding more people diagnosed with SMI at an earlier age, have wider applicability.
Despite its potential to significantly affect study results, to our knowledge, this limitation of applying
UTS criteria has not been reported elsewhere.
Although not part of the initial objectives, we conducted a limited exploration of how diagnosis
order affected demographics, baseline characteristics and outcomes for the study population.
People diagnosed with SMI before T2DM were more likely to be diagnosed at an earlier age for
both conditions, be male, be overweight, live in the most deprived neighbourhoods and be current
smokers. Baseline HbA1c, cholesterol and blood pressure levels were higher. They also had, in general,
better physical and mental health outcomes, with lower risk of macrovascular complications and
hospital admissions. Rates of SMI relapse, depression and anxiety, and mortality were all lower. The
baseline prevalence of microvascular complications was lower, but they were more likely to develop
new complications during the follow-up period than people diagnosed with T2DM before SMI.
People diagnosed with T2DM before SMI were more likely to have depression with psychosis, and a
higher prevalence of comorbidities and prescribed medication other than antipsychotics. This group
had had diabetes for, on average, 5 or 6 years; therefore, they had the ‘opportunity’ to develop
complications in the pre-baseline period. A higher baseline prevalence of microvascular complications,
and fewer new microvascular complications during follow-up, would, therefore, be expected (as found
in the data), compared with those diagnosed with SMI first.
Health-care use and costs for people with severe mental illness and diabetes
To our knowledge, this is the first study to compare health-care use and costs across sectors for people
with SMI and diabetes and people with diabetes alone using patient-level data. We found that use of
primary care services, hospital admissions and duration of hospitalisation were all significantly higher
for people with SMI alongside diabetes. Health-care costs were correspondingly higher (around double)
than costs for diabetes alone. These costs are likely to be an underestimate as they exclude hospital
admissions to specialist mental health facilities (which are likely to be higher for people with SMI).
Health-care interventions and outcomes for people with severe mental illness and diabetes
Our investigation of health-care interventions and how these influence health outcomes using routine
health-care records was constrained by limited availability of information about these interventions in
the data set, and by confounding between intervention and outcomes variables. However, interviews
and co-design workshops provided important insights about the experience of negotiating health care
for people with SMI and diabetes. These indicated that people accessed care separately for their
conditions: diabetes care from their general practice and mental health care from specialist mental
health services.
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Formal and informal relationships with others, including social (family and friends) and health-care
professionals, were highly valued as an important source of support for health management, although
they were notably absent for many people. Such relationships and continuity of care were seen as
essential to support health-care needs, particularly for dealing with the complex and overwhelming
challenges of living with multimorbidity. These relationships helped with motivation, as well as
providing more practical support to navigate health care. A case management approach to help people
navigate across health service silos, sharing health records across different services and increasing staff
knowledge about mental and physical conditions and management of multimorbidity, could be key to
improving care and outcomes for people living with the double burden of SMI and diabetes.
Comparison with other research
These findings confirm results of previous research and also address some important evidence gaps.
The prevalence of diabetes in people with SMI has been consistently estimated to be two to three
times higher than for the general population. Our estimate of 10.2% is similar to previously reported
rates from meta-analyses (10.2%)44 and from interrogation of routine health-care data (8.0%).145
A range of risk factors (which are similar to those in the general population) for developing diabetes in
people with SMI have been previously described,25,146 but studies have been inconsistent. Stubbs et al.122
reported only increasing age to be associated with risk of T2DM. A later meta-analysis implicated older
age, longer illness duration and multiepisode (SMI) status, but not sex, ethnicity or smoking status;44
however, multivariable meta-regression analysis found that multiepisode (vs. first-episode) status was
the only significant predictor for T2DM. These findings diverge from our results, which found a number
of additional demographic and health variables, including Asian or black ethnicity, to be T2DM risk
factors in SMI. Another health-care database study with a high minority ethnic population reported that
increased risk of T2DM in SMI was exacerbated by Asian or Afro-Caribbean ethnicity;147 neighbourhood
socioeconomic disadvantage has been reported as a risk factor in a previous study.148 Antipsychotics,
particularly atypical antipsychotics, are widely reported to be associated with increased risk of T2DM,64
which was confirmed by our results.
Most previous research has reported only on the population of people diagnosed with SMI before T2DM,
has been cross-sectional or has not considered diagnosis order. We found that there were important
differences between the two populations, people diagnosed with SMI before T2DM and people diagnosed
with T2DM before SMI, and these differences warrant further exploration. Diabetes appears to increase
the risk of poor mental illness outcomes. A cross-sectional study reported elevated risk for all mental
illness in people with diabetes, with the greatest excess risk (around threefold) for schizophrenia.149
Although relatively limited, there have been qualitative studies using focus groups, individual interviews
and surveys to explore the experience of people living with comorbid SMI and diabetes.150–153 A common
theme reported in these studies is that mental illness care significantly overshadows diabetes care.
Another strong theme across studies is that of feeling overwhelmed by multiple chronic comorbidities
with differing self-care recommendations. Our study also found that mental illness symptoms and care
needs dominated people’s day-to-day lives, casting a ‘shadow’ over everything else. Multimorbidity was
also a consistent feature, making self-management and accessing health care extremely challenging.
Furthermore, mood influenced the ability to manage, and importance given to managing, physical health.
A further barrier to managing diabetes in SMI was that health care was experienced as being provided
in condition-specific silos.
Previous studies on diabetes health-care interventions received by people with SMI (compared with
people without SMI) have given conflicting results. The NDA144 found that, compared with the general
diabetes population, people with SMI and T2DM were slightly less likely to receive NICE-recommended
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care checks, but there was no difference in treatment target achievement. Overall evidence suggests
that levels of health checks and cardiovascular and metabolic control (e.g. cholesterol, blood pressure,
HbA1c) are comparable (except for retinopathy checks).154–156 However, concerningly, despite similar
achievement of treatment targets as the general diabetes population, morbidity and mortality are
increased for people with SMI.154
Potential explanations for the NDA144 findings and the present study include limitations of data recording
(see Limitations of this study). However, they can potentially also indicate problems with accessing health-
care interventions for the same level of need. We found evidence suggesting service gaps, with similar
rates of recorded macrovascular complications for people with SMI and those without SMI, but differing
patterns of acute versus elective care between the two groups. A study investigating treatment of acute
myocardial infarction in people with SMI157 found that they were less likely to receive revascularisation
therapies than the general population, despite changes in care to improve this situation.
Strengths and limitations
Strengths of this study
We accessed a large, comprehensive longitudinal data set, CPRD (GOLD), with individual data linkages
to HES, ONS and IMD data, allowing us to address important evidence gaps. Patient characteristics in
the CPRD database have been shown to be broadly representative of the general UK population in
terms of age, sex and ethnicity,98 meaning that our findings are likely to have wider generalisability.
There are a growing number of studies using routinely collected health-care data to explore mental
and physical health, health care and outcomes for people with SMI.145,147,155 The large numbers of
records that are usually involved mean that such studies can address important applied health research
questions. However, none, to date, has reported using longitudinal data combined with qualitative
inquiry to develop a more in-depth understanding than can be achieved by cross-sectional designs or
quantitative analyses alone.
Our mixed-methods design means we have been able to fill in ‘gaps’ from the quantitative study, which
allows us to theorise further on the meaning of the findings. Moreover, an integrated approach in
which emerging findings from both quantitative and qualitative inquiry informed further questions,
allowed us to conduct a more detailed, in-depth exploration to address study objectives. The large
qualitative sample size and inclusion of people with SMI and diabetes, their families and a variety of
health-care staff ensured representation of a wide range of views in our data. Co-design workshops
also ensured that, in addition to our multidisciplinary research team, people with SMI and diabetes,
their families and health-care providers helped to interpret study findings. This strengthens the
reliability and relevance of our findings, grounding them in the day-to-day experience of people living
with and managing SMI and diabetes. Strong PPI and clinical input have also helped strengthen
interpretation of findings and their relevance and application to practice.
Limitations of this study
As with all studies using routine health-care data, the quality of the data, in terms of accuracy and
completeness, will influence the questions that can be addressed and the reliability of findings. As with all
observational studies, it is not possible to control for unobserved confounders, and systematic biases in
measurement errors might lead us to over- or underestimate associations of risk factors with outcomes for
people with SMI. We also did not have access to contextual data on lifestyle, or to the environmental and
social determinants of health that were not available in the health-care record or through data linkages.
Despite being representative of the UK population, the CPRD data set has some key limitations.
Geographically, practices with large list sizes in urban areas in the south and north-west of England
are over-represented, whereas practices in the north-east are under-represented.98
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Missing data in the CPRD limited some of the analyses. We found large numbers of missing data for
lifestyle factors (e.g. smoking), which are coded less systematically than information on clinical diagnosis
and prescriptions. It cannot be assumed that these data are missing at random, as missingness may
be influenced by various factors, including the coding behaviour of primary care providers, a patient’s
health status and the implementation of financial incentive schemes. Changes in QOF indicators, for
example, are likely to change recording behaviour, not just practice. Therefore, it is difficult to adjust for
missing data, as the potential impact of all of these factors is unknown.
Data for health-care interventions and pathways were limited in the CPRD (because of unreliability,
e.g. of referral data for diabetes education and specialist services, and a lack of linked outpatient data
in our data set). The ability to explore the influence of health-care interventions on health outcomes
was, therefore, restricted. Related to this, when we found differences in provision of interventions for
people with SMI, it was not possible to identify the level of the ‘service gap’ (referral or access) from
the CPRD. We were also unable to measure severity of mental illness or diabetes, as this information is
not routinely recorded, and cannot be reliably inferred from other parameters.
The study was also limited by the accuracy and completeness of the recording of diagnoses and activities
by practices. The validity of the Read coding system used in practices’ electronic medical records varies
over time and by diagnosis: in a 2010 review, estimates of the positive predictive value of recorded
diagnostic codes in the General Practice Research Database system (precursor to the CPRD) were
98.6 (95% CI 92.2 to 100.0) for diabetes and 81.0 (95% CI 87.0 to 94.0) for schizophrenia.158 However,
completeness of recording in the CPRD has improved over time, particularly for conditions included in
the QOF, for which standard reporting requirements (codes specified under QOF business rules) were
introduced. This includes both diabetes and SMI. Although we based our diagnostic criteria on QOF
business rules, we also extended our definitions to include patients for whom there was a reasonable
presumption of having the condition (e.g. patients without a recorded diagnosis of diabetes receiving
regular prescriptions of insulin or antidiabetic medication).
We estimated hospital use and costs based on the HES data set, which contains detailed information
about admissions to general hospitals (including non-specialist mental health providers), but not
admission to specialist mental health facilities. Use of community mental health care, outpatient
attendances and A&E attendances was also missing from our data (because of limitations on how many
data sets can be linked to avoid inadvertent identification of practices). A further limitation was that
costs for diabetes care could not be separated from other costs.
The qualitative findings indicated fluctuating diabetes management because of changes in mental
health or emotional states. However, this was not captured in the CPRD data because of large gaps
between diabetes checks (often 6 or 12 months). Eligibility criteria for the interview study necessarily
excluded people who were too unwell to participate and probably selected people with less severe SMI
and better diabetes control. They were also less likely to be homeless or have unstable housing.
We were not able to achieve the target sample size for family members, as many participants with SMI
and diabetes were not able to identify a family supporter. However, family members participated in the
PPI group and co-design workshops, providing valuable insights.
Conclusions
We believe that this is the first study to combine interrogation of a large health-care data set with
in-depth interviews to identify the factors associated with developing T2DM and those influencing
mental and physical health outcomes for people with SMI and diabetes, and to estimate health-care
costs and explore the experience of living with SMI and diabetes.
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Implications for practice
The findings from this research indicate that the following five key messages are important for
clinical practice.
Regular diabetes checks for people with severe mental illness
Check all people with SMI regularly to identify those with diabetes and those at high risk of developing
diabetes and offer appropriate intervention.
Address the metabolic side effects of psychotropic medication
Although psychotropic medication forms a key part of the management of SMI, many of these
medications are linked to weight gain and diabetes. Clinicians should therefore carefully consider the
choice of psychotropics, discuss the side effects with patients, monitor for metabolic side effects and
intervene when necessary.
Respond to the challenges of multimorbidity
Health-care professionals and services must take account of multimorbidity in the assessment and
management of diabetes.159 Possible solutions include a keyworker or case management approach to
better integrate support for both mental illness and diabetes, and improved training for health-care
staff on managing multimorbidity.
Provide tailored support for self-management
Provide a bespoke diabetes self-management education package for people with SMI that addresses
the unique challenges to having these conditions together. These include managing side effects of
antipsychotic medications, managing the impact of fluctuating mental health and mood on diabetes
self-management, and distinguishing between mental and physical symptoms.
Address social concerns
Health-care services and professionals should identify difficulties related to diabetes management that
stem from social issues, such as housing, discrimination, transport, poverty, access to benefits and
social capital, given the complex interactions between socioeconomic factors and diabetes and SMI.
When these are identified, patients should be signposted to appropriate services.
Implications for research
This study has implications for future research on SMI and diabetes, and also for research using
similar methods.
Understand the relationship between health checks and outcomes
This study identified a paradoxical association between the number of health checks and poorer
outcomes. There are a number of potential explanations for this finding that require further
investigation, for instance reverse causality or lack of effective intervention. Exploration of this
association using advanced statistical methods (such as instrumental variables regressions) and
dynamic models is a research priority.
The relationship between severe mental illness and other long-term
physical conditions
For this study, we constructed a large number of variables and will make the codes available for other
researchers, reducing future resource needs for conducting research using these data sets. There is
an opportunity, therefore, to replicate our methods to efficiently investigate other health conditions,
such as cardiovascular disease, chronic lung disease and other chronic disorders.
Is diabetes a risk factor for older-age onset of psychosis?
An unanticipated finding of the study was that the diagnosis of diabetes often antedated the onset of
SMI. We were able to conduct only limited analyses because of the nature of the data set. Further
work is needed using a cohort of people with T2DM to fully understand this relationship.
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Are tailored diabetes interventions clinically effective and cost-effective compared
with generic interventions for people with severe mental illness?
Common across all of the recommendations for practice is the need for more intensive support,
requiring additional resources for this high-risk and vulnerable group. This study design could not
assess the effectiveness and cost-effectiveness of such approaches. Research is needed to develop
and to determine the effectiveness and cost-effectiveness of such interventions (e.g. tailored diabetes
self-management education, or changes to organisation of diabetes care for people with SMI) for
improving diabetes and other outcomes.
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Appendix 1 Reflections on the experience
of participating in patient and public
involvement
The DIAMONDS VOICE feedback on involvement in the study has been very positive, withmembers feeling that their contributions are both valuable and valued, and stating that they feel
empowered by their involvement. Their commitment to the research is perhaps evidenced by the
stability of the group membership, the core of which has endured for several years, despite the
challenges created by comorbid SMI and long-term physical health problems.
Feedback from the DIAMONDS VOICE group indicated that members did not always understand how
they could contribute at research meetings, so sometimes they felt that they were not needed. Some
members of the research team used abbreviations and did not explain complex processes/methodology
in lay language, which could make people feel overwhelmed and as if they had nothing to contribute.
These issues could create barriers to discussion and engagement. Changes were made during the study
because of this feedback. Group members are now briefed before and after meetings, and the PPI
co-ordinator is always available to provide support if needed. Research team members chairing meetings
are also asked to be aware of these issues and to ensure that the language and terminology are appropriate.
Unfortunately, these efforts do not always eliminate these challenges. This has been an important
learning point for the research team, which will continue to consider ways to optimise the contribution
of PPI members to research in future studies.
Reflections on patient and public involvement from individual DIAMONDS
VOICE members
Following each DIAMONDS VOICE meeting, comments were gathered by initial debrief and telephone
calls. Two members of the panel agreed that their comments could be included in this report.
Member 1
This person took part in developing question prompts and tools.
l Learning lots and big learning curve. Learning what research is and how it works.
l Being and learning with others from a similar background. Like sharing with others, reaching out to
other people.
l Opens my eyes to different avenues and opportunities how [you] can care for yourself.
l Explained well.
l It’s getting me out.
Member 2
This person helped to identify research priorities, design question tools and prompts, and was involved in
practice interviews. They also wrote notes, reviewed documents prior to submission for ethics approval
and helped to prioritise questions, process some of the findings from the workshops and develop story
boards. They are planning on being involved in study dissemination at research events and NHS trusts and
user groups.
l We feel valued as carers/patients and that our experiences count.
l Been well informed and updated.
l Feel empowered we have a voice.
l Feel that people really care about how difficult it is to cope with SMI and diabetes.
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l It is interesting to see the processes in research and how it evolves.
l Great to have peer support [and] share ideas. Made new friends who understand.
l I have increased confidence [and a] sense of purpose.
l Develop own knowledge, becoming expert by experience.
l Getting out and about to new venues.
l Always supported to attend meetings.
l Being part of something exciting that gives others quality of life.
l Being part of the team working with researchers, clinicians, professionals and stakeholders.
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Appendix 2 Full list of sources included in
the scoping of the literature




Systematic reviews and meta-analyses
Taylor et al.160 2017 The effectiveness of pharmacological and
non-pharmacological interventions for improving
glycaemic control in adults with severe mental
illness: a systematic review and meta-analysis
PLOS ONE
Pillinger et al.37 2017 Impaired glucose homeostasis in first-episode
schizophrenia: a systematic review and meta-analysis
JAMA Psychiatry
Gorczynski et al.161 2017 Are people with schizophrenia adherent to diabetes
medication? A comparative meta-analysis
Psychiatry Research
Vancampfort et al.44 2016 Diabetes mellitus in people with schizophrenia,
bipolar disorder and major depressive disorder:
a systematic review and large scale meta-analysis
World Psychiatry
Galling et al.40 2016 Type 2 diabetes mellitus in youth exposed
to antipsychotics: a systematic review and
meta-analysis
JAMA Psychiatry
Stubbs et al.122 2015 The prevalence and predictors of type two diabetes
mellitus in people with schizophrenia: a systematic




Charles et al.162 2016 Bipolar disorder and diabetes mellitus: evidence for
disease-modifying effects and treatment implications
International Journal of
Bipolar Disorders
McGinty et al.163 2016 Interventions to address medical conditions and
health-risk behaviors among persons with serious
mental illness: a comprehensive review
Schizophrenia Bulletin
McBain et al.164 2016 Self-management interventions for type 2 diabetes in
adult people with severe mental illness (review)
Cochrane Database of
Systematic Reviews
McGinty et al.165 2015 Quality of medical care for persons with serious
mental illness: a comprehensive review
Schizophrenia Research
Ward and Druss166 2015 The epidemiology of diabetes in psychiatric disorders Lancet Psychiatry
Cimo et al.167 2012 Effective lifestyle interventions to improve type II
diabetes self-management for those with




Whitehead168 2017 Self-management of type 2 diabetes and severe
mental illness
Issues in Mental Health
Nursing
Bushe and Holt169 2004 Prevalence of diabetes and impaired glucose
tolerance in patients with schizophrenia
British Journal of Psychiatry
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Brown et al.156 2017 Achievement of adequate glycaemic control in
patients with type 2 diabetes and comorbid mental
health conditions treated in a primary care setting
Diabetes Spectrum
Das-Munshi et al.147 2017 Type 2 diabetes mellitus in people with severe
mental illness: inequalities by ethnicity and age.
Cross-sectional analysis of 588 408 records
from the UK
Diabetic Medicine
Smith et al.115 2019 Glucose, cholesterol and blood pressure in
type II diabetes: a longitudinal observational
study comparing patients with and without severe
mental illness
Journal of Psychiatric and
Mental Health Nursing
Foley et al.170 2016 Awareness of pre-diabetes or diabetes and
associated factors in people with psychosis
Schizophrenia Bulletin





Rathmann et al.172 2016 Diabetes treatment in people with type 2 diabetes
and schizophrenia: retrospective primary care
database analyses
Primary Care Diabetes
Wake et al.173 2016 Altered metabolic parameters in association with
antipsychotic medication use in diabetes: a
population based case–control study
Psychoneuroendocrinology
Wu and Gau174 2016 Association between antipsychotic treatment
and advanced diabetes complications among
schizophrenia patients with type 2 diabetes mellitus
Schizophrenia Bulletin
Wykes et al.175 2016 Self-efficacy and hemoglobin a1c among adults
with serious mental illness and type 2 diabetes:
the roles of cognitive functioning and psychiatric
symptom severity
Psychosomatic Medicine
Foley et al.176 2015 Effect of age, family history of diabetes, and
antipsychotic drug treatment on risk of diabetes
in people with psychosis: a population-based
cross-sectional study
Lancet Psychiatry
Wu et al.177 2015 Complications and mortality in patients with
schizophrenia and diabetes: population-based
cohort study
British Journal of Psychiatry
Foley et al.178 2014 Predictors of type 2 diabetes in a nationally
representative sample of adults with psychosis
World Psychiatry
Chen et al.179 2014 Comparing self-efficacy and self-care behaviours
between outpatients with comorbid schizophrenia
and type 2 diabetes and outpatients with only
type 2 diabetes
Journal of Psychiatric and
Mental Health Nursing
Mathur et al.180 2012 Ethnic differences in primary care management of
diabetes and cardiovascular disease in people with
serious mental illness
British Journal of General
Practice
Schoepf et al.181 2012 Type-2 diabetes mellitus in schizophrenia: increased
prevalence and major risk factor of excess mortality
in a naturalistic 7-year follow-up
European Psychiatry
Becker and Hux182 2011 Risk of acute complications of diabetes among
people with schizophrenia in Ontario, Canada
Diabetes Care
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
152




Nielsen et al.39 2010 Antipsychotics associated with the development of





2010 Effects of severe mental illness on survival of people
with diabetes
British Journal of Psychiatry
Whyte et al.184 2007 Quality of diabetes care in patients with schizophrenia
and bipolar disorder: cross-sectional study
Diabetic Medicine
McKibbin et al.185 2006 A lifestyle intervention for older schizophrenia
patients with diabetes mellitus: a randomized
controlled trial
Schizophrenia Research
Dixon et al.186 2004 A comparison of type 2 diabetes outcomes among
persons with and without severe mental illnesses
Psychiatric Services
Koro et al.187 2002 Assessment of independent effect of olanzapine
and risperidone on risk of diabetes among patients
with schizophrenia: population based nested
case–control study
BMJ




Systematic reviews and meta-analyses
Correll et al.188 2017 Prevalence, incidence and mortality from
cardiovascular disease in patients with pooled and
specific severe mental illness: a large-scale meta-
analysis of 3,211,768 patients and 113,383,368
controls
World Psychiatry
Pillinger et al.189 2017 Cholesterol and triglyceride levels in first-episode
psychosis: systematic review and meta-analysis
British Journal of Psychiatry
Teasdale et al.190 2017 Solving a weighty problem: systematic review and
meta-analysis of nutrition interventions in severe
mental illness
British Journal of Psychiatry
Vancampfort
et al.191
2017 Sedentary behavior and physical activity levels in
people with schizophrenia, bipolar disorder and
major depressive disorder: a global systematic
review and meta-analysis
World Psychiatry
Stubbs et al.192 2016 How much physical activity do people with
schizophrenia engage in? A systematic review,
comparative meta-analysis and meta-regression
Schizophrenia Research
Stubbs et al.193 2016 How sedentary are people with psychosis?
A systematic review and meta-analysis
Schizophrenia Research
Hayes et al.194 2015 A systematic review and meta-analysis of premature





2015 Risk of metabolic syndrome and its components
in people with schizophrenia and related psychotic
disorders, bipolar disorder and major depressive
disorder: a systematic review and meta-analysis
World Psychiatry
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2010 Head-to-head comparisons of metabolic side
effects of second generation antipsychotics in the




Rosenbaum et al.196 2016 How can we increase physical activity and exercise
among youth experiencing first-episode psychosis?
A systematic review of intervention variables
Early Intervention in
Psychiatry
Happell et al.197 2012 Health behaviour interventions to improve physical




Foley and Morley198 2011 Systematic review of early cardiometabolic outcomes





2011 Incentives and barriers to lifestyle interventions for
people with severe mental illness: a narrative




Cabassa et al.200 2010 Lifestyle interventions for adults with serious mental
illness: a systematic literature review
Psychiatric Services
Mitchell et al.201 2009 Quality of medical care for people with and without
comorbid mental illness and substance misuse:
systematic review of comparative studies




2015 Pathophysiological mechanisms of increased
cardiometabolic risk in people with schizophrenia
and other severe mental illnesses
Lancet Psychiatry
Nash203 2011 Improving mental health service users physical





Hayes et al.17 2017 Mortality gap for people with bipolar disorder and
schizophrenia: UK-based cohort study 2000–2014
British Journal of Psychiatry
Stubbs et al.204 2017 Physical activity ameliorates the association between
sedentary behavior and cardiometabolic risk among
inpatients with schizophrenia: a comparison versus
controls using accelerometry
Comprehensive Psychiatry
Das-Munshi et al.205 2017 Ethnicity and excess mortality in severe mental
illness: a cohort study
Lancet Psychiatry
Osborn et al.206 2017 Relative risks of cardiovascular disease in people
prescribed olanzapine, risperidone and quetiapine
Schizophrenia Research
Stubbs et al.207 2016 Physical multimorbidity and psychosis:
comprehensive cross sectional analysis including
242,952 people across 48 low and middle-income
countries
BMC Medicine
Gutacker et al.109 2015 Does the quality and outcomes framework reduce
psychiatric admissions in people with serious mental
illness? A regression analysis
BMJ Open
Reilly et al.20 2015 Inequalities in physical comorbidity: a longitudinal
comparative cohort study of people with severe
mental illness in the UK
BMJ Open
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2015 Negative symptoms are associated with lower
autonomous motivation towards physical activity in
people with schizophrenia
Comprehensive Psychiatry
Daumit et al.210 2013 A behavioral weight-loss intervention in persons with
serious mental illness
New England Journal of
Medicine
Reilly et al.137 2012 The role of primary care in service provision
for people with severe mental illness in the
United Kingdom
PLOS ONE
Brown et al.62 2010 Twenty-five year mortality of a community cohort
with schizophrenia
British Journal of Psychiatry
Osborn et al.211 2007 Relative risk of cardiovascular and cancer mortality
in people with severe mental illness from the United
Kingdom’s General Practice Research Database
Archives of General
Psychiatry




Systematic reviews and meta-analyses
Ricci-Cabello
et al.119
2013 Improving diabetes care in rural areas: a systematic
review and meta-analysis of quality improvement




2013 Health care interventions to improve the quality of
diabetes care in African Americans
Diabetes Care
Systematic reviews
Worswick et al.212 2013 Improving quality of care for persons with diabetes:
an overview of systematic reviews – what does the
evidence tell us?
Systematic Reviews
Zeh et al.120 2012 The impact of culturally competent diabetes care
interventions for improving diabetes-related
outcomes in ethnic minority groups:
a systematic review
Diabetic Medicine
Lind et al.213 2008 A systematic review of HbA1c variables used in the
study of diabetic complications
Diabetes and Metabolic
Syndrome
Peek et al.117 2007 Diabetes health disparities: a systematic review of
health care interventions
Medical Care Research and
Review
Steed et al.214 2003 A systematic review of psychosocial outcomes
following education, self-management and




Peek et al.116 2014 Integrated community-healthcare diabetes
interventions to reduce disparities
Current Diabetes Reports
Betteridge215 2005 Benefits of lipid-lowering therapy in patients with
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2015 Glucose, blood pressure and cholesterol levels and
their relationships to clinical outcomes in type 2
diabetes: a retrospective cohort study
Diabetologia
Nicolucci et al.217 2013 Diabetes attitudes, wishes and needs second study
(DAWN2TM): cross-national benchmarking of
diabetes-related psychosocial outcomes for people
with diabetes
Diabetic Medicine
Farmer et al.218 2012 An explanatory randomised controlled trial of a
nurse-led, consultation-based intervention to support
patients with adherence to taking glucose lowering
medication for type 2 diabetes
BMC Family Practice
Davies et al.219 2008 Effectiveness of the diabetes education and self-
management for ongoing and newly diagnosed
(DESMOND) programme for people with newly
diagnosed type 2 diabetes: cluster randomised
controlled trial
BMJ
Holman et al.220 2008 10-Year follow-up of intensive glucose control in
type 2 diabetes
New England Journal of
Medicine
Peyrot et al.221 2005 Psychosocial problems and barriers to improved
diabetes management: results of the cross-national
Diabetes Attitudes, Wishes and Needs (DAWN)
study
Diabetic Medicine




Price and Ismail222 2017 The management of diabetes in adults and children
with psychiatric disorders in inpatient settings
JBDS 13
NICE223 2015 Psychosis and schizophrenia in adults QS80
NICE32 2015 Type 2 diabetes in adults: management NG28
NICE13 2014 Bipolar disorder: assessment and management CG185
NICE12 2014 Psychosis and schizophrenia in adults: prevention
and management
CG178
NICE224 2012 Type 2 diabetes: prevention in people at high risk PH38
NICE225 2011 Diabetes in adults QS6
CG, clinical guideline; NG, NICE guideline; PH, public health guideline; QS, quality standard.
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Appendix 3 Non-linear impact of age on



























Age at follow-up start (years)
(b)
FIGURE 10 Objective 1: age distribution of eligible patients (a) without diabetes; and (b) with diabetes.
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Appendix 4 Objective 7: a descriptive
summary of provision of health-care
interventions by diagnosis order for people
with severe mental illness and diabetes
TABLE 32 Objective 7: descriptive summary of provision of health-care interventions by diagnosis order for people with
SMI and T2DM
SMI diagnosed before T2DM










Total, N = 9965 [cases, n = 2192 (22.0%); controls, n = 7773 (78.0%)]
Patients (n) 1666 5883 526 1890
Number of additional health checks per year, mean (SD)
Retinopathy screening 0.76 (0.71) 0.89 (0.85) 0.73 (0.53) 0.87 (0.87)
Diabetes education referral 0.22 (1.12) 0.25 (1.22) 0.05 (0.16) 0.34 (8.43)
Influenza vaccination 0.32 (0.45) 0.33 (0.51) 0.20 (0.30) 0.28 (0.39)
Total, N = 8905 [cases, n = 1968 (22.1%); controls, n = 6937 (77.9%)]a
Patients (n) 1456 5239 512 1698
Number of additional health checks per year, mean (SD)
Retinopathy screening 0.79 (0.58) 0.88 (0.57) 0.73 (0.51) 0.85 (0.56)
Diabetes education referral 0.10 (0.26) 0.10 (0.25) 0.04 (0.12) 0.07 (0.19)
Influenza vaccination 0.30 (0.36) 0.31 (0.35) 0.19 (0.26) 0.27 (0.32)
SD, standard deviation.
a Patients with at least 1 year of follow-up.
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Appendix 5 Coding frameworks for the
qualitative data
This appendix has been reproduced with permission from Bellass et al.143 This is an Open Accessarticle distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
There were 11 ‘parent’ codes in the framework (see Box 1), shown with their associated ‘child’ nodes.
There were also two additional codes used to identify any other respondents speaking during the
interview, and when a person exhibited some psychotic symptoms during interview.
There were 13 ‘parent’ codes in this framework (see Box 2), each shown with their associated
‘child’ nodes. There was also an additional code used to identify when a respondent other than the
participant was speaking (‘other respondents’).
There were 20 ‘parent’ codes in this framework (see Box 3), each shown with their associated
‘child’ nodes.
BOX 1 NVivo coding framework for interviews with people with diabetes and SMI for the qualitative study








¢ family health history
¢ hobbies and interests
¢ home and local environment
¢ level of education
¢ lifestyle
¢ mobility
¢ money and income
¢ past trauma
¢ personal history
¢ relationships and social network
¢ religious beliefs.
2. Diabetes education, knowledge and training:
¢ access to education and knowledge
¢ barriers to education and knowledge
¢ being offered education
¢ experience of education courses
¢ impact of education and knowledge
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¢ knowledge of diabetes
¢ knowledge of diabetes management
¢ sources of information
¢ specific education needs for this group.
3. Informal support and social contact:
¢ activity groups
¢ barriers to support
¢ current support
¢ experience of support groups
¢ experiences of charities and organisations
¢ impact of support
¢ loss of support
¢ rejecting support
¢ types of support.
4. Having diabetes with SMI:
¢ three-way interactions of diabetes, SMI and health behaviours
¢ descriptions of interactions
¢ diabetes takes priority
¢ impact of diabetes on mental health
¢ impact of mental health on diabetes
¢ interactions between mental and physical care
¢ mental health takes priority.
5. Experience of diabetes:
¢ burden of diabetes
¢ crisis points
¢ diabetes and diet
¢ diabetes control
¢ duration or timings of diagnosis and treatment
¢ experiences and perceptions of diabetes
¢ family history
¢ first port of call for concerns
¢ good days and bad days
¢ impact of diabetes
¢ perceived causes
¢ stigma and discrimination
¢ symptoms and complications.
6. Experience of mental health care:
¢ access to care
¢ barriers to care
¢ changes to care
¢ current care
¢ experience of medication
¢ impact of care
¢ involvement in care decisions
BOX 1 NVivo coding framework for interviews with people with diabetes and SMI for the qualitative study (continued )
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BOX 1 NVivo coding framework for interviews with people with diabetes and SMI for the qualitative study (continued )
¢ opinions on health care
¢ personal experiences of mental health care
¢ power dynamics
¢ timing of care received
¢ understanding of care received
¢ wishes for and thoughts on improvements
¢ worries about health care.
7. Other health problems:
¢ effect on diabetes
¢ effects on mental health
¢ health worries
¢ medication side effects
¢ medications taken
¢ types of health problem.
8. Employment:
¢ barriers to working and employment
¢ current working status
¢ experience of working with SMI
¢ impact of health on employment
¢ past employment.
9. Experience of mental illness:
¢ behaviours associated with mental illness
¢ burden of mental illness
¢ coping mechanisms
¢ crisis points
¢ current state of mental health
¢ disclosing mental illness
¢ duration or timings of illness and treatment
¢ effect of outside influences
¢ first port of call for concerns
¢ good days and bad days
¢ impact of mental illness
¢ not feeling in control
¢ others’ opinions and perceptions
¢ perceived causes
¢ perceptions of mental illness
¢ personal experiences
¢ stigma and discrimination
¢ symptoms of mental illness
¢ understanding and perceptions of own illness.
10. Experience of physical health care:
¢ access to care
¢ barriers to care
¢ changes to care
DOI: 10.3310/hsdr09100 Health Services and Delivery Research 2021 Vol. 9 No. 10
Copyright © 2021 Lister et al. This work was produced by Lister et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
163
¢ current care
¢ experience of medication
¢ follow-up care
¢ involvement in care decisions
¢ opinions on care
¢ personal experiences of physical health care
¢ wishes and thoughts for improvement.
11. Self-management:
¢ barriers to self-management
¢ deciding to change
¢ enablers of self-management
¢ feeling in control




¢ support for self-management
¢ tools for self-management
¢ worries about self-management.
12. Other respondents.
13. Psychosis during interview.
BOX 1 NVivo coding framework for interviews with people with diabetes and SMI for the qualitative study (continued )
BOX 2 NVivo coding framework for the family member interviews for the qualitative study
1. Carer experiences:
¢ carer dependence on main respondent
¢ carer feelings of distress
¢ carer opinion of medication
¢ carer personal experience of medication
¢ general carer experiences.








¢ family health history
¢ hobbies and interests
¢ home and local environment
¢ level of education
¢ lifestyle
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¢ mobility
¢ money and income
¢ past trauma
¢ personal history
¢ relationships and social network
¢ religious beliefs.
3. Diabetes education, knowledge and training:
¢ access to education and knowledge
¢ barriers to education and knowledge
¢ being offered education
¢ experience of education courses
¢ impact of education and knowledge
¢ knowledge of diabetes
¢ knowledge of diabetes management
¢ sources of information
¢ specific education needs for this group.
4. Employment:
¢ barriers to working and employment
¢ current working status
¢ experience of working with SMI
¢ impact of health on employment
¢ past employment.
5. Experience of diabetes:
¢ burden of diabetes
¢ diabetes and diet
¢ diabetes control
¢ duration or timings of diagnosis and treatment
¢ experiences and perceptions of diabetes
¢ family history
¢ first port of call for concerns
¢ impact of diabetes
¢ perceived causes
¢ symptoms and complications.
6. Experience of mental health care:
¢ access to care
¢ barriers to care
¢ changes to care
¢ current care
¢ experience of medication
¢ impact of care
¢ involvement in care decisions
¢ opinions on health care
¢ personal experiences of mental health care
¢ power dynamics
BOX 2 NVivo coding framework for the family member interviews for the qualitative study (continued )
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¢ timing of care received
¢ understanding of care received
¢ wishes for and thoughts on improvements
¢ worries about health care.
7. Experience of physical health care:
¢ access to care
¢ barriers to care
¢ changes to care
¢ current care
¢ experience of medication
¢ follow-up care
¢ involvement in care decisions
¢ opinions on care
¢ personal experiences of physical health care
¢ wishes and thoughts for improvement.
8. Experience of mental illness:
¢ behaviours associated with mental illness
¢ burden of mental illness
¢ coping mechanisms
¢ crisis points
¢ current state of mental health
¢ disclosing mental illness
¢ duration or timings of illness and treatment
¢ effect of outside influences
¢ first port of call for concerns
¢ good days and bad days
¢ impact of mental illness
¢ not feeling in control
¢ others’ opinions and perceptions
¢ perceived causes
¢ perceptions of mental illness
¢ personal experiences
¢ stigma and discrimination
¢ symptoms of mental illness.
9. Having diabetes with SMI:
¢ three-way interactions of diabetes, SMI and health behaviours
¢ descriptions of interactions
¢ diabetes takes priority
¢ impact of diabetes on mental health
¢ impact of mental health on diabetes
¢ interactions between mental and physical care
¢ mental health takes priority.
BOX 2 NVivo coding framework for the family member interviews for the qualitative study (continued )
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10. Informal support and social contact:
¢ activity groups
¢ barriers to support
¢ current support
¢ experience of support groups
¢ experiences of charities and organisations
¢ impact of support
¢ loss of support
¢ rejecting support
¢ types of support.
11. Other health problems:
¢ effect on diabetes
¢ effects on mental health
¢ health worries
¢ medication side effects
¢ medications taken
¢ types of health problem.
12. Self-management:
¢ barriers to self-management
¢ deciding to change
¢ enablers of self-management
¢ feeling in control




¢ support for self-management
¢ tools for self-management
¢ worries about self-management.
13. Other respondents.
BOX 2 NVivo coding framework for the family member interviews for the qualitative study (continued )
BOX 3 NVivo coding framework for the health-care staff interviews for the qualitative study
1. Barriers to delivering and receiving care.
2. Changes made to care.
3. Changes needed in, and recommendations for, care and support.
4. Demographics and context:
¢ local area, ethnicity and socioeconomic status
¢ personal and health issues
¢ role and responsibilities
¢ special interest or experience
¢ training and career path.
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5. Diabetes education, knowledge and training: patients –
¢ access to education and knowledge
¢ barriers to education and knowledge
¢ education needs for this group
¢ education offered
¢ experience of education courses
¢ impact of education and knowledge
¢ knowledge of diabetes and management
¢ sources of information.
6. Differences between disorders.
7. Employment – patients.
8. Enablers of delivering and receiving care.
9. Informal support: patients –
¢ any other informal support
¢ family support and interactions.
10. Interactions between disciplines and types of care.
11. Interactions of diabetes and SMI:
¢ descriptions of interactions
¢ diabetes takes priority
¢ impact of diabetes on mental health
¢ impact of mental health on diabetes
¢ mental health takes priority.
12. Medication.
13. Opinions on care.
14. Other health problems: patients –
¢ care for comorbidities
¢ effect on diabetes
¢ effects on mental health
¢ types of health problem.
15. Other services and care providers.
16. Patient experience of diabetes.
17. Patient experience of mental illness.
18. Patient self-management:
¢ barriers to self-management
¢ enablers of self-management




¢ support for self-management
¢ tools for self-management.
19. Personal and general experiences in job.
20. Staff training and training needs:
¢ types of care or service delivered and interactions with patients.
BOX 3 NVivo coding framework for the health-care staff interviews for the qualitative study (continued )
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Appendix 6 Supplementary tables of
quotations for the qualitative results
Some of the participant quotations in this section have been reproduced with permission fromBellass et al.143 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon
this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. The text below includes minor additions and formatting changes to the original text.
These supplementary tables give extra participant quotations for the eight key themes (with associated
subthemes) from the qualitative study.
TABLE 33 Supplementary participant quotations for theme 1: mental illness affects everything
Subtheme Associated quotations
The pervasive effect of
SMI, and persistence and
powerlessness
It’s something actually inside your head all the time and it’s like you’re carrying around
mental illness. I can’t describe it, but it’s like being, it’s like having a cold sometimes. Just for
example, it’s just like having a cold. You want to get rid of it but you can’t and it’s in your
head and it’s making you feel naff, but that’s how you feel like with mental illness. Not like a
cold. I’m not saying like a cold, but like a feeling of being ill, you know, being constantly ill all
the time
ES-G3-01
It just keeps going round and re-playing and re-playing and you’ve got to get off the boat
sometimes. It keeps going round and round, this illness keeps going the same thing and when
am I going to get off the circle? When am I going to get on? And you can’t because it’s
mental, it’s a mental thing. It’s not, it’s not, it’s not life. . . . I mean it’s not like a diet. I mean,
you can change your diet. You can’t change your mental illness
ES-G3-01
Well I don’t like going out on my own, I don’t like doing anything on my own, I wait for my
husband, so I’m just getting worse actually, not going out, putting myself off, not going to the
shops or anything like that. I make appointments and then I cancel them, I used to have
friends, but I haven’t got any any more, they’ve all deserted me
ES-G7-01
I’ve made a big effort to pull myself together and I’m trying to do things around my home.
But for instance, I’ve been in my flat for about 2 and a half years and last week was the first
time that I’ve cleaned the kitchen floor. [. . .] I’m delighted with the outcome but found it a
tremendous barrier and effort to do it
ES-G8-1
You’re not allowed to drive for 3 months after being manic, I think it is, and then you can
make an application to carry on, and then they give you a 1-year temporary licence, and I’ve
managed to get to a 3-year one now
ES-T2-03
Really lonely, really. I’ve been let down by so many people that I’m wary in making contact
ES-T2-06
It could be something quite . . . something that triggers it off, like, if they got her going out
and then she had a real bad experience one time when she was out, it was something totally
unforeseen, something that most people would, sort of, treat as a bit annoying or a bit . . . not
a good day, but you’d, sort of, take it in your stride, you’d be back again the next day. [. . .]
Most days it doesn’t happen, that’s the sort of thing which when you . . . to someone with
mental health issues, they become major incidents and set things going backwards
Family member ES-T4-03
continued
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TABLE 33 Supplementary participant quotations for theme 1: mental illness affects everything (continued )
Subtheme Associated quotations
If her attention starts wandering, she has, when we had the previous cooker with the rings
for the hob, she put her hand on it and it made circular marks on her hand there, that was
just through attention wandering
Family member ES-T4-03
[Talking about inpatient centre:] Guys are in there for months, spending months, eating the
same stuff. You can be saying ‘listen, we hope we can make an impact here. We can be
making an impact from the diabetic point of view, to show you there’s different things.
Maybe a brown pasta, whatever it is, you can try . . . whatever. Just other things that you
can eat and it’s really tasty and it looks good. But it’s not going to be as bad for you’
Family member ES-T2-08
So they say, ‘well, you’ve got diabetes so therefore you need to take something to lower your blood
sugar levels because you’re more susceptible to stroke if you do. [sic]’. Where does that apply
to mental health aspects, the other tablets that she takes? They will also be having an effect
somewhere down the line. I don’t know. I’m not a chemist. I’m not a biologist even, so I don’t
know, but there’s no doubt about it. The more you take, the more issues you’re going to have
Family member ES-T2-17
That’s more opportunistic, but, unfortunately, in [city] it’s again choose and book; so when
you refer, they may be travelling 10/20 miles sometimes depending on where the dietitian is
doing the session. [. . .] And imagine if they have got mental health, then it’s quite, in regards
to the social deprivation, it is quite high here so they may not be having a car, they may not
have the money to be travelling on bus and if they are quite disorientated and anxious they
may not want to go to unfamiliar area but, unfortunately, for that, it’s already a non-starter
Staff ES-PC-04
I suppose, it’s not something I actively look out for, but you would, I suppose the effect of not
having, you know, not being able to make healthy eating choices because you can’t afford it
Staff ES-PC-05
OK, I mean I think we’ve got the highest incidence of SMI in [city] in our population for a
number of different reasons, but partly because of the area of the city that it is in, but also
we’ve got quite a lot of hostels, homeless hostels and kind of supported accommodation,
so we have a lot of people on our books with kind of very enduring mental health, and
obviously along with that goes quite a lot of complex medical problems as well, so you know,
there is certainly higher numbers for us. The difficulty we’ve got is in, kind of, accessing them
and trying to get them to engage in follow-up and treatment, basically
Staff ES-PC-06
I think if they live in deprived areas and money is tight, I think it’s more difficult for them to
get a healthy diet, they tend to grab what they can as opposed to being educated enough to
manage living on healthier food really
Staff ES-T1-02
She needs the support but she can’t pay because, you know, she is on benefits, she is on PIP
[Personal Independence Payment] but she has also got a car and she argues to say that she
needs that car because if she doesn’t have the car it means that she can’t go out because of
physical health problems, I think she has got problems with mobility . . . So she said ‘after
paying about £100 for my car insurance every month then it means I am not left with
enough money to even pay for my care’, so that means people like that will end up really
struggling . . . because they need the care, but there is not enough funding in place
Staff ES-T1-03
Well, they are, (a) they’re really time-consuming and (b) people are getting their benefits cut
and you cannot believe that they’re getting them cut when we write really, kind of, explicit
supporting letters as to what their complex needs are, but that’s another story I guess, we
just have to then go through all the appeals, so it’s very time-consuming; however, we try and
make sure that people get what they’re entitled to
Staff ES-T1-04
Oh, absolutely, oh completely, we’ve got another gentleman who’s not diabetic but I guess
he’s a candidate, he’s on high-dose antipsychotics, his self-neglect is terrible, his diet is really
poor, [. . .] and the PIP came along quite soon after I’d met him, he’d filled the form in himself,
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TABLE 33 Supplementary participant quotations for theme 1: mental illness affects everything (continued )
Subtheme Associated quotations
which I felt somebody should have read and thought, ‘this man is quite unwell, we’ll put an
additional supporting letter in saying he’s got a consultant, he’s got Clozaril’, you know, all
kind of nitty-gritty and they cut his benefit entirely, and he rang me out of the blue one day
and said, ‘they’ve cancelled all my money so I’ll have to hang myself now’, and I was
absolutely terrified thinking, ‘oh my word, what if he does?’
Staff ES-T1-04
Yeah most definitely and I suppose I’m coming from, I suppose my patients without mental
health problems are coming from a reduced socioeconomic group here and the places that
I work, so, even more so with patients with mental health, they often are not in employment and
are living on very, very much reduced resources and when you are discussing what foods to buy
and prepare, often it’s very difficult for them to afford a lot of what you are asking them to . . .
Staff ES-PC-02
And then again, there’s the financial implication of that for many people. It’s very difficult.
And also many guys live on their own, they don’t care. They don’t know how to cook a
healthy meal, put together something that’s . . . They’ve got £20 to buy food for the week




It’s mainly mental, it’s not really the diabetes, it isn’t too much of a problem at the moment,
but it’s mainly the mental, I get a lot of anxiety sometimes
ES-T4-13
I told [my CPN], I says, ‘I’ve nothing left, love’, I says, ‘I’ll have to go on my tablets, it’s the last
resort, if I want to carry on. And I want to go on’, I says, ‘but I’ve got to do, ‘cause that’s the
only option I’ve got’
ES-T2-02
Interviewer: What would you say has helped you the most with your mental health, would
you say?
ES-D1-05: [. . .] And then the medication without a shadow of a doubt. Without a shadow of
a doubt the medication
I mean I take around 20 tablets a day, 14 in the morning, but for my diabetes, my mental
health and my other conditions, and then I take about three or four in the evening and I hate
that, I hate that, I hate taking all of them but it’s got to be done
ES-T2-05
I don’t think you quite understand what this is like. The side effects of the drugs are not
good. You cannot be not genuine and take these things because you wouldn’t take them if
you had the choice. I mean, I am desperate, so I take my medication, I never . . . well, as long
as I remember to take them [laugh]. Well, I do usually remember to take them, but I would
never skip on the medication
ES-T2-16
I got the schizophrenia and then I got the Clozaril and then I got the weight gain and then
I got the diabetes
ES-T3-09
. . . because the thing is, to them diabetes might not be that problem that they need to look
at at the moment, because obviously their mental health may be overtaking that, so they
may not see it as a factor or they may not be putting it into, they may not see it as a
significant issue there and then, and, unfortunately for mental health, if the diabetes is quite
bad, the mental health will be going bad as well and they won’t be focusing on that because
they will be having acute episodes from the mental health so they will just think that’s just
something that is going wrong at the moment
Staff ES-PC-04
They neglect themselves. They don’t take their medication as they should be. They don’t eat
the right things and both ways, it’s there . . . it’s, sort of, like the mental illness, I think,
becomes first, prior to the diabetes. They just don’t take any notice of it really
Staff ES-T4-06
continued
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TABLE 33 Supplementary participant quotations for theme 1: mental illness affects everything (continued )
Subtheme Associated quotations
I think it’s more all-consuming, the mental health problems. And actually, breaking through
that, but then some people will take more care of the physical health and ignore the mental
health issues. But then you’ve got the spiralling issues with that and I think, unless your
mental health is very well controlled and very stable, then you’re not going to do very well
with your physical health either
Staff ES-T5-03
[. . .] she got me to send a booklet, it didn’t really help me. You see, it’s governed by mental
health, love. It’s governed by your mental health. You’ve been poorly. They all lean on each
other, the conditions and illnesses, they all lean against it
ES-T2-02
Whereas, I think for somebody who’s diabetic, it would be, your main focus would be on the
diabetes, and you’d be trying to work out what you’re going to eat, and make sure, whereas
for me, I’m always worried about the mental health side, and if I am in a really bad place,
I don’t care anyway
ES-G2-01
The sort of GP service had tried to do a diagnosis, tried to tell me it was important, which
was never going to have any impact, ‘cause when you’re mad as a hatter, you don’t take any
notice. They’re just noise in the corner
ES-T2-03
Like, I can eat healthy, I can do the exercise, I can stop the alcohol, I can take my medication,
I can find ways to distract myself, I can sleep, I can do all the things, but then my diabetes
and my mental health are always right there at the top
ES-T3-03
If someone is unwell with their mental health, they are just trying to survive, aren’t they, day
to day, and they don’t want to hear the advice on smoking and diet, they just need to get
through the day, and if they are eating something, it is sometimes a victory, rather than,
you know, not necessarily about eating a healthy meal, it’s just eating a meal
Staff ES-PC-01
Now I know you’re looking at diabetes and mental health, and . . . but, from my point of view,
the issues are, without a doubt, the mental health issues, not the diabetes. A lot of people
suffer from diabetes and you just have to resolve it in one way or another
Family member ES-T2-17
TABLE 34 Supplementary participant quotations for theme 2: multimorbidity and diabetes management
Subtheme Associated quotations
Multimorbidity And my heart condition, I’ve got a leaking valve. [. . .] And then I’ve got chronic bronchitis,
COPD, and asthma
ES-T2-02
Yeah, so you often get patients who just have several different things, where your diabetic
might have ischemic heart disease or COPD or something like that, often with mental health
and mental illness there is often smoking, which would list on to risk of COPD and other
respiratory problems, so yeah, if they’ve got one thing, they are going to have another
Staff ES-PC-01
. . . and normally if they are diabetes tablets, they are on blood pressure tablets, and if they
are on blood pressure tablets, they are on cholesterol tablets, if they are on cholesterol
tablets, you know they’ll be on something else, so that’s five tablets
Staff ES-PC-04
Yeah, I mean, definitely the rates of the diabetic complications are higher in our group of SMI
patients, so they will often have cardiac disease or pseudovascular disease at an earlier onset,
I would say, than our non-SMI patients
Staff ES-PC-06
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My COPD only allows me to go to the bottom there, and I’m coughing and weeing myself
and everything, and I’ve got to be open and truthful with him, saying that I wear nappies
now, I daren’t go out. I only go somewhere, where my scooter will take me
ES-T2-02
ES-T2-04: Well I’ve got my knee, that’s difficult for a start-off. I’ve had [inaudible] for walking
and that with it. Its cartilage trouble and osteoarthritis
Interviewer: Oh right, OK. So what does that stop you doing?
ES-T2-04: It stops me from doing a lot of walking what I used to like doing
She diagnosed me and I think my eyesight’s getting poor. You know, my eyesight seems to be
getting poor. I’m seeming to look at my phone a lot harder with texting. I’m finding reading
and writing, I like to read it, like put big writing on my text now, you know. So my eyesight is
really taking a hit, you know
ES-G3-01
Well I’m waiting for a knee operation, I can’t get about as well as I used to. [. . .] They won’t do
the operation unless the leg muscle is strong. That is why I try and swim to keep the strength in
the leg muscles. I walk as well. But unfortunately, I can’t do as much as I would like
ES-D1-05
I’ve also been quite recently diagnosed with, with an inflammatory arthritis, which has made
life quite difficult, but that’s coming into play
ES-G8-01
. . . for people who have had it [diabetes] quite a long term and a number of years,
unfortunately for them, it may mean that they may then be susceptible for things like having
strokes, cardiovascular diseases, which then limit the validity then for what they were doing a
couple of years ago if they are quite elderly, which means, if they have had a stroke then they
may not have the quality of life that they did have before because, unfortunately, they have
had series of events, such as strokes or heart attacks, and then that just further deteriorates,
then, to access how, then, because they may be at home or they may not be able to get out
Staff ES-PC-04
I think their illnesses would take more precedence, it depends how extreme the other illness is
and how much that impacts on their day-to-day life. I guess if you’re living with constant pain,
your mobility is poor, you would be focused on that more than you would, than your diabetes.
Staff ES-T1-02
Yes, so the condition that’s causing the most immediate difficulty is going to be the one that
gets the attention, so somebody has daily pain, that pain is going to take more attention
than the diabetes which isn’t causing any immediate pain but is a long-term complication
and consequence. It’s a silent killer
Staff ES-T2-12
So there are studies that have showed that other comorbidities, such as heart condition, etc.,
can also have a detrimental effect on SMI and, in particular, the control of or the lack of
control of diabetes or poor control, inadequate control, if you like. So all of the conditions,
we believe, sort of, work hand in hand . . .
Staff ES-T3-01
I also think she gets quite confused, because she’s got things going on, not just the diabetes
but she’s got other ailments, you know, so she’s got irritable bowel and she’s got a fatty liver,
there’s other sort of ailments that she suffers from. And obviously, there’s different diets
attached to those and I think sometimes that gets a little bit overwhelming for her as well,
in that she knows that there’s certain foods she should avoid and certain things she should
and shouldn’t do in respect of her diabetes. But then also, the same could be said for the
other ailments that she’s got, and I think sometimes it will come as a little bit overwhelming
because she thinks, ‘well, there’s too many things that I’ve got to think about what I can and
can’t eat. I’m just going to ignore it’, if you know what I mean
Family member ES-T3-08
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TABLE 35 Supplementary participant quotations for theme 3: interacting conditions, overlapping symptoms
Subtheme Associated quotations
Symptoms of diabetes
and SMI can overlap and
interact
And something I’ve noticed is there’s quite an overlap between feeling mentally low and
feeling unwell because your blood sugar is up
ES-G8-01
When I was poorly [. . .] it was trying to work out whether it was my diabetes or mental
health. It was a mixture of both
ES-T3-03
If I go on a high, sometimes, they’ve got to check my blood sugars, because they don’t know
if it’s the blood sugars, that are causing me to go a bit loopy. Or it’s my mental illness
ES-T4-10
And on the other hand, if people are diabetic and they’re not maintaining their blood sugars
right, it can give rise to symptoms which are synonymous with anxiety and low mood,
so there is a big interface between diabetes and mental illness
Staff ES-T1-01
It’s difficult to separate out the effects of the SMI and the diabetes
Staff ES-T2-13
She were doing really well, but, for whatever reason, got it into her head that she was
going to wake up having a hypo [an episode where the level of blood glucose drops too low],
and didn’t want that, so stopped using this insulin on a night. And just went up and up
and up, to what looked like quite a manic episode, but it’s not, it’s when the diabetes gets
really unstable
Staff ES-T3-02
And you know, sometimes, the irritability that comes with a low blood sugar could be
interpreted as part of somebody’s mental illness. And it’s diagnosed and mistreated
Staff ES-T5-03
‘Cause they’re so closely linked for me, I can’t speak for other people, but for me it is,
when one gets worse, the other one does too
ES-G2-01
Yes, I think if I’ve, sort of, got a low mood and I don’t want to eat, then I could get a low
blood sugar, or if I was to eat too much sugar, I could get angry and uptight and that could
affect my mood as well
ES-T2-05
When I’m not taking medication and I’m not taking that, then I’m obviously hyper and that
affects my mental health, and they were linked together somehow, it’s the both set each
other off
ES-T3-03
Because you can’t think clearly, that’s . . . not being able to think clearly is hard, because then
you’re not applying the right tools to address your diabetic situation
ES-T7-04
If you were doing a link between my blood sugar and my depression, my mental health goes
down as my blood sugar goes up. There’s a direct correlation between the two
ES-G2-01
I guess if their blood sugar is all over the place, that can potentially impact on their mental
health as well
Staff ES-PC-01
Well, just being ill with your diabetes I don’t think will add to stabilising your mental health,
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I mean, certainly, when they are acutely unwell, their mental health will really slide and often
that can be either that their diabetes is not well controlled or, and then that leads on to
picking up more infections and being susceptible to things. Quite often we will see them
acutely because of a behavioural change that has happened as a result of an acute infection
that has usually happened as a result of their diabetes not being brilliantly controlled
Staff ES-PC-06
When it’s not managed well, when they’re not taking their insulin or taking their metformin
when they should, when the blood sugars are high, they become more aggressive,
argumentative, that’s often a sign that they’re not managing it properly and it might not just
be a sign of their mental health deteriorating, because it could be a physical cause like
diabetes and it’s a good thing that we have these clinics where this can be monitored a bit,
you know, blood glucose
Staff ES-T1-02
Well, the diabetes, obviously the diabetic control has quite an impact on people’s overall
well-being and feelings of energy, or lethargy can lead to depression and anxiety. People can
put weight on, which leads to other problems and low self-esteem
Staff ES-T3-05
SMI medication is linked
to poor physical health
and difficulty with
diabetes management
I’ve got lots of medication going on, so it makes me feel hungry. It makes me feel lazy.
So some days I can sit here all day long with not radio or TV on and be lost in my own
thoughts, and my thoughts can just be going round and round in my head and it does me no
good whatsoever. It makes me worse
ES-G3-01
Yeah. The one I’m on at the moment, the aripiprazole, doesn’t put . . . well, it does put a bit
of weight on me, but the metformin takes it off again. So I’m fairly OK with my weight.
But Dr [GP] has said anything else will put weight on me. Because it gives you an appetite,
it just suppresses your feeling of being full. They all do, all the antipsychotic drugs do.
And that’s a problem, that is a big problem. Because I’m not really a greedy person but
when you get the hunger from the tablets, it is . . . you can’t ignore it
ES-T2-16
It is and the medication that I’m taking. It makes me hungry and it makes me tired. Quite
normal for me to have a couple hours’ sleep during the day, but if I didn’t take the tablets,
I wouldn’t be snoozing like that. I’m feeling a bit drowsy and a bit tired. It’s the medication,
if I’m going to carry on taking it, I’ve just got to put up with it I suppose
ES-T2-18
. . . when I put all this weight on when I first started on my lithium and the Epilim, they put
you a lot of weight on
ES-T3-04
When I went on psychotic medication, I put 4 stone on in about 6 months. I were only about
9 stone and I went up to, at one stage, [to] 14
ES-T3-04
I went on the medication for 3 weeks and I put on at least two sizes of clothing in that time.
It happened very quickly
ES-T3-09
I’ve gone to the psychiatrist, it’s pretty normal with the medication, and she asked how long
it goes on for and I said maybe about 2 hours. Some people, they have it all night. And it
stops them sleeping, which obviously makes your mental illness a lot worse
ES-T3-09
I just slipped and fell on the desk like that and my head hit the desk, so I thought, ‘I can’t do
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On the flip side, the patient can begin as not diabetic, but is known to the services for a long
time with severe and enduring mental illness and is on a range of antipsychotic medication,
which then gives rise to . . . not, as such, direct weight gain, but an increase in diet, an
increase in weight. Then, at some point, they can develop diabetes or poor blood sugar
control, and that happens quite commonly. We call it metabolic syndrome
Staff ES-T1-01
I think it’s a lot to do with that and plus with the medication as well, the medication is a
big thing, they might feel slowed down, the less they do, so that adds to the weight gain.
Also, antipsychotics like olanzapine are renowned for people gaining immense weight,
stones, rather than a few pounds and I’ve got a patient at the moment who is from an
ethnic minority background, who has other health problems besides diabetes, but since
they came to us, and went on olanzapine, he’s developed diabetes
Staff ES-T1-02
I think the difficulties that have been experienced often is that because of the mental health
medication they are on, they have got a very big appetite so they end up eating the
wrong foods
Staff ES-T1-03
You know, that’s keeping him reasonably fit, except that the diabetes and the drugs –
all the drugs say that they’re likely to put the blood sugar up and, as a result of taking the
antipsychotics and the antidepressants or whatever the other one is – he takes metformin to





I don’t know. If my blood sugar’s dodgy, I do feel ill. But I’m not quite sure if there’s a link to
my mental illness and diabetes really
ES-T4-12
. . . educating patients, as well, about how mental illness and physical illness are inter-related,
because oftentimes it’s fixed in the patient’s mind, ‘oh, this is my diabetes, separate, and this
is mental illness, and they don’t have anything to do’, but there is a bearing there, a strong
bearing, in helping people to understand. And once they understand that, that helps us in our
management plan as well
Staff ES-T1-01
No, I wouldn’t say that there’s any connection with them at all. I think they’re separate
matters. I don’t think her mental health problems makes her diabetes worse, but I don’t
think her diabetes influences her mental health problems either. If there is any connection
at all, basically, it’s lost in the mix of what creates our personalities and what creates our
physiological conditions, but I can’t say there’s any difference, any connection, rather
Family member ES-T2-01




I think definitely there is a link there, in if your blood sugar is low and you feel depressed or
fat or you’re anxious or feeling paranoid, then you want comfort, and I find that in naughty
foods like crisps and chocolate that are very bad because crisps are carbohydrates and they
turn to sugar overnight and that’s not good and then the chocolate is full of sugar.
ES-T2-05
Depression. Call it comfort food, comfort drinking.
ES-D1-05
It’s mostly the exercise, but it’s also diet as well. You just eat more poorly and put weight on,
and it’s just all those things that you associate with depression are actually also associated
with poor physical health, if you want to put it that way.
ES-G2-01
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But when you’re having a real bad episode all that goes out the window. And you’re not
looking after yourself. You’re not looking after your diabetes either. And unless somebody is
really on top of it with you, you can get into a mess.
ES-T3-07
When you’re having a bad day, you’re not so bothered about having salad for tea, you might
be naughty.
ES-T3-09
When I’m not well, I’m just not capable of managing my own medication.
ES-T4-09
A packet of shortbreads, five Mars bars, that’s my diet, that’s because of this anxiety that
takes me through sweetness, and all sorts of things.
ES-T7-04
I’ve seen patients who, so when their mental health deteriorates, their eating deteriorates, so
they may start to comfort eat, make the wrong food choices, and so they lose their diabetic
control. I’ve got a patient who, when her mother died, you know, you can date things back,
she said ‘I’ve got dreadful glycaemic control’ and this dates back to the death of her mother
and she is still in a bereavement phase and the diabetes is just not important for her.
Staff ES-PC-05
Obviously when a person is unwell, whether it is schizophrenia or bipolar or depression,
everything will fall out of the window.
Staff ES-T1-01
They’re relapsing but they’re not risky. They’re like, ‘well . . . just see your GP’, would be the
answer. In the meantime, they’re not eating or they’re eating chocolate for five meals a day,
because it’s easy, and they’re not sleeping any more. Their weight is ballooning or shrinking,
they’re getting more physically unwell, their blood sugars are raging. That person is 6 months
down the line and they’re acutely psychotic. At that point they’ve got retinopathy, their blood
sugars are all over the place, then you’ve given yourself two big problems to manage, what
would have been one small problem.
Staff ES-T2-12
I suppose it depends how the impact that’s having on that person. So, if someone’s having
quite a lot of negative symptoms, that might be affecting their motivation, but just purely
their condition, I don’t think, would impact their diabetes management, not that I’ve seen.
Staff ES-T2-14
There are lots of reasons why people don’t or can’t buy the right food options, and then,
usually, because of lack of motivation, either because of negative symptoms and/or because
of low mood, there’s a lot of patients who, even if they’re . . . you know, I’ve got a patient
who is trained as a chef, but from a motivational point of view, they can’t, actually, push
themselves to go to the effort of preparing something.
Staff ES-T2-15
And especially if you’re depressed, you either don’t want to eat anything, or you want to eat
a load of chocolate and chips and things like that, which is partly the fault of the medications
that we use.
Staff ES-T3-05
And if you are depressed, if you are anxious, if you are experiencing hallucinations, you’re
maybe not going to want to go to the gym, to the supermarket to look for healthy food.
You’re maybe not going to have the motivation to cook for yourself, cook healthy meals.
You’re maybe just going to be putting stuff into a microwave.
Staff ES-T6-01
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If she’s stressed or frustrated or angry or just not feeling 100%, she won’t be disciplined,
especially with diet and what should be doing to help, I suppose, control the diabetes,
because it’s almost like a link with food. I mean, she does try but I do notice that when she’s
particularly stressed, it might be, well she goes one or two ways, it’s either not eating very
much at all, you know, so she’s not getting the correct nutrients and all the rest of it. Or, she
eats things that she shouldn’t be eating, then it’s almost like . . . not that there’s an excuse,
but she’s stressed and that what she fancies at that time, so, you know, she would probably
go off the sort of diet that she should be on. Or care a little bit less I suppose.
Family member ES-T3-08
Extreme low mood and
depression affect
management further
I really don’t know, ‘cause when I’m depressed there’s nothing that you could say that would,
‘cause you stop caring, it’s like if you stop caring about yourself, or what happens to you, it’s
very difficult then, for someone to say, ‘well you need to stop eating these, these and these,
and you need to eat a portion size that looks like this, with brown rice on it’, and you get
home and you just think ‘fish and chips’. It’s very, very difficult.
ES-G2-01
You’re mixed up because part of you wants to live but you want to . . . I mean, I said when
I went to Slimming World I want to lose weight, because I want to live longer. You know, with
diabetes, you’re liable for a stroke, a heart attack, **** knows what else. So if I do something
right . . . on that, maybe . . . But other times, no, you don’t want to live. And it’s that, because
you don’t want to live in this hell you haven’t created, but your mind is doing.
ES-T3-07
I’ve got another patient, when her mental health deteriorates, she often goes into crisis and
it’s often related actually to benefits and things like that, so her self-harm increases, her diet
increases, but she does just stop taking her tablets as well, just because she can’t be bothered
with it really, so a lack of motivation, you know, ‘I don’t want to be here; therefore, why
should I bother about this because I don’t care, I forget the complications because I might
not be here long enough to get them.’.
Staff ES-PC-05
I don’t think if differentiates and I think the worst of all is depression. Because somebody’s
proper clinically depressed and flat, they don’t even eat let alone go and see the GP or even
get out of bed . . .
Staff ES-T5-03
Worries about diabetes
can contribute to low
mood
It frightens you, doesn’t it, how you feel, dizzy and . . . sick.
ES-T2-02
I get very worried, because of the eyesight and they took X-rays of my eyes, because you
know what it is, you know another thing, you know when I’m looking at my phone, this is the
main damage it’s done to me, looking at my phone from this distance, now when I want to
send a text or something . . . so I am worried about my eyesight. I need to sort something out,
but it does get me worried, yes.
ES-G9-01
I suppose it’s stress involved, knowing that I had a friend who were diabetic who died when
I was 30, so I’m quite aware that it’s not something to ignore.
ES-T2-06
It does affect me badly because I worry. I worry about going to bed. I worry about sleeping
because I think, ‘am I going to wake up or am I not going to wake up?’.
ES-T3-03
I’ve constantly got to think, ‘oh, I hope this next reading’s going to be OK’. Or I’m always like
that, if you know what I mean, and it . . . that drives my anxiety and that drives, like, the
bipolar type of thing in me.
ES-T3-03
But I just think generally my health has gone down since . . . my mental health has gone
down since I’ve had diabetes. Because it’s another illness, you know, you get fed up having
yet something else added.
ES-T3-04
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Oh yeah, definitely, because you need to be careful what you eat, being overweight. I mean,
that makes me anxious. That does upset me. And knowing that I’m diabetic, knowing I’m
overweight, I am. That upsets me and that makes my anxiety worse and that makes the
hallucinations worse. There’s definitely a connection.
ES-T3-09
I think sometimes, patients I suppose without mental illness as well, if they are injecting so
they are on insulin, it’s just a constant reminder that they have diabetes and so that can
have a negative impact on their mental health.
Staff ES-PC-05
Any physical illness, any long-term chronic physical illness can affect somebody’s mental
health. If you are living a life where you have to constantly worry about an aspect of your
physical health, whether it’s pain, whether it’s fatigue or whether it’s diabetes, and the
difficulty with diabetes sometimes is that it isn’t tangible in the same way, so you either are
worrying about it because you’re not sure what’s going on, you know that your sugars aren’t
quite right but you haven’t got skills or the support to manage it, or you don’t know it’s a
problem until it becomes such a big problem that you have the long-term consequences, you
know? [. . .] You know, in the context of being diagnosed with the consequence of diabetes
is incredibly overwhelming and then to then think about medications and then eventually
insulin, you know, it’s devastating and incredibly stressful, and one stress begets another
stress. So yes, those definitely are related both ways.
Staff ES-T2-12
. . . being diagnosed with diabetes and it’s another thing that she’s got to think about and you
know, sort of contend with. So, I do think it has affected her mental health, in that it’s an
additional thing for her to worry about.
Family member ES-T3-08
TABLE 37 Supplementary participant quotations for theme 5: informal support networks
Subtheme Associated quotations




l Not everyone has this
support available
I talk to people in here and they help me [. . .] I’ve got some good friends.
ES-T2-04
I’ve got one really close friend who I talk to about it, and others that I don’t really mention it
at all to. And that’s because, well sorry, two people I talk to about it.
ES-G2-01
I get pretty good support, me family supports me alright, they’re always concerned if I’m
alright, and what have you.
ES-G4-01
Well he’s my carer, is my husband, he looks after me, he looks after everything, he does all
the financial bills and everything to pay, he sorts holidays out, he pays all the bills.
ES-G7-01
Yes, it means a lot to me, like I said, I’ve been to the mosque about 2 days ago, and I feel
really good with my friends, that’s giving me another motivation, carry on.
ES-G9-01
Who helps me the most in continuing to be here at all? ‘Cause there’ve been occasions when
that’s definitely been a possibility not to be true. My wife. So my unpaid carer, a 24 hour a
day, unpaid carer, is the most critical person in my care.
ES-T2-03
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. . . my relatives are important as well because people with diabetes in my family, we discuss
issues and medication and the best way forward to manage it, so they are
important connections.
ES-T2-05
. . . because I am more open with [husband] my husband now [. . .] because I’ve got to be
because he is my main support person and I haven’t got the support in CPN any more
so in order to manage my mental health situation, I do need to be honest and open with
him 100%.
ES-T2-05
Well, [partner]. Without her, I wouldn’t be around. I would have taken an overdose by now.
She keeps me grounded.
ES-T2-06
And it’s like my family were trying to help me then and they couldn’t because I wouldn’t let
them, but it’s like now, because I’m feeling better, I’m letting them in, I’m letting them
help me.
ES-T3-03
So both my son, even though he’s got his own issues, but my daughter is the one, she can tell
by my voice when I’m not right. So she rings me first thing in the morning and she’ll ring me
at night, and I go over, as I say, every alternate weekend. [. . .] So she’s the one who would
then ring [son] and say, ‘my mum’s not right’, and then they would get in touch with the CPN,
or say to me, ‘mum, what’s on your mind, you know, what are you worrying about?’.
ES-T3-04
My mum and my sister take me to Asda on a Monday and I go to church on a Sunday. My
partner drives me to church and drops me and my daughter off while I’m at church and then
picks me up. On a Monday, my mam and sister take me to Asda and then we go and have a
coffee and then go and do our shopping. And then on a Tuesday and a Thursday, my mam’s
now started taking me to the gym.
ES-T3-09
So only the person I’ve got now is the advocate or friends, you know, Christian friends, you know
because I don’t have a family. All my family passed away when I was in prison. My mum died,
you know.
ES-G3-01
I don’t really have a lot of friends. [. . .] I have one friend who goes to MIND and I see him
sort of once a month, once every couple of months, something like that. And, really, apart
from that, I don’t really see people from one week to the next.
ES-T2-06
I’m surrounded by lots of people who I get along with, I’ve got friends, I’ve got family,
although my mum’s passed away and my dad’s getting on a bit and he’s had heart surgery,
so they can’t look after . . . they can’t help me any more, I’m on my own.
ES-T4-01
I still used to like to go with my friend and we’d go and have lunch. And now that’s gone out
of my life because I can’t physically do it, and that’s because of my diabetes.
ES-T3-04
But yeah, I did really miss my dad and I found it hard, you know, to cope without him.
ES-T4-09
Yeah. I went to a place called the [day centre] and I was there for about 10 or 15 years and
that was a godsend. And I loved going there. But, since it closed down, I’ve missed it.
ES-T5-11
I think the thing that helps them the most is if they’ve got a support worker whose working
with them, who goes in regularly and prompts them or if they’ve got a relative who helps
them because they’re at home.
Staff ES-T1-02
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I think peer support is really important because there might be somebody else sat there with
diabetes who can talk to them about it and they’re most probably more likely to listen to
them, than they would a professional.
Staff ES-T1-02
Now, her aunt wasn’t the best in terms of discouraging the alcohol use because they both
drank together, but her aunt was quite vigilant in making her bathe and look after herself
and do her washing and they [inaudible] better between them when she was there and her
aunt stayed with her a few weeks when her circumstances were difficult.
Staff ES-T1-04
No man is an island, as the saying goes, and family is so important in helping to prop
somebody up when they’re struggling and if they are lacking in the understanding, both
from the physical perspective, but also from the emotional perspective, it makes it so much
harder for the patient because the people who are immediately around them don’t get it.
Staff ES-T2-12
Really important because we may think we’re very important, but actually we may spend a
couple of hours a week with the service user and actually it’s the carers that are going to
spend that long term and that the carers may be very different from a health point of view
and may be able to influence things from a role model point of view. Or the carers and
relatives may have the same kind of health needs, as we often find. So, again, you’re helping
them as well as helping them to help the service users, so that you’re having almost a double
impact. So I think it’s very important to work with carers and relatives as well as, because if
you’re going to get that sustained behavioural change in people.
Staff ES-T6-01
Not all support is
positive
In this case, classically, the culture aspect was that family of the patient was bringing huge
amounts of food, raw cheese and chapattis and all those things, and obviously rice, so
helping the family to understand as well. And why I am mentioning this case is that it is a
classical case, because there was a lot of learned behaviour the patient had developed from
the family. So since an early age, the family had developed this behaviour, to pacify this
person, give food, so that the person doesn’t get [inaudible] this was a tall, huge lady, so
she can be aggressive as well, so if they give food, she will be quiet. So that kind of coping
mechanism, the family developed and obviously that impacted on her physical health as well.
Staff ES-T1-01
Sometimes you’ve got family who would support the patient, [. . .] whereas other families,
they just leave everything to the patient, which is difficult if the patient becomes a bit unwell.
Staff ES-T1-03
Some people, some family members, are not particularly helpful and they don’t understand the
illness. They often think that the person involved is being lazy or difficult and they should do
this, that and the other, and they won’t do this, that and the other, and they believe that is just
because they’re being awkward. So if they come to the clinic, then you have to sort of gently
try and explain that this could be part of the actual illness, not a choice to be awkward.
Staff ES-T3-05
Obviously liaising with their family as well, because lots of the family bring in chocolate and
full-sugar coke and loads of biscuits and so on. [. . .] Or bring tobacco, and they just bring all
sorts of things that aren’t going to help anyone with diabetes.
Staff ES-T5-01
I think creating a culture within the home is helpful. So, if you’ve got somebody who is
dismissive of the attempt of, knocks it down constantly, then that can be very unhelpful.
And if you’ve got somebody who’s encouraging them to get the takeaway or, don’t bother
with that, it’s raining outside. If your own motivation is a bit shaky to begin with, that’s
probably not going to help.
Staff ES-T7-01
It’s easier having both of us having to watch our diet. If I munch away at huge bits of cake
and he’d have to watch me – that would be awful.
Family member ES-D1-02
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The effects of being a
support person
Like I say, it does take over a bit, but, like I say, it’s good. It’s the best part of my life because,
like I say, it wasn’t that happy before and I’m happy with [husband]. I just hope nothing else
is thrown at us.
Family member ES-T5-12
Also when he was sick he believed he had acid on his body, and I was showering him actually
13 times a day. And then every time you shower him you’ve got to wash the washing. So it
does, it puts a lot of strain on everybody in the house.
Family member ES-T2-08
I think she runs the risk and probably does to an extent become a recluse. It’s very easy for
her to be reclusive. That will have a knock-on effect on me because if my wife’s reclusive then
. . . I don’t really like to leave her for great long periods, although I have done.
Family member ES-T2-17
. . . in the past, it did impact on things like my education. Because things happened where
she’s ended up in hospital with it before my finals. When I was doing my degree, things like
that, where it’s had an impact in the past. And so, after I graduated, and I got a job, there
was a few times where I had a call and it was like, ‘She’s been taken into hospital again,
can you get down here?’. Just coming in the car and going straight down. So, in the past,
it’s had a massive impact, I think. But not so much these days.
Family member ES-T3-08
It was very, very hard. There were times, even though you know someone’s ill, whether they
threaten to kill you, which she did, is a very challenge to your relationship, isn’t it?
Family member ES-T2-21
But, you know, when you’ve got somebody who’s swearing blind that there are attackers
around the corner and they’re coming. You know, to wait another hour for somebody to come
back to you on the phone, is a nightmare. An absolute nightmare. I was waiting and waiting
for a phone call back trying to calm him down, trying to stop him going out and sort of trying
to meet his attackers or whatever, you know, with a knife in hand or whatever. You just don’t





I think that it is important that they have the awareness and understanding of diabetes as
well for the importance of it. The education as well, they might be the ones cooking so just
make the health choices, understand, if they are blood glucose testing, you know, the values,
when to be worried, when to react, sometimes teaching the family member to give insulin.
They need as much education as the patient.
Staff ES-PC-05
So if families are caring, explaining to families, because here, in [city], there’s a cultural
variation, so people want to eat, so that also has a bearing. So, in that way, the whole
family needs educating about what you’re getting and cooking in the household. So, yeah,
so those are the bits, as I mentioned, so patient, carers and families, all these need to be
educated alongside.
Staff ES-PC-05
But, in the course of that, she was staying with her mum, just to give her partner a break,
and her mum said, ‘well it’s been interesting all this, ‘cause I know nothing about diabetes
really’. And this is a woman who’s been taking metformin for years.
Staff ES-PC-05
So yeah, kind of, educating the family, as well, and around what foods to bring in on visits;
and when patients go home on visits, not to make too many sugary and fatty meals for them.
Just getting everyone on board to, kind of, manage the diabetes.
Staff ES-T5-01
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TABLE 37 Supplementary participant quotations for theme 5: informal support networks (continued )
Subtheme Associated quotations
You could have a very switched-on family member who wants to encourage their loved one
to eat healthily, but I think it is more likely that that family member will just buy the person
what they want to eat, if they’re the one buying the food or they eat the same food and if
you’ve got somebody who hasn’t got mental health problems and isn’t diabetic, who are going
to eat certain foods and if that person eats pie and chips and a packet of biscuits for their
dinner at night, then that’s what their person with mental health issues and diabetes is also
going to eat.
Staff ES-T5-03
We have had information and I actually had to go to a meeting – not a meeting but, I had
somebody at the hospital who was, I think, a nutritionist or something and she had to give
me a chat about being diabetic and what I should and shouldn’t do, etc. So, I did get a
session and that was a couple of years ago, I think. Maybe more. We get a certain amount
of information and, of course, if you want to know more you can ask. But, generally, just
plodding along on routine check-ups and diabetic clinics.
Family member ES-D1-02
No, the first one-off was a group meeting at the hospital. At the diabetes unit but, there is
one at our own practice quite frequently. Where a group of people with diabetes get together
and exchange views and so on.
Family member ES-D1-03
TABLE 38 Supplementary participant quotations for theme 6: diabetes health care
Subtheme Associated quotations
Diabetes health care Interviewer: And who is it that you see for diabetes? [. . .]
ES-T5-11: GPs, [nurse], you go to the nurse. [. . .] you’ve to go over a year, or every 6 months,
I don’t know. [. . .] She does my finger, asks me what I’m eating, weighs me, my height.
They give me booklets about sugar, diabetes and things like that. They tell me what to eat.
[. . .] They told me to do my bloods regular.
ES-T2-04
Well yes, every 12 months. [. . .] They give me an eye . . . They did this thing, they examined
the back of my eyes for blood clots or something like that. [. . .] I get the podiatrist every
3 months, bending my feet to keep a check on those.
ES-D1-05
They’re 3 months at the moment, yeah. Three months at the moment, normally 6 months.
[. . .] I do tend to go for the eye tests every year, and I do all the things that they ask me to
do, and I do all the blood tests. And, if it’s more frequent, because they’re more worried, then
I will go in.
ES-G2-01
She [diabetic nurse] weighs me, which I hate. [. . .] She tests my feet, asks me questions, does
my blood pressure, that’s it, I think.
ES-G4-02
I go and have my diabetes reviewed, each year, at the GP’s surgery.
ES-T2-03
I have a blood test every 3 months, approximately, for the diabetes, specifically to look at my
blood sugar levels, and I also have my feet checked and a chat with the nurse about the
results, about a couple of weeks after the blood test where we discuss the results and any
changes that need doing vis a vis diet, medication or exercise.
ES-T2-05
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TABLE 38 Supplementary participant quotations for theme 6: diabetes health care (continued )
Subtheme Associated quotations
But they keep monitoring it through blood tests and things. [Pause] I’m seeing lots of
different specialists, hepatologists and dietitian, various others. So, I mean, every month I’m in
hospital for something.
ES-T2-06
Interviewer: Thinking about the help that you’ve had regarding your diabetes [. . .] in terms
of health-care staff, who would you say has helped you the most?
ES-T2-06: No one. Well, the GP for pointing it out in the first place. Apart from that it’s just
been getting weighed and blood tests, so I see the nurse.
I get six-monthly checks and I go to the local health centre, which is in the village. [. . .]
Well HbA1c, blood pressure, my kidney functions, thyroid function, vitamins sometimes,
I think they do that once a year, because I’ve also got a high prolactin level, so I get my
calcium and my vitamin D measured, I’m quite well looked after.
ES-T4-02
TABLE 39 Supplementary participant quotations for theme 7: diabetes knowledge and education
Subtheme Associated quotations
Knowledge of diabetes Not really, no. No one’s said anything why I’ve caught it. I mean, I don’t know how I’ve
caught it. I just think it’s the sugar. I just think it’s the sugar so . . .
ES-G4-01
No, no. I think I’ve basically just been winging it. I know, like, if I eat a big carby dinner,
I get very tired afterwards.
ES-G3-01
I don’t know nowt about diabetes, and understand it. I know you shouldn’t have ‘owt sweet,
when they checked me down at the doctors, she said, [interviewee], ‘fruit, what is it?’. So I go,
‘sweet’. ‘Well, you shouldn’t have it.’ I said, ‘oh well I might as well not exist, [nurse]’.
ES-T2-02
. . . if I wasn’t exercising, and you start to poor eat, that’s when my diabetes get worse and
starts to rise, the sugar levels and the fats as well, the lipids in my bloodstream as well,
go up.
ES-G2-01
Diabetes is all about not being able to handle glucose properly, and one of the signs that you
get is that once you get too much, your kidneys can’t handle it, and you end up peeing it out
in the urine.
ES-T2-03
I’m aware of the complications like amputations and heart attacks and stroke and dementia.
ES-T2-05
There’s all these frightening things to do with circulation and glaucoma, and all the rest of it.
People sort of think, ‘oh, diabetes, yeah, you’ve got to avoid sugar’, but actually it’s quite a
bad one if you don’t take note of it.
ES-T2-16
I think there is a huge variation, some people are very engaged in their health and will often
know more than you do about, you know, diet or they will have been on a diabetes education
programme and the prevention programme as well [. . .], but you always have this big group
that know what they should be doing but just don’t do it for whatever reason, and some
people they have so many other problems that it is just a last thing on their minds.
Staff ES-PC-01
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TABLE 39 Supplementary participant quotations for theme 7: diabetes knowledge and education (continued )
Subtheme Associated quotations
I think usually they don’t have that knowledge. They don’t have, I suppose, the area here that
I am working don’t have the right skills, they are not cooking, they don’t cook at home, they
don’t know what foods to buy, they don’t know what labels to look at when they are looking
at foods, they don’t have, as I was saying, the cooking skills to be able to cook fresh foods,
so there is a lot of processed foods, and also they don’t exercise.
Staff ES-PC-02
[About patient knowledge] It’s probably more frequent that it is inaccurate than it’s accurate.
It’s usually things like ‘eating carbohydrates is bad, I can’t eat fruit if I’ve got diabetes.’.
Staff ES-T2-14
I think, from a food point of view, a dietary point of view, and this is based on my experience
of lots of patients, while it still surprises me sometimes the lack of basic knowledge some
patients have about the healthy food plate, or which things are high in fat, which things are
high in calories. You know, basic things, which I suppose, wrongly, I thought was general
knowledge, but perhaps isn’t, perhaps, actually, it’s a lot to do with educational opportunities,
having family that eat healthily, whatever.
Staff ES-T2-15
Sometimes they have the wrong information – they think that they can eat as much fruit as
they want, for instance, their level of knowledge may not be good.
Staff ES-T5-02
I mean, if you don’t know that you shouldn’t eat McDonald’s three times a day, then you’ve
got your head buried in the sand, even with the people with mental health issues. People





I’ve done my own research on YouTube and asking people who’s had diabetes, or people who
know what good food are [. . .].
ES-G3-01
I did know quite a bit about diabetes, with my husband being a diabetic.
ES-T4-09
We are more involved in sort of promoting their general well-being, so we talk about alcohol
and smoking and general health advice, and part of that is to do with weight management
and if there HBA1C is within, then talking about a diet and that kind of thing.
Staff ES-PC-01
We’ve built up sort of a pack of leaflets to give to people to sort of explain what it is,
complications, so I couldn’t tell you the source of those leaflets, and I use Diabetes UK, some
of their patient information leaflets as well.
Staff ES-PC-05
We rely really heavily on good relationships that we’ve got with some of the carers and the
managers of these places who, you know, they are absolutely fantastic in terms of trying to
do the health promotion side of it and get them to their appointments.
Staff ES-PC-06
In the psychological education, there will be the consultations, and that’s very important,
when you start prescribing, having a discussion with the patient, what are the side effects of
the medication. And one of the clear discussions I have is that medication, as such, will not
give rise to weight gain, but it can increase your diet. So watching what you are eating and
exercise is a really important part in this.
Staff ES-T1-01
Yes, the diabetic nurse or the GP practice. That’s the, sort of, practical support that they get




DOI: 10.3310/hsdr09100 Health Services and Delivery Research 2021 Vol. 9 No. 10
Copyright © 2021 Lister et al. This work was produced by Lister et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
185
TABLE 39 Supplementary participant quotations for theme 7: diabetes knowledge and education (continued )
Subtheme Associated quotations
I will routinely give people self-help workbooks, or YouTube I will quite routinely use because
YouTube has some fabulous resources to simply educate people.
Staff ES-T1-05
I mean one of my clients does use an online forum where she can kind of go for support,
but the problem, as I say, in some ways with online is who is monitoring that, who is
providing the information, you know, how accurate is it and so forth, so yeah I always
say to her, I’m glad you are looking for this information and you’re getting support,
but, you know, just be mindful of where it is coming from’.
Staff ES-T1-05
And I’ve tried to, I mean, I’ve had to educate myself really. Because, before mum got
diagnosed, it wasn’t something, I knew what it was, but I didn’t really know very much
about it. So, you know, there’s been a process I suppose for myself and my mum where
I’ve had to do some research into diabetes and the type of diet and what she can do to
help herself with that condition. So, I’ve bought various books and you know, I’ve read
through them, I’ve bought books for mum, diet books, sort of things that she can follow.
Family member ES-T3-08
Interviewer: So when you go and see the nurse every 6 or 7 weeks, or when you go to the
hospital every 6 months, do they advise you on what kind of things to eat or what to do?
ES-G3-01: Not really, no, I wish they did.
It was the GP really pointed it out in the first place that it showed up in my regular blood
test. He never really sat me down and explained. I got all the leaflets and things, but I’m not
one to read such things.
ES-T2-06
The information I was given was no fat, no sugar, and that was it. [. . .] And you had to work
out what has actually got fat in and what has actually got sugar in.
ES-T3-07
No, so she gave me this website and when I went on it, I was just struggling to find what I




Now, I was offered that by the GP service, and I went, ‘no thanks, I’m too busy being mad’.
So, 3 years later, I still haven’t done it. [. . .] So, I requested it. And there is a note in my notes
saying that I requested it, and there’s a note in my notes, a month later, saying I requested
it again. And there’s a note in my notes, saying, refused.
ES-T2-03
Interviewer: Have you ever been on an education course or been offered an education
course about diabetes?
ES-T3-11: No. But there’s lots of forms in the doctors that you can read.
I’ve been given information, but I’ve not actually been on any courses.
ES-T5-10
So, in terms of the diabetes, when they are actually diabetes, the education course, they
would be offered it when they come for their annual review, so the nurses would offer them
it and refer them on it and we are encouraged to refer as many people and try and get
everyone through it, so that’s done.
Staff ES-PC-01
So once you get put on the diabetic register because your blood indicates that you are
diabetic, automatically you should be referred for dietary diabetic appointment with the
doctor or the nurse and then an expert, which basically is a programme I think developed
in the NHS to say ‘right, you’ve got diabetes that’s do an intense dietary programme and
educational to try and reverse the effects’, so we are not then just leaving you to your own
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TABLE 39 Supplementary participant quotations for theme 7: diabetes knowledge and education (continued )
Subtheme Associated quotations
In [city] that is a current quality improvement programme to offer all type 2 diabetics,
however long they’ve had it or even if they’ve been on a structured education programme
again if that makes sense, there is some funding to promote that and we’ve now got a bigger
choice of programmes so referring people. There is an online one that has been commissioned,
a one-off 4-hour session and then the more traditional 6-hour structured education.
Staff ES-PC-05
We asked them on both sides, what support or what training or what information had they
had about diabetes and I think they’d been offered the DESMOND but that was it. [. . .]
Some of them haven’t been offered that. So I mean, the DESMOND is not really . . .
Our patients aren’t going to sit through the DESMOND.
Staff ES-T5-04
I mean, I knew anyway but there was certain, I can’t remember now, but certain things that
they said ‘oh, you know, you shouldn’t eat that’, I can’t remember what it was, but I was
thinking, ‘oh, I didn’t realise that’. [. . .] So, it was interesting, it did help.
ES-G4-02
And that was by far and away the best thing and the most useful thing, in terms of
management. So the GP has been completely useless in the management of my diabetes.
They might do a bit of monitoring, badly, but actually it was the intervention of the
community trust, with their education, that was provided by a dietitian, that really, really,
made a difference.
ES-T2-03
Like, I’ve only ever been on the DAFNE [Dose Adjustment for Normal Eating] one, that’s the
NHS one, and I found it was good. It taught me about food, and stuff, and it taught me
about what it does to the body, it’s, like, I didn’t find that’s what I needed, to go on course,
I found, like, I needed the support. [. . .] Like, going on the course and sitting there and
listening, I could do that, but it was, like, putting it into action that I found hard.
ES-T2-03
Yeah, the DESMOND, it’s either a full day or 2 half days, I think. I did that years ago but
that’s the only thing that I’ve ever done related to diabetes.
ES-T3-09
So doing the course did help, and it helped me with my husband as well, because, you know,
it was people who knew what they were talking about, you know, giving advice.
ES-T4-09
I went on a Living with Diabetes course. So, that taught me quite a few things.
ES-T4-12
She reported having ‘zero knowledge’ before the course, it opened her eyes to diabetes,
what it is, what it can do, and how it can be controlled. It was really interesting, and was
successful because it was a friendly atmosphere where everyone wanted to join in.
ES-T6-05
. . . it’s not tailored to people with SMI so, you know, the courses aren’t necessarily run in
places that are local to them, they are not run in a way that’s, kind of, made in any way
enticing to them. I mean, for example, I sent a chap on a DESMOND course recently, you
know, the diabetes education course and he got kicked off because they didn’t like his
behaviour. Well, you know, he’s a chap with schizophrenia and actually even getting him
there was massive, and, unfortunately, you know, he was never going to sit there and behave
like everybody else, so yeah, kind of, getting them to access stuff is very multilayered
I suppose, it’s not just getting them in the door, there are lots of other bits that need to
happen to really make that work.
Staff ES-PC-06
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TABLE 40 Supplementary participant quotations for theme 8: person-centred care
Subtheme Associated quotations
The value of care that
takes the whole person
into account
Interviewer: I think you mentioned that you previously had a nurse as support, didn’t you?
ES-D1-05: Yeah, she was great. She was an ex-policewoman. She was absolutely fantastic.
She could tell . . . When we said hello to each other, she could tell my mood straight away.
And she would speak to the psychiatrist before I got to the room, and probably brief him.
[. . .] She asked me in depth about the problems, the real problems and what was at the back
of them. Sometimes she would recommend some medication to the psychiatrist. And that
was a big help. I knew she cared. I knew she was listening, because there was a follow-up,
so to speak.
[About psychiatric nurse] Well, she says things like ‘what do I want to do?, what would I like
to do?’, make sure my tablets are the right ones that I’m taking and then I get some vitamins,
I don’t know what she is, she’s not a social worker, she’s a nurse, a hell of a nurse, but she
comes to the house about once a fortnight and she’ll take me out for a coffee. So, we go out
in her car and we’ll go for a coffee, which isn’t far.
ES-G7-01
TABLE 39 Supplementary participant quotations for theme 7: diabetes knowledge and education (continued )
Subtheme Associated quotations
. . . if we can get someone to commit to a DESMOND course, we’ll go with them, ‘cause that’s
quite a long morning, and again, sometimes they’re quite big groups, and lots of people that
are really interested, are asking loads of questions. So, that’s quite intimidating sometimes,
isn’t it, so occasionally we’ve gone along to DESMOND courses with people . . .
Staff ES-T3-02
And our services users classically tell us that some of them have problems with literacy,
so they go along, they can’t read the information. The information is information overload.
If you think that a lot of our service users have problems with cognition, with attention,
with cognitive deficit. They can’t take on board the information; they don’t understand the
information. And I think some of them feel, in a big group, very inhibited. When some of
them find out that it’s a big group, they don’t even go. It’s run in our local library, which is a
lovely venue, it’s an old Victorian library, but a lot of them don’t even access the training
because they just, when they know what they’re going to, they don’t even access it.
Staff ES-T6-01
. . . often, I think, a barrier to the structured education is the group work, so I don’t know if it
would help if the group was people with similar other comorbidity, so other mental health
problems, or whether a bit more one to one.
Staff ES-PC-05
Obviously, there are lots of patients who, for motivational reasons, paranoia reasons,
difficulties using public transport reasons, lots of reasons, can’t contemplate the thought of
going to [city] Market and doing the course.
Staff ES-T2-15
. . . we had the healthy-eating lady coming – a dietitian. But, saying, as well, that you can
change things. I don’t think I realised how much the carbohydrate part was part of it. And
I think that was the worst bit, you know, the rice and things. And me, bread. Chocolate’s bad
and the biscuits I have with it, but I hadn’t realised that part. And like I said, it was very, very
good, weren’t it? It included everything. Feet and showing what can happen to your feet and
some of it were a bit horrific, but it was good. Like people who had been on holiday and
maybe someone who was careful of their feet. But, someone just went like that on a cruise
to come and have his massage. So, he walked across the deck and when he got back he
blistered. He didn’t realise from walking across that he’s blistered his feet badly because he
couldn’t feel with the diabetes. [. . .], but, now I do check my shoes and check my heels aren’t
rubbing and I try and have the lace-up shoes, in general, when I’m out.
Family member who also has diabetes ES-T5-12
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TABLE 40 Supplementary participant quotations for theme 8: person-centred care (continued )
Subtheme Associated quotations
My care co-ordinator’s brilliant, she comes every fortnight and we’ll just out for a cup of
coffee and walk around the garden centre.
ES-T3-09
Interviewer: How does he [care co-ordinator] help you?
ES-T3-11: He’s an old punk. [. . .] I’m an old hippy. In the seventies, I was a hippy. So, we’re a
bit . . . I like some punk, you know. I mean I like some of it. It were good fun. Yeah, we get on
great. And we talk a lot about music. [. . .] So, we have a common bond.
[About CPN] We have a chat, see how I’m doing, she’s very supportive, sometimes she tells us
about her family to give us a bit of amusing gossip.
ES-T4-02
. . . if they work better in 10-minute bursts, I can see them like that, if they work better as,
yeah, doing something a bit more involved and if they’re going to engage bet . . . I had a
service user before that he wouldn’t really sit in a room and have a chat with me, but if we
cooked a meal together, he’d talk about everything. So, our sessions would be less often,
so I’d see him like once a month, but we’d make a meal and talk while we were cooking
together, sit down, eat the meal together, and all that time we’re having conversations.
Staff ES-T2-14
We’ve got a whole team of doctors down here – you never get to see the same one twice,
but you used to just have one face, GP you knew really well [. . .] There is a lot of difference
between somebody knowing you and just seeing different people each time. If you want to
speak to a particular person, you have to make an appointment. It can take a week or
fortnight, you know, it depends on their schedule.
Family member ES-D1-02
She felt that doctors and nurses don’t seem to have as much time for you as her [care
co-ordinator] does, but diabetes is a serious condition. They don’t give you the information
that you need, that you were looking for. They don’t seem to be as friendly and have as much
time, they seem to be rushed.
ES-T6-05
I get, with a GP, they haven’t got that time to understand mental health . . .
ES-T3-03
I think GPs and practice nurse haven’t got the time to give that support, and it’s nothing
against them, they just . . . their workload is so under pressure, do you know what I mean?
ES-T3-03
Because when you go to your doctor, you’ve got 10 minutes, and that’s what the problem is.
Many of the guys, by the time they’re reaching the stage, like, you’re talking, guys with
diabetes, they’ve got lots of things going on with them. And they’re trying to tell the doctor
and it becomes like . . . So the doctor doesn’t give them . . . he just says ‘come for your annual
diabetes check, come for your tablet, we have to check your liver and your kidneys. We’ll do
that once a year’.
Family member ES-T2-08
I didn’t always want to, in the first 2 or 3 or 4 years, discuss all my feelings with my
husband, and if I was suicidal I wouldn’t want to necessarily tell him that because I wouldn’t
want to frighten or worry him, but I could share that and I would share that with my CPNs.
ES-T2-05
I’ve had the CPN nurse involved it has helped me to understand that mental health, it’s not
this horrible thing that people try and put it down that it is and it can be sorted, it can.
You’ve just not got to think negatively about it.
ES-T3-03
I’m a lot more confident now, but that’s taken a lot of hard work by [. . .] occupational
therapist . . .
ES-T4-02
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TABLE 40 Supplementary participant quotations for theme 8: person-centred care (continued )
Subtheme Associated quotations
Most people over the years have always been supportive – the wife and social workers and
the psychiatrists and yourself, as well. And all these services are very good, because without
these people, we would be a lot worse than what I am now.
ES-T5-11
Nowadays [inaudible] the things that gets me is the social workers will be cut down or
yourselves being cut down. Without these people, people wouldn’t be sane.
ES-T5-11
So they all said, the psychiatrist to get my PIP highered, which I were there last year,
February, in person. And I got it [. . .] I can show you [psychiatrist] letters, that she sent to
the PIP.
ES-T2-02
. . . when it first came out, when they were first looking at benefit, it was looking like I would
have to go for interview. And whoever was my consultant psychiatrist at the time intervened,
so I never went for an interview.
ES-T2-16
The GP’s been very supportive, I think that’s been just amazing, from first getting diagnosed
with diabetes, and first getting proper support for depression, they’ve been outstanding.
And I think probably are the reason why I’m alive, to be honest, because I think, one or
the other would probably have killed me, if I hadn’t have changed, to some extent.
ES-G2-01
[Discussing issues with the PIP:] Almost all of my patients are going through that, and even if
they’ve got a lot of physical health problems as well, and lots of specialists involved, the GPs
charge for doing those reports. Which, I’m sure they have to, but that’s the thing. So, they
can’t get reports from GPs, we, obviously, do them for free, and I will do my utmost to try
and . . . You know, almost all of my patients, I know without hesitation they should be getting
these benefits, and I don’t have any qualms in writing increasingly angry letters explaining
that, talking about the injustices of the system. And, I do that, not because I want to be
difficult, but because I’m trying to advocate for my patients.
Staff ES-T2-15
I also go to the benefits assessments with them because very often I find – if we send a letter
then they don’t go through for the assessment. But, if we send a letter and they still go to the
assessment, I will go with them, so they’ve got that level of support.
Staff ES-T6-03
The separation of mental
and physical health care
Their focus is on diabetes, yeah. Whenever I do anything that’s specifically for diabetes,
obviously, on the blood tests through the GP, and the results go through the diabetic nurse at
the GP’s surgery, but when I go for the eye test and things like that, they never ask me about
mental health problems, it’s never considered.
ES-G2-01
Interviewer: Does the psychiatrist know about your diabetic care and vice versa?
ES-T2-03: They don’t know doodly squat.
But, if I’ve broken a leg, and I was in recovery, and I had angina, and I was being looked
after, and had diabetes and being looked after, then all of that would be under one, under
the GP. But psychiatry, it isn’t, and it’s not joined up.
ES-T2-03
Interivewer: And does he [psychiatrist] show any sort of interest in your diabetes or does he
purely talk to you about your mental health?
ES-T2-05: No, just about my mental health.
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The GPs I tend not to go with anything to do with up here, I treat the GPs with anything
physical. But sometimes it does overlap. Sometimes I go to the GP and I say, ‘oh, I’m not
particularly well’, and they refer me back to the health professionals, mental health
professionals. So it does work, but I tend to keep one from the other.
ES-T2-16
I’m seeing my GP this Wednesday with physical [laugh] things. And the two will interact,
but I can’t go and sit in a GP’s surgery and go on about my paranoia because it would
take up an hour of a GP’s time and that’s not fair, not fair on the GP, not fair on the other
patients. So I don’t do that.
ES-T2-16
Interviewer: Would you ever see your GP about your schizophrenia?
ES-T2-18: No, not really. It’s not really their thing is it? [. . .] What could they do? There’s
nothing they can do is there.
But the mental health team seem to understand it all round, that it is a big picture, that it is
the diabetes and everything, it is the anxiety, not just one thing that the doctor’s trying to get
out of you, they just wanted to know what one thing what’s wrong with you.
ES-T3-03
I don’t think the mental health side of things are necessarily that clued on diabetes.
ES-T3-09
Interviewer: Right, OK. And do they [GP/nurse] ever help you with your mental health as
well or . . .?
ES-T7-03: No, I got a psychiatrist, haven’t I?
So, yes, my experience on the mental health side, experiences on the diabetic side, because . . .
and that is long term and now I’ve been referred to the diabetic centre, the specialist centre,
I would suggest those are borne out of lack of understanding. They haven’t got anybody who
mediates that’s in a mental health capacity there, I find that bizarre.
ES-T7-04
. . . so the majority of our annual review it isn’t really to do with the mental illness because
often they are under secondary services for that.
Staff ES-PC-01
What is our role in supporting them . . . I think at the moment it appears that we are the only
ones that are actually supporting them in managing their diabetes, because I think there is
very little support from secondary care in the management of type 2 diabetes.
Staff ES-PC-02
They don’t tend to ask about it [diabetes] because they don’t see it as part of a mental health
nurse’s role, I don’t think. It’s still very much about a physical illness, so it’s a GP and the
diabetic nurse.
Staff ES-T1-02
I mean, we’re aware of the impacts of the comorbid conditions, but we don’t tend to actually
deal with those, other than via the GP.
Staff ES-T3-05
Co-ordination of mental
and physical health care
We would have to liaise, which can be really frustrating because it’s not a quick answer
that you get, you’ve got the single point-of-access entry into mental health, and so if
somebody isn’t under services at the moment and you are wanting to get some information
on medication review or whatever, you have to go through a single point of access and they
get assessed by the well-being team and then they get passed on to whoever they feel is
most appropriate person to see them or the team, and it’s very long-winded. It can take up
to 4/6 weeks to get a simple medication review or even to get some advice sometimes,
which is not brilliant really. It makes it quite frustrating for the patient and for us.
Staff ES-PC-01
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I don’t think there is much linking between the mental health services and the diabetic
services as such, but would be referring to what we have available for any patient with
diabetes and I suppose most people, I suppose, with mental health problems are already
under the secondary care for their health problems. We do have a mental health nurse here
in the practice that we have on a once a week basis, so she would be able to give me help
specifically with someone with mental health problems, but she is not, I suppose we’ve got
nothing that links both, if that’s what you are meaning.
Staff ES-PC-02
Information doesn’t necessarily come to us directly, it goes to the GP, and so we have to
access the information from the GP. Blood results, if we are sending the bloods from our site,
then they come to us, so can see blood sugars and we’ll have access to that. But the diabetic
plan, as such, we don’t have access to it and it goes to the GP.
Staff ES-T1-01
Interviewer: . . . are you provided with information that someone would have been referred
on for education?
Staff ES-T1-02: No, you just find out from the patient, you don’t get any information passed
back to you. It’s when you say to them, how comes you’ve come on Metformin, when did this
happen that you find things out.’
. . . just trying to encourage them to think about it and to give them suggestions, really, about
this is what you could eat instead and maybe even a referral to the dietitian and getting
them to go back to the GP, because we can’t refer to dietitians, and get the GP to refer to
the dietitian to give them more patient advice about their diet as well.
Staff ES-T1-02
. . . difficult especially with GPs, it is a very difficult to get hold of GPs, it’s very hard to get
hold of GPs, but other experience has been really positive, with other professionals it has
been really positive.
Staff ES-T1-03
We need to have a really good communication between diabetic pain and the mental health
pain because I think that is what is lacking, we don’t have that communication, we don’t
liaise with each other.
Staff ES-T1-03
Nothing for GPs and pharmacists, I think they are OK, I don’t think they need any training,
I think what they need to liaise with mental health services or liaise more with mental
health services.
Staff ES-T1-03
I think that is a bit more disjointed, I think there is still very much a divide between mental
and physical in particular [. . .] people tend to very much still sit within their own branch and
it’s a shame because I think you become blinkered, you know, and you can kind of, if you tap
into what is available around you, I think you can certainly deliver a far more holistic service.
Staff ES-T1-05
Everyone who’s involved with that has responsibility to understand both sides. The psychiatrist
needs to understand the physical impact of both the condition and the treatment. The GP
needs to understand the interactions between the two. Any physician, medical professional,
acute hospital needs to understand that having the two together is going to make things more
complicated. There isn’t a uniform answer, that one-size-fits-all approach.
Staff ES-T2-12
It sounds like, ‘oh, that’s a lot of work’, but actually, if you know your patient and
you understand the patient enough that you’re treating them with medication, with
psychotherapy, with OT [occupational therapy], whatever, then you should be able to put
together a five-point, six-point, three-point plan that just sets it out for an overworked GP,
and equally for a GP, every physician has patients with varying levels of complexity, and
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Like, in 3 minutes he’ll drink three milkshakes, and then he’ll vomit. And then he can’t
understand where it came from. And then they make us appointments with the stomach
doctor. And I said the head doctor should be working on this, it’s got nothing to do with the
stomach doctor. It’s because the psychiatrist does nothing. We’re ending up at the stomach
doctor, who thinks I’m stupid because do you know, with that kind of intake you should be
vomiting. I do know that. I know that, but what do you want me to do about it?
Family member ES-T2-08
But now since it’s out of hospital we have to get one dosette box from the GP and a separate
dosette box from the psychiatry, with different medicine in it. And I’m saying why, if psychiatry
caused the diabetes, why must be the GP be doing it? Why is mental health not interested
enough to see what’s going on with the guys? Because very seldom does your GP talk to your
psychiatrist. Maybe once in a while. They don’t even share the same computer system.
Family member ES-T2-08
I do find that information – even though technology is a wonderful thing and should make
everything easier, sometimes things don’t get passed on that should get passed on. Certainly,
it takes ages for any decisions about medication from the psychiatrist doctor at [mental
health centre] – he changes his medication. It seems to take ages until they readjust.
Family member ES-D1-02
Training needs for staff A better understanding of the types of diabetes, how to look for sign and symptoms of
diabetes because it’s a bit ad hoc, what I remember and just generally managing it [. . .]
So, it would be beneficial to all of us to have some education on it even if they’re not
nurses, anybody.
Staff ES-T1-02
I think if everyone was given the [diabetes] training, then I think it would be really good for
the benefit of our patients.
Staff ES-T1-03
I think there are massive training needs and gaps and I think there’s a lack of understanding,
you know, within mental health nursing, in particular, and having worked very closely with
the nursing staff in mental health, there’s a real lack of understanding of how diabetes should
be managed.
Staff ES-T3-01
I remember sitting with one practice nurse, and advising someone to just eat a normal diet,
and me thinking, ‘****, do you know what this person’s normal diet is like? Don’t say that’,
you know. We’ve spent ages trying to get through to them about just basic things like sugary
drinks, and not drinking tons and tons of orange juice, they think it’s got vitamin C in it,
and it’s like, no. That sort of lack of awareness of our client group.
Staff ES-T3-02
I would say I think I wasn’t quite as aware as perhaps I should have been about the impact
that medications do have on the patient’s weight, especially weight management aims,
because the weight gain is so significant and I think if you were seeing somebody for weight
management advice, [. . .] if you weren’t aware of the significance of that medication, you
probably would just assume that they perhaps were not entirely being . . . they were
withholding things from you.
Staff ES-T6-02
I think it’s very easy to focus on physical side of things, but the mental health is just a
massive side of it and I think if a patient has, I think if we were more trained and more
aware of the mental health of a patient, I think it could probably alleviate a lot of the
problems for both patients and the staff.
Staff ES-PC-04
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